CA2405246A1 - Enrichment method for variant proteins with alterred binding properties - Google Patents
Enrichment method for variant proteins with alterred binding properties Download PDFInfo
- Publication number
- CA2405246A1 CA2405246A1 CA002405246A CA2405246A CA2405246A1 CA 2405246 A1 CA2405246 A1 CA 2405246A1 CA 002405246 A CA002405246 A CA 002405246A CA 2405246 A CA2405246 A CA 2405246A CA 2405246 A1 CA2405246 A1 CA 2405246A1
- Authority
- CA
- Canada
- Prior art keywords
- hgh
- phagemid
- gene
- phage
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/61—Growth hormones [GH] (Somatotropin)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/802—Protein-bacteriophage conjugates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
Abstract
A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered Minding properties for their respective receptor molecules is provided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated b form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.
A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered bind-ing properties for their respective receptor molecules is pro-vided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mu-tated to form a library of ratty rotated fusion proteins that are expressed in low quantity on the surface of a phagem-id particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates, Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.
A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered bind-ing properties for their respective receptor molecules is pro-vided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mu-tated to form a library of ratty rotated fusion proteins that are expressed in low quantity on the surface of a phagem-id particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates, Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.
Description
ENRfCHMENT METHOD FOR VARIANT PROTEINS WITH ALTERED BINDING PROPERTIES
FIELD OF THE INVENTION
This invention relates to the preparation and systematic selectan of novel Minding proteins having altered binding properties for a target molecule. Specifically, this inventan relates to methods for producing foreign polypeptides mimicking the Minding activity of naturany occurring Minding partners. In preferred embodiments, the invention is directed to the preparation of therapeutic or diagnostic compounds that mimic proteins or nonpeptidyi molecules such a hormones, drugs and other small molecules, particularly biologically active mole~ies such as growth harnone.
BACKGROUND OF THE INVENTION
Binding partners are substances that spedtic~lly bind to one another, usuaay through noncovalent interactions. Examples of t~indirx~ partners include agand-receptor, antibody-antigen, drug-target, and enzyme-substrate interactions. Binding partners are extremely useful in both therapeutic and diagnostic fields.
Binding partners have been produced in the past by a variety of methods ~cluding; harvesting them from nature (e.g., antibody-antigen, and tigand-receptor pairings) and by adventitious identification (e.g.
traditional drug development empbying random screening of candidate mofec;ules). 1n some instances these two approaches have Meen comt~ir~ed. For example, variants of proteins or polypeptides, such as polypeptide fragments, have been made that contain key functional residues that participate in binding. These polypeptide fragments, in tum, gave been derivatized by methods akin bo traditional drug development. An example of such derivitization woukf include strategies such as cyctization to confortnationally constrain a polypeptide fragment to produce a novel candidate Minding partner.
The problem with prior art methods is that naturally occurring tigands may not have proper characteristics for ail therapeutic applications. Additionally, polypeptide Ggarxls may not even be available for some target substances. Furthermore, methods for making ran-naturally occurring synthetic binding partners are often expensive and difficult, usually requiring complex synthetic methods to produce each candidate. The inability to characterize the structure of the resulting candidate so that rational drug design methods can be applied for further optimization of candidate molecules further hampers these methods.
In an attempt to overcome these problems, Geysen (Geysen, X6:364-369 (1985]);
and (Geysen et al., gyp" 23:709-715 (1986]) has proposed the use of polypeptide synthesis to provide a framework for systematic iterative binding partner identification and preparation. According to Geysen et at., lbid, short polypeptides, such as dipeptides, are first screened for the ability to bind to a target molecule. The most active dipeptides are then selected for ate additional round of besting comprising linking, to the starting dipeptide, an additional residue (or by internally modifying the components of the original starting dipeptide) and then saeerrting ttus set of candidates for the desired activity. This process is reiterated unfit the Minding partner having the desired properties is identified.
The Geysen et al. method suffers from the disadvantage that the chemistry upon wtuch it is based, peptide synthesis, produces molecules with iU-defined or variable secondary and tertiary structure. As rounds of iterative selection progress, random interactions accelerate among the various st~stituent groups of the poiypeptide so that a true random populat'an of interactive molecules having reproduable higher order structure becomes less and less adainable. For exaunple, interactions between side d~airxs of amino Gads, which are sequentially widely separated but which are spatially neighbors, fneefy occur.
Furthermore, sequences that do not fadlitaie confortnationally stable secondary sinxtunes provide complex peptide-sidechain interactions which may prevent sided~ain interactions of a given amino acrd with the target molecule.
Such complex interadans are fadlitated by the 8exit~itity of the polyamide baci~one of the potypeptide candidates. Additionally, candidates may exist in numerous contortnations making it diffia~t to identify the coMonner that interacts or hinds to the target with greatest affinity or spedficity complicating rational drug design.
A final problem with the iterative polypeptide method of Geysers is that, at present, there are no practical methods with which a great diversity of different peptides can be produced, screened and analyzed. By using the twenty naturally oc~rrirtg amino ands, the total number of all combinations of hexapeptides that must be synthesized is 64,000,000. Even having prepared such a diversity of peptides, there are no methods available with which mixtures of such a diversity of peptides can be rapidly screened to select those peptides having a high affinity for the target molecule. At present, each 'adherent' peptide must be recovered in amounts large enough to carry out protein sequendng.
t 5 To overcome many of the problems inherent in the Geysers approach, t~iokx~ical selection and screening was chosen as an alternative. Biological selec8ons and screens are powerful toots to probe protein function and to isolate variant proteins with desirable properties (Shortle, pJotein Enaineerina. Oxender and Fox, acts., A.R. Liss, Inc., NY, pp.103-108 [1988]) and Bowie et al., , 247:1306-1310 (1990)].
However, a given selection or screen is applicable to only one or a small numt~er of related proteins.
Recently, Smith and coworkers (Smith, , 228:1315-t 3t 7 j1985]) and Parmley and Smith, ~r , 73:305-318 (1985] gave demonstrated tt>at small protein fragments (10-50 amino adds) can be'displayed' efficiently on the surface of filamentous phage by inserting short gene fragments into gene Ill of the fd phage ('fusion phage'). The gene III minor coat protein (present in about 5 copies at one end of the virion) is important for proper phage assembly and for infection by attadunent to the pill of E.
cbli (see Rasched et aL , Microbiol.
$~y" 5Q: 401-427 (1986]). Recently, 'fusion phage' have been shown to be useful for displaying short mutated peptide sequences for identifying peptides that may react with antibodies (Scott et aL, Science 249: 386-390, (1990] )and Cwirla et a!., Proc. ',~1'gg~dJ .LA 137: 6378-&382, (t990j).or a foreign protein (Devlin et al., .
Science, 249: 444-406 [1990]).
There are, however, several important wmitatans in using such 'fusion phage' to identify altered peptides or proteins with new or enharxed binding properties. Frst, it has been shown (Pamtley et aL, ~, 73:
305-318, (1988]) that fusion phage are useful only for displaying proteins of less than 100 and preferably less than 50 amino add residues, because large inserts presumably fisrupt the function of gene Ill and therefore phage assembly and infectivity. Second, prior art methods have been unable 1o select peptides from a library having the highest hinding affinity for a target molecule. For example, after exhaustive panning of a random peptide library with an anti-~ endorphin monoclonal antibody, (~virta et at., supra could not separate moderate amity peptides (ICd - 10 N.M) from higher affinity peptides (1(d ~0.4 p.M) fused to phage. Moreover, the parent ~-endorphin peptide seqt~erxe which has very high affinity (Kd - 7nM], was not panned from the epitope library.
Ladner WO 90N2802 discloses a method for selecting novel binding proteins displayed on the outer surface of cells and viral particles where it is contemplated that the heterologous proteins may have up to 164 amiro add residues . The method contemplates isolating and amplity~g the dsplayed proteins b engineer a new family of binding proteins having desired affinity for a target molecule. More specifically, Ladner discloses a 'fusion phage' displaying proteins having'iritial protein binding domains' ranging from 46 residues (crambin) to 164 residues (T4 lysozyme) fused b the M13 gene III coat protein. Ladner teaches the use of proteins'no larger than necessary' because it is easier b arrange restriction sites in smaller amino acrd sequences and prefers the 58 amino add residue bovine pancreatic trypsin intubitor (BPTI). Small fusion proteins, such as BPTI, are preferred when the target is a protein or macromolecule, wh~e larger fusion proteins, such as T4 lysozyme, are preferred for small target molecules such as sterads because such large proteins gave dells and grooves into which small molecules can fii. The preferred protein, BPTI, is proposed to be fused b gene III at the site disclosed by Smith et aL or de la Cruz etal.,,),,~j~" 263: 4318322 [1988], or b one of the termini!, along with a second synthetic copy of gene III so that 'some' unaltered gene III protein will be present. Ladner does not address the problem of successfully panning high affirity peptides from the random peptide library which plagues the t~iological selection and xreening methods of the prior art.
Human growth hormone (hGH} partidpates in much of the regulation of normal human growth and development. This 22,000 dalton ptuitary hormone exhit~its a multitude of t~iological effects including linear growth (somatogenesis}, lactation, activation of macrophages, insulin-like and diabetogenic effects among otters (Chawla, R, K. (1983} Ann-Rev. ~, fig, 519; Edwards, C. K et al. {t988}
~jg~,Z~,Q, 769; Thomer, M. 0., et al.
(1988) J. Clip. Invest gl,, 745). Growth hormone de6aency in children leads b dwarfism wtuch has been successfully treated for more than a decade by exogenous adminisGation of hGH.
hGH is a member of a family of 2 0 homologous hormones that include placental lactogens, prolactins, and other genetic and spades variants or growth hormone (Nicoll, C. S., et al., {1986) Ep~jpQ, Reviews l,169). hGH is unusual among these in that it exhibits broad species spedfidty and hinds to either the doped somatogenic (Leung, D. W., et aL, [1987] ,fig ~Q, 537) or prolactin receptor (Boutin, J. M.,et al., [f988] ,~; ~,~, 69). The doped gene for hGH has been expressed in a secreted form in t~' ' ~ (Chang, C. N., et al., (1987] ~ x,189) and its DNA
and amino add sequence has been reported {Goeddel, et aL, (1979] ~, 544; Gray, et at., (1985] ~ ~,Q, 247). The ttuee~iimensior~al structure of hGH is not available. However, the three~dimensiorrai folding paftem for porcine growth hormone (pGH} has been reported at moderate resolution and refinement (Abdel-Meguid, S. S., et aL, (1987] ProcNatl.
6c~d. ~i~USA $4, 6434). Human growth farmone's receptor and antibody epitopes have been identified by homolog-scanning mutagenesis (Cunningham etat., Silence x;1330,1989). The structure of novel amino terminal 3 0 methionyl bovine growth hormone containing a spliced-in sequence of human growth hormone irxtuding histidine 1 B
and histidine 21 has been shown {U.S. Patent 4,880,910) Human growth hormone (hGH) causes a variety of physiological and metat~otic effects in various anima!
models including linear bone growth, lactation, activation of macrophages, insulin-tike and diabetogenic effects and others (R. K. Chawla et al., Mnu. Rev. Mad: 34, 519 (1983); 0. G. P. Isaksson et aL, Amu. Rev. PhysioL 47, 483 (1985); C. K. Edwards et al., Science 239, 769 (1988); M. 0. Thorner and M. L.
Varxe, J. Clip. Jnvesf. 82, 745 (1988]; J. P. Hughes and H. G. Friesen, Mn. Rev. PhysioJ. IT, 469 (1985)).
These biological effects derive from the intenac5on between hGH and spedfic cellular receptors..
Accordingly, it is an ot~ject of this invention b provide a rapid and effective method for the systematic preparation of candidate binding substances.
FIELD OF THE INVENTION
This invention relates to the preparation and systematic selectan of novel Minding proteins having altered binding properties for a target molecule. Specifically, this inventan relates to methods for producing foreign polypeptides mimicking the Minding activity of naturany occurring Minding partners. In preferred embodiments, the invention is directed to the preparation of therapeutic or diagnostic compounds that mimic proteins or nonpeptidyi molecules such a hormones, drugs and other small molecules, particularly biologically active mole~ies such as growth harnone.
BACKGROUND OF THE INVENTION
Binding partners are substances that spedtic~lly bind to one another, usuaay through noncovalent interactions. Examples of t~indirx~ partners include agand-receptor, antibody-antigen, drug-target, and enzyme-substrate interactions. Binding partners are extremely useful in both therapeutic and diagnostic fields.
Binding partners have been produced in the past by a variety of methods ~cluding; harvesting them from nature (e.g., antibody-antigen, and tigand-receptor pairings) and by adventitious identification (e.g.
traditional drug development empbying random screening of candidate mofec;ules). 1n some instances these two approaches have Meen comt~ir~ed. For example, variants of proteins or polypeptides, such as polypeptide fragments, have been made that contain key functional residues that participate in binding. These polypeptide fragments, in tum, gave been derivatized by methods akin bo traditional drug development. An example of such derivitization woukf include strategies such as cyctization to confortnationally constrain a polypeptide fragment to produce a novel candidate Minding partner.
The problem with prior art methods is that naturally occurring tigands may not have proper characteristics for ail therapeutic applications. Additionally, polypeptide Ggarxls may not even be available for some target substances. Furthermore, methods for making ran-naturally occurring synthetic binding partners are often expensive and difficult, usually requiring complex synthetic methods to produce each candidate. The inability to characterize the structure of the resulting candidate so that rational drug design methods can be applied for further optimization of candidate molecules further hampers these methods.
In an attempt to overcome these problems, Geysen (Geysen, X6:364-369 (1985]);
and (Geysen et al., gyp" 23:709-715 (1986]) has proposed the use of polypeptide synthesis to provide a framework for systematic iterative binding partner identification and preparation. According to Geysen et at., lbid, short polypeptides, such as dipeptides, are first screened for the ability to bind to a target molecule. The most active dipeptides are then selected for ate additional round of besting comprising linking, to the starting dipeptide, an additional residue (or by internally modifying the components of the original starting dipeptide) and then saeerrting ttus set of candidates for the desired activity. This process is reiterated unfit the Minding partner having the desired properties is identified.
The Geysen et al. method suffers from the disadvantage that the chemistry upon wtuch it is based, peptide synthesis, produces molecules with iU-defined or variable secondary and tertiary structure. As rounds of iterative selection progress, random interactions accelerate among the various st~stituent groups of the poiypeptide so that a true random populat'an of interactive molecules having reproduable higher order structure becomes less and less adainable. For exaunple, interactions between side d~airxs of amino Gads, which are sequentially widely separated but which are spatially neighbors, fneefy occur.
Furthermore, sequences that do not fadlitaie confortnationally stable secondary sinxtunes provide complex peptide-sidechain interactions which may prevent sided~ain interactions of a given amino acrd with the target molecule.
Such complex interadans are fadlitated by the 8exit~itity of the polyamide baci~one of the potypeptide candidates. Additionally, candidates may exist in numerous contortnations making it diffia~t to identify the coMonner that interacts or hinds to the target with greatest affinity or spedficity complicating rational drug design.
A final problem with the iterative polypeptide method of Geysers is that, at present, there are no practical methods with which a great diversity of different peptides can be produced, screened and analyzed. By using the twenty naturally oc~rrirtg amino ands, the total number of all combinations of hexapeptides that must be synthesized is 64,000,000. Even having prepared such a diversity of peptides, there are no methods available with which mixtures of such a diversity of peptides can be rapidly screened to select those peptides having a high affinity for the target molecule. At present, each 'adherent' peptide must be recovered in amounts large enough to carry out protein sequendng.
t 5 To overcome many of the problems inherent in the Geysers approach, t~iokx~ical selection and screening was chosen as an alternative. Biological selec8ons and screens are powerful toots to probe protein function and to isolate variant proteins with desirable properties (Shortle, pJotein Enaineerina. Oxender and Fox, acts., A.R. Liss, Inc., NY, pp.103-108 [1988]) and Bowie et al., , 247:1306-1310 (1990)].
However, a given selection or screen is applicable to only one or a small numt~er of related proteins.
Recently, Smith and coworkers (Smith, , 228:1315-t 3t 7 j1985]) and Parmley and Smith, ~r , 73:305-318 (1985] gave demonstrated tt>at small protein fragments (10-50 amino adds) can be'displayed' efficiently on the surface of filamentous phage by inserting short gene fragments into gene Ill of the fd phage ('fusion phage'). The gene III minor coat protein (present in about 5 copies at one end of the virion) is important for proper phage assembly and for infection by attadunent to the pill of E.
cbli (see Rasched et aL , Microbiol.
$~y" 5Q: 401-427 (1986]). Recently, 'fusion phage' have been shown to be useful for displaying short mutated peptide sequences for identifying peptides that may react with antibodies (Scott et aL, Science 249: 386-390, (1990] )and Cwirla et a!., Proc. ',~1'gg~dJ .LA 137: 6378-&382, (t990j).or a foreign protein (Devlin et al., .
Science, 249: 444-406 [1990]).
There are, however, several important wmitatans in using such 'fusion phage' to identify altered peptides or proteins with new or enharxed binding properties. Frst, it has been shown (Pamtley et aL, ~, 73:
305-318, (1988]) that fusion phage are useful only for displaying proteins of less than 100 and preferably less than 50 amino add residues, because large inserts presumably fisrupt the function of gene Ill and therefore phage assembly and infectivity. Second, prior art methods have been unable 1o select peptides from a library having the highest hinding affinity for a target molecule. For example, after exhaustive panning of a random peptide library with an anti-~ endorphin monoclonal antibody, (~virta et at., supra could not separate moderate amity peptides (ICd - 10 N.M) from higher affinity peptides (1(d ~0.4 p.M) fused to phage. Moreover, the parent ~-endorphin peptide seqt~erxe which has very high affinity (Kd - 7nM], was not panned from the epitope library.
Ladner WO 90N2802 discloses a method for selecting novel binding proteins displayed on the outer surface of cells and viral particles where it is contemplated that the heterologous proteins may have up to 164 amiro add residues . The method contemplates isolating and amplity~g the dsplayed proteins b engineer a new family of binding proteins having desired affinity for a target molecule. More specifically, Ladner discloses a 'fusion phage' displaying proteins having'iritial protein binding domains' ranging from 46 residues (crambin) to 164 residues (T4 lysozyme) fused b the M13 gene III coat protein. Ladner teaches the use of proteins'no larger than necessary' because it is easier b arrange restriction sites in smaller amino acrd sequences and prefers the 58 amino add residue bovine pancreatic trypsin intubitor (BPTI). Small fusion proteins, such as BPTI, are preferred when the target is a protein or macromolecule, wh~e larger fusion proteins, such as T4 lysozyme, are preferred for small target molecules such as sterads because such large proteins gave dells and grooves into which small molecules can fii. The preferred protein, BPTI, is proposed to be fused b gene III at the site disclosed by Smith et aL or de la Cruz etal.,,),,~j~" 263: 4318322 [1988], or b one of the termini!, along with a second synthetic copy of gene III so that 'some' unaltered gene III protein will be present. Ladner does not address the problem of successfully panning high affirity peptides from the random peptide library which plagues the t~iological selection and xreening methods of the prior art.
Human growth hormone (hGH} partidpates in much of the regulation of normal human growth and development. This 22,000 dalton ptuitary hormone exhit~its a multitude of t~iological effects including linear growth (somatogenesis}, lactation, activation of macrophages, insulin-like and diabetogenic effects among otters (Chawla, R, K. (1983} Ann-Rev. ~, fig, 519; Edwards, C. K et al. {t988}
~jg~,Z~,Q, 769; Thomer, M. 0., et al.
(1988) J. Clip. Invest gl,, 745). Growth hormone de6aency in children leads b dwarfism wtuch has been successfully treated for more than a decade by exogenous adminisGation of hGH.
hGH is a member of a family of 2 0 homologous hormones that include placental lactogens, prolactins, and other genetic and spades variants or growth hormone (Nicoll, C. S., et al., {1986) Ep~jpQ, Reviews l,169). hGH is unusual among these in that it exhibits broad species spedfidty and hinds to either the doped somatogenic (Leung, D. W., et aL, [1987] ,fig ~Q, 537) or prolactin receptor (Boutin, J. M.,et al., [f988] ,~; ~,~, 69). The doped gene for hGH has been expressed in a secreted form in t~' ' ~ (Chang, C. N., et al., (1987] ~ x,189) and its DNA
and amino add sequence has been reported {Goeddel, et aL, (1979] ~, 544; Gray, et at., (1985] ~ ~,Q, 247). The ttuee~iimensior~al structure of hGH is not available. However, the three~dimensiorrai folding paftem for porcine growth hormone (pGH} has been reported at moderate resolution and refinement (Abdel-Meguid, S. S., et aL, (1987] ProcNatl.
6c~d. ~i~USA $4, 6434). Human growth farmone's receptor and antibody epitopes have been identified by homolog-scanning mutagenesis (Cunningham etat., Silence x;1330,1989). The structure of novel amino terminal 3 0 methionyl bovine growth hormone containing a spliced-in sequence of human growth hormone irxtuding histidine 1 B
and histidine 21 has been shown {U.S. Patent 4,880,910) Human growth hormone (hGH) causes a variety of physiological and metat~otic effects in various anima!
models including linear bone growth, lactation, activation of macrophages, insulin-tike and diabetogenic effects and others (R. K. Chawla et al., Mnu. Rev. Mad: 34, 519 (1983); 0. G. P. Isaksson et aL, Amu. Rev. PhysioL 47, 483 (1985); C. K. Edwards et al., Science 239, 769 (1988); M. 0. Thorner and M. L.
Varxe, J. Clip. Jnvesf. 82, 745 (1988]; J. P. Hughes and H. G. Friesen, Mn. Rev. PhysioJ. IT, 469 (1985)).
These biological effects derive from the intenac5on between hGH and spedfic cellular receptors..
Accordingly, it is an ot~ject of this invention b provide a rapid and effective method for the systematic preparation of candidate binding substances.
It is another of~ject of this invention to prepare candidate Minding substances displayed on surface of a phagemid particle that an; conformatanally stable.
It is another object of this invention to prepare candidate binding substances comprising fusion proteins of a phage coat protein and a heterologous polypeptide where the polypeptide is greater than t00 amino adds in length and may be more than one suburyt and is c~sptayed on a phagemid particle when: the polypeptide is encoded by the phagemid genome.
h is a further object of this invention to provide a method for the preparation and selection of binding substances that is sulfiaentiy versatile to present, or display, all peptidyl moieties that could potentially partiapate in a norxovalent binding interactan, and Do present these moieties in a fastuon that is sterically t 0 confined.
Still another object of the invention is the production of growth hormone variants that exhibit stronger affinity for growth hormone receptor and binding protein.
It is yet another object of this invention to produce expressan vector phagemids that contain a suppressible termination colon functionally located between the heterologous polypeptide and the phage coat protein such that detectable fusion protein is produced in a host suppressor cell and only the heterologous polypeptide is produced in a non-suppressor host cell.
Fnally, it is an object of this invention to produce a phagemid particle that rarely displays more than one copy of candidate binding proteins on the outer surface of the pt~agemid particle so that etficlent selection of high affinity binding proteins can be achieved.
These and otter objects of this invention will be apparent from consideration of the invenCwn as a whole.
SUMMARY OF TliE INVF.M10N
These objectives have been achieved by providing a method for selecting novel binding polypeptides comprising: (a) constructing a replicable expression vector comprising a first gene encoding a polypeptide, a second gene encoding at least a portion of a natural or wild-type phage coat protein wherein the first and second 2 5 genes are heterologous, and a transcription regulatory element operably (inked to the first and second genes, thereby forming a gene fusion encoding a fusion protein; (b) mutating the vector at one or more selected positions within the first gene thereby tormlng a family of related plasmids; (c) transforming suitable host teas with the plasmids; (d) infecting the transformed host teas with a helper phage having a gene erxxxiing the pf>age coat protein; (e) culturing the transformed infected host cells under conditions suitable for forming recomtur~ant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the condtions ~justed so that no more than a minor amount of phagernid particles display more than one copy of the fusion protein on the surface of the particle; (f) contacting the phagemid particles with a target molecule so that at Least a portion of the phagemid particles hind to the target molearle; and (g) separating the phagemid particles that bind from those that do not. Preferably, the method father comprises transforming suitable host cells with recombinant phagemid particles that bind to the target molecule and repeating steps (d) through (g) one or more times.
Additionally, the method for selecting novel binding proteins where the proteins are composed of more than one subunit is achieved by selecting rwvel binding peptides comprising constructing a repGraWe expression vector comprising a transcription regulatory element operably linked to DNA
encoding a protein of interest containing one or more sutxmits, wherein the DNA encoding at least one of the sub~x~its is fused to the DNA
encoding at Least a portan of a phage coat protein~nutating the DNA encoding the protein of interest at one or more selected positions thereby forming a family of related vectors;
transforming suitable host cells with the vectors; infecting the transformed host cells with a f~elper phage having a gene encoding tfie phage coat protein;
It is another object of this invention to prepare candidate binding substances comprising fusion proteins of a phage coat protein and a heterologous polypeptide where the polypeptide is greater than t00 amino adds in length and may be more than one suburyt and is c~sptayed on a phagemid particle when: the polypeptide is encoded by the phagemid genome.
h is a further object of this invention to provide a method for the preparation and selection of binding substances that is sulfiaentiy versatile to present, or display, all peptidyl moieties that could potentially partiapate in a norxovalent binding interactan, and Do present these moieties in a fastuon that is sterically t 0 confined.
Still another object of the invention is the production of growth hormone variants that exhibit stronger affinity for growth hormone receptor and binding protein.
It is yet another object of this invention to produce expressan vector phagemids that contain a suppressible termination colon functionally located between the heterologous polypeptide and the phage coat protein such that detectable fusion protein is produced in a host suppressor cell and only the heterologous polypeptide is produced in a non-suppressor host cell.
Fnally, it is an object of this invention to produce a phagemid particle that rarely displays more than one copy of candidate binding proteins on the outer surface of the pt~agemid particle so that etficlent selection of high affinity binding proteins can be achieved.
These and otter objects of this invention will be apparent from consideration of the invenCwn as a whole.
SUMMARY OF TliE INVF.M10N
These objectives have been achieved by providing a method for selecting novel binding polypeptides comprising: (a) constructing a replicable expression vector comprising a first gene encoding a polypeptide, a second gene encoding at least a portion of a natural or wild-type phage coat protein wherein the first and second 2 5 genes are heterologous, and a transcription regulatory element operably (inked to the first and second genes, thereby forming a gene fusion encoding a fusion protein; (b) mutating the vector at one or more selected positions within the first gene thereby tormlng a family of related plasmids; (c) transforming suitable host teas with the plasmids; (d) infecting the transformed host teas with a helper phage having a gene erxxxiing the pf>age coat protein; (e) culturing the transformed infected host cells under conditions suitable for forming recomtur~ant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the condtions ~justed so that no more than a minor amount of phagernid particles display more than one copy of the fusion protein on the surface of the particle; (f) contacting the phagemid particles with a target molecule so that at Least a portion of the phagemid particles hind to the target molearle; and (g) separating the phagemid particles that bind from those that do not. Preferably, the method father comprises transforming suitable host cells with recombinant phagemid particles that bind to the target molecule and repeating steps (d) through (g) one or more times.
Additionally, the method for selecting novel binding proteins where the proteins are composed of more than one subunit is achieved by selecting rwvel binding peptides comprising constructing a repGraWe expression vector comprising a transcription regulatory element operably linked to DNA
encoding a protein of interest containing one or more sutxmits, wherein the DNA encoding at least one of the sub~x~its is fused to the DNA
encoding at Least a portan of a phage coat protein~nutating the DNA encoding the protein of interest at one or more selected positions thereby forming a family of related vectors;
transforming suitable host cells with the vectors; infecting the transformed host cells with a f~elper phage having a gene encoding tfie phage coat protein;
5 culturing the transformed infected host cells under conditans suitade for forming r~ecomt~inant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amount of phagemid particles display more than one copy of the fusion protein on the surface of the particle; contacting the pt~agemid particles with a target molea~e so that at (east a portion of the phagemid particles dnd to the target molecule; a~~d separating the phagemid parbdes that bind from those that do not Preferably in the method of this invention the ptasmid is under tight control of the transcription regulatory element, and the culturing conditions are adjusted so chat the amount or number of phagemid particles displaying more than one copy of the fusion protein on the surface of the particle is less than about t%. Also preferably, amount of pt~agemid particles displaying more than one copy of the fusion protein is less than 10°~ the amount of phagemid particles displaying a single copy of the fusion protein.
Most preferably the amount is less than 20%.
Typically, in the method of this invention, the expression vector will further contain a seaetory signal sequences fused to the DNA encoding each suburut of the polypeptide, and the transcription regulatory element will be a promoter system. Preferred promoter systems are selected from; Lac Z, 7v,p~, TAC, T 7 polymerase, 2 0 tryptophan, and alkaline phosphatase promoters and combinations thereof.
Also typically, the 5rst gene will encode a mammalian protein, preferably the protein will be selected from; human growth hortnone(hGH), N-methionyl human growth hormone, t~ovine growth hormone, parathyroid hormone, thyroxine, insulin A~hain, insulin B~d~in, proinsulin, relaxin A~chain, relaxin 8~hain, prorelaxin, glycoprotein hormones such as follicle stimulating hormone(FSH), thyroid stimulating hormone(TSH), and leutinizirg hormone(LH), glycoprotein hormone receptors, caldtonin, gtucagon, factor VIII, an antibody, lung surfactant, urokinase, streptokinase, human tissue-type plasminogen activator (t-PA), bombesin, factor IX, thrombin, hemopoietic growth factor, tumor necrosis factor~alpha aril -beta, enkephalinase, human serum albumin, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, a microbial protein, such as betalactamase, tissue factor protein, inhibin, activin, vascular endothelial growth factor, receptors for hormones or growth factors; integrin, thrombopoietin, protein A or D, fieumabid factors, nerve growth factors such as NGF-~, platelet~rowth factor, transforming growth factors (TGF) such as TGF~alpha and TGF-beta, insulin-like growth factor-I and -It, insulin-like growth factor binding proteins , CDR, ONase, latency assodated peptide, erythropoietin, osteoinductive factors, interferons such as interferon-alpha, -beta, and -gamma, cobny stimulating factors (CSFs) such as M-CSF, GM-CSF, and G-CSF, interteukins (1).s) such as IL~1, IL-2, IL-3, It.-4, superoxide dismutase; decay accelerating factor, viral antigen, HIV
envelope proteins such as GPt20, GPt40, atria) natriuretic peptides A, B or C, ~nmuraglobulins, and fragments of any of the above-listed proteins.
Preferably the first gene will erxode a polypeptide of one a more subunits contairwng more than about 100 amino add residues and will be folded to form a plurality of rigid secondary strucaxes displaying a plurality of amino adds capable of interacting with the target. Preferably the first gene wia be mutated at codons corresponding to only the amino acids capable of interacting with the target so that the in~grity of the rigid secondary struchxes will be preserved.
Normally, the method of this invention will employ a helper phage selected from; M13K07, M13R408, M13-VCS, and Phi X t74. The preferred helper phage is M13K07, and the preferred coat protein is the Mt3 Phage gene III coat protein. The preferred host is E. colt, and protease defidem strains of E. colt. Novel hGH
variants selected by the method of the present irnerrtbn have been detected.
Phagemid expression vectors were constnxted that contain a suppressible termination colon functionally located between the nucleic acids enxroding the pofypeptide and the phage coat protein.
BRIEF DESCRIPTION OF THE RGURES
FIGURE t. Strategy fior displaying large proteins on the surface of fiamentous phage and enriching for altered receptor binding properties. A plasmid, phGH-Ml3glll was constructed that fuses the entire coding sequence of hGH to the carboxyl terminal domain of M13 gene III. Transcription of the fusion protein is under control of the lac promoterloperator sequence, and secretion is directed by the stll signal sequence. Pt~agemid particles are produced by infection with the 'helped phage, Mt3K07, and particles displaying hGH can be enrid~ed by binding bo an affinity matrix containing the hGH receptor. The wild-type gene III (derived from the Mt3K07 phage) is diagramed by 4-5 copies of the multiple arrows on the tip of the phage, and the fusion protein (derived from the phagemid, phGH-Mt3glll) is indicated schematically by the folding diagram of hGH repfadng the arrow head.
FIGURE 2 Immunobbt of whole phage particles shows that hGH comigrates with phage. Phagemid 2 0 particles purified in a cesium chloride gradient were boded into duplicate wells and electrophoresed through a t agarose gel in 375 mM Tris, 40 mM glydne pH 9.6 buffer. The gel was soaked in transfer buffer (25 mM Tris, pH
8.3, 200 mM gfydne, 20°~ methanol) containing 2°~ SDS and 2°~ ~-rnercaptoefhanol for 2 tours, then rinsed in transfer buffer for 6 hours. The proteins in the gel were then electrobbtted onto immotHlon membranes (Millipore). The membrane containing one set of samples was stained with Coomassie blue to show the position of 2 5 the phage proteins (A). The duplicate membrane was immuno-stained for hGH
by reacting the membrane with po(ydonal rabbit anti-hGH antibodies folbwed by reaction with horseradish peroxidase conjugated goat anti-rabbit IgG antibodies (B). Lane t contains the Mt3K07 parent phage and is visible only in the Coomassie blue stained memlxane, since it lades hGH. lanes 2 and 3 contain separate preparatbns of the hormone phagemid particles which is visible both by Coomassie and hGH immuno-staining. The difference in migration distance 30 between the parent M13K07 phage and hormone pt>agemid particles reflects the different size genomes that are packaged within (8.7 kb vs. 5.1 kb, respectively).
FIGURE 3. Summary diagram of steps in the selection process tOr an hGH-phage library randomized at colons 172, t 74, t 76, and 178. The template molecules, pH0415, containing a unique Kpnl restriction site and the hGH(R178G,1179T) gene was mutagenized as described in the text and electrotransfortned into E. cbli strain 35 WJM101 to obtain the initial phagemid library, Litxary 1. An aliquot (approximately 2°~) from Litxary t was used directly in an initial selection round as described in the text to yield Library t G. Meanwtule, double-stranded DNA
(dsDNA) was prepared from tlbrary I, digested with restW lion enzyme Kpnf to eliminate template background, and efectrotransformed into WJM101 to yield l.ibrar~r 2. Subsequent rods of selection (or tfpnl digestion, shaded boxes) foGowed by phagemid propagation were carried out as indicated by the arrows, according to the procedure described in the text. Four irxiependent doves from library 4G4 and four independent doves from Library 5G6 were sequerxaed by dideoxy sequenang. A!1 of these doves had the identical DNA sequence, corresponding to fhe hGH mutant (Glu t74 Ser, Phe 176 Tyr).
FIGURE 4. Stnx;tural model of hGH demred from a 2.8 ~l biding diagram of pordne growth hormone determined aystallographically. Location of residues in hGH that strongly modulate its binding to the hGH-t~inding protein are within the shaded drde. Alarune substitutions that cause a greater than tenfold reduction(), a four- to tenfold reduction (t), or increase (O), a a two- to fo~ioki reduction (e'), in t~irxiing affinity are indicated. Helical wheel projections in the regions of a-helix reveal their amptupathic quality.
Blackened, shaded, or nonshaded residues are d>arged, polar. or nonpotar, respectively. in helix-4 the most important residues for mutation are on the hydrophilic face.
FIGURE 5. Amino acrd substitutions at positions 172,174,176 and 178 of hGH
(The notation, e.g.
KSYR, denotes hGH mutant 172K/174SIt76Y1178R.) found after sequendng a number of doves from rounds 1 and 3 of the selection process for the pathways indicated (hGH elution; Glydne elution; or Glydne elution after pre-adsorption). Non-functional sequences (i.e. vector badkground, or other prematurely terminated andlor frame-shitted mutants) are shown as 'NP. Functional sequences which oor>tained a non-silent, spurbus mutation (i.e. outside the set of target residues) are marked with a'+'. Protein sequences which appeared more than once among all the sequerxed Bones, but with different DNA sequences, are marked with a'#'. Protein sequences which appeared more than once among the sequenced doves and with the same DNA
sequerxe are marked with a "'. Note that after three rounds of selection, 2 diNerent contaminating sequences were found; these Bones did not correspond to cassette mutants, but to prevuously constructed hormone phage. The pS0643 contaminant corresponds to wild-type hGH-phage (hGH 'KEFR'). The pH0457 contaminant, which dominates the ihird-round glycine-selected pool of phage, corresponds to a previously identified mutant of hGH, 'KSYR.' The amplification of these contaminants emphasizes the agility of the hormone-pt~age selection process to select for rarely occumng mutants. The convergence of sequences is also striking in all three pathways: R or K occurs most often at positions 172 and 178; Y or F occurs most oaten at position t76; and S, T, A, and other residues oa,~ur at position 174.
FIGURE 6. Sequences from phage selected on hPRLbp-beads in tt~e presence of zinc. Tt~e notation is as described in Fgure. 5. Here, the convergence of sequences is not predictable, but there appears to be a tHas towards hydroptbt~ic sequences under the most stringent (Glydne) selection conditions; L ,W and P residues are frequently found in this pool.
FIGURE T. Sequences from phage selected on hPRLbp-beads in the abserxe of zinc. The notation is as described in Figure 5. In contrast to the sequences of Figure. 6, these sequences appear more hydrophilic. After 4 rounds of selection using hGH elution, two cbnes (ANHQ, and TLDTIt7tV) dominate the pool.
FIGURE 8. Sequences from phage selected on blank beads. The notation is as described in Fg. 5. After flues rounds of selection with glyane elution, no sidings were observed and a background level of non-functional sequer~oes remained.
FIGURE 9. Construction of phagemid fl on from pH0415. This vector for cassette mutagenesis and expression of the hGH~ene III fusion protein was axistnxted as follows.
Plasmid pS0643 was constnrcted by oligonudeot~de-directed mutagenesis of pSU132, which contains pBR322 and ft o«gins of replication and expresses an hGH-flene III fusion protein (hGH residues 1-191, followed by a single Gly residue, fused to Pro-198 of gene III) under the control of the E.E. coli ~g promoter. Mutagenesis was carried out with the oligonudeotide 5'-GGC-AGC-TGT-GGC-TTC-TAG-AGT-GGC-GGC-GGC-TCT-GGT-3', which introduced a ~
site (underlined) and an amber stop colon (TAG) fonowing Phe-191 of hGH.
FfGURE 10. A. Diagram of ptasmid pDHt88 insert containing the DNA erxoding the light chain and heavy chain (variable and constant domain 1 ) of the F~ tmmanized antibody directed b the HER-2 receptor. V~
and YH are the variable regans for the Ight and heavy chains, respectively. Ck is the constant region of the human kappa Gght chain. CHtGt is the first constant region of the human gamma 1 chain. Both coding regions start with the bacterial st II signal sequence. B. A schematic diagram of the entire plasma pDHt88 containing the insert described in 5A. After transformation of the plasmid into E. Golf SR101 cells and the addition of helper phage, the plasmid is packaged into phage particles. Some of these particles display the Fab-p III fusion (where p tll is the protein encoded by the M 13 gene III DNA). The segments in the plasmid figure correspond to the insert shown in 5A.
FIGURE 11A through C are cdleciiveiy refenrd bo harp as F7gure 11. The rx~deotide (Seq. ID No. 25) sequence of the DNA erxxxlng the 4D5 Fab molecule expressed on the phagemid surface. The amino acid sequence of the light chain is also shown (Seq. tD No. 26), as is the amino aad sequerxe of the heavy chain p III fusion (Seq. It) No. 27).
FIGURE 12 Enrichment of wild-type ~D5 Fab phagemid from variant Fab phagemid.
Mixtures of wild-type phagemid and variant 4D5 Fab phagemid in a ratio of 1:1,000 were selected on plates coated with the extra-cellular domain protein of the HER-2 receptor. After each round of selection, a portion of the eluted phagemid were infected into E. coli and plasmid DNA was prepared. This plasmid DNA was then digested with Eco RV and Pst t, separated on a 5% polyacrylamide gel, and stained with ethidium bromide. The hands were visualized under UV light. The hands due to the wild-type and variant plasmids are marked with arrows. The first round of selection was eluted only under acid conditions; subsequent rounds were eluted with either an add elution (left side of Figure) or with a humanized 4D5 antibody wash step prior to acid elution (right side of Figure) using methods desaibed in Example VIII. Three variant 4D5 Fab molecules were made:
H91 A (amira add histidine at position 91 on the V~ chain mutated to alanine; indicated as 'A' lanes in Figure), Y49A (amino aad tyrosine at position 49 on the V~ chain mutated to alanine; indicated as'B' lanes in the Figure), and Y92A (amino acd tyrosine at position 92 on the V~ chain mutated to alarune; indicated as'C lanes in the Fgure). Amino aad position numbering is according to Kabat et al.,(Sequerx;es of proteins of immunological interest, 4th ed., U.S. Dept of Health and Human Services, Public Health Service, Nat'I. Institute of Health, Bethesda, MD (1987().
FIGURE 13. The Scatchard analysis of tt~e RIA affinity determination described in Experimental Protocols is shown here. The amount of labeled ECD antigen Ihat is bound is shown on the x-axis white the amount tf~at is bound divided by the amount that is free is shown on the y,axis. The slope of the Gne indicates the Ka; the calculated Kd is IIICa.
Most preferably the amount is less than 20%.
Typically, in the method of this invention, the expression vector will further contain a seaetory signal sequences fused to the DNA encoding each suburut of the polypeptide, and the transcription regulatory element will be a promoter system. Preferred promoter systems are selected from; Lac Z, 7v,p~, TAC, T 7 polymerase, 2 0 tryptophan, and alkaline phosphatase promoters and combinations thereof.
Also typically, the 5rst gene will encode a mammalian protein, preferably the protein will be selected from; human growth hortnone(hGH), N-methionyl human growth hormone, t~ovine growth hormone, parathyroid hormone, thyroxine, insulin A~hain, insulin B~d~in, proinsulin, relaxin A~chain, relaxin 8~hain, prorelaxin, glycoprotein hormones such as follicle stimulating hormone(FSH), thyroid stimulating hormone(TSH), and leutinizirg hormone(LH), glycoprotein hormone receptors, caldtonin, gtucagon, factor VIII, an antibody, lung surfactant, urokinase, streptokinase, human tissue-type plasminogen activator (t-PA), bombesin, factor IX, thrombin, hemopoietic growth factor, tumor necrosis factor~alpha aril -beta, enkephalinase, human serum albumin, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, a microbial protein, such as betalactamase, tissue factor protein, inhibin, activin, vascular endothelial growth factor, receptors for hormones or growth factors; integrin, thrombopoietin, protein A or D, fieumabid factors, nerve growth factors such as NGF-~, platelet~rowth factor, transforming growth factors (TGF) such as TGF~alpha and TGF-beta, insulin-like growth factor-I and -It, insulin-like growth factor binding proteins , CDR, ONase, latency assodated peptide, erythropoietin, osteoinductive factors, interferons such as interferon-alpha, -beta, and -gamma, cobny stimulating factors (CSFs) such as M-CSF, GM-CSF, and G-CSF, interteukins (1).s) such as IL~1, IL-2, IL-3, It.-4, superoxide dismutase; decay accelerating factor, viral antigen, HIV
envelope proteins such as GPt20, GPt40, atria) natriuretic peptides A, B or C, ~nmuraglobulins, and fragments of any of the above-listed proteins.
Preferably the first gene will erxode a polypeptide of one a more subunits contairwng more than about 100 amino add residues and will be folded to form a plurality of rigid secondary strucaxes displaying a plurality of amino adds capable of interacting with the target. Preferably the first gene wia be mutated at codons corresponding to only the amino acids capable of interacting with the target so that the in~grity of the rigid secondary struchxes will be preserved.
Normally, the method of this invention will employ a helper phage selected from; M13K07, M13R408, M13-VCS, and Phi X t74. The preferred helper phage is M13K07, and the preferred coat protein is the Mt3 Phage gene III coat protein. The preferred host is E. colt, and protease defidem strains of E. colt. Novel hGH
variants selected by the method of the present irnerrtbn have been detected.
Phagemid expression vectors were constnxted that contain a suppressible termination colon functionally located between the nucleic acids enxroding the pofypeptide and the phage coat protein.
BRIEF DESCRIPTION OF THE RGURES
FIGURE t. Strategy fior displaying large proteins on the surface of fiamentous phage and enriching for altered receptor binding properties. A plasmid, phGH-Ml3glll was constructed that fuses the entire coding sequence of hGH to the carboxyl terminal domain of M13 gene III. Transcription of the fusion protein is under control of the lac promoterloperator sequence, and secretion is directed by the stll signal sequence. Pt~agemid particles are produced by infection with the 'helped phage, Mt3K07, and particles displaying hGH can be enrid~ed by binding bo an affinity matrix containing the hGH receptor. The wild-type gene III (derived from the Mt3K07 phage) is diagramed by 4-5 copies of the multiple arrows on the tip of the phage, and the fusion protein (derived from the phagemid, phGH-Mt3glll) is indicated schematically by the folding diagram of hGH repfadng the arrow head.
FIGURE 2 Immunobbt of whole phage particles shows that hGH comigrates with phage. Phagemid 2 0 particles purified in a cesium chloride gradient were boded into duplicate wells and electrophoresed through a t agarose gel in 375 mM Tris, 40 mM glydne pH 9.6 buffer. The gel was soaked in transfer buffer (25 mM Tris, pH
8.3, 200 mM gfydne, 20°~ methanol) containing 2°~ SDS and 2°~ ~-rnercaptoefhanol for 2 tours, then rinsed in transfer buffer for 6 hours. The proteins in the gel were then electrobbtted onto immotHlon membranes (Millipore). The membrane containing one set of samples was stained with Coomassie blue to show the position of 2 5 the phage proteins (A). The duplicate membrane was immuno-stained for hGH
by reacting the membrane with po(ydonal rabbit anti-hGH antibodies folbwed by reaction with horseradish peroxidase conjugated goat anti-rabbit IgG antibodies (B). Lane t contains the Mt3K07 parent phage and is visible only in the Coomassie blue stained memlxane, since it lades hGH. lanes 2 and 3 contain separate preparatbns of the hormone phagemid particles which is visible both by Coomassie and hGH immuno-staining. The difference in migration distance 30 between the parent M13K07 phage and hormone pt>agemid particles reflects the different size genomes that are packaged within (8.7 kb vs. 5.1 kb, respectively).
FIGURE 3. Summary diagram of steps in the selection process tOr an hGH-phage library randomized at colons 172, t 74, t 76, and 178. The template molecules, pH0415, containing a unique Kpnl restriction site and the hGH(R178G,1179T) gene was mutagenized as described in the text and electrotransfortned into E. cbli strain 35 WJM101 to obtain the initial phagemid library, Litxary 1. An aliquot (approximately 2°~) from Litxary t was used directly in an initial selection round as described in the text to yield Library t G. Meanwtule, double-stranded DNA
(dsDNA) was prepared from tlbrary I, digested with restW lion enzyme Kpnf to eliminate template background, and efectrotransformed into WJM101 to yield l.ibrar~r 2. Subsequent rods of selection (or tfpnl digestion, shaded boxes) foGowed by phagemid propagation were carried out as indicated by the arrows, according to the procedure described in the text. Four irxiependent doves from library 4G4 and four independent doves from Library 5G6 were sequerxaed by dideoxy sequenang. A!1 of these doves had the identical DNA sequence, corresponding to fhe hGH mutant (Glu t74 Ser, Phe 176 Tyr).
FIGURE 4. Stnx;tural model of hGH demred from a 2.8 ~l biding diagram of pordne growth hormone determined aystallographically. Location of residues in hGH that strongly modulate its binding to the hGH-t~inding protein are within the shaded drde. Alarune substitutions that cause a greater than tenfold reduction(), a four- to tenfold reduction (t), or increase (O), a a two- to fo~ioki reduction (e'), in t~irxiing affinity are indicated. Helical wheel projections in the regions of a-helix reveal their amptupathic quality.
Blackened, shaded, or nonshaded residues are d>arged, polar. or nonpotar, respectively. in helix-4 the most important residues for mutation are on the hydrophilic face.
FIGURE 5. Amino acrd substitutions at positions 172,174,176 and 178 of hGH
(The notation, e.g.
KSYR, denotes hGH mutant 172K/174SIt76Y1178R.) found after sequendng a number of doves from rounds 1 and 3 of the selection process for the pathways indicated (hGH elution; Glydne elution; or Glydne elution after pre-adsorption). Non-functional sequences (i.e. vector badkground, or other prematurely terminated andlor frame-shitted mutants) are shown as 'NP. Functional sequences which oor>tained a non-silent, spurbus mutation (i.e. outside the set of target residues) are marked with a'+'. Protein sequences which appeared more than once among all the sequerxed Bones, but with different DNA sequences, are marked with a'#'. Protein sequences which appeared more than once among the sequenced doves and with the same DNA
sequerxe are marked with a "'. Note that after three rounds of selection, 2 diNerent contaminating sequences were found; these Bones did not correspond to cassette mutants, but to prevuously constructed hormone phage. The pS0643 contaminant corresponds to wild-type hGH-phage (hGH 'KEFR'). The pH0457 contaminant, which dominates the ihird-round glycine-selected pool of phage, corresponds to a previously identified mutant of hGH, 'KSYR.' The amplification of these contaminants emphasizes the agility of the hormone-pt~age selection process to select for rarely occumng mutants. The convergence of sequences is also striking in all three pathways: R or K occurs most often at positions 172 and 178; Y or F occurs most oaten at position t76; and S, T, A, and other residues oa,~ur at position 174.
FIGURE 6. Sequences from phage selected on hPRLbp-beads in tt~e presence of zinc. Tt~e notation is as described in Fgure. 5. Here, the convergence of sequences is not predictable, but there appears to be a tHas towards hydroptbt~ic sequences under the most stringent (Glydne) selection conditions; L ,W and P residues are frequently found in this pool.
FIGURE T. Sequences from phage selected on hPRLbp-beads in the abserxe of zinc. The notation is as described in Figure 5. In contrast to the sequences of Figure. 6, these sequences appear more hydrophilic. After 4 rounds of selection using hGH elution, two cbnes (ANHQ, and TLDTIt7tV) dominate the pool.
FIGURE 8. Sequences from phage selected on blank beads. The notation is as described in Fg. 5. After flues rounds of selection with glyane elution, no sidings were observed and a background level of non-functional sequer~oes remained.
FIGURE 9. Construction of phagemid fl on from pH0415. This vector for cassette mutagenesis and expression of the hGH~ene III fusion protein was axistnxted as follows.
Plasmid pS0643 was constnrcted by oligonudeot~de-directed mutagenesis of pSU132, which contains pBR322 and ft o«gins of replication and expresses an hGH-flene III fusion protein (hGH residues 1-191, followed by a single Gly residue, fused to Pro-198 of gene III) under the control of the E.E. coli ~g promoter. Mutagenesis was carried out with the oligonudeotide 5'-GGC-AGC-TGT-GGC-TTC-TAG-AGT-GGC-GGC-GGC-TCT-GGT-3', which introduced a ~
site (underlined) and an amber stop colon (TAG) fonowing Phe-191 of hGH.
FfGURE 10. A. Diagram of ptasmid pDHt88 insert containing the DNA erxoding the light chain and heavy chain (variable and constant domain 1 ) of the F~ tmmanized antibody directed b the HER-2 receptor. V~
and YH are the variable regans for the Ight and heavy chains, respectively. Ck is the constant region of the human kappa Gght chain. CHtGt is the first constant region of the human gamma 1 chain. Both coding regions start with the bacterial st II signal sequence. B. A schematic diagram of the entire plasma pDHt88 containing the insert described in 5A. After transformation of the plasmid into E. Golf SR101 cells and the addition of helper phage, the plasmid is packaged into phage particles. Some of these particles display the Fab-p III fusion (where p tll is the protein encoded by the M 13 gene III DNA). The segments in the plasmid figure correspond to the insert shown in 5A.
FIGURE 11A through C are cdleciiveiy refenrd bo harp as F7gure 11. The rx~deotide (Seq. ID No. 25) sequence of the DNA erxxxlng the 4D5 Fab molecule expressed on the phagemid surface. The amino acid sequence of the light chain is also shown (Seq. tD No. 26), as is the amino aad sequerxe of the heavy chain p III fusion (Seq. It) No. 27).
FIGURE 12 Enrichment of wild-type ~D5 Fab phagemid from variant Fab phagemid.
Mixtures of wild-type phagemid and variant 4D5 Fab phagemid in a ratio of 1:1,000 were selected on plates coated with the extra-cellular domain protein of the HER-2 receptor. After each round of selection, a portion of the eluted phagemid were infected into E. coli and plasmid DNA was prepared. This plasmid DNA was then digested with Eco RV and Pst t, separated on a 5% polyacrylamide gel, and stained with ethidium bromide. The hands were visualized under UV light. The hands due to the wild-type and variant plasmids are marked with arrows. The first round of selection was eluted only under acid conditions; subsequent rounds were eluted with either an add elution (left side of Figure) or with a humanized 4D5 antibody wash step prior to acid elution (right side of Figure) using methods desaibed in Example VIII. Three variant 4D5 Fab molecules were made:
H91 A (amira add histidine at position 91 on the V~ chain mutated to alanine; indicated as 'A' lanes in Figure), Y49A (amino aad tyrosine at position 49 on the V~ chain mutated to alanine; indicated as'B' lanes in the Figure), and Y92A (amino acd tyrosine at position 92 on the V~ chain mutated to alarune; indicated as'C lanes in the Fgure). Amino aad position numbering is according to Kabat et al.,(Sequerx;es of proteins of immunological interest, 4th ed., U.S. Dept of Health and Human Services, Public Health Service, Nat'I. Institute of Health, Bethesda, MD (1987().
FIGURE 13. The Scatchard analysis of tt~e RIA affinity determination described in Experimental Protocols is shown here. The amount of labeled ECD antigen Ihat is bound is shown on the x-axis white the amount tf~at is bound divided by the amount that is free is shown on the y,axis. The slope of the Gne indicates the Ka; the calculated Kd is IIICa.
D!:?AlLEO DESCRIPTION OF THE INVENTION
The following discussion will be best understood by refemng 1o Figure t. In its simplest form, the method of the instant invention comprises a method for selecting novel binding polypeptides, such as protein ligands, having a desired, usually hgh, affinity for a target moleaaie from a library of structurally related binding polypeptides. The ktxary of structurally related polypeptides, fused to a phage coat protein, is produced by mutagenesis and, preferably, a single copy of each related polypeptide is d~sptayad on the surface of a phagemid particle containing DNA encoding that polypeptide. These phagemid particles are then contacted with a target molecule and those particles having the highest affinity for the target are separated from those of lower affinity.
The high affinity binders are then amplified by infection of a bacterial host and the competitive binding step is repeated. This process is reiterated until polypeptides of the desired affinity are obtained.
The novel Minding polypeptides or ligands produced by the method of this invention are useful per se as diagnostics or therapeutics ( eg. agonists or antagonists) used in treatment of biological organisms. Structural analysis of the selected polypeptides may also be used to fadlitate rational drug design.
By 'binding polypeptide' as used herein is meant any polypeptide that hinds with a selectable affinity to a target molecule. Preferably the polypeptide will be a protein that most preferably contains more than about 100 amino add residues. Typically the potypeptide wilt be a hormone or an antibody or a fragment thereof.
By 'high affinity' as used herein is meant an affinity constant (Kd ) of <t0'5 M and preferably <10'~M
under physiological conditions.
By 'target molecule' as used herein is meant any molecule, rot necessarily a prolein, for which it is desirable to produce a ligand. Preferably, however, the target will be a protein and most preferably the target will be a receptor, such as a hormone receptor.
By 'humanized antibody' as used herein is meant an antibody in wtych the complementarity~ieterrninir~g regions (CDRs) of a mouse or other non-human antibody are grafted onto a human antibody framework. By human antibody framework is meant the entire human antibody excluding tt~e CORs.
L
The first step in the method of this invention is to choose a polypeptide having rigid secorxiary structure exposed to the surface of the polypeptide for display on the surface of a phage.
By'polypeptide' as used herein is meant any moleaale whose expression can be directed by a speafic DNA sequence. The pdypeptides of this irnenCan may comprise more than one subunit, where each subunit is erxoded by a separate DNA sequence.
By 'rigid secondary structure' as used herein is meant any polypeptide segment exhibiting a regular repeated structure suds as is found in; a-helices, 3t0 helices, ~c-helices, parallel and antiparallel ~-sheets, and reverse toms. Certain 'ran~rdered' structures that lade recognizable geometric order are also inducted in the definition of rigid secondary structure provided they form a domain or'patch' of amino add residues capable of interaction with a target and that the overall shape of the stnxture is not destroyed by replacement of an amino add within the structure . It is believed that some non-ordered structures are combinations of reverse toms. The geometry of these rigid secondary structures is well defined by ~ and ~r torsional angles about the a-carbons of the peptide 'backbone'.
The requirement that the secondary stnx~xe be exposed b the surface of the polypeptide is to provide a domain or'patch' of amino aad residues that can be exposed to and hind with a target molecule. It is primarily these amino add residues that are replaced by mutagenesis that form the 'library' of structurally related (mutant) Minding polypeptides that are displayed on the surface of the phage and from which novel 5 polypeptide ligands are selected. Mutagenesis or replacement of amino acid residues directed toward the interior of ~e polypeptide is generally avoided so that the overall stnxx~xe of the rigid secondary stnrcture is preserved.
Some replacement of amino acids on the interior region of the rigid secondary structures, especially with hydrophot~ic amino aad residues, may be tolerated sirxx these conservative substitutions are unlikely to distort the overall structure of the polypepGde.
The following discussion will be best understood by refemng 1o Figure t. In its simplest form, the method of the instant invention comprises a method for selecting novel binding polypeptides, such as protein ligands, having a desired, usually hgh, affinity for a target moleaaie from a library of structurally related binding polypeptides. The ktxary of structurally related polypeptides, fused to a phage coat protein, is produced by mutagenesis and, preferably, a single copy of each related polypeptide is d~sptayad on the surface of a phagemid particle containing DNA encoding that polypeptide. These phagemid particles are then contacted with a target molecule and those particles having the highest affinity for the target are separated from those of lower affinity.
The high affinity binders are then amplified by infection of a bacterial host and the competitive binding step is repeated. This process is reiterated until polypeptides of the desired affinity are obtained.
The novel Minding polypeptides or ligands produced by the method of this invention are useful per se as diagnostics or therapeutics ( eg. agonists or antagonists) used in treatment of biological organisms. Structural analysis of the selected polypeptides may also be used to fadlitate rational drug design.
By 'binding polypeptide' as used herein is meant any polypeptide that hinds with a selectable affinity to a target molecule. Preferably the polypeptide will be a protein that most preferably contains more than about 100 amino add residues. Typically the potypeptide wilt be a hormone or an antibody or a fragment thereof.
By 'high affinity' as used herein is meant an affinity constant (Kd ) of <t0'5 M and preferably <10'~M
under physiological conditions.
By 'target molecule' as used herein is meant any molecule, rot necessarily a prolein, for which it is desirable to produce a ligand. Preferably, however, the target will be a protein and most preferably the target will be a receptor, such as a hormone receptor.
By 'humanized antibody' as used herein is meant an antibody in wtych the complementarity~ieterrninir~g regions (CDRs) of a mouse or other non-human antibody are grafted onto a human antibody framework. By human antibody framework is meant the entire human antibody excluding tt~e CORs.
L
The first step in the method of this invention is to choose a polypeptide having rigid secorxiary structure exposed to the surface of the polypeptide for display on the surface of a phage.
By'polypeptide' as used herein is meant any moleaale whose expression can be directed by a speafic DNA sequence. The pdypeptides of this irnenCan may comprise more than one subunit, where each subunit is erxoded by a separate DNA sequence.
By 'rigid secondary structure' as used herein is meant any polypeptide segment exhibiting a regular repeated structure suds as is found in; a-helices, 3t0 helices, ~c-helices, parallel and antiparallel ~-sheets, and reverse toms. Certain 'ran~rdered' structures that lade recognizable geometric order are also inducted in the definition of rigid secondary structure provided they form a domain or'patch' of amino add residues capable of interaction with a target and that the overall shape of the stnxture is not destroyed by replacement of an amino add within the structure . It is believed that some non-ordered structures are combinations of reverse toms. The geometry of these rigid secondary structures is well defined by ~ and ~r torsional angles about the a-carbons of the peptide 'backbone'.
The requirement that the secondary stnx~xe be exposed b the surface of the polypeptide is to provide a domain or'patch' of amino aad residues that can be exposed to and hind with a target molecule. It is primarily these amino add residues that are replaced by mutagenesis that form the 'library' of structurally related (mutant) Minding polypeptides that are displayed on the surface of the phage and from which novel 5 polypeptide ligands are selected. Mutagenesis or replacement of amino acid residues directed toward the interior of ~e polypeptide is generally avoided so that the overall stnxx~xe of the rigid secondary stnrcture is preserved.
Some replacement of amino acids on the interior region of the rigid secondary structures, especially with hydrophot~ic amino aad residues, may be tolerated sirxx these conservative substitutions are unlikely to distort the overall structure of the polypepGde.
10 Repeated cycles of 'polypeptide' selection are used b select is higher and higher affinity binding by the phagemid selection of multiple amino add changes which are selected by multiple selection cycles. Following a first round of phagemid selection, involving a first region or selectan of amino adds in the ligand polypeptide, additional rounds of phagemid selection in other regions or amino acids of the ligand polypeptide are conducted.
The cycles of phagemid selection are repeated until the desired affinity properties of the ligand polypeptide are achieved. To illustrate this process, Example VIII phagemid selection of hGH
was conducted in cycles. In the first cycle h~H amino adds 172,174,176 arxf 178 were mutated and phagemid selected.
In a second cycle hGH amino aads 167,171,175 and 179 were phagemid selected. In a >fiird cycle hGH amino aads 10,14,18 and 21 were phagemid selected. Optimum amino add d~anges from a previous cycle may be irxorporated into the polypeptide before the next cycle of selection. For example, hGH amino adds substitution 174 (serine) and 176 (tyrosine) were irxorporated into the hGH belore the phagemid selection of hGH amino adds 167,171,175 and 179.
From the forgoing it will be appreaated that the amino add residues that form the binding domain of the polypeptide will not be sequentially linked and may reside on different subunits of the polypeptide. That is, the binding domain tracks with the particular secondary structure at the binding site and not the primary structure. Thus, generally, mutations will be introduced into colons erxoding amino acids within a particular secondary structure at sites directed away from the interior of the polypeptide so that they will have the potential to interact with the target. By way of illustration, Figure 2 shows the location of residues ~ hGH that are known to strongly modulate its binding to the hGH-binding protein (t,.tmrungham ef aL, Silence 247:1461-1465 [1990. Thus representative sites suitable for' mutagenesis word include residues 172, 174, t 76, and 178 on helix-4, as well as residue 64 located in a 'ran-ordered' secondary struchue.
There is no requirement that the polypeptide chosen as a Ggand to a target normally hind to that target.
Thus, for example, a glycoprotein hom~one such as TSH can be chosen as a Ggand for ~e FSH receptor and a litxary of mutant TSH molecules are employed in the method of Ibis invention to produce ravel drug candidates.
This invention thus contemplates any polypeptide that binds to a target molecule, and inGudes antibodies. Preferred polypeptides are those that have phartnaoeutical utUity.
More preferred polypeptides 3 5 include; a growth hamone, including human growth hormone, des-N~nethionyl human growth t~om~or>e, and bovine growth hormone; parathyroid hormone; thyroid stimulating hormone; thyroxine;
insulin A~hain; insulin B-drain;
proinsulin; follicle stimulating hormone; caldtoryn; IeuGnizing hormone;
glucagon; factor VIII; an antibody; lung surfactant; a plasminogen activator, such as urokinase or human tissue-type plasmiragen activator (t-PA);
bombesin; factor IX, thromt~in; hemopoietic growth factor; tumor nea~osis factor-alpha and -beta; enkephaGnase; a seem altxnnin such as txxnan senxn alt~urrun; mullerian-inhibiting substance;
r~ala~dn A~chain; r~elaxin B~hain;
prorelaxin; mouse gonadotropin-assoaated peptide;. a microbial protein, such as betalactamase; tissue factor protein; inhibin; activin; vascular endothelial growth factor; receptors for hormones or growth factors; integrin;
thrombopoietin; protein A or D; rheumatoid factors; nerve grvwrth factor such as NGF-~; platelet~lerived growth factor; filxoblast growth tailor such as aFGF and bFGF; epidermal growth factor; transforming growth factor (TGF) such as TGF-alpha and TGF-beta; insulin-like growth factor-I and -If;
insufiMike growth factor binding proteins; CD-4; DNase; laterxy assoaated peptide; eryftxopoietin;
osteoinductive factors; an interferon such as interferon-alpha, -beta, and -gamma; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF;
interleukins (ILs), e.g., IL-1, IL-2, IL-3, IL-4, etc.; superoxide dismutase;
decay accelerating factor; atria) nafiuretic peptides A, B or C; viral antigen such as, for example, a portion of the HIV ernebpe; immunogbt~ulins;
and fragments of any of the above-listed polypeptides. h addition, one or more predetermined amino acrd residues on the polypeptide may be substituted, inserted, or deleted, for example, to produce products with improved t~iological properties. Further, fragments of these polypeptides, espeaally bblogically active fragments, are inGuded. Yet more prefered polypeptides of this invention are human growth hormone , and atria) naturetic peptides A, B, and C, endotoxin, subtilisin, trypsin and other serine proteases.
Still more preferred are polypeptide hormones that can be defined as any amirp acid sequence produced in a first cell that hinds specifically to a receptor on the same cell type (autocrine hormones) or a second cell type (non-autocrine) and causes a physiological response characterisC~c of the receptor-bearing cell. Among such polypeptide hormones are cytokines, lymphokines, neurotrophic hormones and adenohypophyseal pdypeptide 2 0 hormones such as gowth hormone, prolactin, placental lactogen, luteinizing hormone, follicle-stimulating hormone, thyrotropin, cho~bnic gonadotropin, corticotropin, a or ~-melanocyte-stimulating hormone, ~-lipotropin, y-lipotropin and the endorphins; hypothatmic release-~tubit'rcg hormones such as corticotropin-release factor, growth hormone release-inhibiting hormone, growth hormone-release factor; and other polypeptide hormones such as atria) natriuretic peptides A, B or C.
IL
The gene encoding the desired polypeptide (i.e., a polypeptide with a rigid secondary structure) can be obtained by methods known in the art (see generally, Sambrook et al. , Molecular Biolygy~,aboratopr Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York (1989]). If the sequence of the gene is known, the DNA erxoding the gene may be chemically synthesized (Merfield.
,L.901.Sh~.s~G... 85 2149 (1963]). If the 3 0 sequerxe of the gene is not known, a it the gene has not previously been isolated, it may be domed from a cDNA
library (made from RNA obtained from a suitable tissue in which the desired gene is expressed) or from a suitable genomic DNA blxary. The gene is then isolated using an appropriate probe. For cDNA libraries, suitable probes inGude morador~al or polydonal antibodies (provided that the cDNA Gtxary is an expression litxary), oGgorwdeotides, and complementary or homologous cDNAs or fragments thereof.
The probes that may be used to isolate the gene of interest from genomic DNA libraries include cDNAs or fragments thereof that encode the same or a similar gene, tamobgous geramic DNAs a ONA tr~ments, and oligonudeotides.
Saeerwng the cDNA or genomic library with the selected probe is conducted using standard procedures as described in chapters 10-t 2 of Sambrook et al., supra.
M alternative means b isolating the gene encoring the protein of interest is b use polymerise chain reaction methodology (PCR) as described in section 14 of Samtxook et al., supra. This mettad requires the use of oligonudeotides that will hybridize to the gene of interest; thus, at least some of the DNA sequence for this gene must be known in order to generate the oligonudeotides.
After the gene has been isolated, it may be inserted into a suitab4e vector (preferably a plasmid) for ampl'rfication, as described generally in Sambrook et al., sera.
1f<.
While several types of vectors are available and may be used b practice this irnention, plasmid vectors are the preferred vectors for use herein, as they may be carrst<rxted with relative ease, and can be readily amplified. Ptasmid vectors generally contain a variety of components inducting promoters, signal sequences, phemtypc selection genes, origin of replication sibs, and other necessary oomponer>ts as are known to those of ordinary skill in the art.
Promoters most commonly used in prok~afic vedarsino~xie they Z promoter system, the alkaline phosphatase g~ A promoter, the bacd~pr~age ~ promorter to temperature sensitive promoter), the ~
promoter (a hybrid ~-j~ promoter #rat is regulated by the )~, repressor), the tryptophan promoter, and the bacteriophage T7 promoter. For general desaip~ons of promoters, see section 17 of Samtxook et al. supra .
While these are the most commonly used promote, other su~ie r~crobial promoters may be used as well.
Preferred promoters for practicing this inver~an arre (hose that can be tightly regulated such that expression of the fusion gene can be controlled, It is believed that the problem that went unrecognized in the 2 0 prior art was that display of multiple copies of the fusion protein on the surface of ifie phagemid partite lead to multipoint attachment of the phaga~id ~ the target. It is believed this effect, referred to as the 'chelate effect', results in selection of false high affrtrity' palypeptides den multiple copies of the fusion protein are displayed on the phagemid particle in dose proximity m errs a~oft~er so that the target was'chelated'. When multipoint attachment occurs, the effective or apparent Kd may be as high as the product of the individual Kds for each copy of the displayed fusion protein. This effect may be the reason Cwirta and coworkers supra were unable to separate moderate affinity peptides frorti higher affinity peptides.
It has been discovered that by tightly regulating expressan of the (usan protein so that no more than a minor amount, i.e. fewer than about 1%, of the ptragemid particles contain multiple copies of the fusion protein tire 'chelate effect' is overcome allowing proper selection of high affinity polypeptides. Thus, depending on the promoter, culturing conditions of tire host are adjusted b maximize the number of phagemid particles containing a single copy of fhe fusion protein and minimize the number of ptragemid partiGes containing multiple copies of the fusion protein.
Preferred promoters used b practice this invention are the j~ Z promoter and the p~ A promoter.
The (~ Z promoter is regulated by the tic repressor protein 1~ i, and thus transcription of the fusion gene can be controlled by manipulation of the level of the lac repressor protein. By way of ilustration, the phagemid containing the )~ Z promotor is grown in a cea strain that contains a copy of the J~ i repressor gene, a repressor for the )~ Z promobr. Exemplary cell strains containing the j~ i gene irrdude JM 101 and XL1-blue. In the alternative, the host cea can be cotranstected with a plasmid contairrirrg both the repressor j~ i and the ~ Z promobr.
Occasionally both of the above techniques are used simultaneously, that is, phagmide particles containing the l~ Z
promoter are groan in cell strains contairunp the ,~ i gene and the ce1 strains are cotransfected with a plasmid oontairwnp both the ~ Z and )~ t genes. Normally when one wishes b express a gene, b the transfected host above one would add an induoer such as isopropylthiogalacbside (IPTG). h the present invention however, tfys step is omitted to (a) minimize the expression of the gene III fusion protein thereby minimizing the copy number (i.e. the ru~mben of gene III fusans per phagemid rxunber) and b (b) prevent poor or improper packaging of the phagemid caused by induoers such as IPTG even at k>w concer>trations.
Typcally, when no inducer is added, the number of fusion proteins per phagemid particle is about 0.1 (number of bulk fusion proteinslnumber of phagemid particles). The most preferred promoter used b pr~dctice this invention is ~
A. Ttws promoter is believed to be regulated by the level of inorganic phosphate in the cell where the phosphate acts to down-regulate the activity of the promoter. Thus, by depleting cells of phosphate, the activity of the promoter can be increased. The desired result is achieved by growing cells in a phosphate enridied medium such as 2n or l.8 (hereby controlling the expression of the gene III fusion.
One other useful component of vectors used to practice ttys invention is a signal sequence. This sequence is typcally located immediately 5' to the gene encoding the fusion protein, and will thus be transcribed at the amino terminus of the fusion protein. However, h certain cases, the signal sequerxe has been demonstrated to be located at positions other 5' to the gene encoding the protein to be secreted. This sequence targets the protein to which it is attad>ed across the inner membrane of the bacterial cell. The DNA
encoding the signal sequerxe may be obtained as a restriction endonuGease fragment hom any gene encoding a protein that has a signal sequence.
Salable prokaryotic signal sequerx~s may be obtained from genes encoding, for example, l.amB or OmpF (along et aL, ~, 68:193 [1983)), MaIE, PhoA and otter genes. A preferred prokaryotic signal sequence for practiclng this invention is the E. colt teat-stable enterotoxin II (STU) signal sequence as described by Chang et al. , Wig, 55: 189 [1987).
Another useful component of the vectors used to pract'~ce this invention is phenotypic selection genes.
Typical phenotypic selection genes are those encoding proteins that confer antibiotic resistance upon the host cell.
By way of illustration, the ampicillin resistance gent; (~), and the tetracycline resistance gene (I~ are readily empbyed for this prxpose.
Construction of suitable vectors comprising the aforementioned components as wen as the gene encoding the desired polypeptide (gene 1 ) are prepared using standard recombinant DNA
procedures as described in Sambrook et aL supra. Isolated DNA fragments to be combined b form the vector are cleaved, tailored, and ligated together h a spedfic order and orientation to generate the desired vector.
The DNA is cleaved using the appropriate restriction enzyme or enzymes h a suitable buffer. In general, about 0.2-1 ~g of plasmid or DNA fragments is used with about 1-2 units of the appropriate restriction eruyme in about 20 ~( of buffer solution. Appropriate buffers, DNA concentrations, and hcubation times and temperatures are sped6ed by the manufacturers of the restriction enzymes.
Generatiy, incubation times of about 3 5 one or two tours at 3TC are adequate, alttough several enzymes require higher temperatures. After incubation, the enzymes and other cor~aminants are removed by extraction of the dgestion solution with a mixture of phenol and d~lorofarm, and the DNA is recovered from the aqueous fraction by precipitation with ethanol.
To ligate the DNA fragments together to town a functional vector, the ends of the DNA fragments must be compatible with each other. h some cases, the ends w~ be dred~y compatible after erKiorwdease digestion. However, it may be necessary to first convert the sticky ends commoMy produced by endonuGease digestan b blunt ends ~o make them compatible for kgatan. To Bunt tt~e ends, the DNA is treated in a suitable buffer for at least 15 minuDes at 15'C with 10 units of of the Klenow fragment of DNA polymerase I (Klerpw) in the presence of the four deoxynudeotide triphosphates. The DNA is then purified by phenol-d>toroform extraction and ethanol predpitatbn.
The cleaved DNA fragments may be size-separated and selecl3ed using DNA gel electrophoresis. The DNA may be electrophoresed through either an agarose or a potyacrylamide matrix. The selection of the matrix will depend on the size of the DNA fragments to be separated. After electrophoresis, the DNA is extracted from the matrix by eledroewtion, or, if bw~nelting agarose has been used as the matrix, by melting the agarose and extracting the DNA from it, as described in sections 6.30-6.33 of Sambrook et aL, supra.
The DNA fragments that are to be ligated together (previously digested with the appropriate restriction enzymes such that the ends of each fragment to be ligated are compatible) are put in solution in about equimotar amounts. The solution will also contain ATP, Ggase buffer and a ligase such as T4 DNA lipase at about 10 units per 0.5 up of DNA. If the DNA fragment is to be ligated into a vector, the vector is at first linearized by cutting with the appropriate restriction erxionudease(s). The linearized vector is then treated with alkaline phosphatase or calf intestinal phosphatase. The phosphatasing prevents self-ligatbn of the vector during the ligation step.
After ligation, the vector with the foreign gene now inserted is transformed into a suitable host cell.
Prokaryotes are the preferred host cells for this invention. Suitable prokaryotic host cells include E. colt strain JMlOt, E. colt K12 strain 294 (ATCC number 31,446), E. colt strain W3110 (ATCC
number 27,325), E. colt X1776 (ATCC numt~er 31.537), E. colt XL-1 Blue (stratagene), and E. colt B;
however many other strains of E.
colt, such as HBt0l; NM522, NM538, NM539, and many other speaes and genera of prokaryotes may be used as well. in addition to the E. colt strains listed above, bacilli such as ~, other enterobacteriaceae such as Salmonella iwhimurium a and various p,~.t,~~ speaes may all be used as hosts.
Transformation of prokaryotic cells is readily accomplished using the caldum d~loride method as described in section 1.82 of Sambrook et aL, supra. Alternatively, electroporation (Neumann et al., E_mB0 J..
1:841 [1982)) may be used to transform these cells. The transformed cells are selected by growth on an antitrotic, commonly tetracycline (tet) or ampidtlin (amp), to which they are rendered resistant due to the presence of let andlor amp resistance genes on the vecxor.
After selection of the transformed cells, these cells an; grown in a~ture and the plasmid DNA (or other vector with the foreign gene inserted) is then isolated. Ptasmid DNA can be isolated using methods known in the art. Two suitable methods are the small scale preparation of DNA and the large-scale preparation of DNA as described in sedans 125-1.33 of Sambrook e! al., supra. The isolated DNA can be purified by methods known in the art such as Ihat described in section 1.40 of Sambrook etal., supra. This purified plasmid DNA is then analyzed by restriction mapping andlor DNA sequendng. DNA sequendng is generally performed by either the method of Messing et al. 9309 [1981) or by the method of Maxam et aL Meth.
Ep~j" 65:
499 [1980].
11I.
This invention contemplates fusing the gene enclosing the desired polypeptide (gene 1 ) to a second gene (gene 2) such that a fusion protein is generated during transcription. Gene 2 is typically a arat protein gene of a phage, and preferably it is the phage M13 gene III coat protein, or a fragment thereof. Fusan of genes 1 and 2 may 5 be aa~omplished by inserting gene 2 into a partia~lar site on a plasmid that a~ntains gene 1, or by inserting gene t into a particular site on a plasmid that contains gene 2.
Insertion of a gene into a plasmid requires that the plasmid be cut at the precise kxafion that the gene is to be inserted. Thus, (here must be a restriction endonudease site at this bcation (preferably a unique site such that the plasmid will only be cut at a single location during restriction endonudease digestion). The plasmid is 10 digested, phosphatased, and purified as described above. The gene is then inserted into this ~nearized plasmid by Igating ttie two DNAs together. Ligation can be aa~mplished if the ends of the plasmid are compatible with the ends of the gene to be inserted. If the restrictan enzymes are used b cut the plasmid and isolate the gene to be inserted create blunt ends or compatible sticky end s, the DNAs can be ligated together directly using a lipase such as bacteriophage T4 DNA lipase and incubating the mixture at 16'C for 1-4 hours in the presence of ATP
15 and lipase buffer as described in section t .68 of Samtxook et al., ~. If the ends are not compatible, they must first be made blunt by using the benow fragment of DNA polymerase I or bacteriophage T4 DNA polymerase, both of which require the tour deoxyribonudeotide triphosphates to fill-in ovefianging single-stranded ends of the digested DNA. Alternatively, the ends may be Bunted using a nuclease such as nuclease St or mung-bean nuGease, both of which function by cutting back the overhanging single strands of DNA. The DNA is then religated using a lipase as described above. In some cases, it may not be possible to blunt the ends of the gene to tie inserted, as the reading frame of the coding regGm will be altered. To overcome this problem, oligonuceotide linkers may be used. The linkers serve as a bridge to connect the plasmid to the gene b be inserted. These linkers can be made synthetically as double stranded or single stranded DNA using standard methods. The linkers have one end that is compatible with the ends of the gene to be inserted; the linkers are first ligated to ttus gene using ligation methods described above. The other end of the linkers ~s designed to be compatible with the plasmid for ligation. In designing the linkers, care must be taken to not destroy the reading frame of the gene to be inserted or the reading frame of the gene contained on the plasmid. In some cases; it may be necessary 6o design tt~e linkers such that they aide for part of an amino acrd, or such that fey code fa one or more amino acds.
Between gene 1 and gene 2, DNA erxodirg a termination axion may be inserted, such termination oodons are UAG( amber), UAA (ocher) and UGA (opal). (Microbiology, Davis et al.
Harper & Row, New York,1980, pages 237, 245-47 and 274). The termination a>don expressed in a wild type host cell results in the synthesis of the gene 1 protein product without the gene 2 protein attached. However, growth in a suppressor host cell results in the synthesis of detectable quantities of fused protein. Such suppressor host tens contain a tRNA
modified to insert an amino acrd in the terminatan a~don positan of the mRNA
thereby resulting in production of detectable amounts of the fusion protein. Such suppressor host cells are well known and described, such as E.coJi suppressor strain (Bullock et al., BioTechniaues 5, 376-379 [1987]). My aaeptable method may be used to place such a termination a~don into the mRNA erxoding the fusion polypeptide.
The suppressible aKion may be inserted between the first gene encodinD a polypeptide, and a second gene ena>ding at least a portan of a phage a~at protein. Aftematively, the suppressible termination a~don may be inserted adjacent to the fusion site by replacing the last amino acid ~ipiei in the polypeptide or the first amino acrd in the phage coat protein. When the phagemid containing the suppressible colon is grown in a suppressor host cell, it results in the detectable production of a tusan polypeptide containing the polypeptide and the coat protein. When the phagemid is grown in a non-suppressor host cell, the polypepiide is synthesized substantially without fusion b the phage coat protein due to termination at the inserted suppressible triplet encoding UAG, UAA, or UGA. In the non-suppressor cell the polypeptide is synthesized and secreted from the host cell due to the abserxe of the fused phage coat protein which otherwise anchored it to the host cell.
v.
Gene 1, encoding the desired polypeptide, may be altered at one or more selected colons. M alteration is defined as a substitutan, deletion, or insertion of one or more colons h the gene encoding the polypeptide that results in a change in the amino acrd sequence of the polypeptide as compared with the unaltered or native sequence of the same polypeptide. Preferably, the alterations will be by substihrtion of at least one amino acrd with any other amino acrd in one a more regions of the molecule. The alterations may be produced be a variety of methods known in the art. These methods include but are not limited to oligonudeotide-mediated mutagenesis and cassette mutagenesis.
A ~11~Ld Oligonudeotide -mediated mutager~esis is preferred method for preparing substitution, deletion, and insertion variants of gene t . This technique is well known in the art as described by Zoller et al. Nucleic Aads Res.
IQ: 6487~5tM (1987(. Briefly, gene 1 is altered by hytxidizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of the plasmid containing the unaltered or native DNA sequence of gene 1. After hytxidization, a DNA polymerise is used to synthesize an entire second complementary strand of the template will Ihus incorporate the oligonudeotide primer, and will code for the selected alteration in gene 1.
Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonudeotxie will have t2 to t5 nucleotides that are completely complementary to the template on either side of the nudeotide(s) coding for the mutation. This ensures that the oligonudeotide win hytxidize properly to the single-stranded DNA
template molecule. The oligorxxteotides are readily synthesaed using techniques known in the art such as that described by Crea et al. Proc. Natl. Aca,~. Sd. U,~ 75: 5765 (1978).
The DNA template can only be generated by those vectors that are either derived from bacteriophage M13 vectors (the commerclally available Mt3mp18 and M13mp19 vectors are suitable), or those vectors that contain a single-stranded phige origin of replication as described by Y~era ef aL Meth. Enz~ 153: 3 (1987).
Thus, the DNA that is to be mutated must be inserted into one of these vectors in order to generate single-stranded template. Production of the single-stranded template is described in sections 4.21-4.41 of Sambrook et a)., supra.
To alter the native DNA sequence, the aligonucleotide is hytxidized to the single s6~anded template under suitable hytxidization conditions. A DNA polymerizing enzyme, usually the Klerbw fragment of DNA
polymerise I, is then added to synthesize the complementary strand of the template using the ol'gonudeotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of gene 1, and the otter strand (the original template) encodes the native, unaltered sequence of gene 1.
Ttws heTeroduplex mote~e is then transformed inb a suitable host Celt, usually a prokaryote such as E. Colt JM101. After growi~ the cells, they are plated onb agarose plates and screened using the oGgonudeotKie primer radiolabelled with 32-Phosphate to identify tte bacterial colonies that contain the mutated DNA.
The melfwad described immediabety above may be modified such that a homoduplex molecule is created wherein Moth strands of the plasmid contain the mutation(s). The modifications are as follows: The single-stranded oGgonucleotide is annealed to the single-stranded template as described above. A mixhue of three deoxyribonudeotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribofhymidine (dTTP), is combined with a mo~fied thio~deoxyrit~ocybsine called dCTP-(aS) (which can be obtained from Amersham).
This mixture is added to the template-oligonudeotide complex. Upon addition of DNA potymerase to this mixture, a strand of DNA identical b the template except for the mutated bases is generated. h addition, this new strand of DNA will contain dCTP-(aS) instead of dCTP, wtwch serves to protect it from restriction endonudease digest'bn. After the template strand of tte double-strarxied heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with Exolll nuclease or another appropriate nuclease past the region that contains the sites) to be mutageruzed. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA
polymerase in the presence of alt tour deoxyribonucVeotide triptosphates, ATP, and DNA ligase. This homoduplex molecule can then be transformed into a suitable host cell such as E. colt JM101, as described above.
Mutants with more than one amino acid to be subs6d~ted may be generated in one of several ways. If the amino acids are located dose together in the pdypeptide chain, they may t~e.mutated simultaneously using one 2 0 oligonuGeotide that codes for all of the desired amino acid substitutions.
B, fio~wever, the amino aads are located some distance from each otter (separated by more than about ten amino adds), it is more difficult to generate a single ofigonudeotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.
In the first method, a separate oligonudeotide is generated for each amino add to be substituted. The oligonudeotides are then annealed to the single-stranded template DNA
simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acrd substitutions. The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oGgonudeotide encoding the first desired amino acrd substitutan(s) is annealed b this template, and the heteroduplex DNA molea~le is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, ttxs template already contains one a more mutations. The oGgonudeotide encoding the additional desired amino acid substitutions) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the >;rst and second rounds of mutagenesis. This resultant DNA
can be used as a Template in a tturcl round of mutager~esis, and so an.
3 5 B.
This method is also a preferred method for preparing substitution, deletion, and insertion variants of gene t . The method is based on that described by Wells et aL ~,, 34:315 (1985].. The starting material is tt~e plasmid (or other vector) comprising gene 1, the gene to be mutated. The cadon(s) in gene 1 To be mutated are identified. There must be a unique restrictan erxionudease site on each side of the identified mutation site(s). It ra such restriction sites exist, they may be generated using the abov~e~esaibed oligonudeotide-mediated mutagenesis method b infroduoe them at appropriate locations in gene t. After the restriction sites have been inbroduoed into the plasmid, the plasmid is cut at these si6es b linearize d.
A double-stranded oligonudeotide encoding the sequence of the DNA between the restriction sites but contair>ing the desired mutations) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oGgonudeotide is referred b as the cassette. This cassette is designed to have 3' and 5' ends that are campatide with the ends of the lineartzed plasmid, such that it can be directly Igabed b the plasmid. This plasmid now contains the mutated DNA sequence of gene 1.
VI.
i 0 M an alternative embodiment, this invention contemplates produr~on of variants of a desired protein containing one a more subunits. Each subur~t is typic~lfy encoded by separate gene. Each gene encoc~ng each subunit can be obtained by methods krbwn in the art (see, for example, Section II). In some instances, it may be necessary to obtain the gene erxoding the various subunits using separate techniques selected from any of the methods described in Section II_ When constructing a replicable expression vector where the protein of interest contains more than one subunit, all subunits can be regulated by the same promoter, typically located 5' to the DNA encoding the subunits, or each may be regulated by separate promoter suitably oriented in the vector so that each promoter is operably linked to the DNA it is intended to regulate . Selection of promoters is carried out as described in Section Ill above.
In constructing a replicable expression vector containing ONA encoding the protein of interest having multiple subunits, the reader is referred to Figure 10 where, by way of illustration, a vector is diagrammed showing DNA encoding each subunit of an antibody fragment. This figrxe shows that, generally, one of the subunits of the protein of interest will be fused to a phage caat protein such as Mt3 gene III. This gene fusion generally w~l contain its own sgnal sequence. A separate gene encodes the other subunit or suburyts, and it is 2 5 apparent that each suburyt generally has its own signal sequence. Fgure 10 also shows that a single promoter can regulate the expression of both subunits. Alternatively, each subunit may be independently regulated by a different promoter. The protein of interest subunit-phage coat protein fusion construct can be made as described in Section N above.
When constructing a family of variants of the desired multi-subunit protein, DNA encoding each subunit 3 0 in the vector may mutated in one or more positans in each subuNt When mufti-subunit antibody variants are constructed, preferred sites of mutagenesis correspond b colons encoding amino acrd residues located in the comptementarity~letennining regions (CDR) of either the light chain, the heavy chain, or both chains. Tt~e CDRs are commonly referred to as the hypervariable regions. Methods for mutagenizing DNA encoding each subunit of the protein of interest are conducted essentially as described in Section V
above.
VII.
Target proteins, such as receptors, may be isolated from natural sources or prepared by recombinant methods by procedures known in the art. By way of illustration, glycoprotein hormone receptors may be prepared by the technique described by McFariand et al., 245:494-499 [1989], nonglycosylated forms expressed in E. ooli are described by Fuh et al. J. Biol. Chem 265:3111-3115 (1990) Other receptors can be prepared by standard methods.
The purified target protein may be attad~ed to a suitable matrix such as agarose beads, aaylamide beads, glass beads, celhiose, various acrylic copolymers, hydroxytalkyl methacrytate gels, polyacrylic and polymethacrylic copolymers, nylon, neutral and ionic; tamers, and the Yke.
Attad~ment of the target protein to the matrix may be accomplished by methods desa~ibed in jp,Ep~l~ 44 [1976), a by other means known in the art.
After attachment of the target protein to the matrix, the immot~ilized target is contacted with the library of phagemid particles under conditions suitable for binding of at least a portbn of the phagemid particles with the immobilized target. Normally, the conditions, including pH, ionic strength, f0emperature and the Gke will mimic physiological conditions.
Bound phagemid particles ('tHnders') having high af6rity for the immobilized target are separated from those having a low affinity (and thus do not hind to the target) by washing. Binders may be dissoclated from the immobilized target by a variety of methods. These methods inGude competitive dissodation using the wild-type ligand, altering pH andlor ionic strength, and mettx>ds known in the art.
Suitable host cells are infected with the birxlers and helper phage, and the host cells are cultured under conditions suitable for amplification of the phagemid particles. The phagemid particles are then collected and the selection process is repeated one or more times until binders having tt~e desired affinity for the target molecule are selected.
Optionally the library of phagemid particles may be sequentially contacted with more than one immobilized target to improve selectivity for a particx~lar target. For example, it is often the case that a ligand such as hGH has more than one natural receptor. In the case of hGH, both the growth hormone receptor and the prolactin receptor bind the hGH ligand. ft may be desirable to improve the selectivity of hGH for the growth hormone receptor over the prolactin receptor. This can be ad>ieved by first contacting the library of phagemid particles with immotHlized prolactin receptor, eluting those with a low affinity (i.e. lower than wild type hGH) for the prolactin receptor and then contacting the bw affinity proladin 'binders' or non-binders with the immobilized growth hormone receptor, and selecting for high affinity growth hormone receptor hinders. In this case an hGH mutant having a bwer affinity for the prolactin receptor would have therapeutic utility even if the affinity for the growth hormone receptor were somewhat bwer than that of wild type hGH. This same strategy may be employed to improve selectivity of a particular hormone or protein for its primary function receptor over its clearance receptor.
In another embodmer>t of this invention, an improved substrate amino add sequence can be obtained.
These may be useful for making better 'cut sites' for protein linkers, or for better protease substrateslnhibitors. h this embodiment, an immobilizable molecule (e.g. hGH-receptor, biotin-avidin, or one capable of covalent linkage with a matrix) is fused D~ gene tll through a linker. The tinker will preferably be from 3 to 10 amino adds ~ length and will ad as a substrate for a protease. A
phagemid will be constructed as described above where the DNA encoding the linker region is randomly mutated to produce a randomized library of phagemid particles with different amino acid sequerxes at the linking site. The litxary of phagemid particles are then immobilized on a matrix and exposed to a desired protease. Phagemid particles having preferred or better substrate amino add sequences in tte liner region trx the desifed protease W~I
be efubed, first producing an enridied pool of phagemid particles erxoding pfeferred inkers. These phagemid particles are then cycled several more times to produce an erricted pool of particles encoding aonsense sequenoe(s) (see examples XIII and XIV).
vlU.
5 The doped gene for hGH has been expfessed in a seaebed lam in g~ (Chang, C.
t~b, et aL, (1987] ~~189) and its DNA and amino acrd sequence has been reported (Goeddel, etal. (1979] ~gy,$1, 544; Gray et al., (1985] ~ ~,q, 247). The pfesent irnention describes novel hGH variants produced using the phagemid selection methods. Human growth hormo«e variants containir~
substitutions at positions 10, 14, 18, 21, 167,171,172, 174,175,176,178 and 179 have been described. Tfbse having higher dr>ding affinities are 10 described in Tables VII, XIII and XIV. The amino add nomenclature for describing the variants is shown below.
Growth fbrmone variants may be administered and (cumulated in ~e same mamer as fegular growth hormone. The growth hormone variants of the present invention may be expfessed in any recoml~ir~ant system which is capable of expressing native or met hGH.
Therapeutic formulations of hGH for therapeutic administration are prepared for storage by mixing 15 hGH having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers ($~09ton's Pharmace~cal SciE;~~, 16th edition, Osol, A, Ed., (1980)., in tf~e form of lyophilized cake or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, atrate, and other organic acids; antioxidants including ascorbic acid; bw molecular weight (less than about 10 residues) polypeptides; proteins, such as serum 20 albumin, gelatin, or immunoglobulins: hydrophilic polymers such as polyvinylpyrolidone; amino acids such as ~ycine, glutamine, asparagine, arginine, or lysine; monosacd~arides, disaccharides, and other carbohydrates including glucose, mamose, or dextrins; d~elating agents such as EDTA; divalent metal ions such as zinc, cobalt or copper;
sugar alcohols such as mamitol or sorbitol; salt-forming countefions such as sodium; arxilor nonionic surfactants such as Tween,' Pluronics a polyethylene glycol (PEG). Formulations of the present invention may additionally contain a pharmaceutically acceptable buffer, amino add, bu~Cing agent andlor non-ionic surfactant. These include, for example, tx~ffers, d~elating agents, antioxidants, preservatives, cosotvents, and the like; speafic examples of these could include, trimethylamair~e salts ('iris buffer'), and disodium edetate. The phagemids of the present invention may be used to produce quantities of the hGH variants tree of t#~e phage protein. To express hGH
variants flee of the gene III portion of the fusion, pS0643 and derivatives can simply be grown in a non-suppressor strain such as 1609. In this case, the amber colon (TAG) leads to ~rmination of translatan, which yields free hormone, without tt~e need for an independent DNA constnxtion. The hGH variant is secreted from the host and may be isolated from the culture medium.
One or more of the eight hGH amino adds F10, Mt4, H18, H21, 8167, D171, T175 and 1179 may be repel by any amino add other than the one found in that position in naturally occurring hGH as indicated. Therefore, t , 2, 3, 4, 5, 6, 7, or all 8 of the irxiicated amino aads, F10, M14, H18, H2t, 8167, D171, T175 and 1179, may be replaced by any of the otter 19 amino aads out of the 20 amino cads listed below. ~ a preferred embodiment, all eight listed amino aads are replaced by another amino add. The most preferred eight amino aads to be substituted are indicated in Table XIV in Example XII.
"trademark Mino add nab ~ (A) Arg (R) Asn (N) ~P (Q) Cys (C) Gln (D) Glu (E) Gly (G) His (H) (1e (I) Leu (L) Lys (K) Met (M) Phe (F) Pro (P) Ser (S) Thr (T) Trp (W) Tyr (Y) Val (1n The one letter hGH variant nomenclature first gives the hGH amino acrd deleted, for example glutamate 179; then the amino acrd inserted; for example, serine; resulting in (E1795S).
EXAMPLES
Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and illustraCrve examples, make and uti~ze the present invention to the fullest extent. The following working examples therefore spedfically point out preferred embodimertts of the present invention, and are not to 3 0 be constn~ed as limiting in any way of the remainder of the disclosure.
EXAMPLE I
Plasm(d Cor~wcfloris and Preparation of hGH-phagemtd ParSdes The plasmid phGH-Ml3glll (F~g.1), was constructed from M13K077 and the hGH
produdng pfasmid, pB0473 (Cunningham, B. C., et al. , , 243:1330-1336, [1989]). A synthetic oligonucteotide 5'-AGC
TGT-GGC-TTC-~~GG-CCC-TTA-GCA-TTT-AAT-C~CG~TA-3' was used to introduce a unique Apal restriction site (underlined) into pB0473 after the final Phe191 colon of hGH.
The oligonudeotide 5'-TTC-ACA-AAC-GAA-~CCC-CTA-ATT-AAA-GCC-AGA-3' was used to irnroduoe a unique Apal restriction site (underlined), and a GIu197-to-amber stop colon (bold lettering) into M13K07 gene III. The oligonudeotide 5'-CAA-TAA-TAA-CGG-GCTAGC-CAA-AAG-AAC-'TGG-3' introduces a unique Nhel site (underlined) after the 3' end of the gene III coding sequence. The resulting 650 vase pair (bp) Apal-Nhel fragment from the doubly mutated M13K07 gene III was doped into the large Apal-I~el fragment of pB0473 to aeate the plasmid, pS0132. This fuses the carboxyl terminus of hGH (Phel9t) b the Pro198 residue of the gene III protein with the insertion of a glydne residue encoded from the Apal site and places the fusion protein under control of the E. coli alkaline phosphatase (ptaA) promoter and stll secretan signal sequence (Chang, C. N., et al. , ~, 55:189-196, (1987]). For indudble expression of the fusion protein in rich media, we replaced the phoA promoter with the lac promoter and operator. A 138 by EcdRl-XXl~aal fragment captaining the lac promoter, operator, and Cap binding site was produced by PCR of plasmid pUC119 using the oligonudeotides 5'-CACGACA~CCGACTGGAAA-3' and 5'-CTGTT TCTAGAGTGAAATTGTTA-3' that flank the desired lac sequences and introduce the EcoRl and Xbal restriction sites (underlined).
This tac fragment was gel purified and ligated into the large EcoRl-Xbal fragment of pS0132 to aeate the plasmid, phGH-Ml3glll. The sequences of all tailored DNA junctions were verified by the dideoxy sequence method (Sanger, F., et al. Proc. Natl. Acad.
Sci. U.S.A. 74:5463-5467, [1977]). The R64A variant hGH phagemid was constructed as follows: the Nsil-Bglll mutated fragment of hGH (Cunninghamet al. supra ) encoding the Arg64 to Ala substitution (R64A) (Cunningham, B. C., Wells, J. A., ~jgp~., 244:1081-1085, (1989)) was doped between the corresponding restriction sites in the phGH-Ml3glll plasmid (Fig. 1) b replace the wild-type hGH sequence. The R64A hGH
phagemid particles were propagated and titered as desait~ed below for the wild-type hGH-phagemid.
Plasmids were transformed into a male strain of E. coti (JM tOt ) and selected on carbenidllin plates. A
single transformant was grown in 2 ml 2n medium for 4 h at 3TC and infected with 50 W of M13K07 helper phage. The infected culture was diluted into 34 ml 2YT, grown overnight, and phagemid particles were harvested by predpitation with polyethylene glycol (terra, J., Messing, J. ,methods in EpZymoloav,153:3-11, [1987]).
Typical phagemid particle titers ranged from 2 to :i x 1011 cfulml. The particles were purified to homogeneity by CsCI density centrifugation (Day, L.A. ." 3965-277, (1969]) to remove any fusion protein not attadied to virions.
trrrxnod>err~Cal Analyses d hGti on the Fuslan Pte Rabbit polydonal antibodies to hGH were purified with protein A, and coated onto miaotiter plates (Nunc) at a concentration of 2 Rg/ml in 50 mM sodium carbonate buffer (pH 10) at 4'C for 16-20 hours. After washing in PBS containing 0.05°k Tween 20, hGH or hGH-phagemid particles were serially diluted from 2.0 -0.002 nM in buffer A (50 mM Tris (pH 7.5), 50 mM NaCI, 2 mM EDTA, 5 mglml bovine serum albumin, and 0.05%
Tween 20). After 2 hours at room temperature (rt), the plates were washed well and the indicated Mab (Cunninghamet aL supra ) was added at 1 ~ghnl in buffer A for 2 fours at rt.
Following washing, horseradish perox~dase conjugated goat anti-mouse IgG antibody was bound at rt br 1 hour.
After a final wash, the peroxidase activity was assayed with the substrate, o-phenylenediamine.
Coupling d the hGH Blndng Protefn to Pdyaaytarrrfde Beads and Bfndinp Errichments Oxirane polyaaylamide beads (Sigma) were conjugated to the purified exi<acenular domain of the hGH
receptor (hGHbp) (Fuh, G., et al., ,(,~j~,m" 265:31 11-3115 (1990]) containing an extra cysteine residue introduced by site-directed mutagenesis at position 237 that does not affect binding of hGH (J. Wells, unpublished). The hGHbp was corrugated as recommended by the supplier b a level of 1.7 pmol hGHbplmg dry oxirane bead, as measured by birxing of (125fj hGH b the resin. S~equently, any unreacted o~orane groups were blocked with BSA and Tris. As a control for non-spedfic binding of phagemid particles, BSA was similarly coupled to the beads. Buffer for adsorption and washing contained 10 mM
TrisHCl (pH 7.5),1 mM EDTA, 50 mM
Na Cl, t mg~ml BSA, and 0.02° Tween 20. Elutan t~uffers contained wash buffer plus 200 nM hGH or 0.2 M
glycine (pH 2.1 ). Parental phage M 13K07 was mixed with hGH phagemid particles at a rata of nearly 3000:1 (original mixture) and tumbled for 8-12 h with a 5 W abquot (0.2 mg of aaylamide beads) of either absorbent in a 50 ~I volume at room temperature. The beads were peNeted by centrifugation and the s~emate carefully removed. The beads were resuspended in 200 pJ wash buffer and tumbled at room temperature for 4 hours (wash 1 ). After a second wash (wash 2), the beads were eluted twice with 200 nM hGH for E10 hours each (eluate 1, eluate 2). The final elution was with a glyc~r~e buffer (pH 2.1 ) for 4 hours to remove remaining hGH
phagemid particles (eluate 3). Each fraction was diluted appropriately in 2YT
media, mixed with fresh JM101, incubated at 3TC for 5 minutes, and plated with 3 ml of 2n soft agar on LB or LB carbenicllin plates.
EXAMPLE IV
Coral ctlon of hGH-phagemld Parlides wtth a Mixture of Gene Ill Products The gene III protein is composed of 410 residues divided into two domains that are separated by a flexible Hnker sequence (Armstrong, J., et al., F BS Lett..135:167-172, [1981]). The amino-terrnir~al domain is required for attachment to the pill of E. coil, while they carboxyl-terminal domain is imbedded in the phage coat and required for proper phage assembly (Crissman, J. W., Smith, G. P., Yiroloav.
132:445-455, (1984]). The signal sequence and amino-terminal domain of gene III was replaced with the stll sigr~al and entire hGH gene (Chang et al.
supra) by fusion to residue 198 in the carboxyl-terminal domain of gene III
(Fg.1 ). The hGH-gene III fusion was placed under control of the lac promoterloperator in a plasmid (phGH-Ml3glll;
Fg. 1) containing the pBR322 ~-tactamase gene and Col Et replication origin, and ft~e phage f1 intergenic region. The vector can be easily maintained as a small plasmid vector by selection on c;arber>iallin, which avoids relying on a functional gene III fusion for propagation. Alternatively, the plasmid can be effidently packaged into virions (called phagemid particles) by infection with helper phage such as M13K07 (Y~era ef aL. supra ) which avoids problems of phage assembly.
Phagemid infectivity titers based upon transduction to carbenadllin resistanxe in this system varied from 2-5 x 101 lcobny forming units (ctu)/ml. The fiber of the M13K07 helper phage in these phagemid stocks is -1010 plaque forming units (pfu)/ml.
With this system we confirmed previous stud'~es (Partnley, Smith supra) that homogeneous expression of large proteins fused to gene III is deleterious to phage production (data not shown). For example, induction of the lac promoter in phGH-Ml3glll by addition of IPTG produced low phagemid titers.
Moreover, phagemid particles produced by co-infectan with Mt3K07 containing an amber mutation in gene III
gave very low phagemid tfters (<1010 ctuJml). We believed that multiple copies of the gene III fusion attadied to the phagemid surface could lead to multiple point attachment (the 'chelate effect') of the fusion phage to the immobilized target protein.
Therefore to control the fusion protein copy number we limited transaiption of the hGH-gene III fusion by culturing the plasmid in E. coil JMlOt (lacy which krontains a constitutively high level of the lac repressor protein.
The E. cbli JM101 cultures containing phGH-M13g111 were best propagated and infected with M13K07 in the abserxe of the lac operon inducer (IPTG); however, this system is flexible so that co~xpression of other gene III
tusan proteins can be balanced. We estimate that about t0% of the phagemid particles contain one copy of the hGH gene III fusion protein from the ratio of tt~e amount of hGH per virion (based on hGH immurb-reactive material in CsCI gradient pur'rfied phagemid). Therefore, the titer of fusion phage displaying the hGH gene III fusion is about 2 - 5 x 1010hn1. This numt~er is much greater than the titer of E. c~oli (~108 b 1091m1) in the culture from which they are derived. Thus, on average every E. cvG ceu produces 10-100 copies of phage decorated with an hGH gene III fusion protein.
EXAMPLE V
Structural Irttegrlty of the hGfi~ene t1 Fuslon knmunoblot analysis (Fg. 2) of the hGH~ene III phagemid stow that hGH aoss-reactive material aunigrates with phagemid particles in agarose gels. This indicates that the hGH is tightly assoclated with phagemid particles. The hGH-gene III fusion protein from the phagemid particles nms as a single immuno-stained band showing that there is little degradation of the hGH when it is attached to gene III. Wild-type gene III protein is dearly present because about 25°~ of the pt~agemid particles are infectious. This is comparable to speclfic infectivity estimates made for wild-type M13 phage that are similarly purified (by CsCI density gradients) and concentrations estimated by UV absorbance (Smith, G. P. supra and Partnley, Smith supra) Thus, both wild-type gene III and the hGH-gene III fusion proteins are cisplayed in the phage pool.
It was important to confirm that the tertiary structure of the displayed hGH
was maintained in order to have confidence that results from binding selections will translate to the native protein. We used monoclonal antibodies (Mats) to hGH to evaluate the structural integrity of the displayed hGH gene III fusion protein (Table I).
TABLE L Binding of FJght Different Nbnoclonal Antibodies (Mat's) m hGH and hGH Pt~agemld Parades' ICSp (nM) Mat hGH hGH-phagemid ___.__________________.______.___..______.___..._.____._............_..._....._ _....
1 0.4 0.4 2 0.04 0.04 3 0.2 0.2 4 0.1 0.1 5 0.2 >2.0 6 0.07 0.2 7 0.1 0.1 8 0.1 0.1 'Values given represent aye GH or hGH-phagemid particles corxentration (nM) of h to give half-maximal binding to the particular Mab. Standard errors in these measurements are typically at or below t30~
of the reported value.
See Materials and Methods for further details.
3 0 The epitopes on hGH for these Mabs have been mapped (Cunningham et al..
supra) and binding for 7 of 8 Mabs requires that hGH be properly folded. The ICSp values for all Mabs were equivalent to wild-type hGH
except for Mab 5 and 6 . Both Mabs 5 and 6 are known to have binding determinants near the carboxyl-terminus of hGH which is blocked in the gene III fusion protein. The relative ICSp value for Mabt which reacts with both native and denatured hGH is kxxhar~ged compared to the a>r~orrnatanally sensitive Mabs 2-5, 7 and 8. Thus, Mab1 serves as a good internal control for any errors in matching the concentration of the hGH standard to that of the hGH~ene III fusion.
E'KAMPLE VI
Blndtrp Ervfcwnents on Receptor AtfiNty Beads Previous workers (Partnley, Smith supra ; Scott, Smith supra; Cwirla et aL
supra; and Devlin et al.
5 supra) have fractionated phage by panning with streptavidin coated polystyrene petri dishes or miaotiter plates.
However, dxomatographic systems would allow may efficient iradionation of phagemid particles displaying mutant proteins with different binding affinities. We dose non-porous oxirane beads (Sigma) to avoid trapping of phagemid particles in the dromatographic resin. Furthermore, these beads have a small particle size (t u.m) to maximize the surface area to mass ratio. The extraaetlular domain of the hGH
receptor (hGHbp) (Fuh et al. , 10 supra) contairHng a free cystEino residue was eihaentiy coupled b these beads and phagemid particles showed very low non-specific binding to beads coupled ony to bovine senun alb<unin (Table II).
TABLE 11.
15 Specific Blndlng of Hormone Phage to hGHbp-coated Beads Provides an Enrichment for hGH-phage over M13K07 Phage' Sample Absorbent$ Total pfu Total cfu Ratiu (cfu/pfu) Enrichment~
20 Original mixturet 8.3 x 1011 2.9 x 108 3.5 x 10'4(1) Supernatant BSA 7.4 x 1011 2.8 x 108 3.8 x 10'41.1 hGHbp 7.6 x 1011 3.3 x 108 4.3 x 10'41.2 Wash 1 BSA 1.1 x t 6.0 x 106 5.5 x 10'41.6 hGHbp 1.9 x 101 1.7 x 107 8.9 x 10'42.5 25 Wash 2 BSA 5.9 x 107 2.8 x 104 4.7 x 10'41.3 hGHbp 4.9 x 107 2.7 x 106 5.5 x 10'21.6 x Eluate 1 (hGH)BSA 1.t x 106 1.9 x 103 1.7 x 10'34.9 hGHbp 1.2 x 106 2.1 x 106 1.8 5.1 x Eluate 2 (hGH)BSA 5.9 x 105 1.2 x 103 2.0 x 10'35.7 hGHbp 5.5 x 105 1.3 x 106 2.4 6.9 x Eluate 3 (pH 2.1 )BSA 4.6 x 105 2.0 x 103 4.3 x 10'312.3 hGHbp 3.8 x 105 4.0 x 106 10.5 3.0 x 'The titers of M13K07 and hGH-phagemid particles in each fraction was determined by multiplying the number of plaque forming units (pfu) or carbenicillin resistant colony forming units (cfu) by the dilution factor, respectively. See Example IV for details.
tThe ratio of M13K07 to hGH-phagemid particles was adjusted to 3000:1 in the original mixture.
$Absorbents were conjugated with BSA or hGHbp.
~Enrichments are calculated by dividing the cfu/pfu ratio after each step by cfu/pfu ratio in the original mixture.
In a typical enrichment experiment (Table II), one part of hGH phagemid was mixed with >3,000 parts Mt3K07 phage. After one cycle of trn~ding and elution,106 phage were recovered and the ratio of phagemid to M13K07 phage was 2 to 1. Thus, a single binding selection step gave >5000-fold ennidment. Additional elutions with free hGH or acld treatment to remove remaining phagemids produced even greater enrichments. The eruidments are comparable to those obtained by Smith and coworkers using bald elution from coated polystyrene plates (Smith, G.P. supra and Parmely, Smith sipra ) however much smaaer volumes are used on the beads (200 W vs. 6 ml). There was almost no enrichment for the hGH phagemid over M13K07 when we used beads lir>ked only to BSA. The slight erxichmertt observed (or control beads (-10-fold for pH 2.t elution; Table 2) may result from trace contaminants of bovine growth hormone Minding protein present in the BSA linked to the bead. Nevertheless these data show the enrichmer4s for the hGH phage depend upon the presence of the hGHbp on the bead suggesting Minding occurs by specific interaction between hGH and the hGHbp.
We evaluated the enrichment for wild-type hGH over a weaker binding variant of the hGH on fusion phagemids to further demonstrahe enrichment spe~fiaty, and b wnk the reduction i~ binding affinity for the purified hormones to enrichment factors after panning fusion phagemids. A
fusion phagemid was constructed with an hGH mutant in which Arg64 was substituted with Ala (R64A). The R64A
variant hormone is about 20-fold reduced in receptor Minding affinity compared to hGH (Kd values of 7.1 nM
and 0.34 nM, respectively (Cunr>ingham, Wells, supra ]). The titers of the R64A hGH~ene III fusion phagemid were comparable to those of wild-type hGH phagemid. After one round of binding and elution (Table III) the wild-type hGH phagemid was enriched from a mixture of the two phagemids plus Mt3K07 by 8-fold relative b the phagemid R64A, and 104 relative to Mt3K07 helper phage.
TABLE al. hGHbp-coated Beads Select for hGH f~hagemlds Over a Weaker B4ndtng hGH Variant Phagemld Sample enrichment enrichment total phagemid for WT/R64A total phagerrid for WT/R64A
original mixture 8/20 (1 ) 8/20 (1 ) Supernatant ND - 4/10 1.0 Elution 1 (hGH) 7/20 0.8 17/20 8.5$
Elution 2 (pH 2.1 ) 11 /20 1.8 21 /27 5.2 'The parent M13K07 phage, wild-type hGH phagemid and Rfi4A phagemid particles were mixed at a ratio of 104:0.41).6. Binding selections were carried out using beads linked with BSA
(control beads) or with the hGHbp (hGHbp beads) as described in Table II and the Materials and Methods After each step, plasmid DNA was isolated(Bimboim, H. C., Doly, J. , Nucleic Acids Res., 7:1513-1523, (1979)) from carbenicillin resistant colonies and analyzed by restriction analysis to determine it it contained the wild-type hGH or the R64A hGH gene III
fusion.
t'fhe enrichment for wild-type hGH phagemid over R64A mutant was cala~lated from the raCb of hGH phagemid presets after each step to that present in the original mixture (8120), divided by the corresponding ratio for R64A phagemids. WT = wild-type; NO = not determined.
$The enrichment for phagemid over btal M13K07 parental phage was ~104 after this step.
By displaying a mixt<xe of wild-type gene III and the gene III fusion protein on phagemid partiGes one can assemble and propagate virions that display a large and proper folded protein as a fusion b gene III. The copy number of tf~e gene III fusan protein can be effectively controlled to avoid 'chelate effects' yet maintained at high enough levels in the phagemid pool b permit panning of large eptope litxaries (>1010). We have shown Ihat hGH
(a 22 kD protein) can be displayed in its native folded form. Binding selections performed on receptor affinity beads eluted with free hGH, ef6aentfy enrid~ed for wild-type hGH phagemids over a mutant hGH phagemid shown to have reduced receptor binding affinity. Thus, ft is possible to sort pf~agemid particles whose binding constants are down in the nanomolar range.
Protein-protein and antibody,antigen interactions are dominated by discontirx~ous epitopes (Janin, J., er a<. , ,~ MolBiol.. 204:155-1s4, ~198a); Argos, P., fro . no., 2:101-113, f1sa81; Barrow, D.J.,er ac , , 322:747-748, (1987); and Davies, D.R., et al. , J. Biol. Chem.. 253:10541-10544, X1988)); that is the residues directly involved in Minding are dose in tertiary stnxture txit separated by residues not involved in binding. The saeerung system presented here should arrow one to analyze more corHeniently pro0ein-receptor interactans and isolate discontirx~ous eptopes in proteins with r~ew and high affinity Minding properties.
EXAMPLE Vtl Selection of hGH Mutants from a lJbrary Randomlxed at hGH Colons 1T2,174,1T6,1T8 Construction of template A mutant of the hGH-gene III fusion protein was constnx~ed using the method of tCunkel.,et al. I~
154, 367-382 (1987). Template DNA was prepared by growing the plasmid pS0132 (containing the natural hGH gene fused to the carboxy-terminal half of M13 gene Ill, ~s~der control of the alkaline phosphatase promoter) in CJ236 cells with Mt3-K07 phage added as helper. Single-stranded, uracil-containing DNA was prepared for mutagenesis to introduce (1) a mutation in hGH which would greatly reduce minding to the hGH
binding protein (hGHbp): and (2) a unique restriction site (Kpnl) which could be urea ror assaying for -- and selecting against -- parental background phage. Oligonudeotide-directed mutagenesis was carried out using T7 DNA polymerase and the following oligodeoxy-nudeotide:
Gly Thr hGH colon: 17B 179 5'-G ACA TTC CTG SGT ATC GTG CAG T-3' < KpnI >
This oligo introduces the Kpnl site as shown, along with mutations (R178G,1179T) in hGH. These mutations are predicted to reduce Minding of hGH to hGHbp by more than 30-fold. Clones from the mutagenesis were sseened by Kpnl digestion and confirmed by dideoxy DNA sequenang. The resulting constn~ct, to be used as a template for random mutagenesis, was designated pH0415.
B~.~m.mul~S~IIl~~H
Colons 172,174,176,178 were targeted for random mutagenesis in hGH, again using the method of Kunkel. Single-stranded template from pH0415 was prepared as above and mutagenesis was tamed out using the following pool of oligos:
hGH colon: 172 174 5'- GC TTC AGG AAG GAC ATG GAC l~ GTC STS. ACA-Ire - N~. CTG ~ ATC GTG CAG TGC CGC TCT GTG G-3' As shown, this oligo pool reverts colon 179 to wed-type (ore), destroys the unique Kpnl site of pH0415, and introduces random colons (NNS, where N= A,G,C, or T and S= G or C) at positions 172,174,176, and 178. Using 4 0 this colon selection in the context of the above sequence, no additional Kpnl sites can be seated. The dioice of the NNS degenerate sequence yields 32 possible colons (nduding one 'stop' colon, and at least one colon for each amino add) at 4 sites, for a total of (32)4= 1,048,576 possible nudeotide sequences (12% of which contain at least one stop colon), or (20)4F 160,000 possible polypeptide sequences plus 34,481 prematurely terminated sequences (i.e. sequences contairyng at least one slop potion).
$Qp~gatlon of the Inllial Ilbrarv The mutagenesis products were extracted twice with phenolxhbroform (50:50) and ethanol preapitated with an excess of carrier tRNA to avoid adding salt that would confound the subsequent electroporation step. Approximately 50 ng (15 fmols) of DNA was electroporated into WJM101 cells (2.8 x 1010 ceIIsImL) in 45 N.L btal volume in a 0.2 an cuvette at a voltage setting of 2.49 kV with a single pulse (time constant = 4.7 msec.).
The ceNs were aNowed to recover 1 hour at 37°C with shaking, then mixed with 25 mL 2YT medium,100 ~g/mL carberwdllin, and M13-K07 (multipliaty of infection = 1000). Plating of serial dNutions from this culture onto carbeniallin~ontaining media indicated that 8.2 x 106 electrotransformants were obtained. After t0' at 23oC, the culture was incubated overnight (t5 hours) at 37°C with shaking.
After overnight incubation, the cells were peueted, and double-stranded DNA
(dsDNA), designated pL181, was prepared by the alkaline lysis method. The supernatant was spun again to remove any remaining cells, and the phage, designated phage pool ~1, were PE:G-precipitated and resuspended in 1 mL STE buffer (10 mM
Tris, pH 7.6, 1 mM EDTA, 50 mM NaCI). Phage titers were measured as colony-forming units (CFU) for the recombinant phagemid containing hGH~3p gene III fusion (hGH-g3) plasmid, and plaque-forming units (PFU) for the M13-K07 helper phage.
1. BINDING: M aliquot of phage pool ~~I (6 x 109 CFU, 6 x 107 PFU) was diluted 4.5-fold in buffer A
(Phosphate-buffered saline, 0.5°~6 BSA, 0.05% Tween-20, 0.01%
thimerosal) and mixed with a 5 N.l. suspension of oxirane-polyacrylamide beads coupled to the hGHbp containing a Ser237 Cys mutation (350 fmols) in a 1.5 mL
silated polypropylene tune. As a control, an equivalent aliquot of phage were mixed in a separate tube with beads that had been coated with BSA only. The phage were allowed to bind to the beads by incubating 3 hours at room temperature (23°C) with slow rotation (approximately 7 RPM). Subsequent steps were carried out with a constant volume of 200~L and at room temperature.
2. WASH: The beads were spun 15 sec., and the supernatant was removed (Sup. t ). To remove phagefphagemid not speafically bound, the beads were washed twice by resuspending in buffer A, then pelleting.
A final wash consisted of rotating the beads in buffer A for 2 hours.
3. hGH ELUTION: Phagelphagemid Minding weakly to the beads were removed by stepwise elution with hGH. In the first step, the beads were rotated with buffer A containing 2 nM
hGH. Affer 17 hours , the beads were pelleted and resuspended in buffer A containing 20 nM hGH and rotated for 3 hours, then pelleted. In the final hGH wash, the beads were suspended in buffer A containing 200 nM hGH and rotated for 3 hours then peNeted.
4. GLYCINE ELUTION: To remove the tightest-binding phagemid (i.e. those still bound after the hGH
washes), beads were suspended in Glydne buffer (1 ~Glycine, pH 2.0 with HG), rotated 2 hours and pelleted.
The supemataM (fraction 'G'; 200~L) was neutralized by adding 30 P.l. of 1 M
Tris base.
Fraction G eluted from the hGHbp-beads (1 x 106 CFU, 5 x 104 PFU) was not substantially enriched for phagemid over K07 helper phage. We believe this resulted from the tact that K07 phage packaged during propagatan of the recombinant phagemid display the hGH-gap fusion.
However, when compared with traction G eluted firom the BSA~oated control beads, the hGHbp-beads yielded 14 times as many CFU's. This reflects the errichment of tight~irxfing hGH~splaying phagemid over nonspecfically-binding phagemid.
5. PROPAGATION: M aliquot (4.3 x 105 CFU) of fraction G ek~ted from the hGHbp-beads was used to infect bg-phase WJM101 teas. Transductions were cartied out by mixing 100 L~L tractan G with 1 mL WJM101 cells, incubating 20 min. at 37oC, then adding K07 (multipficty of infection=
1000). Cultures (25 mL 2YT plus carbenicuin) were grown as described above and tt~: second pool of phage (Library tG, for first glydne elution) were prepared as described above.
Phage from library 1 G (Fg. 3) were selected for binding to hGHbp beads as described above. Fraction G eluted from hGHbp beads contained 30 times as many CFU's as fraction G
eluted from BSA-beads in this selection. Again, an aliquot of fraction G was propagated in WJM101 cells to yield library 1G2 (indicating that this library had been twice selected by glycne elution). Double-stranded DNA
(pLIB 1G2) was also prepared from this culture.
To reduce the level of background (Kpnl+) template, an aliquot (about 0.5 fig) of pLIB 1G2 was digested with Kpnl and electroporated into WJM101 ells. These cells were grown in the presence of K07 (multiplidty of infection= 100) as described for the initial library, and a new phage pool, pLIB 3, was prepared (Fig, 3).
In addition, an aliquot (about 0.5 fig) of dsDNA from the initial library (pLIBi) was digested with Kpnl and electroporated directly into WJM101 cells. Transformants were allowed to recover as above, infected with M13-K07, and grown overnight to obtain a new library of phage, designated phage Library 2 (Fg. 3).
Pt~agemid tHnding, elution, and propagation were tamed out in successive rounds for phagemid derived from both pLIB 2 aril pLIB 3 (Fig. 3) as described above, except that (1) an excess (10-fold over CFU) of purified K07 phage (not displaying hGH) was added in the bead-binding mil, and (2) the hGH stepwise elutions were replaced with brief washings of buffer A, alone. Also, in some cases, XL1-Blue cells were used for phagemid propagation.
An additional digestan of dsDNA with Kpnl was carried out on pLIB 2G3 and on pLIB 3G5 before the final round of bead-binding selection (Fg. 3).
Four independently isolated Bones from LIB 4G4 and tour independently isolated doves from LIB 5G6 were sequenced by dideoxy sequenang. All eight of these Bones had identical DNA sequerx:es:
hGH codon: 172 174 176 178 5' -AAG GTC TCC ACA TAC CTG AGG ATC-3' Tf~us, all these encode the same mutant of hGH: (E174S, F176Y). Residue 172 in these doves is Lys as in wild-type. The radon selected fw 172 is also identical to wild-type hGH. This is not surprising since AAG is the only lysine~odon possible from a degenerate 'NNS' codon seL Residue 178-Arg is also the same as wild-type, but here, the codon selected from the fibrary was AAG instead of CGC as is found in wild-type hGH, even though the latter colon is also poss'~ble using the'NNS' colon set.
The multiplidty of infectan of K07 infection is an important parameter in the propagation of recombinant phagemids. The K07 multiplidty of infection must be high enough b insure that virtually all cells transformed or transfecEed with phagemid are able a> package new phagemid particles. Furthermore, the 5 cor~centratan of wik!-type gene III in each cell should be kept high b reduce the possitoility of multiple hGH-gene III
fusion molecules being displayed on each phagemid particle, thereby dielate effects in binding. However, it ~e K07 multipGdty of ir>tection is bo high, the packaging of K47 wiU
compete with fat of recombinant phagemid. We find that acceptable phagemid yields, with ony 1-10% background K07 phage, are obtained when the K07 muftiplidty of iMection is t00.
Table N.
Phage Pool mot (K07) Enrichment hGHbpIBSA beads Fractan Kpnl CFUIPFU
LIB 1 1000 ND 14 0.44 LIB 1G 1000 ND 30 0.57 LIB 3 100 ND 1.7 0.26 LIB 3G3 10 ND 8.5 0.18 LIB 3G4 100 460 220 0.13 LIB 2 100 ND 1.7 <0.05 LIB 2G 10 ND 4.1 <0.10 LIB 2G2 100 1000 27 0.18 Phage pools are labelled as shown (Fig. 3). The muftiplidty of infection (mot) refers to the multiptidty of K07 infection (PFU/cetls) in the propagation of phagemid. The enrichment of CFU
over PFU is shown in those cases where purified K07 was added in the binding step. The rata of CFU eluting from hGHbp-beads over CFU eluting from BSA-beads is shown. The traction of Kpnl-containing template (i.e..
pH0415) remaining in the pool was determined by digesting dsDNA with Kpnl plus EcoRl, running the products on a 1 °~ agarose gel, and laser-scanning a negative of the eihidium bromide-stained DNA.
Recent ro btndin~,aHinltv M the hormone~hGh~(E174S. F176Y1 The tact that a single done was isolated from two different pathways of selection (F~g. 3) suggested that the double mutant (E174S,F176Y) hinds strongly to hGHbp. To determine the affinity of this mutant of hGH for hGHbp, we constructed this mutant of hGH by site~directed mutagenesis, using a plasmid (pB0720) which contains the wild-type hGH gene as template and the folbwing oiigonudeotide which changes colons 174 and hGH colon: 172 174 17f 178 Lys Ser Ty:: Arg 5'- ATG GAC AAG GTR ~G ACA T8C CTG CGC ATC GTG -3' The resting construct, pH04588, was t<ansfortned into E. c~oli strain 16C9 for expression of the mutant hormone. Scatchard analysis of competitive binding of hGH(E174S,F176Y) versus 1251-hGH to hGHbp indicated that the (E174S,Ft76Y) mutant has a bindng affinity at least 5.0-told tighter than that of wild-type hGH.
ExArI~P~E vul SELECTION OF hGH VARIANTS FROM A
Human growth hormone variants were produced by the method of the present inventan using the phagemid described in figure 9.
We designed a vector for cassette mutagenesis (Wells et al., ~ 34, 315-323 (t985]) and expression of the hGH-gene III fusion protein with the objectives of (t ) improving the ~nkage between hGH and the gene III
moiety to more favorably display the hGH moiety on the phage (2) limiting expression of the fusion protein to obtain essentially 'monovalent display,' (3) allowing for restriction nuclease selection against the starting vector, (4) eliminating expression of fusion protein from the starting vector, and (5) achieving taale expression of the corresponding free hormone from a given hGH-gene III fusion mutant Plasmid pS0643 was constructed by oligonudeotide-directed mutagenesis (Kunkel et al., y 154, 367-382 (t987)) of pSOt32, which contains pBR322 and ft origins of replication and expresses an hGH-gene III fusion protein (hGH residues t-19t, followed by a single Gly residue, fused to Pro-198 of gene III) under the control of the ~~ promoter (Bass et af., ,proteins 8, 309-314 [t990j)(Rgure 9). Mutagenesis was carried out with the oligonucleotide 5'-GGC-AGC-TGT-GGC-TTC-TAG-AGT-GGC-GGC-GGC-TCT-GGT-3', which introduces a ~ site (underlined) and an amber stop colon (TAG) following Phe-191 of hGH. In the resulting construct, pS0643, a portion of gene III was deleted, and two silent mutations (underlined) occurred, yielding the following junction between hGH and gene III:
__ ~g ________________~_> gene ai >
1B7 188 18A 180 191 am' 24A 254 251 252 253 254 Cry f5ar Gds GAY Phe Qu Ser Cry Q9 C.~' fxr C.~y GGC AGC 'rGT GG~A ThC Ti~IGG AGT (X~ t~t~r'T' t~GGC 'hCT (~(iT
This shortens the total size of the fusion protein from 40t residues in pS0132 to 350 residues in pS0643. Experiments using monoclonal antibodies against hGH have demonstrated that the hGH portion of the new fusion protein, assembled on a phage particle, is more acces~ble Ihan was the previous, bnger fusion.
For propagation of hormone-displaying phage, pS0643 and derivatives can tie grown in a amber-suppresser strain of j~j, such as JM101 or XLt-Blue (BuUodc et al-, j~ 5, 376-379 [t987]). Shown above is substitution of Glu at the amber colon whid~ occurs in ~E suppn;ssor strains. Suppression with other 3 5 amino ands is also possible in various available strains of ~ well kroHm and publ'~cally available.
To express hGH (or mutants) tree of the gene III portion of the fusion, pS0643 and derivatives can simply be grown in a non-suppresser strain such as 1609. h ttus case, the amber colon (TAG) leads to termination of translation, which yields free fwrmone, without the need for an independent DNA construction.
To create sites for cassette mutagenesis, pS0643 was mutated with the oligorx~deotides (1) 5'-CGG-ACT-GGG-CAG-ATA-TTC-AAG-CAG-AGC-3', which destroys the unique ~gll1 site of pS0643; (2) 5'-CTC-AAG-AAC-TAC-GAG-TTA-CCC-TGA-CTG-CTT-CAG-GAA-GG-3', which inserts a unique site, a single-base framesfuft, and a non-amber stop colon (TGA); and (3) 5'-CGC-ATC-GTG-CAG-TGC-~-GTG-GAG-GGG3', which introduces a new ~ site, to yield ft~e startup vector, pH0509. The addition of a trameshift along with a TGA stop colon insures that no genelll-fusion can tie produced from tire starting vector.
The $~1- ~[1[ segment is cut out of pH0509 and replaced with a DNA cassette, mutated at the colons of interest. Other restriction sites for cassette mutagenesis at other locatans in hGH have also been introduced into the hormone-phage vector.
Colons 172,174,176 and 178 of hGH were targeted for random mutagenesis because they all be on or near fhe surface of hGH and contribute sigr>rficantly to reoepDx-binding (Cumingham arxi Wells, 244, 1081-1085 (1989j); they all ie within a well-defined structun:, occupying 2 'tums~ on tire same side of helix 4;
and they are each substidtted by at least one amino aid among known evolutionary variants of hGH.
We chose to substitute NNS (N=AIGICIT; S=GJC) at each of fhe target residues.
The choice of the NNS degenera~ sequerxe yields 32 possible codor~ (inducting at least one colon for each amino aid) at 4 sites, for a total of (32)4= 1,048,576 possible nucleotide sequences, or (20)4.
160,000 possible polypeptide sequences. Only one stop colon, amt~er (TAG), is allowed by this dx>ice of colons, and this colon is suppressible as Glu in ~ strains of ~.
Twb degenerate oligonuGeotides, with NNS at colons 172,174,176, and 178, were synthesized, phosphorylated, and annealed to construct the mutagenic cassette: 5'-GT-TAC-TCT-ACT-GCT-TTC-AGG-AAG-GAC-ATG-GAC-NNS-GTC-NNS-ACA-NNS-CTG-NNS-ATC-GTG-CAG-TGC-A-3', and 5'-GA-TCT-GCA-CTG-CAC-GAT-SNN-CAG-SNN-TGT-SNN-GAC-SNN-GTC-CAT-GTC-CTT-CCT-GAA-GCA-GTA-GA-3'.
The vector was prepared by digesting pH4509 with BstEll followed by ~(. The products were run on a 1°~ agarose gel and the large fragment excised, phenol-extracted, and ethanol precipitated. This fragment was treated with calf intestinal phosphatase (Boehringer), then phenol:chlorofortn extracted, ethanol preapitated, and resuspended for Ggafion with the mutagenic cassette.
ProoaQ,atlon of the Initial Itbrarv In XL1~Blue cNls Following tigation, the reaction products were again digested with ~, then phenolxhloroform extracted, ethanol precipitated and resusperxied in water. (A recognitan site (GGTNACC) is created within cassettes which contain a ~ at position 3 of colon 172 and an ~ (Thr) colon at 174. However, treatment with ~ll at this step should not select against any of the possible mutageruc cassettes, because virtually all cassettes will be heteroduplexes, which caruat be deaved by the enzyme.) Approximately 150 ng (45 fmols) of DNA was electroporated info XLt-Blue cells (1.8 x 109 cells in 0.045 mL) in a 02 cm cuvette at a voltage setting of 2.49 kV with a single pulse (tkne constant = 4.7 msec.).
The cells were allowed to recover 1 tour at 37oC in S.O.C media with shaking, then mixed with 25 mL
2YT medum,100 mglmL Carberuallin, and M13-K07 (mot=100). Af6er 10' at 23oC, the culture was incubated overnight (15 hours) at 37oC with shaking. Plating of serial d'rlutions from this culture onto carbeniallin-containing media indicated that 3.9 x 107 etectrotranstormar>rss were obta~ed.
After overnight incubation, the cells were peAeted, and double-strarxied DNA
(dsDNA), designated pH0529E (the initial library), was prepared by the alkaline lysis method. The supernatant was spun again to remove any remaining cells, and the phage, designated phage pool ~H0529E (the initial library of phage), were PEG-preapitated and resuspended in 1 mL STE offer (10 mM Tris, pH 7.6,1 mM
EDTA, 50 mM NaG). Phage titers were measured as oolong-forming units (CFU) for the reoombirant phagemid containing hGH~3p.
Approximately 4.5 x 1013 CFU were obtained from the starting library.
From the pool of elecb~otransformanis, 58 doves were sequenced in the region of the -~
cassette. Of these,17% corresponded to the starting vec6or,1796 contained at least one frame shift, and 7°~6 contained a non-silent (non-terminating) mutatbn outside the four target colons. We conclude chat 41 °~6 of the doves were defective by one of the above measures, leaving a bta! hx>dional pool of 2.0 x 107 initial transfortnants. This number stiA exceeds the possible number of DNA sequerxes by nearly 20-fokJ. Therefore, we are confident of having all possible sequences represented in the starting library.
We examined the sequsr~ces of non-seledad phage to evaluate the degree of colon bias in the mutagenesis (Table V). The results indicated that, although some colons (and amino adds) are urxler- or over-represented relative to the random expectation, the library is extremely diverse, with no evidence of large-scale 'sibling' degeneracy (Table VI).
Table V.
Colon disiributbn (per 188 colons) of non-selected hormone phage. Cbnes were sequerxed from the starting litxary (pH0529E). All colons were tabulated, including those hom doves wtuch contained spurious mutations andlor frameshifts.' Note: the amber stop colon (TAG) is suppressed as Glu in Xl_t-Blue cells. Highlighted colons were over/under-represented by 50% or more.
Leu 17.6 18 1.0 Ser 17.6 26 1.5 Arg 17.6 10 0.57 Pro 11.8 16 1.4 Thr 11.8 14 1.2 Ala 11.8 13 1.1 Gly 11.8 16 1.4 Val 11.8 4 0.3 fe 5.9 2 0.3 Met 5.9 i 0.2 Tyr 5.9 1 0.2 tits 5.9 2 0.3 Trp 5.9 2 0.3 Phe 5.9 5 0.9 Cys 5.9 5 0.9 Gh 5.9 7 12 Apt 5.9 14 2.4 Ly5 5.9 11 1.9 Asp 5.9 9 1.5 4 Giu 5.9 6 1.0 amber' 5.9 6 1.0 Table YI.
Non-selected (pH0529E) Bones with an open reading frame.
The notafan, e.g. TWGS, denotes the hGH mutant 172TI174W/176G/1785. Amber (TAG) colons, translated as Glu in XL1-Blue cells are shown as ~.
Ke NT KTEQ CVLQ
TWGS NNCR EASL
Pe ER FPCL SSKE
LPPS NSOF ALLL
SLDP HRPS PSHP
QQSN LSLe SYAP
GSKT NGSK ASNG
TPVT LTTE EANN
RSRA PSGG KNAK
LCGL LWFP SRGK
TGRL PADS GLDG
AKAS GRAK NOPI
GNDD GTNG
p~~ara8on of fmmobltlzed hGHbo and hPRLbc Immobilized hGHbp ('hGHbp-beads') was prepared as described (Bass et al., Proteins 8, 309-314 (1990)), except that wild-type hGHbp (Fuh et al., ,~ Biol. Chem. 265, 3111-3115 (1990)) was used. Competitive binding experiments with (1251) hGH indicated that 58 fmols of functional hGHbp were coupled per N.L of bead suspension.
Immobilized hPRLbp ('hPRl~p-beads') was prepared as above, using the 211-residue extracellular domain of the prolactin receptor (Cunningham et al., 254.1709-1712 [1990)).
Competitive binding experiments with (1251) hGH in the preserx~ of 50 ~ zinc indicated that 2.1 fmols of functional hPRLbp were 3 0 coupled per N.L of bead suspen~on.
'Blank beads' were prepared by treating the oxirane-acrylamide beads with 0.6 M ethanolamine (pH
9.2) for 15 hours at 4oC.
Birx~n~ selection usln~ Immobilized hGHbo and hPRl.bo Binding of hormone-phage to beads was carried out ~ one of the following buffers: Buffer A (PBS, 0.5°~ BSA, 0.05°~6 Tween 20, 0.01% thimerosal) (or selections using hGHbp and blank beads; Buffer B (50 mM
tris pH 7.5,10 mM MgCl2, 0.5% BSA, 0.05°~ Tween 20,100 m~ ZnCl2) for selections using hPRLbp in the presence of zinc (+ Zn2+); or Buffer C (PBS, 0.5°~ BSA, 0.05% Tween 20, 0.01 % thimerosal,10 m~ EDTA) for selections using hPRLbp in the abserxe of zinc (+ EDTA). Binding selec5ons were carried out according to each of the following paths: (1) binding to blank beads, (2) binding to hGHbp-beads, (3) binding to hPRLbp-beads (+
Zn2+), (4) binding to hPRLbp-beads (+ EDTA), (5) pre-adsorbing twice with hGHbp beads then binding the non-adsorbed fraction to hPRLbp-beads ('-hGHbp, +hPRLbp' selection), or (6) pre-adsorbing twice with hPRLbp-beads then binding the non-adsorbed fraction to hGHbp-beads ('fiPRLbp, +hGHbp' selection). The latter two procedures are expected to enrich for mutants Minding hPRLbp but not hGHbp, or for mutants binding hGHbp but not hPRLbp, respectively.
4 5 Bindng and elution of phage was varied out in each cyde as fellows:
1. BINDING: An aliquot of hormone phage (typically 109 -1010 CFU) was mixed with an equal amount of non-hormone phage (pCAT), diluted into the appropriate buffer (A, 8, or C), and mixed with a 10 ml suspension of hGHbp, hPRlbp a blank beads in a total volume of 200m1 in a 15 ml pdypropylene tube. The phage were allowed b hind b the beads by incubating t hour at room temperature (23°C) with slow rotation (approximately 7 RPM). Subsequent steps were carried out with a constant volume of 200ir1 and at room temperature.
2. WASHES: The beads were spun 15 sec., and the supernatant was removed. To reduce the number of 5 phage not sped6cally bound, the beads were washed 5 times by resuspending briefly b the appropriate buffer, then pelleting.
3. hGH ELUTION: Phage binding weakly to the beads were removed by elution with hGH. The beads were rotated with the appropriate buffer cantair~ing 400 rI~hGH for 15-17 hours. The supernatant was saved as the 'hGH elution' and the beads. The beads were washed by resuspending briefly in buffer and pelleting.
10 4. GLYCINE ELUTION: To remove the tightest-binding phage (i.e. those stiu bound after the hGH
wash), beads were susperxied in Glydne buffer (&offer A plus 0.2 ~Glyane, pH
2.0 with HCI), rotated 1 hour and pelleted. The supernatant ('Glyane elution'; 200p.L) was neutralized by adding 30 mL of 1 M Tris base and stored at 4o C.
5. PROPAGATION: Aliquots from the hGH elusions and from the Glycine elutions from each set of 15 beads under each set of conditions were used to infect separate cultures of bg-phase XL1-Blue cells.
Transductions were carried out by mixing phage with t mL XL1-Blue cells, incubating 20 min. at 37°C, then adding K07 (moi=100). Cultures (25 mL 2YT plus carbenicillin) were grown as described above and the next pool of phage was prepared as described above.
Phage binding, elution, and propagation were carried out in successive rounds, according to the cyGe 20 described above. For example, the phage amplified from the hGH elution from hGHbp-beads were again selected on hGHbp-beads and eluted with hGH, then used to infect a new culture of XL1-Blue cells. Three to five rounds of selection and propagation were carried out for each of the selection procedures described above.
From the hGH and Glycine elution steps of each cycle, an aliquot of phage was used b inoculate XL1-Blue 25 cells, which were plated on LB media containing carberudllin and tetracyGine to obtain independent doves from each phage pool. Single-stranded DNA was prepared from isolated colony and sequenced in the region of the mutagenic cassette. The results of DNA sequendng are summarized in terms of the deduced amino acrd sequerxes in Figures 5, 6, 7, and 6.
3 0 F.x~lm.~.~~Ih~li To determine the binding affinity of some of the selected hGH mutants for the hGHbp, we transformed DNA from sequenced doves into ~, coli strain 16C9. As described above, this is a non-suppressor strain which terminates translation of protein after the final Phe-191 residue of hGH.
Single-stranded DNA was used for these transformations, but double-stranded DNA or even whole phage can be easily electroporated into a non-35 suppressor strain for expressan of tree hormone.
Mutants of hGH were prepared from osmotically shocked cells by ammonium sulfate predpitation as dexribed for hGH (Olson et al., ~g 293, 408-411 (1981]), and protein concentrations were measured by laser densibmoetry of Coomassie-stained SDS-polyaaylamide gel electrophoresis gels, using hGH as standard (Cunningham and Wells, 244,1081-1085 (1989]).
The binding affinity of each mutant was deoermined by displacement of 1251 hGH
as described (Spencer et al., J. Biol. Chem. 263, 7862-7867 (1988) ; Fuh et al., ,l. Biol. Chem.
265, 3111-3115 (1990J), using an anti-reoeptor monoclonal antibody (Mab263).
The results for a number of hGH mutants, selected by different pathways (F~g.
6) are shown in Table VII. Many of these mutants have a tighter binding affinity for hGHbp than wild-type hGH. The most improved mutant, KSYR, has a binding affinity 5.6 times greater than that of wild-type hGH. The weakest selected mutant, among those assayed was only about 10-fold lower in binding affinity than hGH.
Binding assays may be carved out for mutants selected for hPRlbp-birKiirp.
Teble VU.
~e~ve bhdinD b hGHbP
The selected pool in which each mutant was found is indicated as 1G (first glycne selection), 3G (third glycine selection), 3H (third hGH selecCan), 3' (third selection, not binding to hPRI-bp, but binding to hGHbp).
The number of times each mutant o~ured among all sequenced clones is shown ().
Mutant Kd (nM) Kd(mut)/Kd(hGH) Pod KSYR (6) 0.06 + 0.01 0.18 1G,3G
RSFR 0.10 + 0.05 0.30 3G
RAYR 0.13 + 0.04 0.37 3' KTYK (2) 0.16 + 0.04 0.47 H,3G
RSYR (3) 0.20 + 0.07 0.58 1G,3H,3G
KAYR (3) 0.22 + 0.03 0.66 3G
RFFR (2) 0.26 + 0.05 0.76 3H
K~YR 0.33 + 0.03 1.0 3G
KEFR= wt-(9) 0.34-+- 0.05 1.0 3H,3G,3' RTYH 0.68 + 0.17 2.0 3H
QRYR 0.83 + 0.14 2.5 3' KKYK 1.1 +0.4 3.2 3' RSFS (2) 1.1 + 02 3.3 3G,' KSNR 3.1 + 0.4 9.2 3' At some residues, substitution of a particular amino acrd has essentially the same effect independent of surrounding residues. For example, substitution of F176Y in the background of 172RI174S reduces binding affinity by 2.0-fold (RSFR vs. RSYR). Similarly, in the background of 172K/174A the binding affiridy of the Ft76Y mutant (KAYR) is 2.9-told weaker than the ca<responding 176F mutant (KAFR; Cunningham and Wells, 1989).
On the other hand, the Minding constants determined for several selected mutants of hGH demonstrate non-additive effects of some amino add substitutions at residues 172,174, 176, and 178. For example, in the background of 172KI176Y, the substitution E174S results in a mutant (KSYR) which hinds hGHbp 3.7-fold tighter than the corresponding mutant containing E174A (KAYR). However, in the background of 172R/176Y, the effects of these E174 substitutions are reversed. Here, the E174A mutant (RAYR) hinds 1.5-told tighter than the E174S mutant (RSYR).
Such non,additive effects on finding for substitutions at proximal residues illustrate the utility of protein-ptvage Minding selection as a means of seteccting optimized mutants from a library randomized at several positions. h the absence of detailed stmchral inlortnation, without such a selection process, many combinations of substitutions might be tried before finding the optimum mutant.
EXAMPLE !X
SELECTION OF hGH VARIANTS FROM A HELIX-1 RANDOM CASSETTE
LIBRARY OF HORMONE~PHAGE
Using the methods described in Example VIII, we targeted another region of hGH
involved in binding to the hGHbp and/or hPRLbp, helix t residues 10,14,18, 21, for random mutagenesis in the phGHam~3p vector (also known as pS0643; see Example VIII).
We chose to use the'amber~ hGH-g3 construct (called phGHam~g3p) because it appears ~ make the target protein, hGH, more accessible for binding. This is supported by data from comparative ELISA assays of monoclonal antibody binding. Phage produced hom both pS0132 (S. Bass, R.
Greene, J. A Wells, Proteins 8, 309 (1990).) and phGHam-g3 were tested with three antibodies (Media 2, t B5.G2, and 587.C10) that are known to have binding detertninarrts near the carboxyl-terminus of hGH [B. C.
Cunningt~am, P. Jhurani, P. Ng, J. A. Wells, Science 243,1330 (1989); B. C. CunnirxJham and J. A. Wells, Sderrce 244,1081 (1989); L. ]in and J. Wells, unpublished results], and one antibody (Media t) fat recognizes determinants in tierces 1 and 3 ([B. C.
Cunningham, P. Jtwrani, P. Ng, J. A. Wells, Saenae 243,1330 (1989); B. C.
Cunryngham and J. A. Wells, Saence 244, 1081 (1989)]). Phagemid particles from phGHam-g3 reacted much more strongly with antibodies Media 2, 1BS.G2, and 5B7.C10 than did phagemid particles from pS0132. In particular, binding of pS0132 particles was reduced by >2000-told for both Media 2 and 5B7.C10 and reduced by >25-fold for 1B5.G2 compared to binding b Media t. On the other hand, binding of phGHam~3 phage was weaker by only about 1.5-fold, t.2-fold, and 2.3-fold for the Media 2, t B5.G2, and 587.C10 antibodes, respectively, compared with Minding bo MEDIX t.
We mutated residues in helix 1 that were previously identified by alaryne-scanning mutagenesis [B. C.
Cunningham, P. Jhtrar>i, P. Ng, J. A. Wens, Saeme 243,1330 (1989): B. C.
Cunningham and J. A. Wells, Saenoe 244, 1081 (1989), 15,16) to modulate the binding of the extracellular domains of the hGH andlor hPRI
receptors (called hGHbp and hPRlbp, respectively). Cassette mutagenesis was carried out essentially as described [J. A. Wells, M. Vasser, 0. B. Powers, Gene 34, 315 (1985)]. This library was constmcted by casseGe mutagenesis that fully mutated tour residues at a time (see Example VIII) which utilized a mutated version of phGHam-g3 into which unique Kpnl (at hGH codon 27)and Xtal (at hGH colon 6) restriction sites (underlined below) had been inserted by mutagenesis [ T. A. Kunkel, J. D. Roberts, R. A.
Zakour, Me~ods EnzymoL 154, 367-382) with the oligonucleotides 5'-GCC TTT GAC AGG TAC CAG GAG TTT G-3' and 5'-CCA ACT ATA CCA
CTC TCG AGG TCT ATT CGA TAA C-3', respectively. The later oligo also introduced a +1 frameshift (italiazed) to terminate translation from the starting Necbr and minimize wild-type background in the phagemid library. This strating vector was designated pH0508B. The helix 1 wbrary, which mutated hGH residues 10, 14, 18, 21, was constnxxted by igating to the large Xhol-Kprrl fragment of pH0508B
a cassette made from the complementary ofigonucfeotides 5'-pTCG AGG CTC NNS GAC AAC GC~G NNS CTG CGT
GCT NNS CGT CTT
NNS CAG CTG GCC TTT GAC ACG TAC-3' and 5'~GT GTC AAA GGC CAG CTG SNN AAG ACG
SNN AGC
ACG CAG SNN CGC GTT GTC SNN GAG CC-3'. The Kprfl site was destroyed in the jvx~ction of the ligation product so that restriction enzyme digestion could d: used for analysis of non-mutated background.
The library contained at least t 0~ independent bransfortnants so that if the library were absolutely random (106 different comtrnations of codons) we would have an average of about 10 copies of each possible mutated hGH gene. Resfiction analysis using Kpnl indicated that at least 80°~ of helix 1 library constructs contained the inserted cassette.
Binding enrichments of hGH-phage from the libraries was carried out using hGHbp immobilized on oxirane-polyaaylamide beads (Sigma Chemical Co.) as desaibed (E~cample VIII).
Four residues in helix 1 (F10, M14, H18, orb H21 ) were similarly mutated and after 4 and 6 cycles a non-wild-type consensus developed (Table VIII). Position 10 on the hydrophobic face of helix t tended to be hydrophobic whereas positions 21 and 18 on the hydrophillic face tended were dominated by Asn; no obvious consensus was evident for position 14 (Table IX).
The binding constants for these mutants of hGH to hGHbp was determined by expressing tt~e free hormone variants in the non-suppresser E. coJl strain 1609, purifying the protein, and assaying by competitive displacement of labelled wt-hGH from hGHbp (see Example V111). As indicated, several mutants bind tighter to hGHbp than does wt-hGH.
Table VIII.
Selection of hGH helix 1 mutants Variants of hGH (randomly mutated at residues F10, M14, H18, H21) expressed on phagemid particles were selected by binding to hGHbp-beads and eluting with hGH (0.4 m11~ buffer followed by gtyane (0.2 M, pH 2) buffer (see Example VIII).
Gly elution 4 Cycles H G N N
A W D N
(2) Y T V N
I N I N
L N S H
F S F G
6 Cycles 2 0 H G N N ~6) F S F L
Consensus.
H G N N
Table IX
Consensus sequences from the selecived heAx 1 Ifxary 5 Observed frequency is fraction of a!1 doves sequenced with the indicated amino aad. The nominal frequency is calculated on the basis of NNS 32 colon degeneracy. The maximal enrichment facto varies from 11 to 32 depending upon the raminal frequency value for a given residue. Values of [Kd(Ala mut)IKd(wt hGH)j for single alaryne mutations were taken from B. C. Cumingham and J. A. Wells, Saenoe 244,1081 (1989); B. C. Cunningham, D. J. Henner, J. A. Wells, Silence 247,1461 (1990)" B. C. Cunningham and J. A.
Wells, Proc. Nod. Acad. So. USA
10 88, 3407 (1991 ).
Wild type Selected y Kd(Ala mut) m~d~ Kd(wt hGH) m~d~ °~~~ Enrichment 15 F10 5.9 H 0.50 0.031 17 F 0.14 0.031 5 A 0.14 0.062 2 M14 2.2 G 0.50 0.062 8 20 W 0.14 0.031 5 N 0.14 0.031 5 S 0.14 0.093 2 H 18 1.6 N 0.50 0.031 17 25 D 0.14 0.031 5 F 0.14 0.031 5 H21 0.33 N 0.79 0.031 26 H 0.07 0.031 2 Table X
Blndng of purtBed hGH helix 1 rt>~ar>ts b hGHbp Competition Minding experiments were performed using (t~tJhGH (wild-type), hGHbp (containing the extracellular receptor domain, residues 1-238), and Mab263 (B. C. Cumingham, P. Jhurani, P. Ng, J. A. Wells, Silence 243,1330 (1989));. The number P indicates the fractional ocaurence of each mutant among all the clones sequenced after one or more rounds of selection.
Seqm position P Kd (nll~lf(Kd Kd(wt mut) hGH)) H G N N 0.50 0.14 t 0.04 0.42 A W D N 0.14 0.100.03 0.30 w1_- F M H H 0 0.34 0.05 (1 ) F S F L 0.07 0.680.19 2.0 Y T V N 0.07 0.7510.19 2.2 L N S H 0.07 0.82 ~ 0.20 2.4 I N I N 0.07 12 ~ 0.31 3.4 E~CAMPLE X
SELECTION OF hGH VARIANTS FROM A HEUX-4 RANDOM CASSETTE LIBRARY CONTAIMNG
PREVIOUSLY FOUND MUTATIONS BY ENRtCtiMENT OF HORMONE~PHAGE
Our experience with recruiting non-binding homologs of hGH evolutionary variants suggests that many individual amino acid substitutions can be combined b yield a~mulatively improved mutants of hGH with respect to binding a particular receptor (B. C. Cunningham, D. J. Herner, J. Il Wells, Saenoe 247, 1461 (1990); B. C.
Cunningham and J. A. Wells, Pros. NafL Acad. Sa. USA 88, 3407 (1991 ); H. B.
Cowman, B. C. Cunningham, J. A.
Wells, J. Biol. Chem. 266, in press (1991)].
The helix 4b library was constructed in an attempt to further improve the helix 4 double mutant (E174SIF176Y) selected from the helix 4a library that w~e found bound tighOer to the hGH receptor (see Example VIII). Vlrth the E174S/F176Y hGH mutant as the backgro~d starting tarmone, residues were mutated that surrounded positions 174 and 176 on the hydrophilic face of helix 4 (R167, D171, T175 and 1179) .
Cassette mutagenesis was carried out essentiany as described (J. A. Wells, M.
Vasser, D. B. Powers, Gene 34, 315 (1985)]. The helix 4b library, which mutated residues 167,171,175 and 179 within the E174SIFt76Y background, was consUucted using cassette mutagenesis that fully mutated four residues at a time (see Example VIII) and which utilized a mutated version of phGHam~3 into which ur>rque BstEl1 and BgAI
restriction sites had been inserted prevausly (Example VIII). Inb the BstEl1-8plll sites of the vector was inserted a cassette made from the complementary oGgorwdeotides 5'-pG TTA CTC TAC TGC
TTC NNS AAG GAC ATG
NNS AAG GTC AGC NNS TAC CTG CGC NNS GTG CAG TGC A-3' and 5'-pGA TCT GCA CTG
CAC SNN
GCG CAG GTA SNN GCT GAC CTT SNN CAT GTC CTT SNN GAA GCA GTA GA-3'. The BstEll site was eliminated in the ligated cassette. From the helix: 4b wbrary,15 unseiec~ed doves were sequerxaed. 0t these, none lacked a cassette insert, 20°6 were trams-shifted, and 7% had a non-silent mutatan.
Binding eruid~ments of hGH-phage from the libraries was carved out using hGHbp immot~ilized on oxirane-polyacxytamide beads (Sigma Chemical Co.) as described (Example VIII).
After 6 cycles of binding a reasonably dear consensus developed (Tads XI). Interestingly, all positions tended b contain polar residues, notably Ser, Thr and Asn (X11).
The Minding constants for some of these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the ran-sup<xessor E. aoli strain 16C9, purifying the protein, and assaying by competitive displacement of labelled wtfiGH from hGHbp (see Example VIII). As indicated, the binding affinities of several helix-4b mutants for hGHbp were tighter than tf~at of wt-hGH Table XIII).
Finally, we have begun to analyze the binding affinity of several of the tighter hGHbp binding mutants for their ability to hind to the hPRI_bp. The E174SIF176Y mutant binds 200-fold weaker to the hPRLbp than hGH. The E174T/F176YIR178K and R167NID171S/E174SIF176Y/I179T mutants each bind >500-fold weaker to the hPRt-by than hGH. Thus, it is possible to use the produce new receptor selective mutants of hGH by phage display tedx~ology.
f Of the 12 residues mutated ~ three hGH~hagemid libraries (Examples VIII, IX, X), 4 showed a strong, although not exclusive, conservation of the wild-type residues (K172, 7175, F176, and R178). Not surprisingly, these were residues that when converted to Ala caused the largest disruptions (4- to 60-fold) in binding affinity to the hGHbp. There was a class of 4 other residues (F10, Mt4, D171, and 1179) where Ala substitutions caused weaker effects on bindiAg (2- to 7-fold) and these positions exhibited little wild-type consensus. Finally the other 4 residues (H18, H21, 8167, and E174), that promote binding to he hPRLbp but rat the hGHbp, did not exhibit any consensus for the wild-type hGH sequence by selection on hGHbp-beads. h fact two residues (E174 and H21 ), where Ala substitutions enhance binding affinity to the hGHbp by 2- to 4-fold [B. C. Cunningham, P.
Jhurani, P. Ng, J. A. Wells. Science 243.1330 (1989): B. C. Cunningham and J.
A Wells, Saenoe 244,1081 (t 989); B. C. Cunryrrgham, D. J. Henner, J. A. Wells, Saenoe 247,1461 (1990);
B. C. Cunningham and J. A. Wells, Proc. Nab. Acad. Sd. USA 88, 3407 (1991 )j. Ttx~s, the alanine-scanning mutagenesis data correlates reasonably well with the flexitxlity to substitute each position. In fact , the reduction in binding affirdty caused by alanine substitutions (B. C. Cunningham, P. Jhuraru, P. Ng, J. A. Wells, Silence 243,1330 (1989): B. C. Cunrungham and J. A. Wens, Saerroe 244,1081 (1989)j, B. C. C~ir~gham, D. J. Henner, J. A.
Wells, Saenoe 241,1461 (1990); B.
C. Cunningham and J. A. Wells, Pros. NatL Acad. Sa. USA 88, 3407 (1991 )j is a reasonable predictor of the percentage that the wed-type residue is found in the phagemid pool after 3~
rounds of selection. The alarune-scanning information is useful for targeting side~hains Ihat modulate finding, and the phage selection is appropriate for optimizing them and defirung the Aexibility of each site (and/or combinations of sites) for substitution. Tf~e comdnatan of scanring mutational methods [B. C.
t,.uru>>ingham, P. Jhurani, P. Ng, J. A. Wells, Science 243, 1330 (1989); B. C. Cunningham and J. A- Wells, Sdenae 244,1081 (1989)j and phage display is a powerful approach to designing receptor-ligand interfaces and studying molecular evolution in vibo.
In cases where comt~ined mutations in hGH have additive effects on t~irxiing affinity b receptor, mutatans learned through hormone-phagemid etuichrnent b improve Minding can be combined by simple cutting and ligation of restriction fragments or mutagenesis to yield cumulatively optimized mutants of hGH.
On the other hand, mutations in one region of hGH which optimize receptor binding may be stnxturally or functionally incompatible with mutations in an oveAapping a another region of the molecule. In these cases, hormone phagemid enrichment can be carried out by one of several variations on the iterative enrichment approach (1 ) random DNA litxaries can be generated in each of two (or perhaps more) regions of the molecule by cassette or another mutagenesis method. Thereafter, a comt~ined library can be created by Ggation of restriction fragments from the two DNA libraries; (2) an hGH variant, optimized for binding by mutation in one region of the molecule, can be randomly mutated in a second region of the molecule as in the helix-4b library example; (3) two or more random libraries can be y selected for improved finding by hormone-phagemid enrichment; after this 'roughing-in' of the optimized binding site, the stiil-partially-diverse libraries can be recomt~ir~ed by ligation of restriction fragments to generate a single library, partially diverse in two or more regions of the molecules, which in turn can be further selected for optimized tHndir~g using hormone-phagemid enrichment.
Tabfe p.
Mutant phagerNds of hGH sNec~ed from heltx 4b Itbrary after 4 and 6 cycles of eruidunent Selection of hGH helix 4b mutants (randomly mutated at residues 167,171,175,179), each containing the E174SIF176Y
double mutant, by Minding to hGHbp-beads and Hluting with hGH (0.4 mA~ buffer foliowed by glycine (0.2 M, pH 2) buffer One mutant (+) contained the spurious mutation R178H.
8167 D171 T175 IiT9 4 Cycles N S T T
K S T T
S N T T
D S T T
D S T T+
D S A T
D S A N
T D T T
N D T N
A N T N' A S T T
6 Cycles N S T T (2) N N T T
D S S T
E S T I
K S T L
Corpus:
N S T T' D N
Table XII
Cortserts~ aequer~s Born the aeieded Ifbrary.
Observed frequency is hactan of all doves sequenced with the indicated amino acd. The nominal frequency is calculated on the basis of NNS 32 colon degeneracy. The maximal eruichment factor varies from 11 to 16 to 32 5 depending upon the rx~minal frequency value for a given residue. Values of (Kd{Ala mut)lKd{wt hGH)) for single alarune mutations were taken from refs. t~elow; for position 175 we only have a value for the T175S mutant (B. C.
Cunnir~gham, P. Jhurani, P. Ng, J. A. Wells, Sderx;e 243, 1330 (1989); B. C.
Cumingham and J. A. Wells, Science 244, 1081 ~ 1989); B. C. Cunr>ingham, D. J. Henner, J. A. Wells, S?,47,1461 (1990);
B. C. Cunningham and J. A. Wells, Pros. Natl. Acad. Sci. USA88, 3407 (1991).J.
Wild type Selected FtB,Cl,t~y Kd(Ala mut) residue Kd(wt hGH) residue observed nominal Enrichment R 167 0.75 N 0.35 0.031 t t 15 D 0.24 _ 0.031 8 K 0.12 0.031 4 A O.t2 0.062 2 D171 7.1 S 0.76 0.093 8 N 0.18 0.031 6 2 0 D 0.12 0.031 4 T175 3.5 T 0.88 0.062 14 A 0.12 0.031 4 1179 2.7 T 0.71 0.062 11 N 0.18 0.031 6 Table XIII
Binding of purificed hGH mu»s to hGHbp.
Competition Minding experiments were performed using [1251]hGH (wild-type), hGHbp (containing the 30 extracellular receptor domain, residues 1-238), and Mab263 (11). The number P indicates the fractional oaxxrerxe of each mutant among all the Bones sequenced after one or more rounds of selection. Note that the helix 4b mutations (') are in the background of hGH(E174S/F176Y). In the list of helix 4b mutants" the E174SIF176Y mutant ('), with wt residues at 167,171,175, 179, is shown in bold.
~~ mut) 3 5 Sequer>ce position p ~ (n d(w~ t hGH) 40 N S T T 0.18 0.04 t 0.02 0.12 E S T I 0.06 0.04 f 0.02 0.12 K S T L 0.06 0.05 t 0.03 0.16 N N T T 0.06 0.06 t 0.03 0.17 R 0 T I 0 0.06 t 0.01 (0.18) 4 5 N S T Q 0.06 026 t 0.11 0.77 l~trrbty of F~ Wblea>le on the Pt>apemfd ~Ce Plasmid pDH 188 contains the DNA erxx>ding the F~ portion of a humanized IgG
antibody, called 4D5, that recognizes the HER-2 receptor. This plasmid is contained in E. colt strain SR 101, and has been deposited with the ATCC in Rockville, MD.
Briefly, the plasmid was prepared as follows: the starting ptasmid was pS0132, containing the alkaline phosphatase promoter as described above. The DNA eroding human growth hormone was exdsed and, after a series of manipulations to make the ends of the plasmid compatible for ligatan, the DNA encoding 4D5 was inserted. The 4D5 ONA contains two genes. The first gene encodes the variable and constant regions of the light chain, and contains at its 5' end the DNA encoring the st II signal sequence.
The record gene contains four portions: first, at its 5' end is the DNA encoding the st II signal sequence.
This is followed by the DNA encoding the variable domain of the heavy chain, which is iotbwed by the DNA eroding the first domain of the heavy drain constant region, which in turn is followed by the DNA encoding the M13 gene III. The salient features of this construct are shown in Fgure 10. The sequere of the DNA encoding 4D5 is shown in Figure 11.
Both polyethylene glycol (PEG) and ele~,~troporation were used to transform plasmids into SR101 cells.
(PEG competent cells were prepared and transformed according to the method of Chung and Miller (Nucleic Acids Res.16:3580 (1988]). Cells that were competent for electroporation were prepared, and subsequently transformed via electroporation according to the method of Zabarovsky and Winberg (Nucleic Acids Res.18:5912 (1990J). After placing the cells in 1 ml of the SOC media (desaibed in Sambrook et aL, supra), they were grown for 1 hour at 37°C with shaking. At this time, the corentration of the cells was determined using light scattering at ODSpO. A titered K07 phage stock was added to achieve an multiplicity of infection (M01) of 100, and the phage were allowed to adhere to the cells for 20 minutes at room temperature.
This mixture was then diluted into 25 mls of 2n broth (described in Sambrook et al., supra) and incubated with shaking at 37°C overnight. The next day, cells were pelleted by centrifugation at 5000 x g for 10 mirwtes, the supernatant was collected, and the phage particles were precipitated with 0.5 M NaC;I and 4°~6 PEG (final concentration) at room temperature for t0 minutes. Phage particles were pelteted by centrifugation at 10,000 x g for 10 minutes, resuspended in 1 ml of TEN
(10 mM Tris, pH 7.6,1 mM EDTA, and 150 mM NaCI), and stored at 4°C.
$~
Alpuots of 0.5 ml from a solutbn of 0.1 mglml of the extra~enular domain of the HER-2 antigen (ECD) or a solution of 0.5 mglml of BSA (control antigen) in 0.1 M sodium bicarbonate, pH 8.5 were used to coat one well of a Falcon 12 well tissue wkure plate. Once the solution was applied b the wells, the plates were incubated at 4°C on a rocking plattortn overnight. The plates were then blocked by removing the initial solution, applying 0.5 ml of blocking buffer (30 mghnl BSA in 0.1 M sodium bicarbonate), and incubating at room temperature for one hour.
Finally, the blocking buffer was removed, t m1 of buffer A (PBS, 0.5% BSA, and 0.05°~ Tween-20) was added, and ~e plates were stored up to 10 days at 4°C before being used for phage selection.
Approximately 109 phage particles were mixed with a 100-told excess of K07 helper phage and 1 ml of buffer A . This mixture was divided into two 0.5 ml alpuots; one of which was applied to ECD coated wells, and the other was applied b BSA coated wells. The plates were irxubated at room temperature while shaking for one to three hours, and were then washed three times over a period of 30 minutes with 1 ml alpuots of buffer A.
Elution of the phage from the plates was done at room temperature by one of two methods: t ) an initial overnight incubation of 0.025 mglml purified Mu4D5 antibody (murine) followed by a 30 minute irxubation with 0.4 ml of the add elution buffer (0.2 M glydne, pH 2.1, 0.5°i° BSA, and 0.05°,6 Tween-20), or 2) an incubatan with the acid elutar, buffer alone. Eluates were then neutralized with t M Tris base, and a 0.5 ml aliquot of TEN was added.
These samples were then propagated, titered, and stored at 4°C.
Aliquots of eluted phage were added to 0.4 ml of 2YT broth and mixed with approximately 108 mid-bg phase male E. coil strain SR101. Phage were allowed to adhere to the cells for ZO minutes at room temperature and then added to 5 ml of 2YT broth that contain~,~d 50 trglml of carbenidllin and 5 ~ghnl of tetracycline. These cells were grown at 37°C for 4 to 8 hours until they reached mid-tog phase. The OD6pp was determined, and the cells were superinfected with K07 helper phage fur phage production. Orxe phage particles were obtained, they were titered in order to determine the number of cblony forming units (cfu).
This was done by taking aliquots of serial dilutions of a given phage stock, allowing them to infect mid-log phase SR101, and plating on LB plates containing 50 uglml carbenicillin.
RIA affini dete~(g~
The affinity of h4D5 Fab fragments and Fab phage for the ECD antigen was determined using a competitive receptor binding RIA (Burt, D. R., Receptor Binding in Drug Research. 0'Brien, R.A. (Ed.). pp. 3-29, Dekker, New York (1986)). The ECD antigen was labeled with 125-bdine using the sequential chloramine-T
method (De Larco, J. E. et al., J. Cell. Physiol.109:143-152 [1981J) which produced a radioactive tracer with a spedfic activity of l4~Ci/~g and incorporation of 0.47 moles of Iodine per mole of receptor. A series of 0.2 ml solutions containing 0.5 ng (by ELISA) of Fab or Fab phage, 50 nCi of 1251 ECD
tracer, and a range of unlabeled ECD amounts (6.4 ng to 3277ng) were prepared and incubated at room temperature overnight. The labeled ECD-F~ or ECD-Fab phage complex was separated from the unbound labeled antigen by forming an aggregate complex induced by the addition of an anti-human IgG (Frtzgerald 40-GH23) and 6°~ PEG 8000. The complex was pelleted by centrifugation (t5,000 x g for 20 minutes) and the amount of labeled ECD (in cpm) was determined by a gamma counter. The dissoaation constant (K;d) was calculated by employing a modified version of the program LIGAND (Munson, P. and Rothbard, D., Anal 8iodrem.107~20-239 (1980J) which utilizes Scatchard analysis (Scatdvard, G.,Mn. N. Y. Acad. Sd. 51 ~660~72 [t 949J). The Kd values are shown in Figure 13.
~1L
Murine 4D5 antibody was labeled with 125-I to a spedfic activity of 40-50 ~Cil~g using the lodogen procedure. Solutions containing a constant amount of labeled antibody and increasing amounts of unlabeled variant Fab were prepared and added to near confluent cultures of SK-BR-3 cells grown in 96-welt miaotiter dishes (final concentration of Labeled antibody was 0.1 nM). After an overnight inwbation at 4°C, the supernatant was removed, the cells were washed and the ceu assoaated radioactivity was determined in a gamma counter. Kd Values were determined by analyzing the data using a mo~fied version of the program LiGAND (Mtxtsort, P, and Rothbard, D., supra) This deposit of plasmid pDH188 ATC;C no. 68663 was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture for 30 years from the date of deposit. The organisms will be made available by ATCC
under the terms of the Budapest l reaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent ~~nd unrestncted availability of the progeny of the cultures to the public upon issuance of a Patent on the basis of the application, or the patent application is refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, whichever comes first, and assures 1 0 availability of the progeny to one determined t>y the Commissioner of Patents to be entitled thereto according to Section 109 of the Patent Rules.
The assignee of the present application has agreed that if the cultures on deposit should die or be lost or destroyed when cultivated under suitable conditsons, they will be promptly replaced on notificafan with a viable 15 specimen of the same culture. Availability of the deposited cultures is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordar>Ge with its patent laws.
The foregoing written spedfication is considered to be suffident to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the cultures deposited, since the 20 deposited embodiments are intended as separate illustrations of certain aspects of the invention and any cultures that are funcianany equivalent are within the scope of this invention. The deposit of material herein does not constitute an admissan that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the test mode thereof, nor is tt bo be construed as limiting the scope of the claims to the spedfic illustrations that it represents Indeed, various modifications of the invention in addition to 25 those shown and described herein will become apparent to those skilled in the art from the-foregoing description and fall within the scope of the appended claims.
While the invention has necessarily been described in conjunction with preferred embodiments, one of ordinary skill, after reading the foregoing speafiCation, wt~l be able to effect various d~anges, substitutions of equivalents, and alterations b fhe subject matter set forth herein, without departing from tt>Ie spirit and scope 30 thereof. Hence, the invention can be practiced in ways other than those specificany described herein. ft is therefore intended that the protection granted by utters Patent hereon be limited only by the appended claims and equivalents thereof.
SELECTION OF hGH VARIANTS FROM COMBINATIONS OF HELIX-1 ANO HELJX-4 HORMONE-PHAGE
VARIANTS
According to additivity principles (J. A. Weus, Biochemistry29, 8509 (1990)], mutations in different parts of a protein, ff they are not mutually interacting, are expected to combine b produce additive d~anges in the tree energy of Minding b another molecule (changes are addiCrve in terms of eeGb;~ing, or muftiplicative in terms of Kd = exp(-AGIRT] ). Thus a mutation pndudng a 2-told increase in binding affinity, when combined with a second mutation causing a 3-fold increase, would be predicted to yield a double mutant with a 6-fold increased affinity over the starting variant.
To test whether multiple mutations obtained from hGH-phage selections would produce cumulatively favorable effects on hGHbp (hGH~inding protein; the extraceuular domain of the hGH receptor) binding, we combined mutations found in the three tightest-binding variants of hGH hom the helix-1 library (Example IX:
F10A/M14W/H180/H21N, F10H/M14GIHt8NlH2tN, and F10FIM14S/H18F/H21L) with those found in the three tightest binding variants found in the helix~4b library (Example X:
R167WD171SIT175II179T, R167E/D171 SIT175II179, and R167NID17t NIT~175II179T).
hGH-phagemid double-stranded DNA (dsDNA) from each of the one-helix variants was isolated and digested with the restriction enzymes EcoRl and BstXl. The large fragment from each helix-4b variant was then 2 0 isolated and ligated with the small fragment from each helix-1 variant b yield the new two-helix variants shown in Table XIII. All of these variants also contained tt~: mutations E174SIF176Y
obtained in earlier hGH-phage binding selections (see Example X for details).
Construction of selective combinatorial Ilbrarles of hGH
Although additivity prindples appear b hold for a rwmber of comt~inations of mutations, some combinations (e.g. E174S with F176Y) are dearly non~additive (see examples VIII and X). In order to identify with certainty the tightest binding variant with, for example, 4 mutatans in helix-1 ~ 4 mutations in helix-4, one would ideally mutate all 8 residues at once and then sort the pool for the globally tightest Minding va«ant.
However, such a pool would consist of 1.t x 1012 DNA sequer>ces (utilizing NNS
colon degeneracy) encoding 2.6 x 1010 different polypeptides. Obtaining a random phagemid ~txary large enough to assure representation of all variants (pefiaps 1013 transtortnants) is not practical using ament transformation ledu~ology.
We have addressed this difficulty first by utilizing successive rounds of mutagenesis, taking the lightest binding variant from one library, Ihen mutating otter residues to further improve binding (Example X).
In a second method, we have utilized the principle of additivity b combine the test mutations from two independently sorted Gbra~~es b create multiple mutants with improved binding (described above). Here, we further seard~ed tiuough the possible comt~ir~ations of mutations at positions 10,14,18, 21,167,171,175, and 179 in hGH, by creating comt~ir~atorial libraries of random or partially-random mutants. We constmcted three different comt~ir~atorial libraries of hGH-phagemids, using tf~e pooled phagemids from the helix 1 library (independently sorted for 0, 2, or 4 cycles; F~cample IX) and the pool from the helix-4b library (independently sorted for 0, 2, or 4 cycles; Example X) and sorted the combined variant pool for hGHbp binding. Since some amount of sequence diversity exists in each of these pools; the resulting combir>atorial ~brary can expbre more sequence combinations than what we might canstnxxt manuany (e.g. Table XIII).
hGH-pf~agemid double-stranded DNA (dsONA) from each of the onefielix library pools (selected for 0, 2, a 4 rounds) was isolated and digested with the restriction enzymes Ac~cl and BstXl. The large fragment from each helix-1 variant pool was then isolated and ligated with the smaN fragment from each helix-4b variant pool to yield the three combinatorial wtxaries pH0707A (unseleded helix 1 and helix 4b pools, as described in examples lX
5 and X), pH0707B (twice-selected helix-1 pool with twice-selected helix-4b pool), and pH0707C (4-times selected helix-t pool with 4-times selected helix-4b pool). DupNcate ligations were also set up with less DNA and designated as pH0707D, pH0707E, and pH0707F, corresponding b the 0-,2-, and 4-round starting libraries respectively. All of these variant pools also contained the mutations E174SIF176Y obtained in earlier hGH-phage binding seleaions (see Example X for details).
The rogation products pH0707A-F were processed and eledro-transformed into XL1-Blue cells as described (Example VIII). Based on colony-forming orals (CFU), the number of transfortnants obtained from each pool was as follows: 2.4x106 from pH0707A, l.r~x106 fiom pH07078, 1.6x106 from pH0707C, 8x105 from pH0707D, 3x105 from pH0707E, and 4x105 from pH0707F. hGH-phagemid partides were prepared and selected for hGHbp-binding over 2 to 7 cydes as desait~ed in Example VIII.
In addition to sorting phagemid libraries for tight-binding protein variants, as measured by equilibrium Minding affinity, it is of interest to sort for variants whid7 are altered in either the on-rate (kon) or the off-rate (koff) of binding to a receptor or other molecule. From then~nodyrramics, these rates are related to the equilitxium dissodation constant, ICd = (koH/kpn). We envision that certain variants of a particular protein have similar Kd's for binding while having very different kon's and ko6's.
Conversely, charges in Kd from one variant to another may be due b effects on kon, effects on koff, or both. The pharmacological properties of a protein may be dependent on binding affinity or on Icon or koN, depencfrng on the detailed mechanism of action. Here, we sought to identify hGH variants with higher on-rates to investigate the effects of d~anges in kon. We envision that the selection could aftematively be weighted toward ko(f by increasing the binding time and irxreasing the wash time andlor corxentration with cognate ligand (hGH).
From time~ourse analysis of wild-type hGH-phagemid binding to immobilized hGHbp, it appears that, of the total hGH-phagemid particles that can be eluted in tt~e final pH 2 wash (see Example VIII for the complete Minding and elution protocol), less than 10% are bound after 1 minute of ina~bation, white greater than 90°6 are bound after 15 minutes of irxubatan.
For 'rapid-birxiing selection; phagemid partides from the pH0707B pool (twice-selected for helices 1 and 4 dependently) were incubated with immobilized hGHbp fa only 1 minute, then washed six times with 1 mL of Minding buffer;1he hGH-wash step was omitted; and the remaining hGH-phagemid partides were eluted with a pH2 (0.2M glydne in binding buffer) wash. Enrichment of hGH-phagemid partides over non~dsplaying partides indicated that even with a short binding period and no cognate-ligand (hGH) d~allenge, hGH-phagemid binding selection sorts tight-binding variants out of a randomized pool.
The Minding constants for some of these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the non-suppressor E. aoli strain 1609 or 3488, purifying the protein, and assaying by competitive displacement of labelled wtfiGH from hGHbp (see Example VIII) in a radio-immunopreciptation assay.
In Table XIII -A below, all the variants have glutamate174 roP~~d bY ~~174 ~d p~~a~~176 re~aced by tYro~~176 (E174S and F1176Y) plus the additianal substitutions as indicated at hGH amino acd positions 10, 14,18, 21, t 67,171,175 and 179.
Table XIII-A
hGH
variants from adddon of helbc-t and heax-4b mtrcattons H
f H
f e e oc oc wild-type residue:~,Q ~g ~$ ~, $1Z ~1j1 I1Z~ ll,Z,Q
V
t arian H G N N N S T T
In Table XIV below, hGH variants were selected from comtHrwtorial libraries by the phagemid tHnding selection process. All hGH variants in Table XIV contain two background mutations (E174SIF176Y). hGH-phagemid pools from the libraries pH0707A (Part A), pH0707B and pH0707E (Part B), or pH0707C (Part C) were sorted for 2 b 7 cydes for binding to hGHbp. The number p indicates the fractional occurrence of each variant type among the set of dories sequenced from each pool.
Table XIV
hGH varlaMs from t~omane-pt~aperdd bindnp selection Of combtnabrial Itbraries.
~ ~~ Helix wild-type ~Q ~4 ~ b21 Hl,fiZp~,u I11~ ll18 residue:
Y~I
Part 4 cycles:
A :
0.60 H07t4A.1 H (i N N N S T N
0.40 H0714A.4 A N D A N N T N
' Part B:
2 cycles:
0.13 H0712B.1 F S F G H S T T
0.13 H0712B.2 H C~ T S A D N S
0.13 H07t2B.4 H G N N N A T T
0.13 H0712B.5 F S F L S D T T
0.13 H0712B.6 A S T N R D T I
0.13 H0712B.7 Q 1' N N H S T T
0.13 H0712B.8 W (a S S R D T I
2 0.13 H0712E.1 F 1. S S K N T V
0.13 H0712E.2 W PJ N S H S T T
0.13 H0712E.3 A fJ A S N S T T
0.13 H0712E.4 P ;i D N R D T I
0.13 H0712E.5 H (i N N N N T S
0.13 H0712E.6 F ;; T G R D T I
0.13 H0712E.7 M T S N Q S T T
0.13 H0712E.8 F ;i F L T S T S
4 cycles:
0.17 H07148.1 A W D N R D T I
0.17 H0714B.2 A W D N H S T N
0.17 H0714B.3 M Q M N N S T T
0.17 H0714B.4 H Y D H R D T T
0.17 H0714B.5 L fJ S H R D T I
0.17 H0714B.6 L fJ S H T S T T
3 7 cycles:
0.57 H0717B.1 A W D N N A T T
0.14 H07t7B.2 F S T G R D T I
0.14 H0717B.6 A W D N R D T I
0.14 H0717B.7 I Q E H N S T T
0.50 H0717E.1 F S L A N S T V
Part C:
4 cycles:
0.67 H0714C.2 F S F L K D T T
' s also contained the mutations L15R, K168R.
In Table XV t~ebw, hGH variants were selected from combinatorial libraries by the phagemid Minding selection process. All hGH variants in Table XV contain two background mutations (E174SlF176Y). Trie numt~er P is the fractional occurrence of a given variant among all doves sequenced after 4 cycles of rapid-Minding selection.
Table XV
hGH vartarns from RAPID
hGHbp btndinp selectlm of an hG~+-phagemid combinabo~ial Itbrary Hela 1 Hela _ wild-typeresidue: ~,Q ~g J~$ ~, $
Y~tl~nt 0.14 H07BF4.2 W G S S R D T I
0.57 H07BF4.3 M A D N N S T T
0.14 H078F4.6 A W D N S S V T $
0.14 H07BF4.7 H Q T S R D T I
$ = also contained the mutation Y176F (wild-type hGH also contains F176).
In table XVI below, binding constants were measured by competitive displacement of 1251-labelled hormone H0650BD or labelled hGH using hGHbp (1-238) and either MabS.ar~lAab263. The variant H0650BD
appears tHnd more than 30-fold tighter than wild-type hGH.
Tade XVI
Equlubrt~n bkx~p oor~ar~ of s~ec~ hGH vartanfs.
hGH K~(variantl Kd(variantl Variant Kd(H0650BD) Kd(hGH) Kd (per, hGH 32 -1- 340 t H06508D -1- 0.031 10 t H0650BF 1.5 0.045 15 t H0714B.6 3.4 0.099 34 t H0712B.7 7.4 0.22 74 t H0712E.2 16 0.48 60 t EXAMPLE XIII
Selective enrichment of trGH-phage contalnlng a protease substrate sequence versus r~on-substrate phage As described in Example I, the plasmid pS0132 contains the gene for hGH fused to the residue Pro198 of the gene tll protein with the insertion of an extra glycine residue. This plasmid may be used to produce hGH-phage particles in which fhe hGH~ene III fusion product is displayed monovalently on the phage surface (Example IV). The fusion protein comprises the entire hGH protein fused to tf~e carboxy terminal domain of gene III via a flexible linker sequence.
To investigate the feasit~ility of using phage display technology to select favourable substrate sequences for a given proteolytic enzyme, a genetically engineered variant of subtilisin BPN' was used. (Carter, P.
et al., Proteins: Structure, furxtion and genetics 6:240-248 (1989)). This variant (hereafter referred to as A64SAL subtilisin) contains the folbwing mutations: Ser24Cys, His64Ala, GIu156Ser, GIy169A1a and Tyr217Leu. Since this enzyme lades the essential catalytic residue His64, its substrate spedfidty is greatly restricted so that certain histidine-containing substrates are preferentially hyrdrolysed (tJarter et al., Science 237:394-399 (1987)).
The sequence of the linker region in pS0132 was mutated to aeate a substrate sequence for A64SAL
subtilisin, using the oligonucleotide 5'-TTC-GGG-CCC-TTC-GCT-GCT-CAC-TAT-ACG-CGT-CAG-TCG-ACT-GAC-CTG-CCT-3'. This resulted in the introduction of the protein sequence Phe-Gly-Pro-Phe-Ala-Ala-5 His-Tyr-Thr-Arg-Gln-Ser-Thr-Asp in the linker region between hGH and the carboxy terminal domain of gene III, where the first Phe residue in the above sequence is Phe191 of hGH. The sequerxe AJa-Ala-His-Tyr-Thr-Agr-Gln is krwvm to be a good substrate for A64SAL subtilisin (Carter et al (1989), supra). The resulting plasmid was designated pS0640.
Phagemid particles derived from pS0132 and pS0640 were constructed as described in Example I. In initial experiments, a tON.I aliquot of each phage pool was separately mixed with 30p1 of oxirane beads (prepared as described in Example II) in 100W of buffer comprising 20mM Tris-HCI pH 8.6 and 2.5M NaCI. The binding and washing steps were performed as described in example VII. The beads were then resuspended in 4001 of the same buffer, with or without 50nM of A64SAL subtilisin. Following incubation for 10 minutes, the supernatants were collected and the phage titres (cfu) measured. Table XVII shows that approximately 10 times more substrate-containing phagemid particles (pS0640) were eluted in the presence of enzyme than in the absence of enzyme, or than in the case of the non-substrate phagemids (pS0132) in the presence or absence of enzyme. Increasing the enryme, phagemid or bead concentrations did not improve this ratio.
In an attempt to decrease the non-spedfic elution of immobilised phagemids, a tight-binding variant of hGH was introduced in place of the wild-type hGH gene in pS0132 and pS0640. The hGH variant used was as described in example XI (pH0650bd) and contains the mutations PhelOAla, Metl4Trp, Hisl8Asp, His2fAsn, Arg167Asn, Asp171Ser, GIu174Ser, Phe176Tyr and IIe179Thr. This resulted in the construction of two new phagemids: pDM0390 (containing tight-binding hGH and no substrate sequence) and pDM0411 (containing tight-binding hGH and the substrate sequence Ala-Ala-His-Tyr Thr Agr-Gln). The birx~ng washing and elution protocol was also changed as follows:
() Binding: COSTAR 12-well fassue culture plates were coated for 16 hours with 0.5mUwell 2ug/ml hGHbp in sodium carbonate buffer pH 10Ø The plates were Then Incubated with tmllwell of blocking buffer (phosphate buffered saline (PBS) containing 0.1%wN bovine serum albumen) for 2 hours and washed in an assay buffer containing lOmM Tris-HCI pH 7.5, 1 mM EDTA and 100mM NaCI. Phagemids were again prepared as described in Example I: the phage pool was diluted 1:4 in the above assay buffer and 0.5m1 of phage incubated per well for 2 hours.
(i) Washing: The plates were washed thoroughly with PBS + 0.05% Tween 20 and incubated for 30 minuted with 1 ml of this wash buffer. This washing step was repeated three times.
(ii) Eution: The plates were irxubated for 10 minutes in an elution buffer consisting of 20mM Tris-HCI pH 8.6 + t OOmM NaCI, then the phage were eluted with 0.5m1 of the above buffer with or without 500nM of A64SAL subtilisin.
Table XVI I shows that there was a dramatic incxease in the ratio of specifically eluted substrate-phagemid particles compared to the method previously described for pS0640 and pS0132. ft is likely that this is due tv the fad that the tight-binding hGH
mutant has a significantly sbwer off-rate for binding to hGH binding protein compared to wild-type hGH.
Table XVII
SpecIflc elution of substrate-phagem(ds by A64SAL subt111sIn Colony forming units (du) were estimated by plating out l0pl of 10-fold dilutions of phage on l0pl spots of XL-1 blue cells, on LB agar plates containing 50pg/ml carbeniallinl (i) wld-type hGH gene: binding to hGHbp-oxirane beads pS0640 (substrate) 9x106cfu/l0pl 1.5x106cfu/l0ul pS0132 (non-substrate) l3x105cfu/tOpl 3x105cfu/l0ul (ii) pH0650bd mutant hGH gene: Minding to hGHbp-coated plates pDM0411 (substrate) 1.7x105cfu/tOp.l 2x103cfult0ul pDM0390 (non-substrate) 2x103cfu/l0pl 1x103cfu/tOpl Example XIV
Identlt(catlon of preferred substrates for A64SA~ subttllsln using selective enrichment of a Itbrary of substrate sequences.
We sought to employ the selective enrichment procedure described in Example XIII to identify good substrate sequences from a library of random substrate sequences.
We designed a vector suitable tar introduction of randomised substrate cassettes. and subsequent expression of a library of substrate sequences. The starting point was the vector pS0643, described in Example VIII. Site-directed mutagenesis was carried out using the oligor>ucleotide 5'-AGGTGT-GGC-TTC ' C-GCGGCG-TCG-ACT-GGC-GGT-GGC-TCT-3', which introduces ~[ (GGGCCC) and ; 811 (GTCGAC) restriction sites between hGH
and Gene III. This new construct was designated p0M0253 (The actual sequence of pDM0253 is 5'-AGC-TGT-GGC-TTC-GGG-CCC~CC-ACC-GCG-TCG-ACT-CGC-GGT-GGC-TCT-3', where the underlined base substitution is due to a spurious error in the mutagenic oligonucleotide).
In addition, the tight-binding hGH variant described in example was introduced by exchanging a fragment from pDM041 t (example XIII) The resulting library vector was designated pDM0454.
To introduce a library cassette, pDM0454 was digested with Apal followed by Sall, then precipitated with 13~o PEG 8000+ lOmM MgCl2, washed twice in 7096 ethanol and resuspended This etfaently precipitates the vector but leaves the small Apa-Sal fragment in solution (Paithankar, K. R. and Prasad, K. S. N., Nucleic Acids Research 19:1346). The product was run on a 1% agarose gel and the Apal-Sall digested vector excised, purified using a Bandprep kit (Pharmacia) and resuspended for ligation with the mutagenic cassette.
The cassette to be inserted contained a DNA sequence similar to that in the linker region of pS0640 and pDM0411, but with the colons for the histidine and tyrosine residues in the substrate sequence replaced by randomised colons. We chose to substitute NNS
(N=G/AIT/C; S=G/C) at each of the randomised positions as described in example VIII. The oligonucleotides used in the mutagenic cassettes were: 5'-C-TTC-GCT-GCT-NNS-NNS-ACC-CGG-CAA-3' (ood~ng strand) and 5'-T-CGA-TTG-CCG-GGT-SNN-SNN-AGC-AGC-GAA-GGG-CC-3' (non-coding strand). This cassette also destroys the Sall site, so that digestion with Sall may be used to reduce the vector background. The oligonucteotides were not phosphorylated before insertion iMo the Apa-Sal cassette site, as it was feared that subsequent oligomerisation of a small population of the cassettes may lead to spurious results with multiple cassette inserts. Following annealing and ligation, the reaction products were phenol:chloroform extracted, ethanol precipitated and resuspended in water.
Initially, no digestion with Salt to reduce the background vector was performed.
Approximately 200ng was eledroporated into Xt_-1 blue cells and a phagemid library was prepared as described in example VIII.
$electfon of h[gJy cleawable substrates from the substrate Ilbrarv The selection procedure used was identical to that described for pDM0411 and pDM0390 in example XIII. After each round of selection, the eluted phage were propagated by transduang a fresh culture of Xt-1 blue cells and propagating a new phagemid library as described for hGH-phage in example VIII. The progress of the selection procedure was monitored by measuring eluted phage titres and by sequenang individual clones after each round of selection.
Table A shows the successive phage titres for elution in the presence and absence of enryme after 1, 2 and 3 rounds of selection.
Clearly, the ratio of specifically eluted phage: non-specifically eluted phage (ie phage eluted with enzyme:phage eluted without enzyme) increases dramatically from round 1 to round 3, suggesting that the population of good substrates is increasing with each round of selection.
Sequencing of 10 isolates from the starting library showed them all to consist of the wild-type pDM0464 sequence. This is attributed to the fad that after digestion with Apal, the Sall site is very cbse to the end of the DNA fragment, thus leading to bw efficiency of digestion. Nevertheless, there are only 400 possible sequences in the ibrary, so this population should still be welt represented.
Tables B1 and 82 shows the sequences of isolates obtained after round 2 and round 3 of selection. After 2 rounds of selection, there is clearly a high incidence of histidine residues. This is exactly what is expelled: as described in example XIII, A64SAL subtilisin requires a histidine residue in the substrate as it employs a substrate-assisted catalytic mechanism. After 3 rounds of selection, each of the 10 clones sequenced has a histidine in the randomised cassette. Note, however, that 2 of the sequences are of pDM0411, which was not present in the starting library and is therefore a contaminant.
Table A
Tttratlon of Initial phage pools and eluted phage from 3 rounds of aelectlve enrichment Colony forming units (cfu) were estimated by plating out 10~f of 10-fold dikrtions of phage on 10.1 spots of XL-1 blue cells, on LB agar plates containing 50pg1m1 carberwcillin H~1~1 Starting library:3x1012 cfu/ml LIBRARY: +500nM A64SAL. 4x103 dultOpl :
no enzyme : 3x103 du/l0pl pDM0411: +500nM A64SAL 2x106 cfu/tOpl :
(control) no enzyme : 8x103 cfull0pl Round 1 library:7x1012 cfulml LIBRARY: +500nM A64SAL 3x104 cfu/10p.1 :
no enzyme : 6x103 CfullOUl pDM0411: +500nM A64SAL 3x106 cfu110p1 :
(control) no enzyme : 1.6x104 cfu/10~1 Round 2 library:7x1011 cfu/ml LIBRARY: +500nM A64SAL. 1x105 Cfu/10p1 :
no enzyme : <103 ctu/l0pl pDM0411: +500nM A64SAL 5x106 cfu/10~1 :
(control) no enzyme : 3x104 cfu/l0pl Teble Bt Sequences of eluted phape after 2 rounds of selective enrichment.
5 All protein sequences should be of the form AA"TRH, where' represents a randomised colon. In the table below, the randomised colons and amino acids are underlined and in bold.
After round 2:
Seauence lyo~of ~rences A A $ Y T R Q
... GCT GCT~ ACC CGGCAA ... 2 A A $ $ T R Q
2O ... GCT GCT~ ACC CGGCAA ... 1 A A y $ T R Q
... GCT GCTCTC ACC CGGC:AA ... 1 CAC
A A y $ T R Q
... GCT GCTCTG ACC CGGC:AA ... 1 CAC
A A $ ~ R Q
... GCT GCT~ CGG CAA... 1 #
A A ~ $ T R Q
... GCT GCT??? ACC CGGC;AA 1 CAC
.., wild-type 3 pDM0454 # - spurious deletion of 1 colon within the cassette ## - ambiguous sequence Table B2 S~pncps n~ eluted nha,ge after 3 rounds of selective enrichment All protein represents sequences a should be of the form AA"TRQ, where' rarxiomised the table below, the randomised colon. in colons and amino acids are underlined and in bolo.
After round 3:
i~d~lJ~.~'~
A A $ z T R Q
... GCT GCT TAT ACG CGT CAG ... 2 r$C
A A ji $ T R Q
... GCT GCT ACC CGG CAA ... 2 ~
A A Q $ T' R Q
... GCT GCT ACC CGG C;AA ... 1 A A ~ $ T R Q
... GCT GCT CAC ACC CGG CAA ... 1 A A $ $, R Q
... GCT GCT TCC CGG CAA ... 1 CAC
A A $ $ T R Q
3 . . . GGT GCT ,('$'r ACC CGG CAA 1 # #
0 C~3' A A $ F R Q
... GCT GCT TTC CGG CAA ... 1 ('.8C
A A $ S R Q
... GCT GCT ~ CGG CAA ... 1 ~
# - contaminating sequence from pDM0411 ## - contains "illegal" colon CAT - T should the not appear in the 3rd position of a 4 colon.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Genentech, Inc.
Garrard, Lisa J.
Henner, Dennis J.
Bass, Steven Greene, Ronald Lowman, Henry 8.
Wells, James A.
Matthewa, David J.
(ii) TITLE OF INVENTION: Enrichment Method For Variant Proteins With Altered Binding Properties (iii) NUMBER OF SEQUENCES: 27 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genentech, Inc.
(B) STREET: 460 Point San Bruno Blvd (C) CITY: South San Francisco (D) STATE: California (E) COUNTRY: USA
(F) ZIP: 94080 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: patin (Genentech) (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 03-DEC-91 (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/743614 (8) APPLICATION DATE: 09-Aug-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/715300 (B) APPLICATION DATE: 14-June-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/683400 (B) APPLICATION DATE: 10-Apr-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/621667 (B) APPLICATION DATE: 03-Dec-1990 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Benson, Robert H.
(B) REGISTRATION NUMBER: 30,446 (C) REFERENCE/DOCKET NUMBER: 645P4 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 415/266-1489 (B) TELEFAX: 415/952-9881 (C) TELEX: 910/371-7168 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
(2) INFORMATION FOR SEQ ID N0:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
(2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
(2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 bases (8) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
(2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:5:
(2) INFORMATION FOR SEQ ID N0:6:
(1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
(2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENGE CHARACTERISTICS:
(A) LENGTH: 21 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
(2) INFORMATION FOR SEQ ID N0:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
(2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
(2) INFORMATION FOR SEQ ID NO;11:
5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
(2) INFORMATION FOR SEQ ID N0:12:
(i) SEQUENCE CHARACTERISTICS.:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:12:
(2) INFORMATION FOR SEQ ID N0:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids (B) TYPE: amino acid (D) TOPOLOGY: .linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:13:
Gly Ser Cys Gly Phe Glu Ser Gly Gly Gly Ser Gly (2) INFORMATION FOR SEQ ID N0:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 bases (8) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:14:
(2) INFORMATION FOR SEQ ID N0:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 bases (8) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:15:
(2) INFORMATION FOR SEQ ID N0:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:16:
(2) INFORMATION FOR SEQ ID N0::17:
(i) SEQUENCE CHARACTERISTICtS:
(A) LENGTH: 66 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:
(2) INFORMATION FOR SEQ ID N0:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single>
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:18:
(2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:19:
(2) INFORMATION FOR SEQ ID N0:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:20:
(2) INFORMATION FOR SEQ ID N0:2.1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:21:
(2) INFORMATION FOR SEQ ID N0:22:
(i) SEQUENCE CHARACTERISTICS.:
(A) LENGTH: 58 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:22:
GTGTCAAAGG CCAGCTGSNN AAC:ACGSNNA GCACGCAGSN NCGCGTTGTC 50 (2) INFORMATION FOR SEQ ID N0:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 65 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:23:
(2) INFORMATION FOR SEQ ID N0:24:
(i) SEQUENCE GHARACTERISTICS:
(A) LENGTH: 64 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE SCRIPTION:SEQ ID
DE N0:24:
(2) INFORMATION
FOR SEQ ID N0:25:
(i) SEQUENCE CH ARACTERISTICS:
(A) LENGTH: 2178 bases (B) TYPE: n ucleic acid (C) STRANDE DNESS: le sing (D) TOPOLOG Y: linear (xi) SEQUENCE SCRIPTION:SEQ ID
DE N0:25:
_ GCTGCCTGGT CAAGGACTACT'CCCCCGAACCGGTGACGGTGTCGTGGAAC1350 CAGTCTGACG CTAAAGGCAAAC'.TTGATTCTGTCGCTACTGATTACGGTGC1850 (2) INFORMATION FOR SEQ ID N0:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 237 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:26:
Met Lys Lys Asn Ile Ala Phe Leu Leu Ala Ser Met Phe Val Phe Ser Ile Ala Thr Asn Ala Tyr Ala Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Va). Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lye His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys (2) INFORMATION FOR SEQ ID N0:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 461 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:27:
Met Lys Lys Asn Ile Ala Phe Leu Leu Ala Ser Met Phe Val Phe 1 5 10 ' 15 Ser Ile Ala Thr Aen Ala Tyr Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pra Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Se:r Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Gly Pro Phe Val Cys Glu Tyr Gln Gly Gln Ser Ser Asp Leu Pro Gln Pro Pro Val Asn Ala Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly Aap Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn :Lys Gly Ala Met Thr Glu Asn Ala Asp Glu Aen Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala Thr Aep Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Aan Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn Ser Pro Leu Met Aan Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser
The cycles of phagemid selection are repeated until the desired affinity properties of the ligand polypeptide are achieved. To illustrate this process, Example VIII phagemid selection of hGH
was conducted in cycles. In the first cycle h~H amino adds 172,174,176 arxf 178 were mutated and phagemid selected.
In a second cycle hGH amino aads 167,171,175 and 179 were phagemid selected. In a >fiird cycle hGH amino aads 10,14,18 and 21 were phagemid selected. Optimum amino add d~anges from a previous cycle may be irxorporated into the polypeptide before the next cycle of selection. For example, hGH amino adds substitution 174 (serine) and 176 (tyrosine) were irxorporated into the hGH belore the phagemid selection of hGH amino adds 167,171,175 and 179.
From the forgoing it will be appreaated that the amino add residues that form the binding domain of the polypeptide will not be sequentially linked and may reside on different subunits of the polypeptide. That is, the binding domain tracks with the particular secondary structure at the binding site and not the primary structure. Thus, generally, mutations will be introduced into colons erxoding amino acids within a particular secondary structure at sites directed away from the interior of the polypeptide so that they will have the potential to interact with the target. By way of illustration, Figure 2 shows the location of residues ~ hGH that are known to strongly modulate its binding to the hGH-binding protein (t,.tmrungham ef aL, Silence 247:1461-1465 [1990. Thus representative sites suitable for' mutagenesis word include residues 172, 174, t 76, and 178 on helix-4, as well as residue 64 located in a 'ran-ordered' secondary struchue.
There is no requirement that the polypeptide chosen as a Ggand to a target normally hind to that target.
Thus, for example, a glycoprotein hom~one such as TSH can be chosen as a Ggand for ~e FSH receptor and a litxary of mutant TSH molecules are employed in the method of Ibis invention to produce ravel drug candidates.
This invention thus contemplates any polypeptide that binds to a target molecule, and inGudes antibodies. Preferred polypeptides are those that have phartnaoeutical utUity.
More preferred polypeptides 3 5 include; a growth hamone, including human growth hormone, des-N~nethionyl human growth t~om~or>e, and bovine growth hormone; parathyroid hormone; thyroid stimulating hormone; thyroxine;
insulin A~hain; insulin B-drain;
proinsulin; follicle stimulating hormone; caldtoryn; IeuGnizing hormone;
glucagon; factor VIII; an antibody; lung surfactant; a plasminogen activator, such as urokinase or human tissue-type plasmiragen activator (t-PA);
bombesin; factor IX, thromt~in; hemopoietic growth factor; tumor nea~osis factor-alpha and -beta; enkephaGnase; a seem altxnnin such as txxnan senxn alt~urrun; mullerian-inhibiting substance;
r~ala~dn A~chain; r~elaxin B~hain;
prorelaxin; mouse gonadotropin-assoaated peptide;. a microbial protein, such as betalactamase; tissue factor protein; inhibin; activin; vascular endothelial growth factor; receptors for hormones or growth factors; integrin;
thrombopoietin; protein A or D; rheumatoid factors; nerve grvwrth factor such as NGF-~; platelet~lerived growth factor; filxoblast growth tailor such as aFGF and bFGF; epidermal growth factor; transforming growth factor (TGF) such as TGF-alpha and TGF-beta; insulin-like growth factor-I and -If;
insufiMike growth factor binding proteins; CD-4; DNase; laterxy assoaated peptide; eryftxopoietin;
osteoinductive factors; an interferon such as interferon-alpha, -beta, and -gamma; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF;
interleukins (ILs), e.g., IL-1, IL-2, IL-3, IL-4, etc.; superoxide dismutase;
decay accelerating factor; atria) nafiuretic peptides A, B or C; viral antigen such as, for example, a portion of the HIV ernebpe; immunogbt~ulins;
and fragments of any of the above-listed polypeptides. h addition, one or more predetermined amino acrd residues on the polypeptide may be substituted, inserted, or deleted, for example, to produce products with improved t~iological properties. Further, fragments of these polypeptides, espeaally bblogically active fragments, are inGuded. Yet more prefered polypeptides of this invention are human growth hormone , and atria) naturetic peptides A, B, and C, endotoxin, subtilisin, trypsin and other serine proteases.
Still more preferred are polypeptide hormones that can be defined as any amirp acid sequence produced in a first cell that hinds specifically to a receptor on the same cell type (autocrine hormones) or a second cell type (non-autocrine) and causes a physiological response characterisC~c of the receptor-bearing cell. Among such polypeptide hormones are cytokines, lymphokines, neurotrophic hormones and adenohypophyseal pdypeptide 2 0 hormones such as gowth hormone, prolactin, placental lactogen, luteinizing hormone, follicle-stimulating hormone, thyrotropin, cho~bnic gonadotropin, corticotropin, a or ~-melanocyte-stimulating hormone, ~-lipotropin, y-lipotropin and the endorphins; hypothatmic release-~tubit'rcg hormones such as corticotropin-release factor, growth hormone release-inhibiting hormone, growth hormone-release factor; and other polypeptide hormones such as atria) natriuretic peptides A, B or C.
IL
The gene encoding the desired polypeptide (i.e., a polypeptide with a rigid secondary structure) can be obtained by methods known in the art (see generally, Sambrook et al. , Molecular Biolygy~,aboratopr Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York (1989]). If the sequence of the gene is known, the DNA erxoding the gene may be chemically synthesized (Merfield.
,L.901.Sh~.s~G... 85 2149 (1963]). If the 3 0 sequerxe of the gene is not known, a it the gene has not previously been isolated, it may be domed from a cDNA
library (made from RNA obtained from a suitable tissue in which the desired gene is expressed) or from a suitable genomic DNA blxary. The gene is then isolated using an appropriate probe. For cDNA libraries, suitable probes inGude morador~al or polydonal antibodies (provided that the cDNA Gtxary is an expression litxary), oGgorwdeotides, and complementary or homologous cDNAs or fragments thereof.
The probes that may be used to isolate the gene of interest from genomic DNA libraries include cDNAs or fragments thereof that encode the same or a similar gene, tamobgous geramic DNAs a ONA tr~ments, and oligonudeotides.
Saeerwng the cDNA or genomic library with the selected probe is conducted using standard procedures as described in chapters 10-t 2 of Sambrook et al., supra.
M alternative means b isolating the gene encoring the protein of interest is b use polymerise chain reaction methodology (PCR) as described in section 14 of Samtxook et al., supra. This mettad requires the use of oligonudeotides that will hybridize to the gene of interest; thus, at least some of the DNA sequence for this gene must be known in order to generate the oligonudeotides.
After the gene has been isolated, it may be inserted into a suitab4e vector (preferably a plasmid) for ampl'rfication, as described generally in Sambrook et al., sera.
1f<.
While several types of vectors are available and may be used b practice this irnention, plasmid vectors are the preferred vectors for use herein, as they may be carrst<rxted with relative ease, and can be readily amplified. Ptasmid vectors generally contain a variety of components inducting promoters, signal sequences, phemtypc selection genes, origin of replication sibs, and other necessary oomponer>ts as are known to those of ordinary skill in the art.
Promoters most commonly used in prok~afic vedarsino~xie they Z promoter system, the alkaline phosphatase g~ A promoter, the bacd~pr~age ~ promorter to temperature sensitive promoter), the ~
promoter (a hybrid ~-j~ promoter #rat is regulated by the )~, repressor), the tryptophan promoter, and the bacteriophage T7 promoter. For general desaip~ons of promoters, see section 17 of Samtxook et al. supra .
While these are the most commonly used promote, other su~ie r~crobial promoters may be used as well.
Preferred promoters for practicing this inver~an arre (hose that can be tightly regulated such that expression of the fusion gene can be controlled, It is believed that the problem that went unrecognized in the 2 0 prior art was that display of multiple copies of the fusion protein on the surface of ifie phagemid partite lead to multipoint attachment of the phaga~id ~ the target. It is believed this effect, referred to as the 'chelate effect', results in selection of false high affrtrity' palypeptides den multiple copies of the fusion protein are displayed on the phagemid particle in dose proximity m errs a~oft~er so that the target was'chelated'. When multipoint attachment occurs, the effective or apparent Kd may be as high as the product of the individual Kds for each copy of the displayed fusion protein. This effect may be the reason Cwirta and coworkers supra were unable to separate moderate affinity peptides frorti higher affinity peptides.
It has been discovered that by tightly regulating expressan of the (usan protein so that no more than a minor amount, i.e. fewer than about 1%, of the ptragemid particles contain multiple copies of the fusion protein tire 'chelate effect' is overcome allowing proper selection of high affinity polypeptides. Thus, depending on the promoter, culturing conditions of tire host are adjusted b maximize the number of phagemid particles containing a single copy of fhe fusion protein and minimize the number of ptragemid partiGes containing multiple copies of the fusion protein.
Preferred promoters used b practice this invention are the j~ Z promoter and the p~ A promoter.
The (~ Z promoter is regulated by the tic repressor protein 1~ i, and thus transcription of the fusion gene can be controlled by manipulation of the level of the lac repressor protein. By way of ilustration, the phagemid containing the )~ Z promotor is grown in a cea strain that contains a copy of the J~ i repressor gene, a repressor for the )~ Z promobr. Exemplary cell strains containing the j~ i gene irrdude JM 101 and XL1-blue. In the alternative, the host cea can be cotranstected with a plasmid contairrirrg both the repressor j~ i and the ~ Z promobr.
Occasionally both of the above techniques are used simultaneously, that is, phagmide particles containing the l~ Z
promoter are groan in cell strains contairunp the ,~ i gene and the ce1 strains are cotransfected with a plasmid oontairwnp both the ~ Z and )~ t genes. Normally when one wishes b express a gene, b the transfected host above one would add an induoer such as isopropylthiogalacbside (IPTG). h the present invention however, tfys step is omitted to (a) minimize the expression of the gene III fusion protein thereby minimizing the copy number (i.e. the ru~mben of gene III fusans per phagemid rxunber) and b (b) prevent poor or improper packaging of the phagemid caused by induoers such as IPTG even at k>w concer>trations.
Typcally, when no inducer is added, the number of fusion proteins per phagemid particle is about 0.1 (number of bulk fusion proteinslnumber of phagemid particles). The most preferred promoter used b pr~dctice this invention is ~
A. Ttws promoter is believed to be regulated by the level of inorganic phosphate in the cell where the phosphate acts to down-regulate the activity of the promoter. Thus, by depleting cells of phosphate, the activity of the promoter can be increased. The desired result is achieved by growing cells in a phosphate enridied medium such as 2n or l.8 (hereby controlling the expression of the gene III fusion.
One other useful component of vectors used to practice ttys invention is a signal sequence. This sequence is typcally located immediately 5' to the gene encoding the fusion protein, and will thus be transcribed at the amino terminus of the fusion protein. However, h certain cases, the signal sequerxe has been demonstrated to be located at positions other 5' to the gene encoding the protein to be secreted. This sequence targets the protein to which it is attad>ed across the inner membrane of the bacterial cell. The DNA
encoding the signal sequerxe may be obtained as a restriction endonuGease fragment hom any gene encoding a protein that has a signal sequence.
Salable prokaryotic signal sequerx~s may be obtained from genes encoding, for example, l.amB or OmpF (along et aL, ~, 68:193 [1983)), MaIE, PhoA and otter genes. A preferred prokaryotic signal sequence for practiclng this invention is the E. colt teat-stable enterotoxin II (STU) signal sequence as described by Chang et al. , Wig, 55: 189 [1987).
Another useful component of the vectors used to pract'~ce this invention is phenotypic selection genes.
Typical phenotypic selection genes are those encoding proteins that confer antibiotic resistance upon the host cell.
By way of illustration, the ampicillin resistance gent; (~), and the tetracycline resistance gene (I~ are readily empbyed for this prxpose.
Construction of suitable vectors comprising the aforementioned components as wen as the gene encoding the desired polypeptide (gene 1 ) are prepared using standard recombinant DNA
procedures as described in Sambrook et aL supra. Isolated DNA fragments to be combined b form the vector are cleaved, tailored, and ligated together h a spedfic order and orientation to generate the desired vector.
The DNA is cleaved using the appropriate restriction enzyme or enzymes h a suitable buffer. In general, about 0.2-1 ~g of plasmid or DNA fragments is used with about 1-2 units of the appropriate restriction eruyme in about 20 ~( of buffer solution. Appropriate buffers, DNA concentrations, and hcubation times and temperatures are sped6ed by the manufacturers of the restriction enzymes.
Generatiy, incubation times of about 3 5 one or two tours at 3TC are adequate, alttough several enzymes require higher temperatures. After incubation, the enzymes and other cor~aminants are removed by extraction of the dgestion solution with a mixture of phenol and d~lorofarm, and the DNA is recovered from the aqueous fraction by precipitation with ethanol.
To ligate the DNA fragments together to town a functional vector, the ends of the DNA fragments must be compatible with each other. h some cases, the ends w~ be dred~y compatible after erKiorwdease digestion. However, it may be necessary to first convert the sticky ends commoMy produced by endonuGease digestan b blunt ends ~o make them compatible for kgatan. To Bunt tt~e ends, the DNA is treated in a suitable buffer for at least 15 minuDes at 15'C with 10 units of of the Klenow fragment of DNA polymerase I (Klerpw) in the presence of the four deoxynudeotide triphosphates. The DNA is then purified by phenol-d>toroform extraction and ethanol predpitatbn.
The cleaved DNA fragments may be size-separated and selecl3ed using DNA gel electrophoresis. The DNA may be electrophoresed through either an agarose or a potyacrylamide matrix. The selection of the matrix will depend on the size of the DNA fragments to be separated. After electrophoresis, the DNA is extracted from the matrix by eledroewtion, or, if bw~nelting agarose has been used as the matrix, by melting the agarose and extracting the DNA from it, as described in sections 6.30-6.33 of Sambrook et aL, supra.
The DNA fragments that are to be ligated together (previously digested with the appropriate restriction enzymes such that the ends of each fragment to be ligated are compatible) are put in solution in about equimotar amounts. The solution will also contain ATP, Ggase buffer and a ligase such as T4 DNA lipase at about 10 units per 0.5 up of DNA. If the DNA fragment is to be ligated into a vector, the vector is at first linearized by cutting with the appropriate restriction erxionudease(s). The linearized vector is then treated with alkaline phosphatase or calf intestinal phosphatase. The phosphatasing prevents self-ligatbn of the vector during the ligation step.
After ligation, the vector with the foreign gene now inserted is transformed into a suitable host cell.
Prokaryotes are the preferred host cells for this invention. Suitable prokaryotic host cells include E. colt strain JMlOt, E. colt K12 strain 294 (ATCC number 31,446), E. colt strain W3110 (ATCC
number 27,325), E. colt X1776 (ATCC numt~er 31.537), E. colt XL-1 Blue (stratagene), and E. colt B;
however many other strains of E.
colt, such as HBt0l; NM522, NM538, NM539, and many other speaes and genera of prokaryotes may be used as well. in addition to the E. colt strains listed above, bacilli such as ~, other enterobacteriaceae such as Salmonella iwhimurium a and various p,~.t,~~ speaes may all be used as hosts.
Transformation of prokaryotic cells is readily accomplished using the caldum d~loride method as described in section 1.82 of Sambrook et aL, supra. Alternatively, electroporation (Neumann et al., E_mB0 J..
1:841 [1982)) may be used to transform these cells. The transformed cells are selected by growth on an antitrotic, commonly tetracycline (tet) or ampidtlin (amp), to which they are rendered resistant due to the presence of let andlor amp resistance genes on the vecxor.
After selection of the transformed cells, these cells an; grown in a~ture and the plasmid DNA (or other vector with the foreign gene inserted) is then isolated. Ptasmid DNA can be isolated using methods known in the art. Two suitable methods are the small scale preparation of DNA and the large-scale preparation of DNA as described in sedans 125-1.33 of Sambrook e! al., supra. The isolated DNA can be purified by methods known in the art such as Ihat described in section 1.40 of Sambrook etal., supra. This purified plasmid DNA is then analyzed by restriction mapping andlor DNA sequendng. DNA sequendng is generally performed by either the method of Messing et al. 9309 [1981) or by the method of Maxam et aL Meth.
Ep~j" 65:
499 [1980].
11I.
This invention contemplates fusing the gene enclosing the desired polypeptide (gene 1 ) to a second gene (gene 2) such that a fusion protein is generated during transcription. Gene 2 is typically a arat protein gene of a phage, and preferably it is the phage M13 gene III coat protein, or a fragment thereof. Fusan of genes 1 and 2 may 5 be aa~omplished by inserting gene 2 into a partia~lar site on a plasmid that a~ntains gene 1, or by inserting gene t into a particular site on a plasmid that contains gene 2.
Insertion of a gene into a plasmid requires that the plasmid be cut at the precise kxafion that the gene is to be inserted. Thus, (here must be a restriction endonudease site at this bcation (preferably a unique site such that the plasmid will only be cut at a single location during restriction endonudease digestion). The plasmid is 10 digested, phosphatased, and purified as described above. The gene is then inserted into this ~nearized plasmid by Igating ttie two DNAs together. Ligation can be aa~mplished if the ends of the plasmid are compatible with the ends of the gene to be inserted. If the restrictan enzymes are used b cut the plasmid and isolate the gene to be inserted create blunt ends or compatible sticky end s, the DNAs can be ligated together directly using a lipase such as bacteriophage T4 DNA lipase and incubating the mixture at 16'C for 1-4 hours in the presence of ATP
15 and lipase buffer as described in section t .68 of Samtxook et al., ~. If the ends are not compatible, they must first be made blunt by using the benow fragment of DNA polymerase I or bacteriophage T4 DNA polymerase, both of which require the tour deoxyribonudeotide triphosphates to fill-in ovefianging single-stranded ends of the digested DNA. Alternatively, the ends may be Bunted using a nuclease such as nuclease St or mung-bean nuGease, both of which function by cutting back the overhanging single strands of DNA. The DNA is then religated using a lipase as described above. In some cases, it may not be possible to blunt the ends of the gene to tie inserted, as the reading frame of the coding regGm will be altered. To overcome this problem, oligonuceotide linkers may be used. The linkers serve as a bridge to connect the plasmid to the gene b be inserted. These linkers can be made synthetically as double stranded or single stranded DNA using standard methods. The linkers have one end that is compatible with the ends of the gene to be inserted; the linkers are first ligated to ttus gene using ligation methods described above. The other end of the linkers ~s designed to be compatible with the plasmid for ligation. In designing the linkers, care must be taken to not destroy the reading frame of the gene to be inserted or the reading frame of the gene contained on the plasmid. In some cases; it may be necessary 6o design tt~e linkers such that they aide for part of an amino acrd, or such that fey code fa one or more amino acds.
Between gene 1 and gene 2, DNA erxodirg a termination axion may be inserted, such termination oodons are UAG( amber), UAA (ocher) and UGA (opal). (Microbiology, Davis et al.
Harper & Row, New York,1980, pages 237, 245-47 and 274). The termination a>don expressed in a wild type host cell results in the synthesis of the gene 1 protein product without the gene 2 protein attached. However, growth in a suppressor host cell results in the synthesis of detectable quantities of fused protein. Such suppressor host tens contain a tRNA
modified to insert an amino acrd in the terminatan a~don positan of the mRNA
thereby resulting in production of detectable amounts of the fusion protein. Such suppressor host cells are well known and described, such as E.coJi suppressor strain (Bullock et al., BioTechniaues 5, 376-379 [1987]). My aaeptable method may be used to place such a termination a~don into the mRNA erxoding the fusion polypeptide.
The suppressible aKion may be inserted between the first gene encodinD a polypeptide, and a second gene ena>ding at least a portan of a phage a~at protein. Aftematively, the suppressible termination a~don may be inserted adjacent to the fusion site by replacing the last amino acid ~ipiei in the polypeptide or the first amino acrd in the phage coat protein. When the phagemid containing the suppressible colon is grown in a suppressor host cell, it results in the detectable production of a tusan polypeptide containing the polypeptide and the coat protein. When the phagemid is grown in a non-suppressor host cell, the polypepiide is synthesized substantially without fusion b the phage coat protein due to termination at the inserted suppressible triplet encoding UAG, UAA, or UGA. In the non-suppressor cell the polypeptide is synthesized and secreted from the host cell due to the abserxe of the fused phage coat protein which otherwise anchored it to the host cell.
v.
Gene 1, encoding the desired polypeptide, may be altered at one or more selected colons. M alteration is defined as a substitutan, deletion, or insertion of one or more colons h the gene encoding the polypeptide that results in a change in the amino acrd sequence of the polypeptide as compared with the unaltered or native sequence of the same polypeptide. Preferably, the alterations will be by substihrtion of at least one amino acrd with any other amino acrd in one a more regions of the molecule. The alterations may be produced be a variety of methods known in the art. These methods include but are not limited to oligonudeotide-mediated mutagenesis and cassette mutagenesis.
A ~11~Ld Oligonudeotide -mediated mutager~esis is preferred method for preparing substitution, deletion, and insertion variants of gene t . This technique is well known in the art as described by Zoller et al. Nucleic Aads Res.
IQ: 6487~5tM (1987(. Briefly, gene 1 is altered by hytxidizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of the plasmid containing the unaltered or native DNA sequence of gene 1. After hytxidization, a DNA polymerise is used to synthesize an entire second complementary strand of the template will Ihus incorporate the oligonudeotide primer, and will code for the selected alteration in gene 1.
Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonudeotxie will have t2 to t5 nucleotides that are completely complementary to the template on either side of the nudeotide(s) coding for the mutation. This ensures that the oligonudeotide win hytxidize properly to the single-stranded DNA
template molecule. The oligorxxteotides are readily synthesaed using techniques known in the art such as that described by Crea et al. Proc. Natl. Aca,~. Sd. U,~ 75: 5765 (1978).
The DNA template can only be generated by those vectors that are either derived from bacteriophage M13 vectors (the commerclally available Mt3mp18 and M13mp19 vectors are suitable), or those vectors that contain a single-stranded phige origin of replication as described by Y~era ef aL Meth. Enz~ 153: 3 (1987).
Thus, the DNA that is to be mutated must be inserted into one of these vectors in order to generate single-stranded template. Production of the single-stranded template is described in sections 4.21-4.41 of Sambrook et a)., supra.
To alter the native DNA sequence, the aligonucleotide is hytxidized to the single s6~anded template under suitable hytxidization conditions. A DNA polymerizing enzyme, usually the Klerbw fragment of DNA
polymerise I, is then added to synthesize the complementary strand of the template using the ol'gonudeotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of gene 1, and the otter strand (the original template) encodes the native, unaltered sequence of gene 1.
Ttws heTeroduplex mote~e is then transformed inb a suitable host Celt, usually a prokaryote such as E. Colt JM101. After growi~ the cells, they are plated onb agarose plates and screened using the oGgonudeotKie primer radiolabelled with 32-Phosphate to identify tte bacterial colonies that contain the mutated DNA.
The melfwad described immediabety above may be modified such that a homoduplex molecule is created wherein Moth strands of the plasmid contain the mutation(s). The modifications are as follows: The single-stranded oGgonucleotide is annealed to the single-stranded template as described above. A mixhue of three deoxyribonudeotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribofhymidine (dTTP), is combined with a mo~fied thio~deoxyrit~ocybsine called dCTP-(aS) (which can be obtained from Amersham).
This mixture is added to the template-oligonudeotide complex. Upon addition of DNA potymerase to this mixture, a strand of DNA identical b the template except for the mutated bases is generated. h addition, this new strand of DNA will contain dCTP-(aS) instead of dCTP, wtwch serves to protect it from restriction endonudease digest'bn. After the template strand of tte double-strarxied heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with Exolll nuclease or another appropriate nuclease past the region that contains the sites) to be mutageruzed. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA
polymerase in the presence of alt tour deoxyribonucVeotide triptosphates, ATP, and DNA ligase. This homoduplex molecule can then be transformed into a suitable host cell such as E. colt JM101, as described above.
Mutants with more than one amino acid to be subs6d~ted may be generated in one of several ways. If the amino acids are located dose together in the pdypeptide chain, they may t~e.mutated simultaneously using one 2 0 oligonuGeotide that codes for all of the desired amino acid substitutions.
B, fio~wever, the amino aads are located some distance from each otter (separated by more than about ten amino adds), it is more difficult to generate a single ofigonudeotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.
In the first method, a separate oligonudeotide is generated for each amino add to be substituted. The oligonudeotides are then annealed to the single-stranded template DNA
simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acrd substitutions. The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oGgonudeotide encoding the first desired amino acrd substitutan(s) is annealed b this template, and the heteroduplex DNA molea~le is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, ttxs template already contains one a more mutations. The oGgonudeotide encoding the additional desired amino acid substitutions) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the >;rst and second rounds of mutagenesis. This resultant DNA
can be used as a Template in a tturcl round of mutager~esis, and so an.
3 5 B.
This method is also a preferred method for preparing substitution, deletion, and insertion variants of gene t . The method is based on that described by Wells et aL ~,, 34:315 (1985].. The starting material is tt~e plasmid (or other vector) comprising gene 1, the gene to be mutated. The cadon(s) in gene 1 To be mutated are identified. There must be a unique restrictan erxionudease site on each side of the identified mutation site(s). It ra such restriction sites exist, they may be generated using the abov~e~esaibed oligonudeotide-mediated mutagenesis method b infroduoe them at appropriate locations in gene t. After the restriction sites have been inbroduoed into the plasmid, the plasmid is cut at these si6es b linearize d.
A double-stranded oligonudeotide encoding the sequence of the DNA between the restriction sites but contair>ing the desired mutations) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oGgonudeotide is referred b as the cassette. This cassette is designed to have 3' and 5' ends that are campatide with the ends of the lineartzed plasmid, such that it can be directly Igabed b the plasmid. This plasmid now contains the mutated DNA sequence of gene 1.
VI.
i 0 M an alternative embodiment, this invention contemplates produr~on of variants of a desired protein containing one a more subunits. Each subur~t is typic~lfy encoded by separate gene. Each gene encoc~ng each subunit can be obtained by methods krbwn in the art (see, for example, Section II). In some instances, it may be necessary to obtain the gene erxoding the various subunits using separate techniques selected from any of the methods described in Section II_ When constructing a replicable expression vector where the protein of interest contains more than one subunit, all subunits can be regulated by the same promoter, typically located 5' to the DNA encoding the subunits, or each may be regulated by separate promoter suitably oriented in the vector so that each promoter is operably linked to the DNA it is intended to regulate . Selection of promoters is carried out as described in Section Ill above.
In constructing a replicable expression vector containing ONA encoding the protein of interest having multiple subunits, the reader is referred to Figure 10 where, by way of illustration, a vector is diagrammed showing DNA encoding each subunit of an antibody fragment. This figrxe shows that, generally, one of the subunits of the protein of interest will be fused to a phage caat protein such as Mt3 gene III. This gene fusion generally w~l contain its own sgnal sequence. A separate gene encodes the other subunit or suburyts, and it is 2 5 apparent that each suburyt generally has its own signal sequence. Fgure 10 also shows that a single promoter can regulate the expression of both subunits. Alternatively, each subunit may be independently regulated by a different promoter. The protein of interest subunit-phage coat protein fusion construct can be made as described in Section N above.
When constructing a family of variants of the desired multi-subunit protein, DNA encoding each subunit 3 0 in the vector may mutated in one or more positans in each subuNt When mufti-subunit antibody variants are constructed, preferred sites of mutagenesis correspond b colons encoding amino acrd residues located in the comptementarity~letennining regions (CDR) of either the light chain, the heavy chain, or both chains. Tt~e CDRs are commonly referred to as the hypervariable regions. Methods for mutagenizing DNA encoding each subunit of the protein of interest are conducted essentially as described in Section V
above.
VII.
Target proteins, such as receptors, may be isolated from natural sources or prepared by recombinant methods by procedures known in the art. By way of illustration, glycoprotein hormone receptors may be prepared by the technique described by McFariand et al., 245:494-499 [1989], nonglycosylated forms expressed in E. ooli are described by Fuh et al. J. Biol. Chem 265:3111-3115 (1990) Other receptors can be prepared by standard methods.
The purified target protein may be attad~ed to a suitable matrix such as agarose beads, aaylamide beads, glass beads, celhiose, various acrylic copolymers, hydroxytalkyl methacrytate gels, polyacrylic and polymethacrylic copolymers, nylon, neutral and ionic; tamers, and the Yke.
Attad~ment of the target protein to the matrix may be accomplished by methods desa~ibed in jp,Ep~l~ 44 [1976), a by other means known in the art.
After attachment of the target protein to the matrix, the immot~ilized target is contacted with the library of phagemid particles under conditions suitable for binding of at least a portbn of the phagemid particles with the immobilized target. Normally, the conditions, including pH, ionic strength, f0emperature and the Gke will mimic physiological conditions.
Bound phagemid particles ('tHnders') having high af6rity for the immobilized target are separated from those having a low affinity (and thus do not hind to the target) by washing. Binders may be dissoclated from the immobilized target by a variety of methods. These methods inGude competitive dissodation using the wild-type ligand, altering pH andlor ionic strength, and mettx>ds known in the art.
Suitable host cells are infected with the birxlers and helper phage, and the host cells are cultured under conditions suitable for amplification of the phagemid particles. The phagemid particles are then collected and the selection process is repeated one or more times until binders having tt~e desired affinity for the target molecule are selected.
Optionally the library of phagemid particles may be sequentially contacted with more than one immobilized target to improve selectivity for a particx~lar target. For example, it is often the case that a ligand such as hGH has more than one natural receptor. In the case of hGH, both the growth hormone receptor and the prolactin receptor bind the hGH ligand. ft may be desirable to improve the selectivity of hGH for the growth hormone receptor over the prolactin receptor. This can be ad>ieved by first contacting the library of phagemid particles with immotHlized prolactin receptor, eluting those with a low affinity (i.e. lower than wild type hGH) for the prolactin receptor and then contacting the bw affinity proladin 'binders' or non-binders with the immobilized growth hormone receptor, and selecting for high affinity growth hormone receptor hinders. In this case an hGH mutant having a bwer affinity for the prolactin receptor would have therapeutic utility even if the affinity for the growth hormone receptor were somewhat bwer than that of wild type hGH. This same strategy may be employed to improve selectivity of a particular hormone or protein for its primary function receptor over its clearance receptor.
In another embodmer>t of this invention, an improved substrate amino add sequence can be obtained.
These may be useful for making better 'cut sites' for protein linkers, or for better protease substrateslnhibitors. h this embodiment, an immobilizable molecule (e.g. hGH-receptor, biotin-avidin, or one capable of covalent linkage with a matrix) is fused D~ gene tll through a linker. The tinker will preferably be from 3 to 10 amino adds ~ length and will ad as a substrate for a protease. A
phagemid will be constructed as described above where the DNA encoding the linker region is randomly mutated to produce a randomized library of phagemid particles with different amino acid sequerxes at the linking site. The litxary of phagemid particles are then immobilized on a matrix and exposed to a desired protease. Phagemid particles having preferred or better substrate amino add sequences in tte liner region trx the desifed protease W~I
be efubed, first producing an enridied pool of phagemid particles erxoding pfeferred inkers. These phagemid particles are then cycled several more times to produce an erricted pool of particles encoding aonsense sequenoe(s) (see examples XIII and XIV).
vlU.
5 The doped gene for hGH has been expfessed in a seaebed lam in g~ (Chang, C.
t~b, et aL, (1987] ~~189) and its DNA and amino acrd sequence has been reported (Goeddel, etal. (1979] ~gy,$1, 544; Gray et al., (1985] ~ ~,q, 247). The pfesent irnention describes novel hGH variants produced using the phagemid selection methods. Human growth hormo«e variants containir~
substitutions at positions 10, 14, 18, 21, 167,171,172, 174,175,176,178 and 179 have been described. Tfbse having higher dr>ding affinities are 10 described in Tables VII, XIII and XIV. The amino add nomenclature for describing the variants is shown below.
Growth fbrmone variants may be administered and (cumulated in ~e same mamer as fegular growth hormone. The growth hormone variants of the present invention may be expfessed in any recoml~ir~ant system which is capable of expressing native or met hGH.
Therapeutic formulations of hGH for therapeutic administration are prepared for storage by mixing 15 hGH having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers ($~09ton's Pharmace~cal SciE;~~, 16th edition, Osol, A, Ed., (1980)., in tf~e form of lyophilized cake or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, atrate, and other organic acids; antioxidants including ascorbic acid; bw molecular weight (less than about 10 residues) polypeptides; proteins, such as serum 20 albumin, gelatin, or immunoglobulins: hydrophilic polymers such as polyvinylpyrolidone; amino acids such as ~ycine, glutamine, asparagine, arginine, or lysine; monosacd~arides, disaccharides, and other carbohydrates including glucose, mamose, or dextrins; d~elating agents such as EDTA; divalent metal ions such as zinc, cobalt or copper;
sugar alcohols such as mamitol or sorbitol; salt-forming countefions such as sodium; arxilor nonionic surfactants such as Tween,' Pluronics a polyethylene glycol (PEG). Formulations of the present invention may additionally contain a pharmaceutically acceptable buffer, amino add, bu~Cing agent andlor non-ionic surfactant. These include, for example, tx~ffers, d~elating agents, antioxidants, preservatives, cosotvents, and the like; speafic examples of these could include, trimethylamair~e salts ('iris buffer'), and disodium edetate. The phagemids of the present invention may be used to produce quantities of the hGH variants tree of t#~e phage protein. To express hGH
variants flee of the gene III portion of the fusion, pS0643 and derivatives can simply be grown in a non-suppressor strain such as 1609. In this case, the amber colon (TAG) leads to ~rmination of translatan, which yields free hormone, without tt~e need for an independent DNA constnxtion. The hGH variant is secreted from the host and may be isolated from the culture medium.
One or more of the eight hGH amino adds F10, Mt4, H18, H21, 8167, D171, T175 and 1179 may be repel by any amino add other than the one found in that position in naturally occurring hGH as indicated. Therefore, t , 2, 3, 4, 5, 6, 7, or all 8 of the irxiicated amino aads, F10, M14, H18, H2t, 8167, D171, T175 and 1179, may be replaced by any of the otter 19 amino aads out of the 20 amino cads listed below. ~ a preferred embodiment, all eight listed amino aads are replaced by another amino add. The most preferred eight amino aads to be substituted are indicated in Table XIV in Example XII.
"trademark Mino add nab ~ (A) Arg (R) Asn (N) ~P (Q) Cys (C) Gln (D) Glu (E) Gly (G) His (H) (1e (I) Leu (L) Lys (K) Met (M) Phe (F) Pro (P) Ser (S) Thr (T) Trp (W) Tyr (Y) Val (1n The one letter hGH variant nomenclature first gives the hGH amino acrd deleted, for example glutamate 179; then the amino acrd inserted; for example, serine; resulting in (E1795S).
EXAMPLES
Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and illustraCrve examples, make and uti~ze the present invention to the fullest extent. The following working examples therefore spedfically point out preferred embodimertts of the present invention, and are not to 3 0 be constn~ed as limiting in any way of the remainder of the disclosure.
EXAMPLE I
Plasm(d Cor~wcfloris and Preparation of hGH-phagemtd ParSdes The plasmid phGH-Ml3glll (F~g.1), was constructed from M13K077 and the hGH
produdng pfasmid, pB0473 (Cunningham, B. C., et al. , , 243:1330-1336, [1989]). A synthetic oligonucteotide 5'-AGC
TGT-GGC-TTC-~~GG-CCC-TTA-GCA-TTT-AAT-C~CG~TA-3' was used to introduce a unique Apal restriction site (underlined) into pB0473 after the final Phe191 colon of hGH.
The oligonudeotide 5'-TTC-ACA-AAC-GAA-~CCC-CTA-ATT-AAA-GCC-AGA-3' was used to irnroduoe a unique Apal restriction site (underlined), and a GIu197-to-amber stop colon (bold lettering) into M13K07 gene III. The oligonudeotide 5'-CAA-TAA-TAA-CGG-GCTAGC-CAA-AAG-AAC-'TGG-3' introduces a unique Nhel site (underlined) after the 3' end of the gene III coding sequence. The resulting 650 vase pair (bp) Apal-Nhel fragment from the doubly mutated M13K07 gene III was doped into the large Apal-I~el fragment of pB0473 to aeate the plasmid, pS0132. This fuses the carboxyl terminus of hGH (Phel9t) b the Pro198 residue of the gene III protein with the insertion of a glydne residue encoded from the Apal site and places the fusion protein under control of the E. coli alkaline phosphatase (ptaA) promoter and stll secretan signal sequence (Chang, C. N., et al. , ~, 55:189-196, (1987]). For indudble expression of the fusion protein in rich media, we replaced the phoA promoter with the lac promoter and operator. A 138 by EcdRl-XXl~aal fragment captaining the lac promoter, operator, and Cap binding site was produced by PCR of plasmid pUC119 using the oligonudeotides 5'-CACGACA~CCGACTGGAAA-3' and 5'-CTGTT TCTAGAGTGAAATTGTTA-3' that flank the desired lac sequences and introduce the EcoRl and Xbal restriction sites (underlined).
This tac fragment was gel purified and ligated into the large EcoRl-Xbal fragment of pS0132 to aeate the plasmid, phGH-Ml3glll. The sequences of all tailored DNA junctions were verified by the dideoxy sequence method (Sanger, F., et al. Proc. Natl. Acad.
Sci. U.S.A. 74:5463-5467, [1977]). The R64A variant hGH phagemid was constructed as follows: the Nsil-Bglll mutated fragment of hGH (Cunninghamet al. supra ) encoding the Arg64 to Ala substitution (R64A) (Cunningham, B. C., Wells, J. A., ~jgp~., 244:1081-1085, (1989)) was doped between the corresponding restriction sites in the phGH-Ml3glll plasmid (Fig. 1) b replace the wild-type hGH sequence. The R64A hGH
phagemid particles were propagated and titered as desait~ed below for the wild-type hGH-phagemid.
Plasmids were transformed into a male strain of E. coti (JM tOt ) and selected on carbenidllin plates. A
single transformant was grown in 2 ml 2n medium for 4 h at 3TC and infected with 50 W of M13K07 helper phage. The infected culture was diluted into 34 ml 2YT, grown overnight, and phagemid particles were harvested by predpitation with polyethylene glycol (terra, J., Messing, J. ,methods in EpZymoloav,153:3-11, [1987]).
Typical phagemid particle titers ranged from 2 to :i x 1011 cfulml. The particles were purified to homogeneity by CsCI density centrifugation (Day, L.A. ." 3965-277, (1969]) to remove any fusion protein not attadied to virions.
trrrxnod>err~Cal Analyses d hGti on the Fuslan Pte Rabbit polydonal antibodies to hGH were purified with protein A, and coated onto miaotiter plates (Nunc) at a concentration of 2 Rg/ml in 50 mM sodium carbonate buffer (pH 10) at 4'C for 16-20 hours. After washing in PBS containing 0.05°k Tween 20, hGH or hGH-phagemid particles were serially diluted from 2.0 -0.002 nM in buffer A (50 mM Tris (pH 7.5), 50 mM NaCI, 2 mM EDTA, 5 mglml bovine serum albumin, and 0.05%
Tween 20). After 2 hours at room temperature (rt), the plates were washed well and the indicated Mab (Cunninghamet aL supra ) was added at 1 ~ghnl in buffer A for 2 fours at rt.
Following washing, horseradish perox~dase conjugated goat anti-mouse IgG antibody was bound at rt br 1 hour.
After a final wash, the peroxidase activity was assayed with the substrate, o-phenylenediamine.
Coupling d the hGH Blndng Protefn to Pdyaaytarrrfde Beads and Bfndinp Errichments Oxirane polyaaylamide beads (Sigma) were conjugated to the purified exi<acenular domain of the hGH
receptor (hGHbp) (Fuh, G., et al., ,(,~j~,m" 265:31 11-3115 (1990]) containing an extra cysteine residue introduced by site-directed mutagenesis at position 237 that does not affect binding of hGH (J. Wells, unpublished). The hGHbp was corrugated as recommended by the supplier b a level of 1.7 pmol hGHbplmg dry oxirane bead, as measured by birxing of (125fj hGH b the resin. S~equently, any unreacted o~orane groups were blocked with BSA and Tris. As a control for non-spedfic binding of phagemid particles, BSA was similarly coupled to the beads. Buffer for adsorption and washing contained 10 mM
TrisHCl (pH 7.5),1 mM EDTA, 50 mM
Na Cl, t mg~ml BSA, and 0.02° Tween 20. Elutan t~uffers contained wash buffer plus 200 nM hGH or 0.2 M
glycine (pH 2.1 ). Parental phage M 13K07 was mixed with hGH phagemid particles at a rata of nearly 3000:1 (original mixture) and tumbled for 8-12 h with a 5 W abquot (0.2 mg of aaylamide beads) of either absorbent in a 50 ~I volume at room temperature. The beads were peNeted by centrifugation and the s~emate carefully removed. The beads were resuspended in 200 pJ wash buffer and tumbled at room temperature for 4 hours (wash 1 ). After a second wash (wash 2), the beads were eluted twice with 200 nM hGH for E10 hours each (eluate 1, eluate 2). The final elution was with a glyc~r~e buffer (pH 2.1 ) for 4 hours to remove remaining hGH
phagemid particles (eluate 3). Each fraction was diluted appropriately in 2YT
media, mixed with fresh JM101, incubated at 3TC for 5 minutes, and plated with 3 ml of 2n soft agar on LB or LB carbenicllin plates.
EXAMPLE IV
Coral ctlon of hGH-phagemld Parlides wtth a Mixture of Gene Ill Products The gene III protein is composed of 410 residues divided into two domains that are separated by a flexible Hnker sequence (Armstrong, J., et al., F BS Lett..135:167-172, [1981]). The amino-terrnir~al domain is required for attachment to the pill of E. coil, while they carboxyl-terminal domain is imbedded in the phage coat and required for proper phage assembly (Crissman, J. W., Smith, G. P., Yiroloav.
132:445-455, (1984]). The signal sequence and amino-terminal domain of gene III was replaced with the stll sigr~al and entire hGH gene (Chang et al.
supra) by fusion to residue 198 in the carboxyl-terminal domain of gene III
(Fg.1 ). The hGH-gene III fusion was placed under control of the lac promoterloperator in a plasmid (phGH-Ml3glll;
Fg. 1) containing the pBR322 ~-tactamase gene and Col Et replication origin, and ft~e phage f1 intergenic region. The vector can be easily maintained as a small plasmid vector by selection on c;arber>iallin, which avoids relying on a functional gene III fusion for propagation. Alternatively, the plasmid can be effidently packaged into virions (called phagemid particles) by infection with helper phage such as M13K07 (Y~era ef aL. supra ) which avoids problems of phage assembly.
Phagemid infectivity titers based upon transduction to carbenadllin resistanxe in this system varied from 2-5 x 101 lcobny forming units (ctu)/ml. The fiber of the M13K07 helper phage in these phagemid stocks is -1010 plaque forming units (pfu)/ml.
With this system we confirmed previous stud'~es (Partnley, Smith supra) that homogeneous expression of large proteins fused to gene III is deleterious to phage production (data not shown). For example, induction of the lac promoter in phGH-Ml3glll by addition of IPTG produced low phagemid titers.
Moreover, phagemid particles produced by co-infectan with Mt3K07 containing an amber mutation in gene III
gave very low phagemid tfters (<1010 ctuJml). We believed that multiple copies of the gene III fusion attadied to the phagemid surface could lead to multiple point attachment (the 'chelate effect') of the fusion phage to the immobilized target protein.
Therefore to control the fusion protein copy number we limited transaiption of the hGH-gene III fusion by culturing the plasmid in E. coil JMlOt (lacy which krontains a constitutively high level of the lac repressor protein.
The E. cbli JM101 cultures containing phGH-M13g111 were best propagated and infected with M13K07 in the abserxe of the lac operon inducer (IPTG); however, this system is flexible so that co~xpression of other gene III
tusan proteins can be balanced. We estimate that about t0% of the phagemid particles contain one copy of the hGH gene III fusion protein from the ratio of tt~e amount of hGH per virion (based on hGH immurb-reactive material in CsCI gradient pur'rfied phagemid). Therefore, the titer of fusion phage displaying the hGH gene III fusion is about 2 - 5 x 1010hn1. This numt~er is much greater than the titer of E. c~oli (~108 b 1091m1) in the culture from which they are derived. Thus, on average every E. cvG ceu produces 10-100 copies of phage decorated with an hGH gene III fusion protein.
EXAMPLE V
Structural Irttegrlty of the hGfi~ene t1 Fuslon knmunoblot analysis (Fg. 2) of the hGH~ene III phagemid stow that hGH aoss-reactive material aunigrates with phagemid particles in agarose gels. This indicates that the hGH is tightly assoclated with phagemid particles. The hGH-gene III fusion protein from the phagemid particles nms as a single immuno-stained band showing that there is little degradation of the hGH when it is attached to gene III. Wild-type gene III protein is dearly present because about 25°~ of the pt~agemid particles are infectious. This is comparable to speclfic infectivity estimates made for wild-type M13 phage that are similarly purified (by CsCI density gradients) and concentrations estimated by UV absorbance (Smith, G. P. supra and Partnley, Smith supra) Thus, both wild-type gene III and the hGH-gene III fusion proteins are cisplayed in the phage pool.
It was important to confirm that the tertiary structure of the displayed hGH
was maintained in order to have confidence that results from binding selections will translate to the native protein. We used monoclonal antibodies (Mats) to hGH to evaluate the structural integrity of the displayed hGH gene III fusion protein (Table I).
TABLE L Binding of FJght Different Nbnoclonal Antibodies (Mat's) m hGH and hGH Pt~agemld Parades' ICSp (nM) Mat hGH hGH-phagemid ___.__________________.______.___..______.___..._.____._............_..._....._ _....
1 0.4 0.4 2 0.04 0.04 3 0.2 0.2 4 0.1 0.1 5 0.2 >2.0 6 0.07 0.2 7 0.1 0.1 8 0.1 0.1 'Values given represent aye GH or hGH-phagemid particles corxentration (nM) of h to give half-maximal binding to the particular Mab. Standard errors in these measurements are typically at or below t30~
of the reported value.
See Materials and Methods for further details.
3 0 The epitopes on hGH for these Mabs have been mapped (Cunningham et al..
supra) and binding for 7 of 8 Mabs requires that hGH be properly folded. The ICSp values for all Mabs were equivalent to wild-type hGH
except for Mab 5 and 6 . Both Mabs 5 and 6 are known to have binding determinants near the carboxyl-terminus of hGH which is blocked in the gene III fusion protein. The relative ICSp value for Mabt which reacts with both native and denatured hGH is kxxhar~ged compared to the a>r~orrnatanally sensitive Mabs 2-5, 7 and 8. Thus, Mab1 serves as a good internal control for any errors in matching the concentration of the hGH standard to that of the hGH~ene III fusion.
E'KAMPLE VI
Blndtrp Ervfcwnents on Receptor AtfiNty Beads Previous workers (Partnley, Smith supra ; Scott, Smith supra; Cwirla et aL
supra; and Devlin et al.
5 supra) have fractionated phage by panning with streptavidin coated polystyrene petri dishes or miaotiter plates.
However, dxomatographic systems would allow may efficient iradionation of phagemid particles displaying mutant proteins with different binding affinities. We dose non-porous oxirane beads (Sigma) to avoid trapping of phagemid particles in the dromatographic resin. Furthermore, these beads have a small particle size (t u.m) to maximize the surface area to mass ratio. The extraaetlular domain of the hGH
receptor (hGHbp) (Fuh et al. , 10 supra) contairHng a free cystEino residue was eihaentiy coupled b these beads and phagemid particles showed very low non-specific binding to beads coupled ony to bovine senun alb<unin (Table II).
TABLE 11.
15 Specific Blndlng of Hormone Phage to hGHbp-coated Beads Provides an Enrichment for hGH-phage over M13K07 Phage' Sample Absorbent$ Total pfu Total cfu Ratiu (cfu/pfu) Enrichment~
20 Original mixturet 8.3 x 1011 2.9 x 108 3.5 x 10'4(1) Supernatant BSA 7.4 x 1011 2.8 x 108 3.8 x 10'41.1 hGHbp 7.6 x 1011 3.3 x 108 4.3 x 10'41.2 Wash 1 BSA 1.1 x t 6.0 x 106 5.5 x 10'41.6 hGHbp 1.9 x 101 1.7 x 107 8.9 x 10'42.5 25 Wash 2 BSA 5.9 x 107 2.8 x 104 4.7 x 10'41.3 hGHbp 4.9 x 107 2.7 x 106 5.5 x 10'21.6 x Eluate 1 (hGH)BSA 1.t x 106 1.9 x 103 1.7 x 10'34.9 hGHbp 1.2 x 106 2.1 x 106 1.8 5.1 x Eluate 2 (hGH)BSA 5.9 x 105 1.2 x 103 2.0 x 10'35.7 hGHbp 5.5 x 105 1.3 x 106 2.4 6.9 x Eluate 3 (pH 2.1 )BSA 4.6 x 105 2.0 x 103 4.3 x 10'312.3 hGHbp 3.8 x 105 4.0 x 106 10.5 3.0 x 'The titers of M13K07 and hGH-phagemid particles in each fraction was determined by multiplying the number of plaque forming units (pfu) or carbenicillin resistant colony forming units (cfu) by the dilution factor, respectively. See Example IV for details.
tThe ratio of M13K07 to hGH-phagemid particles was adjusted to 3000:1 in the original mixture.
$Absorbents were conjugated with BSA or hGHbp.
~Enrichments are calculated by dividing the cfu/pfu ratio after each step by cfu/pfu ratio in the original mixture.
In a typical enrichment experiment (Table II), one part of hGH phagemid was mixed with >3,000 parts Mt3K07 phage. After one cycle of trn~ding and elution,106 phage were recovered and the ratio of phagemid to M13K07 phage was 2 to 1. Thus, a single binding selection step gave >5000-fold ennidment. Additional elutions with free hGH or acld treatment to remove remaining phagemids produced even greater enrichments. The eruidments are comparable to those obtained by Smith and coworkers using bald elution from coated polystyrene plates (Smith, G.P. supra and Parmely, Smith sipra ) however much smaaer volumes are used on the beads (200 W vs. 6 ml). There was almost no enrichment for the hGH phagemid over M13K07 when we used beads lir>ked only to BSA. The slight erxichmertt observed (or control beads (-10-fold for pH 2.t elution; Table 2) may result from trace contaminants of bovine growth hormone Minding protein present in the BSA linked to the bead. Nevertheless these data show the enrichmer4s for the hGH phage depend upon the presence of the hGHbp on the bead suggesting Minding occurs by specific interaction between hGH and the hGHbp.
We evaluated the enrichment for wild-type hGH over a weaker binding variant of the hGH on fusion phagemids to further demonstrahe enrichment spe~fiaty, and b wnk the reduction i~ binding affinity for the purified hormones to enrichment factors after panning fusion phagemids. A
fusion phagemid was constructed with an hGH mutant in which Arg64 was substituted with Ala (R64A). The R64A
variant hormone is about 20-fold reduced in receptor Minding affinity compared to hGH (Kd values of 7.1 nM
and 0.34 nM, respectively (Cunr>ingham, Wells, supra ]). The titers of the R64A hGH~ene III fusion phagemid were comparable to those of wild-type hGH phagemid. After one round of binding and elution (Table III) the wild-type hGH phagemid was enriched from a mixture of the two phagemids plus Mt3K07 by 8-fold relative b the phagemid R64A, and 104 relative to Mt3K07 helper phage.
TABLE al. hGHbp-coated Beads Select for hGH f~hagemlds Over a Weaker B4ndtng hGH Variant Phagemld Sample enrichment enrichment total phagemid for WT/R64A total phagerrid for WT/R64A
original mixture 8/20 (1 ) 8/20 (1 ) Supernatant ND - 4/10 1.0 Elution 1 (hGH) 7/20 0.8 17/20 8.5$
Elution 2 (pH 2.1 ) 11 /20 1.8 21 /27 5.2 'The parent M13K07 phage, wild-type hGH phagemid and Rfi4A phagemid particles were mixed at a ratio of 104:0.41).6. Binding selections were carried out using beads linked with BSA
(control beads) or with the hGHbp (hGHbp beads) as described in Table II and the Materials and Methods After each step, plasmid DNA was isolated(Bimboim, H. C., Doly, J. , Nucleic Acids Res., 7:1513-1523, (1979)) from carbenicillin resistant colonies and analyzed by restriction analysis to determine it it contained the wild-type hGH or the R64A hGH gene III
fusion.
t'fhe enrichment for wild-type hGH phagemid over R64A mutant was cala~lated from the raCb of hGH phagemid presets after each step to that present in the original mixture (8120), divided by the corresponding ratio for R64A phagemids. WT = wild-type; NO = not determined.
$The enrichment for phagemid over btal M13K07 parental phage was ~104 after this step.
By displaying a mixt<xe of wild-type gene III and the gene III fusion protein on phagemid partiGes one can assemble and propagate virions that display a large and proper folded protein as a fusion b gene III. The copy number of tf~e gene III fusan protein can be effectively controlled to avoid 'chelate effects' yet maintained at high enough levels in the phagemid pool b permit panning of large eptope litxaries (>1010). We have shown Ihat hGH
(a 22 kD protein) can be displayed in its native folded form. Binding selections performed on receptor affinity beads eluted with free hGH, ef6aentfy enrid~ed for wild-type hGH phagemids over a mutant hGH phagemid shown to have reduced receptor binding affinity. Thus, ft is possible to sort pf~agemid particles whose binding constants are down in the nanomolar range.
Protein-protein and antibody,antigen interactions are dominated by discontirx~ous epitopes (Janin, J., er a<. , ,~ MolBiol.. 204:155-1s4, ~198a); Argos, P., fro . no., 2:101-113, f1sa81; Barrow, D.J.,er ac , , 322:747-748, (1987); and Davies, D.R., et al. , J. Biol. Chem.. 253:10541-10544, X1988)); that is the residues directly involved in Minding are dose in tertiary stnxture txit separated by residues not involved in binding. The saeerung system presented here should arrow one to analyze more corHeniently pro0ein-receptor interactans and isolate discontirx~ous eptopes in proteins with r~ew and high affinity Minding properties.
EXAMPLE Vtl Selection of hGH Mutants from a lJbrary Randomlxed at hGH Colons 1T2,174,1T6,1T8 Construction of template A mutant of the hGH-gene III fusion protein was constnx~ed using the method of tCunkel.,et al. I~
154, 367-382 (1987). Template DNA was prepared by growing the plasmid pS0132 (containing the natural hGH gene fused to the carboxy-terminal half of M13 gene Ill, ~s~der control of the alkaline phosphatase promoter) in CJ236 cells with Mt3-K07 phage added as helper. Single-stranded, uracil-containing DNA was prepared for mutagenesis to introduce (1) a mutation in hGH which would greatly reduce minding to the hGH
binding protein (hGHbp): and (2) a unique restriction site (Kpnl) which could be urea ror assaying for -- and selecting against -- parental background phage. Oligonudeotide-directed mutagenesis was carried out using T7 DNA polymerase and the following oligodeoxy-nudeotide:
Gly Thr hGH colon: 17B 179 5'-G ACA TTC CTG SGT ATC GTG CAG T-3' < KpnI >
This oligo introduces the Kpnl site as shown, along with mutations (R178G,1179T) in hGH. These mutations are predicted to reduce Minding of hGH to hGHbp by more than 30-fold. Clones from the mutagenesis were sseened by Kpnl digestion and confirmed by dideoxy DNA sequenang. The resulting constn~ct, to be used as a template for random mutagenesis, was designated pH0415.
B~.~m.mul~S~IIl~~H
Colons 172,174,176,178 were targeted for random mutagenesis in hGH, again using the method of Kunkel. Single-stranded template from pH0415 was prepared as above and mutagenesis was tamed out using the following pool of oligos:
hGH colon: 172 174 5'- GC TTC AGG AAG GAC ATG GAC l~ GTC STS. ACA-Ire - N~. CTG ~ ATC GTG CAG TGC CGC TCT GTG G-3' As shown, this oligo pool reverts colon 179 to wed-type (ore), destroys the unique Kpnl site of pH0415, and introduces random colons (NNS, where N= A,G,C, or T and S= G or C) at positions 172,174,176, and 178. Using 4 0 this colon selection in the context of the above sequence, no additional Kpnl sites can be seated. The dioice of the NNS degenerate sequence yields 32 possible colons (nduding one 'stop' colon, and at least one colon for each amino add) at 4 sites, for a total of (32)4= 1,048,576 possible nudeotide sequences (12% of which contain at least one stop colon), or (20)4F 160,000 possible polypeptide sequences plus 34,481 prematurely terminated sequences (i.e. sequences contairyng at least one slop potion).
$Qp~gatlon of the Inllial Ilbrarv The mutagenesis products were extracted twice with phenolxhbroform (50:50) and ethanol preapitated with an excess of carrier tRNA to avoid adding salt that would confound the subsequent electroporation step. Approximately 50 ng (15 fmols) of DNA was electroporated into WJM101 cells (2.8 x 1010 ceIIsImL) in 45 N.L btal volume in a 0.2 an cuvette at a voltage setting of 2.49 kV with a single pulse (time constant = 4.7 msec.).
The ceNs were aNowed to recover 1 hour at 37°C with shaking, then mixed with 25 mL 2YT medium,100 ~g/mL carberwdllin, and M13-K07 (multipliaty of infection = 1000). Plating of serial dNutions from this culture onto carbeniallin~ontaining media indicated that 8.2 x 106 electrotransformants were obtained. After t0' at 23oC, the culture was incubated overnight (t5 hours) at 37°C with shaking.
After overnight incubation, the cells were peueted, and double-stranded DNA
(dsDNA), designated pL181, was prepared by the alkaline lysis method. The supernatant was spun again to remove any remaining cells, and the phage, designated phage pool ~1, were PE:G-precipitated and resuspended in 1 mL STE buffer (10 mM
Tris, pH 7.6, 1 mM EDTA, 50 mM NaCI). Phage titers were measured as colony-forming units (CFU) for the recombinant phagemid containing hGH~3p gene III fusion (hGH-g3) plasmid, and plaque-forming units (PFU) for the M13-K07 helper phage.
1. BINDING: M aliquot of phage pool ~~I (6 x 109 CFU, 6 x 107 PFU) was diluted 4.5-fold in buffer A
(Phosphate-buffered saline, 0.5°~6 BSA, 0.05% Tween-20, 0.01%
thimerosal) and mixed with a 5 N.l. suspension of oxirane-polyacrylamide beads coupled to the hGHbp containing a Ser237 Cys mutation (350 fmols) in a 1.5 mL
silated polypropylene tune. As a control, an equivalent aliquot of phage were mixed in a separate tube with beads that had been coated with BSA only. The phage were allowed to bind to the beads by incubating 3 hours at room temperature (23°C) with slow rotation (approximately 7 RPM). Subsequent steps were carried out with a constant volume of 200~L and at room temperature.
2. WASH: The beads were spun 15 sec., and the supernatant was removed (Sup. t ). To remove phagefphagemid not speafically bound, the beads were washed twice by resuspending in buffer A, then pelleting.
A final wash consisted of rotating the beads in buffer A for 2 hours.
3. hGH ELUTION: Phagelphagemid Minding weakly to the beads were removed by stepwise elution with hGH. In the first step, the beads were rotated with buffer A containing 2 nM
hGH. Affer 17 hours , the beads were pelleted and resuspended in buffer A containing 20 nM hGH and rotated for 3 hours, then pelleted. In the final hGH wash, the beads were suspended in buffer A containing 200 nM hGH and rotated for 3 hours then peNeted.
4. GLYCINE ELUTION: To remove the tightest-binding phagemid (i.e. those still bound after the hGH
washes), beads were suspended in Glydne buffer (1 ~Glycine, pH 2.0 with HG), rotated 2 hours and pelleted.
The supemataM (fraction 'G'; 200~L) was neutralized by adding 30 P.l. of 1 M
Tris base.
Fraction G eluted from the hGHbp-beads (1 x 106 CFU, 5 x 104 PFU) was not substantially enriched for phagemid over K07 helper phage. We believe this resulted from the tact that K07 phage packaged during propagatan of the recombinant phagemid display the hGH-gap fusion.
However, when compared with traction G eluted firom the BSA~oated control beads, the hGHbp-beads yielded 14 times as many CFU's. This reflects the errichment of tight~irxfing hGH~splaying phagemid over nonspecfically-binding phagemid.
5. PROPAGATION: M aliquot (4.3 x 105 CFU) of fraction G ek~ted from the hGHbp-beads was used to infect bg-phase WJM101 teas. Transductions were cartied out by mixing 100 L~L tractan G with 1 mL WJM101 cells, incubating 20 min. at 37oC, then adding K07 (multipficty of infection=
1000). Cultures (25 mL 2YT plus carbenicuin) were grown as described above and tt~: second pool of phage (Library tG, for first glydne elution) were prepared as described above.
Phage from library 1 G (Fg. 3) were selected for binding to hGHbp beads as described above. Fraction G eluted from hGHbp beads contained 30 times as many CFU's as fraction G
eluted from BSA-beads in this selection. Again, an aliquot of fraction G was propagated in WJM101 cells to yield library 1G2 (indicating that this library had been twice selected by glycne elution). Double-stranded DNA
(pLIB 1G2) was also prepared from this culture.
To reduce the level of background (Kpnl+) template, an aliquot (about 0.5 fig) of pLIB 1G2 was digested with Kpnl and electroporated into WJM101 ells. These cells were grown in the presence of K07 (multiplidty of infection= 100) as described for the initial library, and a new phage pool, pLIB 3, was prepared (Fig, 3).
In addition, an aliquot (about 0.5 fig) of dsDNA from the initial library (pLIBi) was digested with Kpnl and electroporated directly into WJM101 cells. Transformants were allowed to recover as above, infected with M13-K07, and grown overnight to obtain a new library of phage, designated phage Library 2 (Fg. 3).
Pt~agemid tHnding, elution, and propagation were tamed out in successive rounds for phagemid derived from both pLIB 2 aril pLIB 3 (Fig. 3) as described above, except that (1) an excess (10-fold over CFU) of purified K07 phage (not displaying hGH) was added in the bead-binding mil, and (2) the hGH stepwise elutions were replaced with brief washings of buffer A, alone. Also, in some cases, XL1-Blue cells were used for phagemid propagation.
An additional digestan of dsDNA with Kpnl was carried out on pLIB 2G3 and on pLIB 3G5 before the final round of bead-binding selection (Fg. 3).
Four independently isolated Bones from LIB 4G4 and tour independently isolated doves from LIB 5G6 were sequenced by dideoxy sequenang. All eight of these Bones had identical DNA sequerx:es:
hGH codon: 172 174 176 178 5' -AAG GTC TCC ACA TAC CTG AGG ATC-3' Tf~us, all these encode the same mutant of hGH: (E174S, F176Y). Residue 172 in these doves is Lys as in wild-type. The radon selected fw 172 is also identical to wild-type hGH. This is not surprising since AAG is the only lysine~odon possible from a degenerate 'NNS' codon seL Residue 178-Arg is also the same as wild-type, but here, the codon selected from the fibrary was AAG instead of CGC as is found in wild-type hGH, even though the latter colon is also poss'~ble using the'NNS' colon set.
The multiplidty of infectan of K07 infection is an important parameter in the propagation of recombinant phagemids. The K07 multiplidty of infection must be high enough b insure that virtually all cells transformed or transfecEed with phagemid are able a> package new phagemid particles. Furthermore, the 5 cor~centratan of wik!-type gene III in each cell should be kept high b reduce the possitoility of multiple hGH-gene III
fusion molecules being displayed on each phagemid particle, thereby dielate effects in binding. However, it ~e K07 multipGdty of ir>tection is bo high, the packaging of K47 wiU
compete with fat of recombinant phagemid. We find that acceptable phagemid yields, with ony 1-10% background K07 phage, are obtained when the K07 muftiplidty of iMection is t00.
Table N.
Phage Pool mot (K07) Enrichment hGHbpIBSA beads Fractan Kpnl CFUIPFU
LIB 1 1000 ND 14 0.44 LIB 1G 1000 ND 30 0.57 LIB 3 100 ND 1.7 0.26 LIB 3G3 10 ND 8.5 0.18 LIB 3G4 100 460 220 0.13 LIB 2 100 ND 1.7 <0.05 LIB 2G 10 ND 4.1 <0.10 LIB 2G2 100 1000 27 0.18 Phage pools are labelled as shown (Fig. 3). The muftiplidty of infection (mot) refers to the multiptidty of K07 infection (PFU/cetls) in the propagation of phagemid. The enrichment of CFU
over PFU is shown in those cases where purified K07 was added in the binding step. The rata of CFU eluting from hGHbp-beads over CFU eluting from BSA-beads is shown. The traction of Kpnl-containing template (i.e..
pH0415) remaining in the pool was determined by digesting dsDNA with Kpnl plus EcoRl, running the products on a 1 °~ agarose gel, and laser-scanning a negative of the eihidium bromide-stained DNA.
Recent ro btndin~,aHinltv M the hormone~hGh~(E174S. F176Y1 The tact that a single done was isolated from two different pathways of selection (F~g. 3) suggested that the double mutant (E174S,F176Y) hinds strongly to hGHbp. To determine the affinity of this mutant of hGH for hGHbp, we constructed this mutant of hGH by site~directed mutagenesis, using a plasmid (pB0720) which contains the wild-type hGH gene as template and the folbwing oiigonudeotide which changes colons 174 and hGH colon: 172 174 17f 178 Lys Ser Ty:: Arg 5'- ATG GAC AAG GTR ~G ACA T8C CTG CGC ATC GTG -3' The resting construct, pH04588, was t<ansfortned into E. c~oli strain 16C9 for expression of the mutant hormone. Scatchard analysis of competitive binding of hGH(E174S,F176Y) versus 1251-hGH to hGHbp indicated that the (E174S,Ft76Y) mutant has a bindng affinity at least 5.0-told tighter than that of wild-type hGH.
ExArI~P~E vul SELECTION OF hGH VARIANTS FROM A
Human growth hormone variants were produced by the method of the present inventan using the phagemid described in figure 9.
We designed a vector for cassette mutagenesis (Wells et al., ~ 34, 315-323 (t985]) and expression of the hGH-gene III fusion protein with the objectives of (t ) improving the ~nkage between hGH and the gene III
moiety to more favorably display the hGH moiety on the phage (2) limiting expression of the fusion protein to obtain essentially 'monovalent display,' (3) allowing for restriction nuclease selection against the starting vector, (4) eliminating expression of fusion protein from the starting vector, and (5) achieving taale expression of the corresponding free hormone from a given hGH-gene III fusion mutant Plasmid pS0643 was constructed by oligonudeotide-directed mutagenesis (Kunkel et al., y 154, 367-382 (t987)) of pSOt32, which contains pBR322 and ft origins of replication and expresses an hGH-gene III fusion protein (hGH residues t-19t, followed by a single Gly residue, fused to Pro-198 of gene III) under the control of the ~~ promoter (Bass et af., ,proteins 8, 309-314 [t990j)(Rgure 9). Mutagenesis was carried out with the oligonucleotide 5'-GGC-AGC-TGT-GGC-TTC-TAG-AGT-GGC-GGC-GGC-TCT-GGT-3', which introduces a ~ site (underlined) and an amber stop colon (TAG) following Phe-191 of hGH. In the resulting construct, pS0643, a portion of gene III was deleted, and two silent mutations (underlined) occurred, yielding the following junction between hGH and gene III:
__ ~g ________________~_> gene ai >
1B7 188 18A 180 191 am' 24A 254 251 252 253 254 Cry f5ar Gds GAY Phe Qu Ser Cry Q9 C.~' fxr C.~y GGC AGC 'rGT GG~A ThC Ti~IGG AGT (X~ t~t~r'T' t~GGC 'hCT (~(iT
This shortens the total size of the fusion protein from 40t residues in pS0132 to 350 residues in pS0643. Experiments using monoclonal antibodies against hGH have demonstrated that the hGH portion of the new fusion protein, assembled on a phage particle, is more acces~ble Ihan was the previous, bnger fusion.
For propagation of hormone-displaying phage, pS0643 and derivatives can tie grown in a amber-suppresser strain of j~j, such as JM101 or XLt-Blue (BuUodc et al-, j~ 5, 376-379 [t987]). Shown above is substitution of Glu at the amber colon whid~ occurs in ~E suppn;ssor strains. Suppression with other 3 5 amino ands is also possible in various available strains of ~ well kroHm and publ'~cally available.
To express hGH (or mutants) tree of the gene III portion of the fusion, pS0643 and derivatives can simply be grown in a non-suppresser strain such as 1609. h ttus case, the amber colon (TAG) leads to termination of translation, which yields free fwrmone, without the need for an independent DNA construction.
To create sites for cassette mutagenesis, pS0643 was mutated with the oligorx~deotides (1) 5'-CGG-ACT-GGG-CAG-ATA-TTC-AAG-CAG-AGC-3', which destroys the unique ~gll1 site of pS0643; (2) 5'-CTC-AAG-AAC-TAC-GAG-TTA-CCC-TGA-CTG-CTT-CAG-GAA-GG-3', which inserts a unique site, a single-base framesfuft, and a non-amber stop colon (TGA); and (3) 5'-CGC-ATC-GTG-CAG-TGC-~-GTG-GAG-GGG3', which introduces a new ~ site, to yield ft~e startup vector, pH0509. The addition of a trameshift along with a TGA stop colon insures that no genelll-fusion can tie produced from tire starting vector.
The $~1- ~[1[ segment is cut out of pH0509 and replaced with a DNA cassette, mutated at the colons of interest. Other restriction sites for cassette mutagenesis at other locatans in hGH have also been introduced into the hormone-phage vector.
Colons 172,174,176 and 178 of hGH were targeted for random mutagenesis because they all be on or near fhe surface of hGH and contribute sigr>rficantly to reoepDx-binding (Cumingham arxi Wells, 244, 1081-1085 (1989j); they all ie within a well-defined structun:, occupying 2 'tums~ on tire same side of helix 4;
and they are each substidtted by at least one amino aid among known evolutionary variants of hGH.
We chose to substitute NNS (N=AIGICIT; S=GJC) at each of fhe target residues.
The choice of the NNS degenera~ sequerxe yields 32 possible codor~ (inducting at least one colon for each amino aid) at 4 sites, for a total of (32)4= 1,048,576 possible nucleotide sequences, or (20)4.
160,000 possible polypeptide sequences. Only one stop colon, amt~er (TAG), is allowed by this dx>ice of colons, and this colon is suppressible as Glu in ~ strains of ~.
Twb degenerate oligonuGeotides, with NNS at colons 172,174,176, and 178, were synthesized, phosphorylated, and annealed to construct the mutagenic cassette: 5'-GT-TAC-TCT-ACT-GCT-TTC-AGG-AAG-GAC-ATG-GAC-NNS-GTC-NNS-ACA-NNS-CTG-NNS-ATC-GTG-CAG-TGC-A-3', and 5'-GA-TCT-GCA-CTG-CAC-GAT-SNN-CAG-SNN-TGT-SNN-GAC-SNN-GTC-CAT-GTC-CTT-CCT-GAA-GCA-GTA-GA-3'.
The vector was prepared by digesting pH4509 with BstEll followed by ~(. The products were run on a 1°~ agarose gel and the large fragment excised, phenol-extracted, and ethanol precipitated. This fragment was treated with calf intestinal phosphatase (Boehringer), then phenol:chlorofortn extracted, ethanol preapitated, and resuspended for Ggafion with the mutagenic cassette.
ProoaQ,atlon of the Initial Itbrarv In XL1~Blue cNls Following tigation, the reaction products were again digested with ~, then phenolxhloroform extracted, ethanol precipitated and resusperxied in water. (A recognitan site (GGTNACC) is created within cassettes which contain a ~ at position 3 of colon 172 and an ~ (Thr) colon at 174. However, treatment with ~ll at this step should not select against any of the possible mutageruc cassettes, because virtually all cassettes will be heteroduplexes, which caruat be deaved by the enzyme.) Approximately 150 ng (45 fmols) of DNA was electroporated info XLt-Blue cells (1.8 x 109 cells in 0.045 mL) in a 02 cm cuvette at a voltage setting of 2.49 kV with a single pulse (tkne constant = 4.7 msec.).
The cells were allowed to recover 1 tour at 37oC in S.O.C media with shaking, then mixed with 25 mL
2YT medum,100 mglmL Carberuallin, and M13-K07 (mot=100). Af6er 10' at 23oC, the culture was incubated overnight (15 hours) at 37oC with shaking. Plating of serial d'rlutions from this culture onto carbeniallin-containing media indicated that 3.9 x 107 etectrotranstormar>rss were obta~ed.
After overnight incubation, the cells were peAeted, and double-strarxied DNA
(dsDNA), designated pH0529E (the initial library), was prepared by the alkaline lysis method. The supernatant was spun again to remove any remaining cells, and the phage, designated phage pool ~H0529E (the initial library of phage), were PEG-preapitated and resuspended in 1 mL STE offer (10 mM Tris, pH 7.6,1 mM
EDTA, 50 mM NaG). Phage titers were measured as oolong-forming units (CFU) for the reoombirant phagemid containing hGH~3p.
Approximately 4.5 x 1013 CFU were obtained from the starting library.
From the pool of elecb~otransformanis, 58 doves were sequenced in the region of the -~
cassette. Of these,17% corresponded to the starting vec6or,1796 contained at least one frame shift, and 7°~6 contained a non-silent (non-terminating) mutatbn outside the four target colons. We conclude chat 41 °~6 of the doves were defective by one of the above measures, leaving a bta! hx>dional pool of 2.0 x 107 initial transfortnants. This number stiA exceeds the possible number of DNA sequerxes by nearly 20-fokJ. Therefore, we are confident of having all possible sequences represented in the starting library.
We examined the sequsr~ces of non-seledad phage to evaluate the degree of colon bias in the mutagenesis (Table V). The results indicated that, although some colons (and amino adds) are urxler- or over-represented relative to the random expectation, the library is extremely diverse, with no evidence of large-scale 'sibling' degeneracy (Table VI).
Table V.
Colon disiributbn (per 188 colons) of non-selected hormone phage. Cbnes were sequerxed from the starting litxary (pH0529E). All colons were tabulated, including those hom doves wtuch contained spurious mutations andlor frameshifts.' Note: the amber stop colon (TAG) is suppressed as Glu in Xl_t-Blue cells. Highlighted colons were over/under-represented by 50% or more.
Leu 17.6 18 1.0 Ser 17.6 26 1.5 Arg 17.6 10 0.57 Pro 11.8 16 1.4 Thr 11.8 14 1.2 Ala 11.8 13 1.1 Gly 11.8 16 1.4 Val 11.8 4 0.3 fe 5.9 2 0.3 Met 5.9 i 0.2 Tyr 5.9 1 0.2 tits 5.9 2 0.3 Trp 5.9 2 0.3 Phe 5.9 5 0.9 Cys 5.9 5 0.9 Gh 5.9 7 12 Apt 5.9 14 2.4 Ly5 5.9 11 1.9 Asp 5.9 9 1.5 4 Giu 5.9 6 1.0 amber' 5.9 6 1.0 Table YI.
Non-selected (pH0529E) Bones with an open reading frame.
The notafan, e.g. TWGS, denotes the hGH mutant 172TI174W/176G/1785. Amber (TAG) colons, translated as Glu in XL1-Blue cells are shown as ~.
Ke NT KTEQ CVLQ
TWGS NNCR EASL
Pe ER FPCL SSKE
LPPS NSOF ALLL
SLDP HRPS PSHP
QQSN LSLe SYAP
GSKT NGSK ASNG
TPVT LTTE EANN
RSRA PSGG KNAK
LCGL LWFP SRGK
TGRL PADS GLDG
AKAS GRAK NOPI
GNDD GTNG
p~~ara8on of fmmobltlzed hGHbo and hPRLbc Immobilized hGHbp ('hGHbp-beads') was prepared as described (Bass et al., Proteins 8, 309-314 (1990)), except that wild-type hGHbp (Fuh et al., ,~ Biol. Chem. 265, 3111-3115 (1990)) was used. Competitive binding experiments with (1251) hGH indicated that 58 fmols of functional hGHbp were coupled per N.L of bead suspension.
Immobilized hPRLbp ('hPRl~p-beads') was prepared as above, using the 211-residue extracellular domain of the prolactin receptor (Cunningham et al., 254.1709-1712 [1990)).
Competitive binding experiments with (1251) hGH in the preserx~ of 50 ~ zinc indicated that 2.1 fmols of functional hPRLbp were 3 0 coupled per N.L of bead suspen~on.
'Blank beads' were prepared by treating the oxirane-acrylamide beads with 0.6 M ethanolamine (pH
9.2) for 15 hours at 4oC.
Birx~n~ selection usln~ Immobilized hGHbo and hPRl.bo Binding of hormone-phage to beads was carried out ~ one of the following buffers: Buffer A (PBS, 0.5°~ BSA, 0.05°~6 Tween 20, 0.01% thimerosal) (or selections using hGHbp and blank beads; Buffer B (50 mM
tris pH 7.5,10 mM MgCl2, 0.5% BSA, 0.05°~ Tween 20,100 m~ ZnCl2) for selections using hPRLbp in the presence of zinc (+ Zn2+); or Buffer C (PBS, 0.5°~ BSA, 0.05% Tween 20, 0.01 % thimerosal,10 m~ EDTA) for selections using hPRLbp in the abserxe of zinc (+ EDTA). Binding selec5ons were carried out according to each of the following paths: (1) binding to blank beads, (2) binding to hGHbp-beads, (3) binding to hPRLbp-beads (+
Zn2+), (4) binding to hPRLbp-beads (+ EDTA), (5) pre-adsorbing twice with hGHbp beads then binding the non-adsorbed fraction to hPRLbp-beads ('-hGHbp, +hPRLbp' selection), or (6) pre-adsorbing twice with hPRLbp-beads then binding the non-adsorbed fraction to hGHbp-beads ('fiPRLbp, +hGHbp' selection). The latter two procedures are expected to enrich for mutants Minding hPRLbp but not hGHbp, or for mutants binding hGHbp but not hPRLbp, respectively.
4 5 Bindng and elution of phage was varied out in each cyde as fellows:
1. BINDING: An aliquot of hormone phage (typically 109 -1010 CFU) was mixed with an equal amount of non-hormone phage (pCAT), diluted into the appropriate buffer (A, 8, or C), and mixed with a 10 ml suspension of hGHbp, hPRlbp a blank beads in a total volume of 200m1 in a 15 ml pdypropylene tube. The phage were allowed b hind b the beads by incubating t hour at room temperature (23°C) with slow rotation (approximately 7 RPM). Subsequent steps were carried out with a constant volume of 200ir1 and at room temperature.
2. WASHES: The beads were spun 15 sec., and the supernatant was removed. To reduce the number of 5 phage not sped6cally bound, the beads were washed 5 times by resuspending briefly b the appropriate buffer, then pelleting.
3. hGH ELUTION: Phage binding weakly to the beads were removed by elution with hGH. The beads were rotated with the appropriate buffer cantair~ing 400 rI~hGH for 15-17 hours. The supernatant was saved as the 'hGH elution' and the beads. The beads were washed by resuspending briefly in buffer and pelleting.
10 4. GLYCINE ELUTION: To remove the tightest-binding phage (i.e. those stiu bound after the hGH
wash), beads were susperxied in Glydne buffer (&offer A plus 0.2 ~Glyane, pH
2.0 with HCI), rotated 1 hour and pelleted. The supernatant ('Glyane elution'; 200p.L) was neutralized by adding 30 mL of 1 M Tris base and stored at 4o C.
5. PROPAGATION: Aliquots from the hGH elusions and from the Glycine elutions from each set of 15 beads under each set of conditions were used to infect separate cultures of bg-phase XL1-Blue cells.
Transductions were carried out by mixing phage with t mL XL1-Blue cells, incubating 20 min. at 37°C, then adding K07 (moi=100). Cultures (25 mL 2YT plus carbenicillin) were grown as described above and the next pool of phage was prepared as described above.
Phage binding, elution, and propagation were carried out in successive rounds, according to the cyGe 20 described above. For example, the phage amplified from the hGH elution from hGHbp-beads were again selected on hGHbp-beads and eluted with hGH, then used to infect a new culture of XL1-Blue cells. Three to five rounds of selection and propagation were carried out for each of the selection procedures described above.
From the hGH and Glycine elution steps of each cycle, an aliquot of phage was used b inoculate XL1-Blue 25 cells, which were plated on LB media containing carberudllin and tetracyGine to obtain independent doves from each phage pool. Single-stranded DNA was prepared from isolated colony and sequenced in the region of the mutagenic cassette. The results of DNA sequendng are summarized in terms of the deduced amino acrd sequerxes in Figures 5, 6, 7, and 6.
3 0 F.x~lm.~.~~Ih~li To determine the binding affinity of some of the selected hGH mutants for the hGHbp, we transformed DNA from sequenced doves into ~, coli strain 16C9. As described above, this is a non-suppressor strain which terminates translation of protein after the final Phe-191 residue of hGH.
Single-stranded DNA was used for these transformations, but double-stranded DNA or even whole phage can be easily electroporated into a non-35 suppressor strain for expressan of tree hormone.
Mutants of hGH were prepared from osmotically shocked cells by ammonium sulfate predpitation as dexribed for hGH (Olson et al., ~g 293, 408-411 (1981]), and protein concentrations were measured by laser densibmoetry of Coomassie-stained SDS-polyaaylamide gel electrophoresis gels, using hGH as standard (Cunningham and Wells, 244,1081-1085 (1989]).
The binding affinity of each mutant was deoermined by displacement of 1251 hGH
as described (Spencer et al., J. Biol. Chem. 263, 7862-7867 (1988) ; Fuh et al., ,l. Biol. Chem.
265, 3111-3115 (1990J), using an anti-reoeptor monoclonal antibody (Mab263).
The results for a number of hGH mutants, selected by different pathways (F~g.
6) are shown in Table VII. Many of these mutants have a tighter binding affinity for hGHbp than wild-type hGH. The most improved mutant, KSYR, has a binding affinity 5.6 times greater than that of wild-type hGH. The weakest selected mutant, among those assayed was only about 10-fold lower in binding affinity than hGH.
Binding assays may be carved out for mutants selected for hPRlbp-birKiirp.
Teble VU.
~e~ve bhdinD b hGHbP
The selected pool in which each mutant was found is indicated as 1G (first glycne selection), 3G (third glycine selection), 3H (third hGH selecCan), 3' (third selection, not binding to hPRI-bp, but binding to hGHbp).
The number of times each mutant o~ured among all sequenced clones is shown ().
Mutant Kd (nM) Kd(mut)/Kd(hGH) Pod KSYR (6) 0.06 + 0.01 0.18 1G,3G
RSFR 0.10 + 0.05 0.30 3G
RAYR 0.13 + 0.04 0.37 3' KTYK (2) 0.16 + 0.04 0.47 H,3G
RSYR (3) 0.20 + 0.07 0.58 1G,3H,3G
KAYR (3) 0.22 + 0.03 0.66 3G
RFFR (2) 0.26 + 0.05 0.76 3H
K~YR 0.33 + 0.03 1.0 3G
KEFR= wt-(9) 0.34-+- 0.05 1.0 3H,3G,3' RTYH 0.68 + 0.17 2.0 3H
QRYR 0.83 + 0.14 2.5 3' KKYK 1.1 +0.4 3.2 3' RSFS (2) 1.1 + 02 3.3 3G,' KSNR 3.1 + 0.4 9.2 3' At some residues, substitution of a particular amino acrd has essentially the same effect independent of surrounding residues. For example, substitution of F176Y in the background of 172RI174S reduces binding affinity by 2.0-fold (RSFR vs. RSYR). Similarly, in the background of 172K/174A the binding affiridy of the Ft76Y mutant (KAYR) is 2.9-told weaker than the ca<responding 176F mutant (KAFR; Cunningham and Wells, 1989).
On the other hand, the Minding constants determined for several selected mutants of hGH demonstrate non-additive effects of some amino add substitutions at residues 172,174, 176, and 178. For example, in the background of 172KI176Y, the substitution E174S results in a mutant (KSYR) which hinds hGHbp 3.7-fold tighter than the corresponding mutant containing E174A (KAYR). However, in the background of 172R/176Y, the effects of these E174 substitutions are reversed. Here, the E174A mutant (RAYR) hinds 1.5-told tighter than the E174S mutant (RSYR).
Such non,additive effects on finding for substitutions at proximal residues illustrate the utility of protein-ptvage Minding selection as a means of seteccting optimized mutants from a library randomized at several positions. h the absence of detailed stmchral inlortnation, without such a selection process, many combinations of substitutions might be tried before finding the optimum mutant.
EXAMPLE !X
SELECTION OF hGH VARIANTS FROM A HELIX-1 RANDOM CASSETTE
LIBRARY OF HORMONE~PHAGE
Using the methods described in Example VIII, we targeted another region of hGH
involved in binding to the hGHbp and/or hPRLbp, helix t residues 10,14,18, 21, for random mutagenesis in the phGHam~3p vector (also known as pS0643; see Example VIII).
We chose to use the'amber~ hGH-g3 construct (called phGHam~g3p) because it appears ~ make the target protein, hGH, more accessible for binding. This is supported by data from comparative ELISA assays of monoclonal antibody binding. Phage produced hom both pS0132 (S. Bass, R.
Greene, J. A Wells, Proteins 8, 309 (1990).) and phGHam-g3 were tested with three antibodies (Media 2, t B5.G2, and 587.C10) that are known to have binding detertninarrts near the carboxyl-terminus of hGH [B. C.
Cunningt~am, P. Jhurani, P. Ng, J. A. Wells, Science 243,1330 (1989); B. C. CunnirxJham and J. A. Wells, Sderrce 244,1081 (1989); L. ]in and J. Wells, unpublished results], and one antibody (Media t) fat recognizes determinants in tierces 1 and 3 ([B. C.
Cunningham, P. Jtwrani, P. Ng, J. A. Wells, Saenae 243,1330 (1989); B. C.
Cunryngham and J. A. Wells, Saence 244, 1081 (1989)]). Phagemid particles from phGHam-g3 reacted much more strongly with antibodies Media 2, 1BS.G2, and 5B7.C10 than did phagemid particles from pS0132. In particular, binding of pS0132 particles was reduced by >2000-told for both Media 2 and 5B7.C10 and reduced by >25-fold for 1B5.G2 compared to binding b Media t. On the other hand, binding of phGHam~3 phage was weaker by only about 1.5-fold, t.2-fold, and 2.3-fold for the Media 2, t B5.G2, and 587.C10 antibodes, respectively, compared with Minding bo MEDIX t.
We mutated residues in helix 1 that were previously identified by alaryne-scanning mutagenesis [B. C.
Cunningham, P. Jhtrar>i, P. Ng, J. A. Wens, Saeme 243,1330 (1989): B. C.
Cunningham and J. A. Wells, Saenoe 244, 1081 (1989), 15,16) to modulate the binding of the extracellular domains of the hGH andlor hPRI
receptors (called hGHbp and hPRlbp, respectively). Cassette mutagenesis was carried out essentially as described [J. A. Wells, M. Vasser, 0. B. Powers, Gene 34, 315 (1985)]. This library was constmcted by casseGe mutagenesis that fully mutated tour residues at a time (see Example VIII) which utilized a mutated version of phGHam-g3 into which unique Kpnl (at hGH codon 27)and Xtal (at hGH colon 6) restriction sites (underlined below) had been inserted by mutagenesis [ T. A. Kunkel, J. D. Roberts, R. A.
Zakour, Me~ods EnzymoL 154, 367-382) with the oligonucleotides 5'-GCC TTT GAC AGG TAC CAG GAG TTT G-3' and 5'-CCA ACT ATA CCA
CTC TCG AGG TCT ATT CGA TAA C-3', respectively. The later oligo also introduced a +1 frameshift (italiazed) to terminate translation from the starting Necbr and minimize wild-type background in the phagemid library. This strating vector was designated pH0508B. The helix 1 wbrary, which mutated hGH residues 10, 14, 18, 21, was constnxxted by igating to the large Xhol-Kprrl fragment of pH0508B
a cassette made from the complementary ofigonucfeotides 5'-pTCG AGG CTC NNS GAC AAC GC~G NNS CTG CGT
GCT NNS CGT CTT
NNS CAG CTG GCC TTT GAC ACG TAC-3' and 5'~GT GTC AAA GGC CAG CTG SNN AAG ACG
SNN AGC
ACG CAG SNN CGC GTT GTC SNN GAG CC-3'. The Kprfl site was destroyed in the jvx~ction of the ligation product so that restriction enzyme digestion could d: used for analysis of non-mutated background.
The library contained at least t 0~ independent bransfortnants so that if the library were absolutely random (106 different comtrnations of codons) we would have an average of about 10 copies of each possible mutated hGH gene. Resfiction analysis using Kpnl indicated that at least 80°~ of helix 1 library constructs contained the inserted cassette.
Binding enrichments of hGH-phage from the libraries was carried out using hGHbp immobilized on oxirane-polyaaylamide beads (Sigma Chemical Co.) as desaibed (E~cample VIII).
Four residues in helix 1 (F10, M14, H18, orb H21 ) were similarly mutated and after 4 and 6 cycles a non-wild-type consensus developed (Table VIII). Position 10 on the hydrophobic face of helix t tended to be hydrophobic whereas positions 21 and 18 on the hydrophillic face tended were dominated by Asn; no obvious consensus was evident for position 14 (Table IX).
The binding constants for these mutants of hGH to hGHbp was determined by expressing tt~e free hormone variants in the non-suppresser E. coJl strain 1609, purifying the protein, and assaying by competitive displacement of labelled wt-hGH from hGHbp (see Example V111). As indicated, several mutants bind tighter to hGHbp than does wt-hGH.
Table VIII.
Selection of hGH helix 1 mutants Variants of hGH (randomly mutated at residues F10, M14, H18, H21) expressed on phagemid particles were selected by binding to hGHbp-beads and eluting with hGH (0.4 m11~ buffer followed by gtyane (0.2 M, pH 2) buffer (see Example VIII).
Gly elution 4 Cycles H G N N
A W D N
(2) Y T V N
I N I N
L N S H
F S F G
6 Cycles 2 0 H G N N ~6) F S F L
Consensus.
H G N N
Table IX
Consensus sequences from the selecived heAx 1 Ifxary 5 Observed frequency is fraction of a!1 doves sequenced with the indicated amino aad. The nominal frequency is calculated on the basis of NNS 32 colon degeneracy. The maximal enrichment facto varies from 11 to 32 depending upon the raminal frequency value for a given residue. Values of [Kd(Ala mut)IKd(wt hGH)j for single alaryne mutations were taken from B. C. Cumingham and J. A. Wells, Saenoe 244,1081 (1989); B. C. Cunningham, D. J. Henner, J. A. Wells, Silence 247,1461 (1990)" B. C. Cunningham and J. A.
Wells, Proc. Nod. Acad. So. USA
10 88, 3407 (1991 ).
Wild type Selected y Kd(Ala mut) m~d~ Kd(wt hGH) m~d~ °~~~ Enrichment 15 F10 5.9 H 0.50 0.031 17 F 0.14 0.031 5 A 0.14 0.062 2 M14 2.2 G 0.50 0.062 8 20 W 0.14 0.031 5 N 0.14 0.031 5 S 0.14 0.093 2 H 18 1.6 N 0.50 0.031 17 25 D 0.14 0.031 5 F 0.14 0.031 5 H21 0.33 N 0.79 0.031 26 H 0.07 0.031 2 Table X
Blndng of purtBed hGH helix 1 rt>~ar>ts b hGHbp Competition Minding experiments were performed using (t~tJhGH (wild-type), hGHbp (containing the extracellular receptor domain, residues 1-238), and Mab263 (B. C. Cumingham, P. Jhurani, P. Ng, J. A. Wells, Silence 243,1330 (1989));. The number P indicates the fractional ocaurence of each mutant among all the clones sequenced after one or more rounds of selection.
Seqm position P Kd (nll~lf(Kd Kd(wt mut) hGH)) H G N N 0.50 0.14 t 0.04 0.42 A W D N 0.14 0.100.03 0.30 w1_- F M H H 0 0.34 0.05 (1 ) F S F L 0.07 0.680.19 2.0 Y T V N 0.07 0.7510.19 2.2 L N S H 0.07 0.82 ~ 0.20 2.4 I N I N 0.07 12 ~ 0.31 3.4 E~CAMPLE X
SELECTION OF hGH VARIANTS FROM A HEUX-4 RANDOM CASSETTE LIBRARY CONTAIMNG
PREVIOUSLY FOUND MUTATIONS BY ENRtCtiMENT OF HORMONE~PHAGE
Our experience with recruiting non-binding homologs of hGH evolutionary variants suggests that many individual amino acid substitutions can be combined b yield a~mulatively improved mutants of hGH with respect to binding a particular receptor (B. C. Cunningham, D. J. Herner, J. Il Wells, Saenoe 247, 1461 (1990); B. C.
Cunningham and J. A. Wells, Pros. NafL Acad. Sa. USA 88, 3407 (1991 ); H. B.
Cowman, B. C. Cunningham, J. A.
Wells, J. Biol. Chem. 266, in press (1991)].
The helix 4b library was constructed in an attempt to further improve the helix 4 double mutant (E174SIF176Y) selected from the helix 4a library that w~e found bound tighOer to the hGH receptor (see Example VIII). Vlrth the E174S/F176Y hGH mutant as the backgro~d starting tarmone, residues were mutated that surrounded positions 174 and 176 on the hydrophilic face of helix 4 (R167, D171, T175 and 1179) .
Cassette mutagenesis was carried out essentiany as described (J. A. Wells, M.
Vasser, D. B. Powers, Gene 34, 315 (1985)]. The helix 4b library, which mutated residues 167,171,175 and 179 within the E174SIFt76Y background, was consUucted using cassette mutagenesis that fully mutated four residues at a time (see Example VIII) and which utilized a mutated version of phGHam~3 into which ur>rque BstEl1 and BgAI
restriction sites had been inserted prevausly (Example VIII). Inb the BstEl1-8plll sites of the vector was inserted a cassette made from the complementary oGgorwdeotides 5'-pG TTA CTC TAC TGC
TTC NNS AAG GAC ATG
NNS AAG GTC AGC NNS TAC CTG CGC NNS GTG CAG TGC A-3' and 5'-pGA TCT GCA CTG
CAC SNN
GCG CAG GTA SNN GCT GAC CTT SNN CAT GTC CTT SNN GAA GCA GTA GA-3'. The BstEll site was eliminated in the ligated cassette. From the helix: 4b wbrary,15 unseiec~ed doves were sequerxaed. 0t these, none lacked a cassette insert, 20°6 were trams-shifted, and 7% had a non-silent mutatan.
Binding eruid~ments of hGH-phage from the libraries was carved out using hGHbp immot~ilized on oxirane-polyacxytamide beads (Sigma Chemical Co.) as described (Example VIII).
After 6 cycles of binding a reasonably dear consensus developed (Tads XI). Interestingly, all positions tended b contain polar residues, notably Ser, Thr and Asn (X11).
The Minding constants for some of these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the ran-sup<xessor E. aoli strain 16C9, purifying the protein, and assaying by competitive displacement of labelled wtfiGH from hGHbp (see Example VIII). As indicated, the binding affinities of several helix-4b mutants for hGHbp were tighter than tf~at of wt-hGH Table XIII).
Finally, we have begun to analyze the binding affinity of several of the tighter hGHbp binding mutants for their ability to hind to the hPRI_bp. The E174SIF176Y mutant binds 200-fold weaker to the hPRLbp than hGH. The E174T/F176YIR178K and R167NID171S/E174SIF176Y/I179T mutants each bind >500-fold weaker to the hPRt-by than hGH. Thus, it is possible to use the produce new receptor selective mutants of hGH by phage display tedx~ology.
f Of the 12 residues mutated ~ three hGH~hagemid libraries (Examples VIII, IX, X), 4 showed a strong, although not exclusive, conservation of the wild-type residues (K172, 7175, F176, and R178). Not surprisingly, these were residues that when converted to Ala caused the largest disruptions (4- to 60-fold) in binding affinity to the hGHbp. There was a class of 4 other residues (F10, Mt4, D171, and 1179) where Ala substitutions caused weaker effects on bindiAg (2- to 7-fold) and these positions exhibited little wild-type consensus. Finally the other 4 residues (H18, H21, 8167, and E174), that promote binding to he hPRLbp but rat the hGHbp, did not exhibit any consensus for the wild-type hGH sequence by selection on hGHbp-beads. h fact two residues (E174 and H21 ), where Ala substitutions enhance binding affinity to the hGHbp by 2- to 4-fold [B. C. Cunningham, P.
Jhurani, P. Ng, J. A. Wells. Science 243.1330 (1989): B. C. Cunningham and J.
A Wells, Saenoe 244,1081 (t 989); B. C. Cunryrrgham, D. J. Henner, J. A. Wells, Saenoe 247,1461 (1990);
B. C. Cunningham and J. A. Wells, Proc. Nab. Acad. Sd. USA 88, 3407 (1991 )j. Ttx~s, the alanine-scanning mutagenesis data correlates reasonably well with the flexitxlity to substitute each position. In fact , the reduction in binding affirdty caused by alanine substitutions (B. C. Cunningham, P. Jhuraru, P. Ng, J. A. Wells, Silence 243,1330 (1989): B. C. Cunrungham and J. A. Wens, Saerroe 244,1081 (1989)j, B. C. C~ir~gham, D. J. Henner, J. A.
Wells, Saenoe 241,1461 (1990); B.
C. Cunningham and J. A. Wells, Pros. NatL Acad. Sa. USA 88, 3407 (1991 )j is a reasonable predictor of the percentage that the wed-type residue is found in the phagemid pool after 3~
rounds of selection. The alarune-scanning information is useful for targeting side~hains Ihat modulate finding, and the phage selection is appropriate for optimizing them and defirung the Aexibility of each site (and/or combinations of sites) for substitution. Tf~e comdnatan of scanring mutational methods [B. C.
t,.uru>>ingham, P. Jhurani, P. Ng, J. A. Wells, Science 243, 1330 (1989); B. C. Cunningham and J. A- Wells, Sdenae 244,1081 (1989)j and phage display is a powerful approach to designing receptor-ligand interfaces and studying molecular evolution in vibo.
In cases where comt~ined mutations in hGH have additive effects on t~irxiing affinity b receptor, mutatans learned through hormone-phagemid etuichrnent b improve Minding can be combined by simple cutting and ligation of restriction fragments or mutagenesis to yield cumulatively optimized mutants of hGH.
On the other hand, mutations in one region of hGH which optimize receptor binding may be stnxturally or functionally incompatible with mutations in an oveAapping a another region of the molecule. In these cases, hormone phagemid enrichment can be carried out by one of several variations on the iterative enrichment approach (1 ) random DNA litxaries can be generated in each of two (or perhaps more) regions of the molecule by cassette or another mutagenesis method. Thereafter, a comt~ined library can be created by Ggation of restriction fragments from the two DNA libraries; (2) an hGH variant, optimized for binding by mutation in one region of the molecule, can be randomly mutated in a second region of the molecule as in the helix-4b library example; (3) two or more random libraries can be y selected for improved finding by hormone-phagemid enrichment; after this 'roughing-in' of the optimized binding site, the stiil-partially-diverse libraries can be recomt~ir~ed by ligation of restriction fragments to generate a single library, partially diverse in two or more regions of the molecules, which in turn can be further selected for optimized tHndir~g using hormone-phagemid enrichment.
Tabfe p.
Mutant phagerNds of hGH sNec~ed from heltx 4b Itbrary after 4 and 6 cycles of eruidunent Selection of hGH helix 4b mutants (randomly mutated at residues 167,171,175,179), each containing the E174SIF176Y
double mutant, by Minding to hGHbp-beads and Hluting with hGH (0.4 mA~ buffer foliowed by glycine (0.2 M, pH 2) buffer One mutant (+) contained the spurious mutation R178H.
8167 D171 T175 IiT9 4 Cycles N S T T
K S T T
S N T T
D S T T
D S T T+
D S A T
D S A N
T D T T
N D T N
A N T N' A S T T
6 Cycles N S T T (2) N N T T
D S S T
E S T I
K S T L
Corpus:
N S T T' D N
Table XII
Cortserts~ aequer~s Born the aeieded Ifbrary.
Observed frequency is hactan of all doves sequenced with the indicated amino acd. The nominal frequency is calculated on the basis of NNS 32 colon degeneracy. The maximal eruichment factor varies from 11 to 16 to 32 5 depending upon the rx~minal frequency value for a given residue. Values of (Kd{Ala mut)lKd{wt hGH)) for single alarune mutations were taken from refs. t~elow; for position 175 we only have a value for the T175S mutant (B. C.
Cunnir~gham, P. Jhurani, P. Ng, J. A. Wells, Sderx;e 243, 1330 (1989); B. C.
Cumingham and J. A. Wells, Science 244, 1081 ~ 1989); B. C. Cunr>ingham, D. J. Henner, J. A. Wells, S?,47,1461 (1990);
B. C. Cunningham and J. A. Wells, Pros. Natl. Acad. Sci. USA88, 3407 (1991).J.
Wild type Selected FtB,Cl,t~y Kd(Ala mut) residue Kd(wt hGH) residue observed nominal Enrichment R 167 0.75 N 0.35 0.031 t t 15 D 0.24 _ 0.031 8 K 0.12 0.031 4 A O.t2 0.062 2 D171 7.1 S 0.76 0.093 8 N 0.18 0.031 6 2 0 D 0.12 0.031 4 T175 3.5 T 0.88 0.062 14 A 0.12 0.031 4 1179 2.7 T 0.71 0.062 11 N 0.18 0.031 6 Table XIII
Binding of purificed hGH mu»s to hGHbp.
Competition Minding experiments were performed using [1251]hGH (wild-type), hGHbp (containing the 30 extracellular receptor domain, residues 1-238), and Mab263 (11). The number P indicates the fractional oaxxrerxe of each mutant among all the Bones sequenced after one or more rounds of selection. Note that the helix 4b mutations (') are in the background of hGH(E174S/F176Y). In the list of helix 4b mutants" the E174SIF176Y mutant ('), with wt residues at 167,171,175, 179, is shown in bold.
~~ mut) 3 5 Sequer>ce position p ~ (n d(w~ t hGH) 40 N S T T 0.18 0.04 t 0.02 0.12 E S T I 0.06 0.04 f 0.02 0.12 K S T L 0.06 0.05 t 0.03 0.16 N N T T 0.06 0.06 t 0.03 0.17 R 0 T I 0 0.06 t 0.01 (0.18) 4 5 N S T Q 0.06 026 t 0.11 0.77 l~trrbty of F~ Wblea>le on the Pt>apemfd ~Ce Plasmid pDH 188 contains the DNA erxx>ding the F~ portion of a humanized IgG
antibody, called 4D5, that recognizes the HER-2 receptor. This plasmid is contained in E. colt strain SR 101, and has been deposited with the ATCC in Rockville, MD.
Briefly, the plasmid was prepared as follows: the starting ptasmid was pS0132, containing the alkaline phosphatase promoter as described above. The DNA eroding human growth hormone was exdsed and, after a series of manipulations to make the ends of the plasmid compatible for ligatan, the DNA encoding 4D5 was inserted. The 4D5 ONA contains two genes. The first gene encodes the variable and constant regions of the light chain, and contains at its 5' end the DNA encoring the st II signal sequence.
The record gene contains four portions: first, at its 5' end is the DNA encoding the st II signal sequence.
This is followed by the DNA encoding the variable domain of the heavy chain, which is iotbwed by the DNA eroding the first domain of the heavy drain constant region, which in turn is followed by the DNA encoding the M13 gene III. The salient features of this construct are shown in Fgure 10. The sequere of the DNA encoding 4D5 is shown in Figure 11.
Both polyethylene glycol (PEG) and ele~,~troporation were used to transform plasmids into SR101 cells.
(PEG competent cells were prepared and transformed according to the method of Chung and Miller (Nucleic Acids Res.16:3580 (1988]). Cells that were competent for electroporation were prepared, and subsequently transformed via electroporation according to the method of Zabarovsky and Winberg (Nucleic Acids Res.18:5912 (1990J). After placing the cells in 1 ml of the SOC media (desaibed in Sambrook et aL, supra), they were grown for 1 hour at 37°C with shaking. At this time, the corentration of the cells was determined using light scattering at ODSpO. A titered K07 phage stock was added to achieve an multiplicity of infection (M01) of 100, and the phage were allowed to adhere to the cells for 20 minutes at room temperature.
This mixture was then diluted into 25 mls of 2n broth (described in Sambrook et al., supra) and incubated with shaking at 37°C overnight. The next day, cells were pelleted by centrifugation at 5000 x g for 10 mirwtes, the supernatant was collected, and the phage particles were precipitated with 0.5 M NaC;I and 4°~6 PEG (final concentration) at room temperature for t0 minutes. Phage particles were pelteted by centrifugation at 10,000 x g for 10 minutes, resuspended in 1 ml of TEN
(10 mM Tris, pH 7.6,1 mM EDTA, and 150 mM NaCI), and stored at 4°C.
$~
Alpuots of 0.5 ml from a solutbn of 0.1 mglml of the extra~enular domain of the HER-2 antigen (ECD) or a solution of 0.5 mglml of BSA (control antigen) in 0.1 M sodium bicarbonate, pH 8.5 were used to coat one well of a Falcon 12 well tissue wkure plate. Once the solution was applied b the wells, the plates were incubated at 4°C on a rocking plattortn overnight. The plates were then blocked by removing the initial solution, applying 0.5 ml of blocking buffer (30 mghnl BSA in 0.1 M sodium bicarbonate), and incubating at room temperature for one hour.
Finally, the blocking buffer was removed, t m1 of buffer A (PBS, 0.5% BSA, and 0.05°~ Tween-20) was added, and ~e plates were stored up to 10 days at 4°C before being used for phage selection.
Approximately 109 phage particles were mixed with a 100-told excess of K07 helper phage and 1 ml of buffer A . This mixture was divided into two 0.5 ml alpuots; one of which was applied to ECD coated wells, and the other was applied b BSA coated wells. The plates were irxubated at room temperature while shaking for one to three hours, and were then washed three times over a period of 30 minutes with 1 ml alpuots of buffer A.
Elution of the phage from the plates was done at room temperature by one of two methods: t ) an initial overnight incubation of 0.025 mglml purified Mu4D5 antibody (murine) followed by a 30 minute irxubation with 0.4 ml of the add elution buffer (0.2 M glydne, pH 2.1, 0.5°i° BSA, and 0.05°,6 Tween-20), or 2) an incubatan with the acid elutar, buffer alone. Eluates were then neutralized with t M Tris base, and a 0.5 ml aliquot of TEN was added.
These samples were then propagated, titered, and stored at 4°C.
Aliquots of eluted phage were added to 0.4 ml of 2YT broth and mixed with approximately 108 mid-bg phase male E. coil strain SR101. Phage were allowed to adhere to the cells for ZO minutes at room temperature and then added to 5 ml of 2YT broth that contain~,~d 50 trglml of carbenidllin and 5 ~ghnl of tetracycline. These cells were grown at 37°C for 4 to 8 hours until they reached mid-tog phase. The OD6pp was determined, and the cells were superinfected with K07 helper phage fur phage production. Orxe phage particles were obtained, they were titered in order to determine the number of cblony forming units (cfu).
This was done by taking aliquots of serial dilutions of a given phage stock, allowing them to infect mid-log phase SR101, and plating on LB plates containing 50 uglml carbenicillin.
RIA affini dete~(g~
The affinity of h4D5 Fab fragments and Fab phage for the ECD antigen was determined using a competitive receptor binding RIA (Burt, D. R., Receptor Binding in Drug Research. 0'Brien, R.A. (Ed.). pp. 3-29, Dekker, New York (1986)). The ECD antigen was labeled with 125-bdine using the sequential chloramine-T
method (De Larco, J. E. et al., J. Cell. Physiol.109:143-152 [1981J) which produced a radioactive tracer with a spedfic activity of l4~Ci/~g and incorporation of 0.47 moles of Iodine per mole of receptor. A series of 0.2 ml solutions containing 0.5 ng (by ELISA) of Fab or Fab phage, 50 nCi of 1251 ECD
tracer, and a range of unlabeled ECD amounts (6.4 ng to 3277ng) were prepared and incubated at room temperature overnight. The labeled ECD-F~ or ECD-Fab phage complex was separated from the unbound labeled antigen by forming an aggregate complex induced by the addition of an anti-human IgG (Frtzgerald 40-GH23) and 6°~ PEG 8000. The complex was pelleted by centrifugation (t5,000 x g for 20 minutes) and the amount of labeled ECD (in cpm) was determined by a gamma counter. The dissoaation constant (K;d) was calculated by employing a modified version of the program LIGAND (Munson, P. and Rothbard, D., Anal 8iodrem.107~20-239 (1980J) which utilizes Scatchard analysis (Scatdvard, G.,Mn. N. Y. Acad. Sd. 51 ~660~72 [t 949J). The Kd values are shown in Figure 13.
~1L
Murine 4D5 antibody was labeled with 125-I to a spedfic activity of 40-50 ~Cil~g using the lodogen procedure. Solutions containing a constant amount of labeled antibody and increasing amounts of unlabeled variant Fab were prepared and added to near confluent cultures of SK-BR-3 cells grown in 96-welt miaotiter dishes (final concentration of Labeled antibody was 0.1 nM). After an overnight inwbation at 4°C, the supernatant was removed, the cells were washed and the ceu assoaated radioactivity was determined in a gamma counter. Kd Values were determined by analyzing the data using a mo~fied version of the program LiGAND (Mtxtsort, P, and Rothbard, D., supra) This deposit of plasmid pDH188 ATC;C no. 68663 was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture for 30 years from the date of deposit. The organisms will be made available by ATCC
under the terms of the Budapest l reaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent ~~nd unrestncted availability of the progeny of the cultures to the public upon issuance of a Patent on the basis of the application, or the patent application is refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, whichever comes first, and assures 1 0 availability of the progeny to one determined t>y the Commissioner of Patents to be entitled thereto according to Section 109 of the Patent Rules.
The assignee of the present application has agreed that if the cultures on deposit should die or be lost or destroyed when cultivated under suitable conditsons, they will be promptly replaced on notificafan with a viable 15 specimen of the same culture. Availability of the deposited cultures is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordar>Ge with its patent laws.
The foregoing written spedfication is considered to be suffident to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the cultures deposited, since the 20 deposited embodiments are intended as separate illustrations of certain aspects of the invention and any cultures that are funcianany equivalent are within the scope of this invention. The deposit of material herein does not constitute an admissan that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the test mode thereof, nor is tt bo be construed as limiting the scope of the claims to the spedfic illustrations that it represents Indeed, various modifications of the invention in addition to 25 those shown and described herein will become apparent to those skilled in the art from the-foregoing description and fall within the scope of the appended claims.
While the invention has necessarily been described in conjunction with preferred embodiments, one of ordinary skill, after reading the foregoing speafiCation, wt~l be able to effect various d~anges, substitutions of equivalents, and alterations b fhe subject matter set forth herein, without departing from tt>Ie spirit and scope 30 thereof. Hence, the invention can be practiced in ways other than those specificany described herein. ft is therefore intended that the protection granted by utters Patent hereon be limited only by the appended claims and equivalents thereof.
SELECTION OF hGH VARIANTS FROM COMBINATIONS OF HELIX-1 ANO HELJX-4 HORMONE-PHAGE
VARIANTS
According to additivity principles (J. A. Weus, Biochemistry29, 8509 (1990)], mutations in different parts of a protein, ff they are not mutually interacting, are expected to combine b produce additive d~anges in the tree energy of Minding b another molecule (changes are addiCrve in terms of eeGb;~ing, or muftiplicative in terms of Kd = exp(-AGIRT] ). Thus a mutation pndudng a 2-told increase in binding affinity, when combined with a second mutation causing a 3-fold increase, would be predicted to yield a double mutant with a 6-fold increased affinity over the starting variant.
To test whether multiple mutations obtained from hGH-phage selections would produce cumulatively favorable effects on hGHbp (hGH~inding protein; the extraceuular domain of the hGH receptor) binding, we combined mutations found in the three tightest-binding variants of hGH hom the helix-1 library (Example IX:
F10A/M14W/H180/H21N, F10H/M14GIHt8NlH2tN, and F10FIM14S/H18F/H21L) with those found in the three tightest binding variants found in the helix~4b library (Example X:
R167WD171SIT175II179T, R167E/D171 SIT175II179, and R167NID17t NIT~175II179T).
hGH-phagemid double-stranded DNA (dsDNA) from each of the one-helix variants was isolated and digested with the restriction enzymes EcoRl and BstXl. The large fragment from each helix-4b variant was then 2 0 isolated and ligated with the small fragment from each helix-1 variant b yield the new two-helix variants shown in Table XIII. All of these variants also contained tt~: mutations E174SIF176Y
obtained in earlier hGH-phage binding selections (see Example X for details).
Construction of selective combinatorial Ilbrarles of hGH
Although additivity prindples appear b hold for a rwmber of comt~inations of mutations, some combinations (e.g. E174S with F176Y) are dearly non~additive (see examples VIII and X). In order to identify with certainty the tightest binding variant with, for example, 4 mutatans in helix-1 ~ 4 mutations in helix-4, one would ideally mutate all 8 residues at once and then sort the pool for the globally tightest Minding va«ant.
However, such a pool would consist of 1.t x 1012 DNA sequer>ces (utilizing NNS
colon degeneracy) encoding 2.6 x 1010 different polypeptides. Obtaining a random phagemid ~txary large enough to assure representation of all variants (pefiaps 1013 transtortnants) is not practical using ament transformation ledu~ology.
We have addressed this difficulty first by utilizing successive rounds of mutagenesis, taking the lightest binding variant from one library, Ihen mutating otter residues to further improve binding (Example X).
In a second method, we have utilized the principle of additivity b combine the test mutations from two independently sorted Gbra~~es b create multiple mutants with improved binding (described above). Here, we further seard~ed tiuough the possible comt~ir~ations of mutations at positions 10,14,18, 21,167,171,175, and 179 in hGH, by creating comt~ir~atorial libraries of random or partially-random mutants. We constmcted three different comt~ir~atorial libraries of hGH-phagemids, using tf~e pooled phagemids from the helix 1 library (independently sorted for 0, 2, or 4 cycles; F~cample IX) and the pool from the helix-4b library (independently sorted for 0, 2, or 4 cycles; Example X) and sorted the combined variant pool for hGHbp binding. Since some amount of sequence diversity exists in each of these pools; the resulting combir>atorial ~brary can expbre more sequence combinations than what we might canstnxxt manuany (e.g. Table XIII).
hGH-pf~agemid double-stranded DNA (dsONA) from each of the onefielix library pools (selected for 0, 2, a 4 rounds) was isolated and digested with the restriction enzymes Ac~cl and BstXl. The large fragment from each helix-1 variant pool was then isolated and ligated with the smaN fragment from each helix-4b variant pool to yield the three combinatorial wtxaries pH0707A (unseleded helix 1 and helix 4b pools, as described in examples lX
5 and X), pH0707B (twice-selected helix-1 pool with twice-selected helix-4b pool), and pH0707C (4-times selected helix-t pool with 4-times selected helix-4b pool). DupNcate ligations were also set up with less DNA and designated as pH0707D, pH0707E, and pH0707F, corresponding b the 0-,2-, and 4-round starting libraries respectively. All of these variant pools also contained the mutations E174SIF176Y obtained in earlier hGH-phage binding seleaions (see Example X for details).
The rogation products pH0707A-F were processed and eledro-transformed into XL1-Blue cells as described (Example VIII). Based on colony-forming orals (CFU), the number of transfortnants obtained from each pool was as follows: 2.4x106 from pH0707A, l.r~x106 fiom pH07078, 1.6x106 from pH0707C, 8x105 from pH0707D, 3x105 from pH0707E, and 4x105 from pH0707F. hGH-phagemid partides were prepared and selected for hGHbp-binding over 2 to 7 cydes as desait~ed in Example VIII.
In addition to sorting phagemid libraries for tight-binding protein variants, as measured by equilibrium Minding affinity, it is of interest to sort for variants whid7 are altered in either the on-rate (kon) or the off-rate (koff) of binding to a receptor or other molecule. From then~nodyrramics, these rates are related to the equilitxium dissodation constant, ICd = (koH/kpn). We envision that certain variants of a particular protein have similar Kd's for binding while having very different kon's and ko6's.
Conversely, charges in Kd from one variant to another may be due b effects on kon, effects on koff, or both. The pharmacological properties of a protein may be dependent on binding affinity or on Icon or koN, depencfrng on the detailed mechanism of action. Here, we sought to identify hGH variants with higher on-rates to investigate the effects of d~anges in kon. We envision that the selection could aftematively be weighted toward ko(f by increasing the binding time and irxreasing the wash time andlor corxentration with cognate ligand (hGH).
From time~ourse analysis of wild-type hGH-phagemid binding to immobilized hGHbp, it appears that, of the total hGH-phagemid particles that can be eluted in tt~e final pH 2 wash (see Example VIII for the complete Minding and elution protocol), less than 10% are bound after 1 minute of ina~bation, white greater than 90°6 are bound after 15 minutes of irxubatan.
For 'rapid-birxiing selection; phagemid partides from the pH0707B pool (twice-selected for helices 1 and 4 dependently) were incubated with immobilized hGHbp fa only 1 minute, then washed six times with 1 mL of Minding buffer;1he hGH-wash step was omitted; and the remaining hGH-phagemid partides were eluted with a pH2 (0.2M glydne in binding buffer) wash. Enrichment of hGH-phagemid partides over non~dsplaying partides indicated that even with a short binding period and no cognate-ligand (hGH) d~allenge, hGH-phagemid binding selection sorts tight-binding variants out of a randomized pool.
The Minding constants for some of these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the non-suppressor E. aoli strain 1609 or 3488, purifying the protein, and assaying by competitive displacement of labelled wtfiGH from hGHbp (see Example VIII) in a radio-immunopreciptation assay.
In Table XIII -A below, all the variants have glutamate174 roP~~d bY ~~174 ~d p~~a~~176 re~aced by tYro~~176 (E174S and F1176Y) plus the additianal substitutions as indicated at hGH amino acd positions 10, 14,18, 21, t 67,171,175 and 179.
Table XIII-A
hGH
variants from adddon of helbc-t and heax-4b mtrcattons H
f H
f e e oc oc wild-type residue:~,Q ~g ~$ ~, $1Z ~1j1 I1Z~ ll,Z,Q
V
t arian H G N N N S T T
In Table XIV below, hGH variants were selected from comtHrwtorial libraries by the phagemid tHnding selection process. All hGH variants in Table XIV contain two background mutations (E174SIF176Y). hGH-phagemid pools from the libraries pH0707A (Part A), pH0707B and pH0707E (Part B), or pH0707C (Part C) were sorted for 2 b 7 cydes for binding to hGHbp. The number p indicates the fractional occurrence of each variant type among the set of dories sequenced from each pool.
Table XIV
hGH varlaMs from t~omane-pt~aperdd bindnp selection Of combtnabrial Itbraries.
~ ~~ Helix wild-type ~Q ~4 ~ b21 Hl,fiZp~,u I11~ ll18 residue:
Y~I
Part 4 cycles:
A :
0.60 H07t4A.1 H (i N N N S T N
0.40 H0714A.4 A N D A N N T N
' Part B:
2 cycles:
0.13 H0712B.1 F S F G H S T T
0.13 H0712B.2 H C~ T S A D N S
0.13 H07t2B.4 H G N N N A T T
0.13 H0712B.5 F S F L S D T T
0.13 H0712B.6 A S T N R D T I
0.13 H0712B.7 Q 1' N N H S T T
0.13 H0712B.8 W (a S S R D T I
2 0.13 H0712E.1 F 1. S S K N T V
0.13 H0712E.2 W PJ N S H S T T
0.13 H0712E.3 A fJ A S N S T T
0.13 H0712E.4 P ;i D N R D T I
0.13 H0712E.5 H (i N N N N T S
0.13 H0712E.6 F ;; T G R D T I
0.13 H0712E.7 M T S N Q S T T
0.13 H0712E.8 F ;i F L T S T S
4 cycles:
0.17 H07148.1 A W D N R D T I
0.17 H0714B.2 A W D N H S T N
0.17 H0714B.3 M Q M N N S T T
0.17 H0714B.4 H Y D H R D T T
0.17 H0714B.5 L fJ S H R D T I
0.17 H0714B.6 L fJ S H T S T T
3 7 cycles:
0.57 H0717B.1 A W D N N A T T
0.14 H07t7B.2 F S T G R D T I
0.14 H0717B.6 A W D N R D T I
0.14 H0717B.7 I Q E H N S T T
0.50 H0717E.1 F S L A N S T V
Part C:
4 cycles:
0.67 H0714C.2 F S F L K D T T
' s also contained the mutations L15R, K168R.
In Table XV t~ebw, hGH variants were selected from combinatorial libraries by the phagemid Minding selection process. All hGH variants in Table XV contain two background mutations (E174SlF176Y). Trie numt~er P is the fractional occurrence of a given variant among all doves sequenced after 4 cycles of rapid-Minding selection.
Table XV
hGH vartarns from RAPID
hGHbp btndinp selectlm of an hG~+-phagemid combinabo~ial Itbrary Hela 1 Hela _ wild-typeresidue: ~,Q ~g J~$ ~, $
Y~tl~nt 0.14 H07BF4.2 W G S S R D T I
0.57 H07BF4.3 M A D N N S T T
0.14 H078F4.6 A W D N S S V T $
0.14 H07BF4.7 H Q T S R D T I
$ = also contained the mutation Y176F (wild-type hGH also contains F176).
In table XVI below, binding constants were measured by competitive displacement of 1251-labelled hormone H0650BD or labelled hGH using hGHbp (1-238) and either MabS.ar~lAab263. The variant H0650BD
appears tHnd more than 30-fold tighter than wild-type hGH.
Tade XVI
Equlubrt~n bkx~p oor~ar~ of s~ec~ hGH vartanfs.
hGH K~(variantl Kd(variantl Variant Kd(H0650BD) Kd(hGH) Kd (per, hGH 32 -1- 340 t H06508D -1- 0.031 10 t H0650BF 1.5 0.045 15 t H0714B.6 3.4 0.099 34 t H0712B.7 7.4 0.22 74 t H0712E.2 16 0.48 60 t EXAMPLE XIII
Selective enrichment of trGH-phage contalnlng a protease substrate sequence versus r~on-substrate phage As described in Example I, the plasmid pS0132 contains the gene for hGH fused to the residue Pro198 of the gene tll protein with the insertion of an extra glycine residue. This plasmid may be used to produce hGH-phage particles in which fhe hGH~ene III fusion product is displayed monovalently on the phage surface (Example IV). The fusion protein comprises the entire hGH protein fused to tf~e carboxy terminal domain of gene III via a flexible linker sequence.
To investigate the feasit~ility of using phage display technology to select favourable substrate sequences for a given proteolytic enzyme, a genetically engineered variant of subtilisin BPN' was used. (Carter, P.
et al., Proteins: Structure, furxtion and genetics 6:240-248 (1989)). This variant (hereafter referred to as A64SAL subtilisin) contains the folbwing mutations: Ser24Cys, His64Ala, GIu156Ser, GIy169A1a and Tyr217Leu. Since this enzyme lades the essential catalytic residue His64, its substrate spedfidty is greatly restricted so that certain histidine-containing substrates are preferentially hyrdrolysed (tJarter et al., Science 237:394-399 (1987)).
The sequence of the linker region in pS0132 was mutated to aeate a substrate sequence for A64SAL
subtilisin, using the oligonucleotide 5'-TTC-GGG-CCC-TTC-GCT-GCT-CAC-TAT-ACG-CGT-CAG-TCG-ACT-GAC-CTG-CCT-3'. This resulted in the introduction of the protein sequence Phe-Gly-Pro-Phe-Ala-Ala-5 His-Tyr-Thr-Arg-Gln-Ser-Thr-Asp in the linker region between hGH and the carboxy terminal domain of gene III, where the first Phe residue in the above sequence is Phe191 of hGH. The sequerxe AJa-Ala-His-Tyr-Thr-Agr-Gln is krwvm to be a good substrate for A64SAL subtilisin (Carter et al (1989), supra). The resulting plasmid was designated pS0640.
Phagemid particles derived from pS0132 and pS0640 were constructed as described in Example I. In initial experiments, a tON.I aliquot of each phage pool was separately mixed with 30p1 of oxirane beads (prepared as described in Example II) in 100W of buffer comprising 20mM Tris-HCI pH 8.6 and 2.5M NaCI. The binding and washing steps were performed as described in example VII. The beads were then resuspended in 4001 of the same buffer, with or without 50nM of A64SAL subtilisin. Following incubation for 10 minutes, the supernatants were collected and the phage titres (cfu) measured. Table XVII shows that approximately 10 times more substrate-containing phagemid particles (pS0640) were eluted in the presence of enzyme than in the absence of enzyme, or than in the case of the non-substrate phagemids (pS0132) in the presence or absence of enzyme. Increasing the enryme, phagemid or bead concentrations did not improve this ratio.
In an attempt to decrease the non-spedfic elution of immobilised phagemids, a tight-binding variant of hGH was introduced in place of the wild-type hGH gene in pS0132 and pS0640. The hGH variant used was as described in example XI (pH0650bd) and contains the mutations PhelOAla, Metl4Trp, Hisl8Asp, His2fAsn, Arg167Asn, Asp171Ser, GIu174Ser, Phe176Tyr and IIe179Thr. This resulted in the construction of two new phagemids: pDM0390 (containing tight-binding hGH and no substrate sequence) and pDM0411 (containing tight-binding hGH and the substrate sequence Ala-Ala-His-Tyr Thr Agr-Gln). The birx~ng washing and elution protocol was also changed as follows:
() Binding: COSTAR 12-well fassue culture plates were coated for 16 hours with 0.5mUwell 2ug/ml hGHbp in sodium carbonate buffer pH 10Ø The plates were Then Incubated with tmllwell of blocking buffer (phosphate buffered saline (PBS) containing 0.1%wN bovine serum albumen) for 2 hours and washed in an assay buffer containing lOmM Tris-HCI pH 7.5, 1 mM EDTA and 100mM NaCI. Phagemids were again prepared as described in Example I: the phage pool was diluted 1:4 in the above assay buffer and 0.5m1 of phage incubated per well for 2 hours.
(i) Washing: The plates were washed thoroughly with PBS + 0.05% Tween 20 and incubated for 30 minuted with 1 ml of this wash buffer. This washing step was repeated three times.
(ii) Eution: The plates were irxubated for 10 minutes in an elution buffer consisting of 20mM Tris-HCI pH 8.6 + t OOmM NaCI, then the phage were eluted with 0.5m1 of the above buffer with or without 500nM of A64SAL subtilisin.
Table XVI I shows that there was a dramatic incxease in the ratio of specifically eluted substrate-phagemid particles compared to the method previously described for pS0640 and pS0132. ft is likely that this is due tv the fad that the tight-binding hGH
mutant has a significantly sbwer off-rate for binding to hGH binding protein compared to wild-type hGH.
Table XVII
SpecIflc elution of substrate-phagem(ds by A64SAL subt111sIn Colony forming units (du) were estimated by plating out l0pl of 10-fold dilutions of phage on l0pl spots of XL-1 blue cells, on LB agar plates containing 50pg/ml carbeniallinl (i) wld-type hGH gene: binding to hGHbp-oxirane beads pS0640 (substrate) 9x106cfu/l0pl 1.5x106cfu/l0ul pS0132 (non-substrate) l3x105cfu/tOpl 3x105cfu/l0ul (ii) pH0650bd mutant hGH gene: Minding to hGHbp-coated plates pDM0411 (substrate) 1.7x105cfu/tOp.l 2x103cfult0ul pDM0390 (non-substrate) 2x103cfu/l0pl 1x103cfu/tOpl Example XIV
Identlt(catlon of preferred substrates for A64SA~ subttllsln using selective enrichment of a Itbrary of substrate sequences.
We sought to employ the selective enrichment procedure described in Example XIII to identify good substrate sequences from a library of random substrate sequences.
We designed a vector suitable tar introduction of randomised substrate cassettes. and subsequent expression of a library of substrate sequences. The starting point was the vector pS0643, described in Example VIII. Site-directed mutagenesis was carried out using the oligor>ucleotide 5'-AGGTGT-GGC-TTC ' C-GCGGCG-TCG-ACT-GGC-GGT-GGC-TCT-3', which introduces ~[ (GGGCCC) and ; 811 (GTCGAC) restriction sites between hGH
and Gene III. This new construct was designated p0M0253 (The actual sequence of pDM0253 is 5'-AGC-TGT-GGC-TTC-GGG-CCC~CC-ACC-GCG-TCG-ACT-CGC-GGT-GGC-TCT-3', where the underlined base substitution is due to a spurious error in the mutagenic oligonucleotide).
In addition, the tight-binding hGH variant described in example was introduced by exchanging a fragment from pDM041 t (example XIII) The resulting library vector was designated pDM0454.
To introduce a library cassette, pDM0454 was digested with Apal followed by Sall, then precipitated with 13~o PEG 8000+ lOmM MgCl2, washed twice in 7096 ethanol and resuspended This etfaently precipitates the vector but leaves the small Apa-Sal fragment in solution (Paithankar, K. R. and Prasad, K. S. N., Nucleic Acids Research 19:1346). The product was run on a 1% agarose gel and the Apal-Sall digested vector excised, purified using a Bandprep kit (Pharmacia) and resuspended for ligation with the mutagenic cassette.
The cassette to be inserted contained a DNA sequence similar to that in the linker region of pS0640 and pDM0411, but with the colons for the histidine and tyrosine residues in the substrate sequence replaced by randomised colons. We chose to substitute NNS
(N=G/AIT/C; S=G/C) at each of the randomised positions as described in example VIII. The oligonucleotides used in the mutagenic cassettes were: 5'-C-TTC-GCT-GCT-NNS-NNS-ACC-CGG-CAA-3' (ood~ng strand) and 5'-T-CGA-TTG-CCG-GGT-SNN-SNN-AGC-AGC-GAA-GGG-CC-3' (non-coding strand). This cassette also destroys the Sall site, so that digestion with Sall may be used to reduce the vector background. The oligonucteotides were not phosphorylated before insertion iMo the Apa-Sal cassette site, as it was feared that subsequent oligomerisation of a small population of the cassettes may lead to spurious results with multiple cassette inserts. Following annealing and ligation, the reaction products were phenol:chloroform extracted, ethanol precipitated and resuspended in water.
Initially, no digestion with Salt to reduce the background vector was performed.
Approximately 200ng was eledroporated into Xt_-1 blue cells and a phagemid library was prepared as described in example VIII.
$electfon of h[gJy cleawable substrates from the substrate Ilbrarv The selection procedure used was identical to that described for pDM0411 and pDM0390 in example XIII. After each round of selection, the eluted phage were propagated by transduang a fresh culture of Xt-1 blue cells and propagating a new phagemid library as described for hGH-phage in example VIII. The progress of the selection procedure was monitored by measuring eluted phage titres and by sequenang individual clones after each round of selection.
Table A shows the successive phage titres for elution in the presence and absence of enryme after 1, 2 and 3 rounds of selection.
Clearly, the ratio of specifically eluted phage: non-specifically eluted phage (ie phage eluted with enzyme:phage eluted without enzyme) increases dramatically from round 1 to round 3, suggesting that the population of good substrates is increasing with each round of selection.
Sequencing of 10 isolates from the starting library showed them all to consist of the wild-type pDM0464 sequence. This is attributed to the fad that after digestion with Apal, the Sall site is very cbse to the end of the DNA fragment, thus leading to bw efficiency of digestion. Nevertheless, there are only 400 possible sequences in the ibrary, so this population should still be welt represented.
Tables B1 and 82 shows the sequences of isolates obtained after round 2 and round 3 of selection. After 2 rounds of selection, there is clearly a high incidence of histidine residues. This is exactly what is expelled: as described in example XIII, A64SAL subtilisin requires a histidine residue in the substrate as it employs a substrate-assisted catalytic mechanism. After 3 rounds of selection, each of the 10 clones sequenced has a histidine in the randomised cassette. Note, however, that 2 of the sequences are of pDM0411, which was not present in the starting library and is therefore a contaminant.
Table A
Tttratlon of Initial phage pools and eluted phage from 3 rounds of aelectlve enrichment Colony forming units (cfu) were estimated by plating out 10~f of 10-fold dikrtions of phage on 10.1 spots of XL-1 blue cells, on LB agar plates containing 50pg1m1 carberwcillin H~1~1 Starting library:3x1012 cfu/ml LIBRARY: +500nM A64SAL. 4x103 dultOpl :
no enzyme : 3x103 du/l0pl pDM0411: +500nM A64SAL 2x106 cfu/tOpl :
(control) no enzyme : 8x103 cfull0pl Round 1 library:7x1012 cfulml LIBRARY: +500nM A64SAL 3x104 cfu/10p.1 :
no enzyme : 6x103 CfullOUl pDM0411: +500nM A64SAL 3x106 cfu110p1 :
(control) no enzyme : 1.6x104 cfu/10~1 Round 2 library:7x1011 cfu/ml LIBRARY: +500nM A64SAL. 1x105 Cfu/10p1 :
no enzyme : <103 ctu/l0pl pDM0411: +500nM A64SAL 5x106 cfu/10~1 :
(control) no enzyme : 3x104 cfu/l0pl Teble Bt Sequences of eluted phape after 2 rounds of selective enrichment.
5 All protein sequences should be of the form AA"TRH, where' represents a randomised colon. In the table below, the randomised colons and amino acids are underlined and in bold.
After round 2:
Seauence lyo~of ~rences A A $ Y T R Q
... GCT GCT~ ACC CGGCAA ... 2 A A $ $ T R Q
2O ... GCT GCT~ ACC CGGCAA ... 1 A A y $ T R Q
... GCT GCTCTC ACC CGGC:AA ... 1 CAC
A A y $ T R Q
... GCT GCTCTG ACC CGGC:AA ... 1 CAC
A A $ ~ R Q
... GCT GCT~ CGG CAA... 1 #
A A ~ $ T R Q
... GCT GCT??? ACC CGGC;AA 1 CAC
.., wild-type 3 pDM0454 # - spurious deletion of 1 colon within the cassette ## - ambiguous sequence Table B2 S~pncps n~ eluted nha,ge after 3 rounds of selective enrichment All protein represents sequences a should be of the form AA"TRQ, where' rarxiomised the table below, the randomised colon. in colons and amino acids are underlined and in bolo.
After round 3:
i~d~lJ~.~'~
A A $ z T R Q
... GCT GCT TAT ACG CGT CAG ... 2 r$C
A A ji $ T R Q
... GCT GCT ACC CGG CAA ... 2 ~
A A Q $ T' R Q
... GCT GCT ACC CGG C;AA ... 1 A A ~ $ T R Q
... GCT GCT CAC ACC CGG CAA ... 1 A A $ $, R Q
... GCT GCT TCC CGG CAA ... 1 CAC
A A $ $ T R Q
3 . . . GGT GCT ,('$'r ACC CGG CAA 1 # #
0 C~3' A A $ F R Q
... GCT GCT TTC CGG CAA ... 1 ('.8C
A A $ S R Q
... GCT GCT ~ CGG CAA ... 1 ~
# - contaminating sequence from pDM0411 ## - contains "illegal" colon CAT - T should the not appear in the 3rd position of a 4 colon.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Genentech, Inc.
Garrard, Lisa J.
Henner, Dennis J.
Bass, Steven Greene, Ronald Lowman, Henry 8.
Wells, James A.
Matthewa, David J.
(ii) TITLE OF INVENTION: Enrichment Method For Variant Proteins With Altered Binding Properties (iii) NUMBER OF SEQUENCES: 27 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genentech, Inc.
(B) STREET: 460 Point San Bruno Blvd (C) CITY: South San Francisco (D) STATE: California (E) COUNTRY: USA
(F) ZIP: 94080 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: patin (Genentech) (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 03-DEC-91 (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/743614 (8) APPLICATION DATE: 09-Aug-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/715300 (B) APPLICATION DATE: 14-June-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/683400 (B) APPLICATION DATE: 10-Apr-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/621667 (B) APPLICATION DATE: 03-Dec-1990 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Benson, Robert H.
(B) REGISTRATION NUMBER: 30,446 (C) REFERENCE/DOCKET NUMBER: 645P4 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 415/266-1489 (B) TELEFAX: 415/952-9881 (C) TELEX: 910/371-7168 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
(2) INFORMATION FOR SEQ ID N0:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
(2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
(2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 bases (8) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
(2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:5:
(2) INFORMATION FOR SEQ ID N0:6:
(1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
(2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENGE CHARACTERISTICS:
(A) LENGTH: 21 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
(2) INFORMATION FOR SEQ ID N0:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
(2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
(2) INFORMATION FOR SEQ ID NO;11:
5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
(2) INFORMATION FOR SEQ ID N0:12:
(i) SEQUENCE CHARACTERISTICS.:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:12:
(2) INFORMATION FOR SEQ ID N0:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids (B) TYPE: amino acid (D) TOPOLOGY: .linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:13:
Gly Ser Cys Gly Phe Glu Ser Gly Gly Gly Ser Gly (2) INFORMATION FOR SEQ ID N0:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 bases (8) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:14:
(2) INFORMATION FOR SEQ ID N0:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 bases (8) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:15:
(2) INFORMATION FOR SEQ ID N0:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:16:
(2) INFORMATION FOR SEQ ID N0::17:
(i) SEQUENCE CHARACTERISTICtS:
(A) LENGTH: 66 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:
(2) INFORMATION FOR SEQ ID N0:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single>
(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:18:
(2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:19:
(2) INFORMATION FOR SEQ ID N0:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:20:
(2) INFORMATION FOR SEQ ID N0:2.1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:21:
(2) INFORMATION FOR SEQ ID N0:22:
(i) SEQUENCE CHARACTERISTICS.:
(A) LENGTH: 58 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:22:
GTGTCAAAGG CCAGCTGSNN AAC:ACGSNNA GCACGCAGSN NCGCGTTGTC 50 (2) INFORMATION FOR SEQ ID N0:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 65 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:23:
(2) INFORMATION FOR SEQ ID N0:24:
(i) SEQUENCE GHARACTERISTICS:
(A) LENGTH: 64 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE SCRIPTION:SEQ ID
DE N0:24:
(2) INFORMATION
FOR SEQ ID N0:25:
(i) SEQUENCE CH ARACTERISTICS:
(A) LENGTH: 2178 bases (B) TYPE: n ucleic acid (C) STRANDE DNESS: le sing (D) TOPOLOG Y: linear (xi) SEQUENCE SCRIPTION:SEQ ID
DE N0:25:
_ GCTGCCTGGT CAAGGACTACT'CCCCCGAACCGGTGACGGTGTCGTGGAAC1350 CAGTCTGACG CTAAAGGCAAAC'.TTGATTCTGTCGCTACTGATTACGGTGC1850 (2) INFORMATION FOR SEQ ID N0:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 237 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:26:
Met Lys Lys Asn Ile Ala Phe Leu Leu Ala Ser Met Phe Val Phe Ser Ile Ala Thr Asn Ala Tyr Ala Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Va). Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lye His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys (2) INFORMATION FOR SEQ ID N0:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 461 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:27:
Met Lys Lys Asn Ile Ala Phe Leu Leu Ala Ser Met Phe Val Phe 1 5 10 ' 15 Ser Ile Ala Thr Aen Ala Tyr Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pra Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Se:r Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Gly Pro Phe Val Cys Glu Tyr Gln Gly Gln Ser Ser Asp Leu Pro Gln Pro Pro Val Asn Ala Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly Aap Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn :Lys Gly Ala Met Thr Glu Asn Ala Asp Glu Aen Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala Thr Aep Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Aan Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn Ser Pro Leu Met Aan Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser
Claims (15)
1. A phagemid expression vector, containing a transcription regulatory element operably linked to a gene fusion encoding a fusion protein, wherein the gene fusion comprises a first gene encoding a polypeptide and a second gene encoding at least a portion of a phage coat protein, wherein (a) the vector does not contain a gene encoding the mature coat protein, (b) does not contain a complete phage genome, or (c) transformation of host cells with the vector does not produce phage particles in the absence of helper phage.
2. The phagemid vector of Claim 1, wherein the first gene encodes a mammalian protein, preferably a human protein.
3. The phagemid vector of Claim 1 or 2, wherein the protein is selected from the group consisting of growth hormone, human growth hormone (hGH), des-N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin A-chain, insulin B-chain, proinsulin, relaxin A-chain, relaxin B-chain, prorelaxin, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), leutinizing hormone (LH), glycoprotein hormone receptors, calcitonin, glucagon, factor VIII, lung surfactant, urokinase, streptokinase, human tissue-type plasminogen activator (t-PA), bombesin, factor IX, thrombin, hemopoietic growth factor, tumor necrosis factor-alpha and-beta, enkephalinase, human serum albumin, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, -lactamase, tissue factor protein, inhibin, activin, vascular endothelial growth factor, integrin receptors, thrombopoietin, protein A and D, rheumatoid factors, nerve growth factor -b (NGF-b), platelet-growth factor, transforming growth factor (TGF), TGF-alpha and TGF-beta, insulin-like growth-I and -II, insulin-like growth factor binding proteins, CD-4, DNase, latency associated peptide, erythropoietin, osteoinductive factors, interferon-alpha, -beta, and -gamma, colony stimulating factors (CSFs), M-CSF, GM-CSF, and G-CSF, interleukins (ILs), IL-1, IL-2, IL-3, IL-4, superoxide dismutase; decay accelerating factor, viral antigen, HIV envelope proteins GP120 and GP140, atrial natriuretic peptides A, B and C, proteins containing more than one subunit, immunoglobulins, and fragments of the above-listed proteins.
4. The phagmeid vector of any one of claims 1 to 3, wherein the coat protein is encoded by gene III or gene VIII of a filamentous phage.
5. A phagemid particle, containing at least a portion of the phagemid expression vector of any of Claims 1 to 4 and displaying the fusion protein on the surface thereof.
6. The phagemid particle of Claim 5, wherein a DNA triplet codon encoding an mRNA suppressible terminator codon, preferably UAG, UAA or UGA, is inserted between the fused ends of the first and second genes, or is substituted for an amino acid encoding triplet codon adjacent to the gene fusion junction.
7. The phagemid particle of Claim 5 or 6, which displays an antibody Fab portion on the surface thereof.
8. A group of the phagemid particles of any one of Claims 5 to 7, wherein no more than a minor amount of phagemid particles in the group display more than one copy of the fusion protein on the surface of the particle.
9. The group of phagemid particles of Claim 8, wherein different phagemid particles display different fusion proteins on the surface of the particles.
10. The group of phagemid particles of Claim 8 or 9, wherein the number of phagemid particles displaying g mare than once copy of the fusion protein on the surface of the particles is less than about 20%, preferably less than about 10%, more preferably less than 1%.
11. Host cells containing the vector of any one of Claims 1 to 4.
12. A method for selecting novel binding polypeptides, comprising the steps of:
(a) constructing a family of phagemid expression vectors of any one of Claims 1-4, wherein the phagemid expression vectors contain variant first genes encoding variant polypeptides;
(b) transforming suitable host cells with the expression vectors;
(c) infecting the transformed host cells with an amount of helper phage encoding the phage coat protein sufficient to produce recombinant phagemid particles wherein no more than a minor amount of the phagemid particles display more than one copy of the fusion protein on the surface of the phagemid particles;
(d) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the expression vector and capable of transforming the host cells;
(e) contacting the recombinant phagemid particles with a target molecule so that at least a portion of the phagemid particles bind to the target molecule; and (f) separating phagemid particles that bind to the target molecule from those that do not bind.
(a) constructing a family of phagemid expression vectors of any one of Claims 1-4, wherein the phagemid expression vectors contain variant first genes encoding variant polypeptides;
(b) transforming suitable host cells with the expression vectors;
(c) infecting the transformed host cells with an amount of helper phage encoding the phage coat protein sufficient to produce recombinant phagemid particles wherein no more than a minor amount of the phagemid particles display more than one copy of the fusion protein on the surface of the phagemid particles;
(d) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the expression vector and capable of transforming the host cells;
(e) contacting the recombinant phagemid particles with a target molecule so that at least a portion of the phagemid particles bind to the target molecule; and (f) separating phagemid particles that bind to the target molecule from those that do not bind.
13. The method of Claim 12, wherein the amount of phagemid particles displaying more than one copy of the fusion protein is less than 20%, preferably less than 10%, more preferably less than about 1%, of the amount of phagemid particles displaying a single copy of the fusion protein.
14. A group of phagemid particles produced by the method of Claim 12 or 13.
15. The method of Claim 12, wherein the first gene encodes a polypeptide linked to a linker amino acid sequence; the phagemid expression vectors contain variant first genes encoding variant linker amino acid sequences, and wherein step (f) is replaced by:
(f) contacting the bound phagemid particles with a protease capable of hydrolyzing the linking amino acid sequence of at least a portion of the bound phagemid particles, and (g) isolating the hydrolyzed phagemid particles, and optionally (h) further comprising infecting suitable host cells with the hydrolyzed phagemid particles and repeating steps (d) through (g).
(f) contacting the bound phagemid particles with a protease capable of hydrolyzing the linking amino acid sequence of at least a portion of the bound phagemid particles, and (g) isolating the hydrolyzed phagemid particles, and optionally (h) further comprising infecting suitable host cells with the hydrolyzed phagemid particles and repeating steps (d) through (g).
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62166790A | 1990-12-03 | 1990-12-03 | |
US07/621,667 | 1990-12-03 | ||
US68340091A | 1991-04-10 | 1991-04-10 | |
US07/683,400 | 1991-04-10 | ||
US71530091A | 1991-06-14 | 1991-06-14 | |
US07/715,300 | 1991-06-14 | ||
US74361491A | 1991-08-08 | 1991-08-08 | |
US07/743,614 | 1991-08-08 | ||
CA002095633A CA2095633C (en) | 1990-12-03 | 1991-12-03 | Enrichment method for variant proteins with altered binding properties |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002095633A Division CA2095633C (en) | 1990-12-03 | 1991-12-03 | Enrichment method for variant proteins with altered binding properties |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2405246A1 true CA2405246A1 (en) | 1992-06-11 |
Family
ID=27505166
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002405246A Abandoned CA2405246A1 (en) | 1990-12-03 | 1991-12-03 | Enrichment method for variant proteins with alterred binding properties |
CA002095633A Expired - Lifetime CA2095633C (en) | 1990-12-03 | 1991-12-03 | Enrichment method for variant proteins with altered binding properties |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002095633A Expired - Lifetime CA2095633C (en) | 1990-12-03 | 1991-12-03 | Enrichment method for variant proteins with altered binding properties |
Country Status (9)
Country | Link |
---|---|
US (7) | US5750373A (en) |
EP (1) | EP0564531B1 (en) |
AT (1) | ATE164395T1 (en) |
CA (2) | CA2405246A1 (en) |
DE (1) | DE69129154T2 (en) |
DK (1) | DK0564531T3 (en) |
ES (1) | ES2113940T3 (en) |
GR (1) | GR3026468T3 (en) |
WO (1) | WO1992009690A2 (en) |
Families Citing this family (2183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5534617A (en) * | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
US5688666A (en) * | 1988-10-28 | 1997-11-18 | Genentech, Inc. | Growth hormone variants with altered binding properties |
US5750373A (en) * | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6916605B1 (en) * | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9206318D0 (en) * | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
DK1471142T3 (en) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
DE69231467T2 (en) | 1991-05-10 | 2001-01-25 | Genentech Inc | SELECTION OF AGONISTS AND ANTAGONISTS OF LIGANDS |
US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
US5962255A (en) * | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
DE69230142T2 (en) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Tech | METHOD FOR PRODUCING SPECIFIC BINDING PAIRS |
US5858657A (en) * | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
DE4122599C2 (en) * | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
US5733731A (en) * | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
DE69233745D1 (en) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Preparation of Autoantibodies on Phage Surfaces Starting from Antibody Segment Libraries |
US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5716789A (en) | 1993-07-26 | 1998-02-10 | Cor Therapeutics, Inc. | Method to determine ligands, agonist and antagonist of C140 receptor |
NZ278765A (en) | 1993-12-30 | 1998-05-27 | Harvard College | Vertebrate proteins involved in spatial arrangements of differentiated tissues called hedgehog proteins, their production and use |
US5837458A (en) * | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6576236B1 (en) | 1994-07-01 | 2003-06-10 | Dana Farber Cancer Institute | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain |
US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US7820798B2 (en) * | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US6335319B1 (en) * | 1994-11-15 | 2002-01-01 | Metabolic Pharmaceuticals, Inc. | Treatment of obesity |
US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
US6475806B1 (en) | 1995-06-07 | 2002-11-05 | Praecis Pharmaceuticals, Inc. | Anchor libraries and identification of peptide binding sequences |
PT1568772E (en) * | 1995-09-21 | 2010-04-14 | Genentech Inc | Human growth hormone variants |
US7368111B2 (en) | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
EP0859959B1 (en) * | 1995-11-10 | 2003-08-06 | ELAN CORPORATION, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
AU2531397A (en) * | 1996-03-21 | 1997-10-10 | President And Fellows Of Harvard College | Enantiomeric screening process, and compositions therefor |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
US20070185032A1 (en) * | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
US6497874B1 (en) | 1997-02-05 | 2002-12-24 | Maardh Sven | Recombinant phages |
ATE505543T1 (en) | 1997-04-16 | 2011-04-15 | Millennium Pharm Inc | A COMPOSITION COMPRISING AN ANTIBODY THAT SELECTIVELY BINDS TO A CYSTEINE-RICH SECRETED PROTEIN (CRSP). |
US6306826B1 (en) | 1997-06-04 | 2001-10-23 | The Regents Of The University Of California | Treatment of heart failure with growth hormone |
US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US7378506B2 (en) | 1997-07-21 | 2008-05-27 | Ohio University | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
US6639050B1 (en) | 1997-07-21 | 2003-10-28 | Ohio University | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
EP1005569A2 (en) | 1997-08-01 | 2000-06-07 | MorphoSys AG | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
GB9723955D0 (en) | 1997-11-14 | 1998-01-07 | Generic Biolog Limited | Improvements in or relating to detection of molecules in samples |
GB2375765B (en) * | 1997-11-14 | 2003-02-26 | Kymed Gb Ltd | Tagged growth hormone molecules |
ATE364049T1 (en) | 1997-11-21 | 2007-06-15 | Genentech Inc | ANTIGENS RELATED TO A33 AND THEIR PHARMACEUTICAL USES |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
ATE490980T1 (en) | 1998-03-19 | 2010-12-15 | Human Genome Sciences | CYTOKINE RECEPTOR SIMILAR TO THE COMMON GAMMA CHAIN |
US7056517B2 (en) | 1998-04-13 | 2006-06-06 | The Forsyth Institute | Glucosyltransferase immunogens |
US7163682B2 (en) | 1998-04-13 | 2007-01-16 | The Forsyth Institute | Glucan binding protein and glucosyltransferase immunogens |
JP2002522029A (en) | 1998-07-27 | 2002-07-23 | ジェネンテック・インコーポレーテッド | Improved transformation efficiency in phage display by modification of coat protein |
US6387888B1 (en) * | 1998-09-30 | 2002-05-14 | American Foundation For Biological Research, Inc. | Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen |
US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
US6420110B1 (en) | 1998-10-19 | 2002-07-16 | Gpc Biotech, Inc. | Methods and reagents for isolating biologically active peptides |
WO2000024415A2 (en) * | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
US6696063B1 (en) | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
EP2206785A1 (en) | 1998-12-31 | 2010-07-14 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
JP2003523721A (en) * | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | Polynucleotides encoding antigenic HIVC-type polypeptides, polypeptides, and uses thereof |
ES2299276T3 (en) | 1998-12-31 | 2008-05-16 | Novartis Vaccines And Diagnostics, Inc. | MODIFIED HIV ENV POLIPEPTIDES. |
WO2000040612A1 (en) | 1999-01-06 | 2000-07-13 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
EP1141014B1 (en) | 1999-01-06 | 2004-12-08 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variant |
EP2357192A1 (en) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
EP2301947A3 (en) | 1999-02-26 | 2011-11-23 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
EP1119368A2 (en) | 1999-03-03 | 2001-08-01 | Biogen, Inc. | Methods of modulating lipid metabolism and storage |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
CN101333256A (en) | 1999-03-25 | 2008-12-31 | 艾博特股份有限两合公司 | Human antibodies that bind human il-12 and methods for producing |
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
AU4057600A (en) * | 1999-03-31 | 2000-10-16 | Rosetta Inpharmatics, Inc. | Methods for the identification of reporter and target molecules using comprehensive gene expression profiles |
DE19915057A1 (en) | 1999-04-01 | 2000-10-19 | Forschungszentrum Borstel | Monoclonal antibodies to the human Mcm3 protein, process for their preparation and their use |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
US7270969B2 (en) * | 1999-05-05 | 2007-09-18 | Phylogica Limited | Methods of constructing and screening diverse expression libraries |
US7803765B2 (en) * | 1999-05-05 | 2010-09-28 | Phylogica Limited | Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom |
ATE469979T1 (en) | 1999-05-05 | 2010-06-15 | Phylogica Ltd | ISOLATION OF BIOLOGICAL MODULATORS FROM LIBRARIES OF BIOLOGICALLY DIVERSE GENE FRAGMENTS |
US6200803B1 (en) | 1999-05-21 | 2001-03-13 | Rosetta Inpharmatics, Inc. | Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs |
US6221597B1 (en) | 1999-05-21 | 2001-04-24 | Rosetta Inpharmatics, Inc. | Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs |
US6197517B1 (en) | 1999-05-21 | 2001-03-06 | Rosetta Inpharmatics, Inc. | Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs |
US7396905B1 (en) | 1999-05-21 | 2008-07-08 | Mckeon Frank | Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto |
EP1187914B1 (en) | 1999-06-14 | 2005-05-25 | Genentech, Inc. | A structured peptide scaffold for displaying turn libraries on phage |
US20030166003A1 (en) * | 1999-06-14 | 2003-09-04 | Cochran Andrea G. | Structured peptide scaffold for displaying turn libraries on phage |
US20040001826A1 (en) * | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
ES2327382T3 (en) | 1999-07-20 | 2009-10-29 | Morphosys Ag | METHODS FOR SUBMITTING (POLI) PEPTIDES / PROTEINS IN PARTICLES OF BACTERIOPHAGES THROUGH DISULFIDE LINKS. |
PT1210428E (en) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, a receptor for b7-4, and uses therefor |
DE19943743C2 (en) * | 1999-09-03 | 2002-02-07 | Jerini Biotools Gmbh | Procedure for the identification of binding partners with position-specific arrays |
CA2389317A1 (en) * | 1999-10-20 | 2001-04-26 | Frederic J. De Sauvage | Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
US20060073509A1 (en) * | 1999-11-18 | 2006-04-06 | Michael Kilpatrick | Method for detecting and quantitating multiple subcellular components |
US6951839B1 (en) | 1999-11-30 | 2005-10-04 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
US8168178B2 (en) | 1999-11-30 | 2012-05-01 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
US20030180714A1 (en) * | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
US20020004247A1 (en) * | 1999-12-23 | 2002-01-10 | Genentech, Inc. | Assay method |
PT1254169E (en) | 1999-12-30 | 2007-08-21 | Harvard College | Methods relating to modulation of th2 cell subset activity by modulation of xbp-1 activity |
IL151044A0 (en) | 2000-02-10 | 2003-04-10 | Abbott Lab | Antibodies that bind human interleukin-18 and methods of making and using |
US6436677B1 (en) | 2000-03-02 | 2002-08-20 | Promega Corporation | Method of reverse transcription |
US6632645B1 (en) | 2000-03-02 | 2003-10-14 | Promega Corporation | Thermophilic DNA polymerases from Thermoactinomyces vulgaris |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
PT2857516T (en) | 2000-04-11 | 2017-08-28 | Genentech Inc | Multivalent antibodies and uses therefor |
ES2529300T3 (en) | 2000-04-12 | 2015-02-18 | Novozymes Biopharma Dk A/S | Albumin fusion proteins |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
EP1276855B1 (en) * | 2000-04-17 | 2012-10-24 | Dyax Corp. | Methods of constructing display libraries of genetic packages for members of a diverse family of peptides |
US7495070B2 (en) * | 2000-04-24 | 2009-02-24 | Yale University | Protein binding miniature proteins |
JP2004528802A (en) * | 2000-04-24 | 2004-09-24 | イエール・ユニバーシテイ | Small proteins that bind DNA and proteins |
ATE389416T1 (en) * | 2000-05-16 | 2008-04-15 | Genentech Inc | TREATMENT OF CARTILARY DISEASES |
US6573370B1 (en) | 2000-05-19 | 2003-06-03 | Regents Of The University Of Michigan | PON3 and uses thereof |
EP1714661A3 (en) | 2000-05-19 | 2012-03-14 | The Center for Blood Research, INC. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
CN1443074A (en) | 2000-06-08 | 2003-09-17 | 血液研究中心 | Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury |
EP2431054A3 (en) | 2000-06-15 | 2013-03-06 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
ES2358885T3 (en) | 2000-06-16 | 2011-05-16 | Human Genome Sciences, Inc. | ANTIBODIES THAT BIND BLyS IMMUNO-SPECIFICALLY. |
BR0111298A (en) * | 2000-06-28 | 2005-05-10 | Bristol Myers Squibb Co | Selective androgen receptor modulators and methods for their identification, design and use |
JP2004501631A (en) | 2000-06-28 | 2004-01-22 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | PD-L2 molecule: novel PD-1 ligand and use thereof |
CZ2003291A3 (en) | 2000-06-29 | 2003-05-14 | Abbott Laboratories | Dual specific antibodies, processes of their preparation and use |
US7176037B2 (en) * | 2000-07-13 | 2007-02-13 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
US6951947B2 (en) * | 2000-07-13 | 2005-10-04 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
WO2002028893A2 (en) | 2000-07-14 | 2002-04-11 | Cropdesign N.V. | Plant cyclin-dependent kinase inhibitors |
US6878861B2 (en) | 2000-07-21 | 2005-04-12 | Washington State University Research Foundation | Acyl coenzyme A thioesterases |
WO2002009755A2 (en) | 2000-07-27 | 2002-02-07 | Genentech, Inc. | Apo-2l receptor agonist and cpt-11 synergism |
US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US20080194022A1 (en) * | 2000-08-03 | 2008-08-14 | Clarke Michael F | Isolation and use of solid tumor stem cells |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
TWI283182B (en) * | 2000-08-07 | 2007-07-01 | Nektar Therapeutics | Inhalable spray dried 4-helix bundle protein powders having minimized aggregation |
ES2387537T3 (en) * | 2000-09-13 | 2012-09-25 | Glaxosmithkline Llc | Pharmaceutical compositions for sustained administration of peptides |
GB0022978D0 (en) | 2000-09-19 | 2000-11-01 | Oxford Glycosciences Uk Ltd | Detection of peptides |
IL154522A0 (en) | 2000-09-26 | 2003-09-17 | Genentech Inc | IgE RECEPTOR ANTAGONISTS |
US7393532B1 (en) | 2000-10-18 | 2008-07-01 | Genentech, Inc. | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
US6841359B2 (en) * | 2000-10-31 | 2005-01-11 | The General Hospital Corporation | Streptavidin-binding peptides and uses thereof |
US7405276B2 (en) | 2000-11-01 | 2008-07-29 | Elusys Therapeutics, Inc. | Method of producing bispecific molecules by protein trans-splicing |
TWI327599B (en) | 2000-11-28 | 2010-07-21 | Medimmune Llc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
NZ526708A (en) | 2000-11-28 | 2005-07-29 | Wyeth Corp | Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
HUP0303905A3 (en) | 2000-11-28 | 2005-11-28 | Wyeth Corp | Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
WO2002046238A2 (en) * | 2000-12-05 | 2002-06-13 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
US20040253242A1 (en) * | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
EP1341902A2 (en) * | 2000-12-08 | 2003-09-10 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US9249229B2 (en) * | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
EP2354149B1 (en) | 2000-12-12 | 2017-08-30 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
ES2430857T3 (en) * | 2000-12-18 | 2013-11-22 | Dyax Corp. | Targeted libraries of genetic packages |
JP4986370B2 (en) | 2000-12-22 | 2012-07-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Uses of RGM and its modulators |
US8372954B2 (en) * | 2000-12-22 | 2013-02-12 | National Research Council Of Canada | Phage display libraries of human VH fragments |
HN2001000283A (en) | 2001-01-05 | 2002-05-09 | Pfizer Prod Inc | ANTIBODIES AGAINST INSULIN-SIMILAR GROWTH FACTOR RECEPTOR. |
WO2002064612A2 (en) | 2001-02-09 | 2002-08-22 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor (ccr5) hdgnr10 |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
US7323327B2 (en) | 2001-02-23 | 2008-01-29 | Dsm Ip Assets B.V. | Genes encoding novel proteolytic enzymes |
DE60239097D1 (en) | 2001-03-02 | 2011-03-17 | Gpc Biotech Ag | THREE-HYBRID ASSAY SYSTEM |
AU2002250236A1 (en) * | 2001-03-02 | 2002-09-19 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
CA2342376C (en) * | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
US8231878B2 (en) * | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US20090081199A1 (en) * | 2001-03-20 | 2009-03-26 | Bioxell S.P.A. | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
EP1379125A4 (en) | 2001-03-22 | 2004-12-08 | Abbott Gmbh & Co Kg | Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
EP1383912A4 (en) | 2001-04-02 | 2007-11-28 | Wyeth Corp | Pd-1, a receptor for b7-4, and uses therefor |
EP1385864B1 (en) | 2001-04-13 | 2010-06-09 | Human Genome Sciences, Inc. | Anti-VEGF-2 antibodies |
KR100886095B1 (en) | 2001-04-16 | 2009-02-27 | 와이어쓰 홀딩스 코포레이션 | Novel Streptococcus pneumoniae open reading frames encoding polypeptide antigens and a composition comprising the same |
US6914123B2 (en) | 2001-04-17 | 2005-07-05 | Genentech, Inc. | Hairpin peptides with a novel structural motif and methods relating thereto |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
PT1572874E (en) | 2001-05-25 | 2013-12-11 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to trail receptors |
WO2002098280A2 (en) * | 2001-06-04 | 2002-12-12 | Ikonisys Inc. | Method for detecting infectious agents using computer controlled automated image analysis |
US20030148380A1 (en) * | 2001-06-05 | 2003-08-07 | Belcher Angela M. | Molecular recognition of materials |
US20030113714A1 (en) * | 2001-09-28 | 2003-06-19 | Belcher Angela M. | Biological control of nanoparticles |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
US20050164515A9 (en) * | 2001-06-05 | 2005-07-28 | Belcher Angela M. | Biological control of nanoparticle nucleation, shape and crystal phase |
CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
KR100603488B1 (en) | 2001-06-20 | 2006-07-24 | 제넨테크, 인크. | Compositions and Methods for the Diagnosis and Treatment of Tumor |
US7803915B2 (en) * | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
US20050107595A1 (en) * | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2270165A3 (en) | 2001-06-22 | 2011-09-07 | Pioneer Hi-Bred International, Inc. | Defensin polynucleotides and methods of use |
EP2280074A3 (en) * | 2001-07-05 | 2011-06-22 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
EP2412242A3 (en) * | 2001-07-05 | 2012-06-13 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
DE10135039C1 (en) * | 2001-07-18 | 2003-03-13 | Nemod Immuntherapie Ag | Method for isolating large variances of specific molecules for a target molecule from phagemid gene libraries |
US6867189B2 (en) * | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
KR100458083B1 (en) * | 2001-08-29 | 2004-11-18 | 주식회사 아이지세라피 | Method for the construction of phage display library using helper phage variants |
WO2003020876A2 (en) * | 2001-08-31 | 2003-03-13 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
JP4360906B2 (en) * | 2001-09-14 | 2009-11-11 | サイトス バイオテクノロジー アーゲー | In vivo activation of antigen-presenting cells to enhance the immune response induced by virus-like particles |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
ATE486092T1 (en) | 2001-09-18 | 2010-11-15 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF TUMORS |
US20030073104A1 (en) * | 2001-10-02 | 2003-04-17 | Belcher Angela M. | Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus |
US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
DE60234713D1 (en) | 2001-12-18 | 2010-01-21 | Endocube Sas | NEW PROTEINS ASSOCIATED WITH CELL-DATE FROM THE THAP FAMILY AND PAR4 RELATED SIGNALING PATHS INVOLVED IN THE CONTROL OF APOPTOSIS |
US7858297B2 (en) | 2001-12-18 | 2010-12-28 | Centre National De La Recherche Scientifique Cnrs | Chemokine-binding protein and methods of use |
AU2002359721A1 (en) | 2001-12-19 | 2003-07-09 | Bristol-Myers Squibb Company | Pichia pastoris formate dehydrogenase and uses therefor |
EP2277889B1 (en) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
EP1575571A4 (en) | 2002-01-02 | 2008-06-25 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
CN1639185A (en) * | 2002-01-03 | 2005-07-13 | 斯克里普斯研究学院 | Cancer-associated epitope |
EP1534739A4 (en) * | 2002-01-18 | 2006-05-31 | Bristol Myers Squibb Co | Identification of polynucleotides and polypeptide for predicting activity of compounds that interact with protein tyrosine kinases and/or protein tyrosine kinase pathways |
US7094579B2 (en) | 2002-02-13 | 2006-08-22 | Xoma Technology Ltd. | Eukaryotic signal sequences for prokaryotic expression |
WO2003073909A2 (en) | 2002-03-01 | 2003-09-12 | Bayer Corporation | Assays to monitor levels of epidermal growth factor receptor (egfr) extracellular domain (ecd) in cancer patients |
US20030180819A1 (en) * | 2002-03-01 | 2003-09-25 | Carney Walter P. | Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples |
JP2005531511A (en) | 2002-03-07 | 2005-10-20 | ザ フォーシス インスティチュート | Immunogenicity of glucan binding proteins |
AU2003218456A1 (en) * | 2002-04-01 | 2003-10-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
GB0207533D0 (en) | 2002-04-02 | 2002-05-08 | Oxford Glycosciences Uk Ltd | Protein |
US7745192B2 (en) | 2002-04-03 | 2010-06-29 | Venomics Pty Limited | Prothrombin activating protein |
EP1499352A4 (en) | 2002-04-12 | 2006-10-11 | Medimmune Inc | Recombinant anti-interleukin-9 antibodies |
CA2481507A1 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
ES2347550T3 (en) | 2002-05-21 | 2010-11-02 | Dsm Ip Assets B.V. | NEW PHOSPHOLIPASES AND USES OF THE SAME. |
JP4753578B2 (en) * | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | Synthetic antibody phage library |
EP2305710A3 (en) * | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
US7563882B2 (en) * | 2002-06-10 | 2009-07-21 | University Of Rochester | Polynucleotides encoding antibodies that bind to the C35 polypeptide |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
WO2003106640A2 (en) * | 2002-06-14 | 2003-12-24 | Case Western Reserve University | Cell targeting methods and compositions |
WO2004001003A2 (en) | 2002-06-20 | 2003-12-31 | Board Of Trustees Operating Michigan State University | Plastid division and related genes and proteins, and methods of use |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
NZ555692A (en) | 2002-07-19 | 2009-02-28 | Abbott Biotech Ltd | Treatment of TNF alpha related disorders |
US7250551B2 (en) | 2002-07-24 | 2007-07-31 | President And Fellows Of Harvard College | Transgenic mice expressing inducible human p25 |
PL375301A1 (en) | 2002-08-10 | 2005-11-28 | Biogen Idec Ma Inc. | Nogo receptor antagonists |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
PT1534335E (en) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Fcgammariib-specific antibodies and methods of use thereof |
CA2495198C (en) | 2002-08-19 | 2014-03-11 | Dsm Ip Assets B.V. | Novel lipases and uses thereof |
DE10238846A1 (en) * | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Active fusion proteins and processes for their production |
US7361511B2 (en) | 2002-08-20 | 2008-04-22 | Millenium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
US7455989B2 (en) | 2002-08-20 | 2008-11-25 | Yeda Research And Development Co. Ltd. | AKAP84 and its use for visualization of biological structures |
WO2004019857A2 (en) * | 2002-08-29 | 2004-03-11 | Genentech, Inc. | Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor |
DE60331925D1 (en) | 2002-09-04 | 2010-05-12 | Biopolymer Engineering Inc | CANCER THERAPY WITH WHOLE GLUCAN PARTICLES AND ANTIBODIES |
EP1539960B1 (en) * | 2002-09-09 | 2010-04-28 | Hanall Pharmaceutical Co., Ltd. | Protease-resistant modified interferon alpha polypeptides |
US20050064508A1 (en) * | 2003-09-22 | 2005-03-24 | Semzyme | Peptide mediated synthesis of metallic and magnetic materials |
CN1723039B (en) | 2002-10-08 | 2013-01-16 | 里纳特神经系统学公司 | Use for nerve growth factor antagonist in preparing medicine for treating post-surgical pain |
US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
WO2004032868A2 (en) * | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
ES2535742T3 (en) | 2002-10-16 | 2015-05-14 | Purdue Pharma L.P. | Antibodies that bind to CA 125 / 0722P associated with cells and methods of use thereof |
ATE472556T1 (en) * | 2002-12-02 | 2010-07-15 | Amgen Fremont Inc | ANTIBODIES DIRECTED AGAINST THE TUMOR NECROSIS FACTOR AND THEIR USES |
US7056702B2 (en) * | 2002-12-16 | 2006-06-06 | Kimberly Clark Co | Detecting lipocalin |
WO2004058190A2 (en) * | 2002-12-23 | 2004-07-15 | Rinat Neuroscience Corp. | Methods for treating taxol-induced sensory neuropathy |
AU2003293958A1 (en) * | 2002-12-23 | 2004-07-22 | Apalexo Biotechnologie Gmbh | Purification of recombinant filamental bacteriophages by means of affinity chromatography to increase the immunogenicity and efficacy of phagic vaccines |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
KR101410692B1 (en) | 2002-12-24 | 2014-06-24 | 리나트 뉴로사이언스 코프. | Anti-ngf antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
ATE500345T1 (en) | 2003-01-07 | 2011-03-15 | Dyax Corp | KUNITZ DOMAIN LIBRARY |
WO2004065416A2 (en) * | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
WO2004065551A2 (en) * | 2003-01-21 | 2004-08-05 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof |
EP2455458B1 (en) * | 2003-01-31 | 2015-01-07 | Promega Corporation | Covalent tethering of functional groups to proteins |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
US7429472B2 (en) | 2003-01-31 | 2008-09-30 | Promega Corporation | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule |
HUE028407T2 (en) * | 2003-02-01 | 2016-12-28 | Tanox Inc | High affinity anti-human IgE antibodies |
DE602004030535D1 (en) | 2003-02-19 | 2011-01-27 | Rinat Neuroscience Corp | METHOD FOR TREATING PAIN BY ADMINISTERING A NERVE GROWTH FACTOR ANTAGONIST AND A NSAID AND COMPOSITION CONTAINING THEREOF |
DK1594542T3 (en) | 2003-02-20 | 2010-10-11 | Seattle Genetics Inc | Anti-CD70 antibody-drug conjugates and their use in the treatment of cancer |
US20040180387A1 (en) | 2003-03-13 | 2004-09-16 | Fujirebio Diagnostics, Inc. | Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer |
DE602004028916D1 (en) | 2003-03-19 | 2010-10-14 | Biogen Idec Inc | NOGO RECEPTOR BINDING PROTEIN |
JP2006520806A (en) * | 2003-03-20 | 2006-09-14 | ライナット ニューロサイエンス コーポレイション | Methods for treating taxol-induced bowel disorder |
US7294701B2 (en) * | 2003-04-02 | 2007-11-13 | Technion Research & Development Foundation Ltd. | Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
JP4764818B2 (en) | 2003-04-11 | 2011-09-07 | メディミューン,エルエルシー | Recombinant IL-9 antibody and use thereof |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
CA2527694C (en) | 2003-05-30 | 2015-07-14 | Hendricus Renerus Jacobus Mattheus Hoogenboom | Fab library for the preparation of anti vegf and anti rabies virus fabs |
CN101274098A (en) | 2003-05-30 | 2008-10-01 | 健泰科生物技术公司 | Treatment with anti-VEGF antibodies |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
DE602004019919D1 (en) | 2003-06-06 | 2009-04-23 | Genentech Inc | MODULATION OF THE INTERACTION BETWEEN HGF BETA CHAIN AND C-MET |
JP4716517B2 (en) | 2003-06-09 | 2011-07-06 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Methods for treating neurodegenerative diseases |
EP1639090A4 (en) * | 2003-06-09 | 2008-04-16 | Univ Michigan | Compositions and methods for treating and diagnosing cancer |
NZ573837A (en) | 2003-07-08 | 2010-07-30 | Genentech Inc | IL-17 A/F heterologous polypeptides and therapeutic uses thereof |
US20050058658A1 (en) * | 2003-07-15 | 2005-03-17 | Barros Research Institute | Compositions and methods for immunotherapy of human immunodeficiency virus (HIV) |
AU2004259727A1 (en) * | 2003-07-15 | 2005-02-03 | Barros Research Institute | Compositions and methods for immunotherapy of cancer and infectious diseases. |
US7727752B2 (en) | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
HN2004000285A (en) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTIBODIES DIRECTED TO c-MET |
EP1668111A4 (en) | 2003-08-08 | 2008-07-02 | Genenews Inc | Osteoarthritis biomarkers and uses thereof |
WO2005042743A2 (en) | 2003-08-18 | 2005-05-12 | Medimmune, Inc. | Humanization of antibodies |
JP2007504250A (en) * | 2003-09-05 | 2007-03-01 | ザ スクリプス リサーチ インスティテュート | Detection of cholesterol ozonation products |
TR200600945T1 (en) | 2003-09-05 | 2006-10-26 | The Scripps Research Institute | Therapeutic methods. |
AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
EP1670350A4 (en) | 2003-10-07 | 2008-02-13 | Millennium Pharm Inc | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
WO2005037232A2 (en) | 2003-10-17 | 2005-04-28 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating adipocyte function |
US7329725B1 (en) * | 2003-10-29 | 2008-02-12 | Nastech Pharmaceutical Company Inc. | Phage displayed Trp cage ligands |
GB0325836D0 (en) * | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
PL2295073T3 (en) | 2003-11-17 | 2014-09-30 | Genentech Inc | Antibody against CD22 for the treatment of tumour of hematopoietic origin |
EP1687026B1 (en) | 2003-11-21 | 2008-05-14 | UCB Pharma, S.A. | Method for the treatment of multiple sclerosis by inhibiting il-17 activity |
JP5042631B2 (en) * | 2003-12-04 | 2012-10-03 | バクシネックス インコーポレーティッド | Method of killing tumor cells by targeting intracellular antigens exposed on apoptotic tumor cells |
KR101195291B1 (en) | 2003-12-11 | 2012-10-26 | 제넨테크, 인크. | Methods and compositions for inhibiting C-MET dimerization and activation |
GB0329825D0 (en) * | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
AU2004308482A1 (en) * | 2003-12-23 | 2005-07-14 | Rinat Neuroscience Corp. | Agonist anti-trkC antibodies and methods using same |
US20050266425A1 (en) * | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
CN1956738B (en) | 2004-01-09 | 2013-05-29 | 辉瑞大药厂 | Antibodies to MAdCAM |
US20060026719A1 (en) | 2004-01-14 | 2006-02-02 | Kieliszewski Marcia J | Methods of producing peptides/proteins in plants and peptides/proteins produced thereby |
US7981843B2 (en) | 2004-01-20 | 2011-07-19 | Kalobios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
DK1737971T3 (en) | 2004-01-20 | 2017-11-13 | Merus Nv | MIXTURES OF BINDING PROTEINS |
US20060014211A1 (en) | 2004-01-21 | 2006-01-19 | Fujirebio Diagnostics, Inc. | Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity |
CA2552043A1 (en) | 2004-01-21 | 2005-08-04 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
CA2553034A1 (en) * | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
US20050232927A1 (en) * | 2004-02-03 | 2005-10-20 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
CA2554089C (en) | 2004-02-09 | 2013-10-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
DE602005018325D1 (en) | 2004-02-19 | 2010-01-28 | Genentech Inc | ANTIBODIES WITH CORRECTED CDR |
CA2560066A1 (en) | 2004-03-01 | 2005-09-15 | The Cbr Institute For Biomedical Research, Inc. | Natural igm antibodies and inhibitors thereof |
WO2005088308A2 (en) * | 2004-03-12 | 2005-09-22 | The Scripps Research Institute | Fluorescent signal emitting live cell biosensor molecules and dyes for detection and quantification of protein activities |
US7157233B2 (en) | 2004-03-24 | 2007-01-02 | Tripath Imaging, Inc. | Methods and compositions for the detection of cervical disease |
WO2005097184A2 (en) * | 2004-03-26 | 2005-10-20 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
JP5128935B2 (en) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | Humanized anti-TGF-β antibody |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
EP1732949B1 (en) | 2004-04-07 | 2010-01-27 | Rinat Neuroscience Corp. | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
TWI439284B (en) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | Multiple-variable dose regimen for treating tnfα-related disorders |
US7785903B2 (en) * | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
CA2578670C (en) | 2004-04-15 | 2017-03-07 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
EP1735336A2 (en) * | 2004-04-16 | 2006-12-27 | Genentech, Inc. | Omi pdz modulators |
WO2005110015A2 (en) | 2004-04-19 | 2005-11-24 | Ohio University | Cross-linkable glycoproteins and methods of making the same |
US8318905B2 (en) | 2004-04-23 | 2012-11-27 | Richard Kroczek | Antibodies for depletion of ICOS-positive cells in vivo |
EP1789453A2 (en) * | 2004-05-18 | 2007-05-30 | Genentech, Inc. | M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein |
EP1602928A1 (en) * | 2004-06-01 | 2005-12-07 | Universiteit Maastricht | Process and kit for determining binding parameters of bioaffinity binding reactions |
EP1766014A4 (en) | 2004-06-03 | 2008-12-10 | Athlomics Pty Ltd | Agents and methods for diagnosing stress |
CA2568644C (en) * | 2004-06-03 | 2015-11-24 | Phylogica Limited | Peptide modulators of cellular phenotype and bi-nucleic acid fragment library |
US7604947B2 (en) * | 2004-06-09 | 2009-10-20 | Cornell Research Foundation, Inc. | Detection and modulation of cancer stem cells |
AU2005265163B2 (en) * | 2004-06-18 | 2009-10-01 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
US8486893B2 (en) | 2004-06-24 | 2013-07-16 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
US6986264B1 (en) * | 2004-07-15 | 2006-01-17 | Carrier Corporation | Economized dehumidification system |
NZ552091A (en) | 2004-07-16 | 2009-09-25 | Pfizer Prod Inc | Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody |
US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
PT1771474E (en) | 2004-07-20 | 2010-05-03 | Genentech Inc | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
CA2569381A1 (en) * | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
US7342093B2 (en) | 2004-07-23 | 2008-03-11 | University Of Massachusetts | Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins |
US20070087400A1 (en) * | 2004-07-30 | 2007-04-19 | Aldis Darzins | Covalent tethering of functional groups to proteins and substrates therefor |
US7927594B2 (en) | 2004-07-30 | 2011-04-19 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide |
US7425436B2 (en) | 2004-07-30 | 2008-09-16 | Promega Corporation | Covalent tethering of functional groups to proteins and substrates therefor |
WO2006017673A2 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
KR101433494B1 (en) | 2004-09-03 | 2014-08-22 | 제넨테크, 인크. | Humanized anti-beta7 antagonists and uses therefor |
CA2580921C (en) | 2004-09-21 | 2016-04-12 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
WO2006047417A2 (en) | 2004-10-21 | 2006-05-04 | University Of Florida Research Foundation, Inc. | Detection of cannabinoid receptor biomarkers and uses thereof |
ES2390676T3 (en) | 2004-10-21 | 2012-11-15 | Genentech, Inc. | Method for the treatment of intraocular neovascular diseases |
EP1809326A4 (en) | 2004-10-27 | 2009-11-04 | Medimmune Inc | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
EP1828250A2 (en) * | 2004-12-16 | 2007-09-05 | Genentech, Inc. | Methods for treating autoimmune disorders |
JP4990792B2 (en) * | 2004-12-22 | 2012-08-01 | アンブレツクス・インコーポレイテツド | Compositions of aminoacyl-tRNA synthetases and uses thereof |
JP2008525032A (en) * | 2004-12-22 | 2008-07-17 | アンブレツクス・インコーポレイテツド | Methods for expressing and purifying recombinant human growth hormone |
US7816320B2 (en) * | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
KR20070100307A (en) | 2004-12-22 | 2007-10-10 | 제넨테크, 인크. | Methods for producing soluble multi-membrane-spanning proteins |
KR20070090023A (en) * | 2004-12-22 | 2007-09-04 | 암브룩스, 인코포레이티드 | Modified human growth hormone |
ATE423140T1 (en) | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES MODIFIED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE AREAS DETERMINING COMPLEMENTARITY |
CN101137673B (en) | 2005-01-05 | 2013-12-04 | 比奥根艾迪克Ma公司 | Cripto binding molecules |
GT200600031A (en) | 2005-01-28 | 2006-08-29 | ANTI-BETA ANTIBODY FORMULATION | |
US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
CN101495498B (en) | 2005-02-07 | 2013-09-18 | 基因信息公司 | Mild osteoarthritis biomarkers and uses thereof |
JP5651285B2 (en) | 2005-02-15 | 2015-01-07 | デューク ユニバーシティ | Anti-CD19 antibodies and use in oncology |
US8211430B2 (en) * | 2005-03-04 | 2012-07-03 | Curedm Group Holdings, Llc | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
BRPI0607985A2 (en) | 2005-03-10 | 2009-10-27 | Genentech Inc | dscr1 modulator, treatment methods, side effect amelioration method and tumor growth inhibition method |
WO2006102095A2 (en) | 2005-03-18 | 2006-09-28 | Medimmune, Inc. | Framework-shuffling of antibodies |
SG171690A1 (en) | 2005-03-22 | 2011-06-29 | Harvard College | Treatment of protein degradation disorders |
CN107033243B (en) | 2005-03-23 | 2020-12-15 | 根马布股份公司 | CD38 antibodies for the treatment of multiple myeloma |
GB0506912D0 (en) | 2005-04-05 | 2005-05-11 | Celltech R&D Ltd | Biological products |
AU2006236439B2 (en) | 2005-04-15 | 2012-05-03 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US20060269556A1 (en) * | 2005-04-18 | 2006-11-30 | Karl Nocka | Mast cell activation using siglec 6 antibodies |
CN101203241B (en) | 2005-04-19 | 2012-02-22 | 西雅图基因公司 | Humanized anti-CD70 binding agents and uses thereof |
BRPI0610248A2 (en) | 2005-04-25 | 2010-06-08 | Pfizer | antibodies to myostatin, pharmaceutical composition comprising them, cell lines producing them, nucleic acid molecules encoding them as well as their uses |
AR054260A1 (en) * | 2005-04-26 | 2007-06-13 | Rinat Neuroscience Corp | METHODS OF TREATMENT OF DISEASES OF THE LOWER MOTOR NEURONE AND COMPOSITIONS USED IN THE SAME |
AP2552A (en) | 2005-04-26 | 2013-01-08 | Pfizer | P-cadherin antibodies |
US7595380B2 (en) | 2005-04-27 | 2009-09-29 | Tripath Imaging, Inc. | Monoclonal antibodies and methods for their use in the detection of cervical disease |
PA8672101A1 (en) | 2005-04-29 | 2006-12-07 | Centocor Inc | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
CN102961746B (en) | 2005-05-16 | 2016-06-15 | 艾伯维生物技术有限公司 | The purposes of TNF α inhibitor for treatment of erosive polyarthritis |
MX2007014474A (en) | 2005-05-17 | 2008-02-07 | Univ Connecticut | Compositions and methods for immunomodulation in an organism. |
CA2726759C (en) * | 2005-05-25 | 2016-02-16 | Curedm Group Holdings, Llc | Human proislet peptide, derivatives and analogs thereof, and methods of using same |
AU2006252830B2 (en) | 2005-05-27 | 2012-11-22 | Biogen Ma Inc. | Tweak binding antibodies |
MX2007015058A (en) * | 2005-06-03 | 2008-01-28 | Ambrx Inc | Improved human interferon molecules and their uses. |
JP2008541781A (en) | 2005-06-06 | 2008-11-27 | ジェネンテック・インコーポレーテッド | Transgenic animals for different genes and their use for characterizing genes |
US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
MX2007015952A (en) | 2005-06-17 | 2008-03-07 | Elan Pharma Int Ltd | Methods of purifying anti a beta antibodies. |
CA2613512A1 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
CA2848662A1 (en) | 2005-06-30 | 2007-01-11 | Abbvie Inc. | Il-12/p40 binding proteins |
SI1896073T1 (en) | 2005-06-30 | 2013-06-28 | Janssen Biotech, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
WO2007006091A1 (en) | 2005-07-07 | 2007-01-18 | Athlomics Pty Ltd | Polynucleotide marker genes and their expression, for diagnosis of endotoxemia |
JP2009502123A (en) | 2005-07-08 | 2009-01-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Sp35 antibody and use thereof |
US7482124B2 (en) * | 2005-07-08 | 2009-01-27 | Bristol-Myers Squibb Company | Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema |
KR20080039929A (en) | 2005-07-22 | 2008-05-07 | 와이스 테라퓨틱스 가부시키가이샤 | Anti-cd26 antibodies and methods of use thereof |
DE602006014691D1 (en) | 2005-08-02 | 2010-07-15 | Xbiotech Inc | DIAGNOSIS, TREATMENT AND PREVENTION OF VASCULAR DISEASES USING IL-1alpha AUTOANTIC BODIES |
CA2617594C (en) | 2005-08-03 | 2016-08-02 | Grains Research & Development Corporation | Polysaccharide synthases |
WO2007021423A2 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
JP4829969B2 (en) | 2005-08-18 | 2011-12-07 | アンブルックス,インコーポレイテッド | tRNA compositions and uses thereof |
US20070202512A1 (en) * | 2005-08-19 | 2007-08-30 | Bristol-Myers Squibb Company | Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof |
EP2500355A3 (en) | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
SG2014010029A (en) | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
AP2723A (en) | 2005-09-07 | 2013-08-31 | Amgen Fremont Inc | Human monoclonal antibodies to activ in receptor-like Kinase-1 |
CA2620362A1 (en) * | 2005-09-14 | 2007-03-22 | Ucb Pharma S.A. | Comb polymers |
EP1928905B1 (en) | 2005-09-30 | 2015-04-15 | AbbVie Deutschland GmbH & Co KG | Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use |
KR101176830B1 (en) | 2005-10-17 | 2012-08-27 | 주식회사 아이지세라피 | Novel method for phage display |
EP1945816B1 (en) | 2005-10-21 | 2011-07-27 | GeneNews Inc. | Method and apparatus for correlating levels of biomarker products with disease |
ES2526705T3 (en) | 2005-10-25 | 2015-01-14 | The Johns Hopkins University | Methods and compositions for the treatment of Marfan syndrome and associated disorders |
CN102827287B (en) | 2005-10-31 | 2015-08-12 | 昂考梅德药品有限公司 | For the diagnosis and treatment of composition and the method for cancer |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
CA2628255C (en) * | 2005-10-31 | 2016-04-19 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
KR20140012160A (en) | 2005-11-01 | 2014-01-29 | 애브비 바이오테크놀로지 리미티드 | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
EP2510934A1 (en) | 2005-11-04 | 2012-10-17 | Biogen Idec MA Inc. | Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
US20100028358A1 (en) | 2005-11-07 | 2010-02-04 | Wolfram Ruf | Compositions and Methods for Controlling Tissue Factor Signaling Specificity |
US8679490B2 (en) | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
UA96139C2 (en) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Anti-neuropilin-1 (nrp1) antibody |
KR101379071B1 (en) * | 2005-11-08 | 2014-03-28 | 암브룩스, 인코포레이티드 | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
KR101250049B1 (en) | 2005-11-14 | 2013-04-04 | 리나트 뉴로사이언스 코프. | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
EP2365334A1 (en) | 2005-11-14 | 2011-09-14 | MetaMol Theranostics, LLC | Peptide sequence that promotes tumor invasion |
DK2339014T3 (en) | 2005-11-16 | 2015-07-20 | Ambrx Inc | Methods and compositions comprising non-natural amino acids |
JP2009516514A (en) | 2005-11-21 | 2009-04-23 | ジェネンテック・インコーポレーテッド | Novel gene disruptions, compositions and methods related thereto |
DK1963369T3 (en) | 2005-11-28 | 2013-06-03 | Zymogenetics Inc | IL-21 Antagonists |
KR20180058863A (en) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | Monoclonal antibodies against amyloid beta protein and uses thereof |
PL2289909T3 (en) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
MX2008006945A (en) | 2005-11-30 | 2008-10-02 | Massachusetts Inst Technology | Pathogen detection biosensor. |
KR101434682B1 (en) | 2005-12-02 | 2014-08-27 | 제넨테크, 인크. | Binding polypeptides and uses thereof |
EP1973951A2 (en) * | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
NZ621483A (en) | 2005-12-02 | 2015-10-30 | Genentech Inc | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
CA2631181A1 (en) | 2005-12-02 | 2007-06-07 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
EA018044B1 (en) | 2005-12-09 | 2013-05-30 | Юсб Фарма С.А. | Antibody molecules having specificity for human il-6 |
AU2006326404B2 (en) * | 2005-12-14 | 2011-11-03 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
AR057237A1 (en) | 2005-12-15 | 2007-11-21 | Genentech Inc | METHODS AND COMPOSITIONS TO ACT ON POLYUBIQUITINE |
US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
US20070264687A1 (en) | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
US7632498B2 (en) | 2005-12-19 | 2009-12-15 | Tripath Imaging, Inc. | MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease |
SG10201505755YA (en) | 2005-12-29 | 2015-09-29 | Centocor Inc | Human anti-il-23 antibodies, compositions, methods and uses |
WO2007130697A2 (en) | 2006-01-05 | 2007-11-15 | Genentech, Inc. | Anti-ephb4 antibodies and methods using same |
PL2463305T3 (en) | 2006-01-12 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
CN101420977B (en) | 2006-01-27 | 2016-08-10 | 比奥根Ma公司 | NOGO receptor antagonist |
MX2008009592A (en) | 2006-01-27 | 2008-09-08 | Tripath Imaging Inc | Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor. |
WO2007090126A2 (en) * | 2006-01-30 | 2007-08-09 | Invitrogen Corporation | Compositions and methods for detecting and quantifying toxic substances in disease states |
US20070175313A1 (en) * | 2006-01-31 | 2007-08-02 | Kevin Vandervliet | MP3 player holder assembly |
CN101400703B (en) | 2006-02-01 | 2013-05-08 | 赛法隆澳大利亚控股有限公司 | Domain antibody construct |
CA2642273C (en) | 2006-02-14 | 2016-09-20 | President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
AU2007233263A1 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
CA2638912A1 (en) * | 2006-02-20 | 2007-08-30 | Phylogica Limited | Method of constructing and screening libraries of peptide structures |
WO2008121102A2 (en) * | 2006-02-21 | 2008-10-09 | The Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
TWI417301B (en) | 2006-02-21 | 2013-12-01 | Wyeth Corp | Antibodies against human il-22 and uses therefor |
US20070243192A1 (en) * | 2006-02-21 | 2007-10-18 | Regents Of The University Of Michigan | Growth hormone receptor antagonist cancer treatment |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
US8021839B2 (en) * | 2006-02-24 | 2011-09-20 | Investigen, Inc. | Methods and compositions for detecting polynucleotides |
EP2540741A1 (en) | 2006-03-06 | 2013-01-02 | Aeres Biomedical Limited | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
AR059851A1 (en) | 2006-03-16 | 2008-04-30 | Genentech Inc | ANTIBODIES OF EGFL7 AND METHODS OF USE |
US8278421B2 (en) | 2006-03-20 | 2012-10-02 | Xoma Techolology Ltd. | Human antibodies specific for gastrin materials and methods |
CA2647277A1 (en) | 2006-04-05 | 2007-11-08 | Genentech, Inc. | Method for using boc/cdo to modulate hedgehog signaling |
CN102391358B (en) | 2006-04-05 | 2016-08-10 | 艾伯维生物技术有限公司 | Antibody purification |
EP2703010A3 (en) | 2006-04-10 | 2014-08-06 | AbbVie Biotechnology Ltd | Uses and compositions for treatment of rheumatoid arthritis |
US9624295B2 (en) | 2006-04-10 | 2017-04-18 | Abbvie Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
ES2487637T3 (en) | 2006-04-10 | 2014-08-22 | Genentech, Inc. | PDZ Modulators Disheveled |
CA2564435A1 (en) | 2006-04-10 | 2007-10-10 | Abbott Biotechnology Ltd. | Methods for monitoring and treating intestinal disorders |
JP2009536022A (en) | 2006-04-19 | 2009-10-08 | ジェネンテック・インコーポレーテッド | Novel gene disruption and related compositions and methods |
AU2007248656B2 (en) | 2006-05-03 | 2013-04-04 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase and tubulin deacetylase inhibitors |
US7702468B2 (en) | 2006-05-03 | 2010-04-20 | Population Diagnostics, Inc. | Evaluating genetic disorders |
US10522240B2 (en) | 2006-05-03 | 2019-12-31 | Population Bio, Inc. | Evaluating genetic disorders |
AR060871A1 (en) * | 2006-05-09 | 2008-07-16 | Genentech Inc | UNION OF POLYPEPTIDES WITH OPTIMIZED SUPERCONTIGES |
US20090142259A1 (en) * | 2006-05-12 | 2009-06-04 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors |
SG172656A1 (en) | 2006-05-30 | 2011-07-28 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
CL2007001623A1 (en) | 2006-06-06 | 2008-01-18 | Genentech Inc | Anti-dll4 antibody; polynucleotide that encodes it; vector and host cell comprising said polynucleotide; method for making the antibody and immunojugate; method of detection of dll4 and diagnostic method of a disorder associated with dll4; composition comprising the antibody. |
GB0611116D0 (en) | 2006-06-06 | 2006-07-19 | Oxford Genome Sciences Uk Ltd | Proteins |
TWI429658B (en) * | 2006-06-07 | 2014-03-11 | Bioalliance Cv | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
SG177907A1 (en) | 2006-06-14 | 2012-02-28 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
EP2029173B1 (en) | 2006-06-26 | 2016-07-20 | MacroGenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
DE102006030028A1 (en) * | 2006-06-29 | 2008-02-14 | Forschungszentrum Jülich GmbH | A method for finding bait-binding specific molecules and bait-binding molecules and their use |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
KR101396797B1 (en) | 2006-06-30 | 2014-05-26 | 애브비 바이오테크놀로지 리미티드 | Automatic injection device |
TW201139677A (en) | 2006-07-05 | 2011-11-16 | Catalyst Biosciences Inc | Protease screening methods and proteases identified thereby |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
EP2044122B1 (en) * | 2006-07-18 | 2018-03-28 | Sanofi | Antagonist antibody against epha2 for the treatment of cancer |
EP2054444B1 (en) | 2006-08-04 | 2016-11-02 | MedImmune Limited | Antibodies to erbb2 |
US8586006B2 (en) | 2006-08-09 | 2013-11-19 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
EA021255B1 (en) | 2006-08-28 | 2015-05-29 | Киова Хакко Кирин Ко., Лимитед | Antagonistic human light-specific human monoclonal antibodies |
JP5994121B2 (en) | 2006-09-07 | 2016-09-21 | オタゴ イノベーション リミテッド | Biomarker |
WO2008030613A2 (en) * | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Hybrid suppressor trna for vertebrate cells |
KR101625961B1 (en) * | 2006-09-08 | 2016-05-31 | 애브비 바하마스 리미티드 | Interleukin-13 binding proteins |
DK2064333T3 (en) * | 2006-09-08 | 2014-05-05 | Ambrx Inc | SUPPRESSOR-TRNA TRANSCRIPTION IN SPANISH ANIMAL CELLS |
CN104193815A (en) * | 2006-09-08 | 2014-12-10 | Ambrx公司 | Modified human plasma polypeptide or Fc scaffolds and their uses |
WO2008033782A2 (en) | 2006-09-12 | 2008-03-20 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker |
CA2663545A1 (en) * | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
EP3569245A1 (en) | 2006-09-26 | 2019-11-20 | Genmab A/S | Combination treatment of cd38-expressing tumors |
ES2557953T3 (en) * | 2006-09-29 | 2016-01-29 | Oncomed Pharmaceuticals, Inc. | Compositions and methods to diagnose and treat cancer |
NZ576032A (en) | 2006-10-12 | 2012-03-30 | Genentech Inc | Antibodies to lymphotoxin-alpha |
CN101522219A (en) | 2006-10-12 | 2009-09-02 | 惠氏公司 | Methods and compositions with reduced opalescence |
EP2407548A1 (en) | 2006-10-16 | 2012-01-18 | MedImmune, LLC | Molecules with reduced half-lives, compositions and uses thereof |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US20080096193A1 (en) * | 2006-10-24 | 2008-04-24 | Charles Robert Bupp | Methods and compositions for detecting polynucleotides |
PL2502938T3 (en) | 2006-10-27 | 2015-07-31 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
EP2492342B1 (en) | 2006-10-30 | 2015-06-03 | Promega Corporation | Mutant hydrolase proteins with enhanced kinetics and functional expression |
WO2008055260A2 (en) | 2006-11-03 | 2008-05-08 | Wyeth | Glycolysis-inhibiting substances in cell culture |
US7964708B2 (en) | 2006-11-15 | 2011-06-21 | Limin Li | Anti-TSG101 antibodies and their uses for treatment of viral infections |
WO2008064306A2 (en) * | 2006-11-22 | 2008-05-29 | Curedm, Inc. | Methods and compositions relating to islet cell neogenesis |
US7488807B2 (en) | 2006-11-22 | 2009-02-10 | 3M Innovative Properties Company | Antibody with protein A selectivity |
US8067179B2 (en) | 2006-11-30 | 2011-11-29 | Research Development Foundation | Immunoglobulin libraries |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008070593A2 (en) | 2006-12-01 | 2008-06-12 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
US8637244B2 (en) | 2006-12-05 | 2014-01-28 | Decode Genetics Ehf. | Genetic markers for risk management of atrial fibrillation, atrial flutter, and stroke |
EP2687232A1 (en) | 2006-12-06 | 2014-01-22 | MedImmune, LLC | Methods of treating systemic lupus erythematosus |
KR20140031996A (en) | 2006-12-19 | 2014-03-13 | 제넨테크, 인크. | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
EP3124045A3 (en) | 2006-12-20 | 2017-05-03 | Xoma (Us) Llc | Treatment of il-1 beta related diseases |
TW200833711A (en) * | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
US20100129358A1 (en) | 2006-12-22 | 2010-05-27 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
EP2079760B1 (en) | 2006-12-27 | 2016-04-27 | Emory University | Compositions and methods for the treatment of infections |
EP2114443A4 (en) | 2006-12-29 | 2011-08-10 | Abbott Lab | Dual-specific il-1a/ il-1b antibodies |
CA2674603C (en) | 2007-01-09 | 2016-03-29 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
SG177982A1 (en) | 2007-01-16 | 2012-02-28 | Abbott Lab | Methods for treating psoriasis |
WO2008092041A2 (en) | 2007-01-24 | 2008-07-31 | Carnegie Mellon University | Optical biosensors |
EP2106439B1 (en) | 2007-01-24 | 2014-11-12 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
WO2008096375A2 (en) | 2007-02-07 | 2008-08-14 | Decode Genetics Ehf. | Genetic variants contributing to risk of prostate cancer |
BRPI0806403A2 (en) | 2007-02-09 | 2011-09-06 | Genentech Inc | anti-robo4 antibody, use an antibody and imaging method |
US8685666B2 (en) * | 2007-02-16 | 2014-04-01 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies and uses thereof |
WO2008101184A2 (en) * | 2007-02-16 | 2008-08-21 | The Board Of Trustees Of Southern Illinois University | Arl-1 specific antibodies |
BRPI0807927A2 (en) | 2007-02-21 | 2014-06-24 | Decode Genetics Ehf | METHODS FOR DETERMINING CARDIOVASCULAR DISEASE SUSTAINABILITY IN A HUMAN INDIVIDUAL, IDENTIFICATION OF A BOOKMARK FOR USE TO ASSESS CARDIOVASCULAR DISEASE, FOR GENOTIPAYING A SAMPLE OF A PREPARATILE FOR NUCLEAR PROBABLE ACTIVITY PROGNOSIS OF A DIAGNOSTIC INDIVIDUAL WITH CARDIOVASCULAR DISEASE, AND TO MONITOR PROGRESS OF TREATMENT OF AN INDIVIDUAL GOING TO TREATMENT FOR CARDIOVASCULAR DISEASE, A HUMAN DEVELOPMENT, CARDIOVASCULAR DISEASE , DEVICE FOR DETERMINING A GENETIC INDICATOR FOR CARDIOVASCULAR DISEASE IN A HUMAN GUY |
DK2436781T3 (en) | 2007-02-22 | 2016-01-11 | Genentech Inc | Methods for the detection of inflammatory bowel disease |
US7771947B2 (en) * | 2007-02-23 | 2010-08-10 | Investigen, Inc. | Methods and compositions for rapid light-activated isolation and detection of analytes |
EP2121745A2 (en) | 2007-02-26 | 2009-11-25 | Oxford Genome Sciences (UK) Limited | Proteins |
WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
GB2456235B8 (en) | 2007-03-22 | 2009-12-09 | Heptares Therapeutics Ltd | Stable beta-adrenergic receptor mutants |
PT2125894T (en) | 2007-03-22 | 2019-02-27 | Biogen Ma Inc | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
US8168760B2 (en) | 2007-03-29 | 2012-05-01 | Abbott Laboratories | Crystalline anti-human IL-12 antibodies |
CA2682170A1 (en) | 2007-03-30 | 2008-10-09 | Medimmune, Llc | Antibodies with decreased deamidation profiles |
PT2068909E (en) * | 2007-03-30 | 2012-07-04 | Ambrx Inc | Modified fgf-21 polypeptides and their uses |
PA8775101A1 (en) | 2007-04-02 | 2008-11-19 | Pfizer | ANTI-IGE ANTIBODIES |
EP2132339B1 (en) * | 2007-04-04 | 2011-03-09 | Chimera Biotec GmbH | Method for the detection of an analyte in biological matrix |
US7807168B2 (en) * | 2007-04-10 | 2010-10-05 | Vaccinex, Inc. | Selection of human TNFα specific antibodies |
CN101743309B (en) | 2007-04-13 | 2014-01-29 | 催化剂生物科学公司 | Modified factor vii polypetides and uses thereof |
CA2685596A1 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
AU2008246442B2 (en) | 2007-05-04 | 2014-07-03 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Engineered rabbit antibody variable domains and uses thereof |
EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
RU2519227C2 (en) | 2007-05-14 | 2014-06-10 | Медиммун, Ллк | Method for reducing eosinophil count |
ES2541051T3 (en) | 2007-05-17 | 2015-07-15 | Genentech, Inc. | Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
JP2010527603A (en) | 2007-05-25 | 2010-08-19 | ディコーデ ジェネテクス イーエイチエフ | Genetic variation on CHR5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |
US7906149B2 (en) * | 2007-05-25 | 2011-03-15 | Boval Company, L.P. | Method for treating allergic dermatitis |
PE20090329A1 (en) * | 2007-05-30 | 2009-03-27 | Abbott Lab | HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES |
US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
EP2171451A4 (en) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | Methods for treating juvenile idiopathic arthritis |
JP5921066B2 (en) | 2007-06-15 | 2016-05-24 | ドイチェス クレブスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェンレヒツ | Treatment of tumors with specific anti-L1 antibodies |
WO2008154700A1 (en) * | 2007-06-20 | 2008-12-24 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith |
EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
JP5602625B2 (en) | 2007-06-26 | 2014-10-08 | エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング | Binding substance display |
JP5931336B2 (en) | 2007-07-02 | 2016-06-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Compositions and methods for treating and diagnosing cancer |
EP2176295B1 (en) | 2007-07-16 | 2014-11-19 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
CL2008002085A1 (en) | 2007-07-16 | 2008-11-21 | Genentech Inc | Humanized anti-cd79b / igbeta / b29 antibody; coding polynucleotide, vector, host cell; manufacturing method; immunoconjugate; pharmaceutical composition; use to treat cancer; in vitro method to determine the presence of cd79b, or inhibit growth of quqe cells expressing cd79b; in vitro assay to detect b cells |
EP2182943B1 (en) | 2007-07-23 | 2016-10-26 | Janssen Biotech, Inc. | Methods and compositions for treating fibrosis related disorders using il-17 antagonists |
MX2010000979A (en) * | 2007-07-25 | 2010-03-26 | Alexion Pharma Inc | Methods and compositions for treating autoimmune disease. |
US20100273722A1 (en) * | 2007-08-06 | 2010-10-28 | Yale University | Modified miniature proteins |
KR20100089816A (en) | 2007-08-21 | 2010-08-12 | 모르포시스 아게 | Improved methods for the formation of disulphide bonds |
JP2010538017A (en) * | 2007-08-30 | 2010-12-09 | キュアーディーエム、インク. | Compositions and methods using islet formation-promoting peptides and analogs thereof |
GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
CA2964398C (en) | 2007-09-14 | 2023-03-07 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
CA2700714C (en) | 2007-09-26 | 2018-09-11 | Ucb Pharma S.A. | Dual specificity antibody fusions |
MY163473A (en) | 2007-09-26 | 2017-09-15 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
AU2008307145B2 (en) * | 2007-10-04 | 2014-07-10 | Bionomics Limited | Markers of endothelial cells and uses thereof |
EP2219452B1 (en) | 2007-11-05 | 2015-10-14 | MedImmune, LLC | Methods of treating scleroderma |
KR101867606B1 (en) | 2007-11-07 | 2018-06-18 | 제넨테크, 인크. | Compositions and methods for treatment of microbial disorders |
WO2009067546A2 (en) | 2007-11-19 | 2009-05-28 | Celera Corpration | Lung cancer markers and uses thereof |
JP5547083B2 (en) | 2007-11-20 | 2014-07-09 | アンブルックス,インコーポレイテッド | Modified insulin polypeptides and their use |
EP2225275A4 (en) * | 2007-11-28 | 2013-04-03 | Medimmune Llc | Protein formulation |
US8697360B2 (en) | 2007-11-30 | 2014-04-15 | Decode Genetics Ehf. | Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition |
AR069501A1 (en) * | 2007-11-30 | 2010-01-27 | Genentech Inc | ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR) |
US8426153B2 (en) | 2007-12-03 | 2013-04-23 | Carnegie Mellon University | Linked peptides fluorogenic biosensors |
GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
KR20130087632A (en) | 2007-12-17 | 2013-08-06 | 화이자 리미티드 | Treatment of interstitial cystitis |
SG186669A1 (en) | 2007-12-18 | 2013-01-30 | Bioalliance Cv | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
JP5536666B2 (en) | 2007-12-20 | 2014-07-02 | ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー | Methods for the treatment of gout |
AU2008341050B2 (en) | 2007-12-26 | 2013-10-24 | Vaccinex, Inc. | Anti-C35 antibody combination therapies and methods |
NZ586875A (en) | 2007-12-28 | 2012-10-26 | Elan Pharm Inc | Treatment and prophylaxis of amyloidosis with an antibody that binds a specific epitope of human amyloid A peptide |
GB0800277D0 (en) | 2008-01-08 | 2008-02-13 | Imagination Tech Ltd | Video motion compensation |
CA2711771C (en) | 2008-01-11 | 2017-01-24 | Gene Techno Science Co., Ltd. | Humanized anti-.alpha.9 integrin antibodies and the uses thereof |
JP2011509675A (en) | 2008-01-18 | 2011-03-31 | メディミューン,エルエルシー | Cysteine engineered antibodies for site-specific conjugation |
SI2657253T1 (en) | 2008-01-31 | 2017-10-30 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
BR122020023189B1 (en) | 2008-02-08 | 2022-02-01 | Astrazeneca Ab | Use of a pharmaceutical composition comprising an antibody specific for ifnar1 |
GB0802474D0 (en) | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
NZ587903A (en) | 2008-02-14 | 2013-05-31 | Decode Genetics Ehf | Susceptibility for lung cancer using the polymorphic marker rs1051730 |
BRPI0906060A2 (en) | 2008-02-28 | 2015-12-01 | 3M Innovative Properties Co | isolated antibodies, methods of preparing an anti-clostridium difficile antibody, composition and method for detecting the presence of a clostridium difficile spore in a sample |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
WO2009109572A2 (en) * | 2008-03-03 | 2009-09-11 | Ablynx Nv | Monovalent phage display of single variable domains |
RU2467765C2 (en) | 2008-03-04 | 2012-11-27 | Пфайзер Лимитед | Method of treating inflammatory pain |
CN107296957A (en) | 2008-03-04 | 2017-10-27 | 梯瓦制药国际有限责任公司 | The method for treating chronic ache |
WO2009111644A2 (en) * | 2008-03-05 | 2009-09-11 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
US9630985B2 (en) * | 2008-03-12 | 2017-04-25 | Otago Innovation Limited | Biomarkers |
CA2715921A1 (en) | 2008-03-12 | 2009-09-17 | Otago Innovation Limited | Biomarkers |
US9873957B2 (en) * | 2008-03-13 | 2018-01-23 | Dyax Corp. | Libraries of genetic packages comprising novel HC CDR3 designs |
JP2011515404A (en) | 2008-03-18 | 2011-05-19 | アボット・ラボラトリーズ | Methods for treating psoriasis |
WO2009118300A1 (en) | 2008-03-25 | 2009-10-01 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
US20110123530A1 (en) * | 2008-03-31 | 2011-05-26 | Arron Joseph R | Compositions and methods for treating and diagnosing asthma |
NZ588905A (en) | 2008-04-01 | 2012-08-31 | Decode Genetics Ehf | Genetic testing method for determining susceptibility to abdominal aortic aneurysm by assay for selected polymorphisms associated with the disease |
CA2720368C (en) | 2008-04-02 | 2017-08-22 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
KR101614494B1 (en) | 2008-04-02 | 2016-04-22 | 마크로제닉스, 인크. | Bcr-complex-specific antibodies and methods of using same |
RU2556129C2 (en) | 2008-04-11 | 2015-07-10 | Сиэтл Дженетикс, Инк. | Diagnostics and treatment of malignant tumours of pancreas, ovaries and other malignant tumours |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
CA2721716C (en) | 2008-04-24 | 2019-09-24 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof |
AU2009240481B2 (en) | 2008-04-24 | 2015-07-30 | Takeda Pharmaceutical Company Limited | Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs |
US20090269786A1 (en) * | 2008-04-25 | 2009-10-29 | The Board Of Trustees Of The University Of Illinois | RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies |
ES2650804T3 (en) | 2008-04-25 | 2018-01-22 | Dyax Corp. | Antibodies against FcRn and use thereof |
EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
JP5624535B2 (en) | 2008-05-02 | 2014-11-12 | シアトル ジェネティクス,インコーポレーテッド | Methods and compositions for preparing antibodies and antibody derivatives having low core fucosylation |
KR101690590B1 (en) | 2008-05-06 | 2016-12-28 | 제넨테크, 인크. | AFFINITY MATURED CRIg VARIANTS |
CN104558178A (en) | 2008-05-09 | 2015-04-29 | Abbvie公司 | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
EP2279004B1 (en) * | 2008-05-16 | 2015-01-14 | F. Hoffmann-La Roche AG | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists |
US8093018B2 (en) | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
EP2304439A4 (en) | 2008-05-29 | 2012-07-04 | Nuclea Biotechnologies Llc | Anti-phospho-akt antibodies |
UY31861A (en) | 2008-06-03 | 2010-01-05 | Abbott Lab | IMMUNOGLOBULIN WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
US9035027B2 (en) | 2008-06-03 | 2015-05-19 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
EP2282770B1 (en) | 2008-06-04 | 2018-03-07 | MacroGenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
WO2010004591A2 (en) | 2008-07-07 | 2010-01-14 | Decode Genetics Ehf | Genetic variants for breast cancer risk assessment |
US8834875B2 (en) | 2010-01-13 | 2014-09-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
BRPI0915825A2 (en) | 2008-07-08 | 2015-11-03 | Abbott Lab | prostaglandin binding proteins and uses thereof |
KR101682490B1 (en) | 2008-07-08 | 2016-12-05 | 온코메드 파마슈티칼스, 인크. | Notch-binding agents and antagonists and methods of use thereof |
EP2321422A4 (en) | 2008-07-08 | 2013-06-19 | Abbvie Inc | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
JP2011527572A (en) | 2008-07-09 | 2011-11-04 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Composition comprising a LINGO antibody or fragment |
DK2318832T3 (en) | 2008-07-15 | 2014-01-20 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated slides and related methods |
AU2009274549B2 (en) | 2008-07-23 | 2014-05-01 | Dana-Farber Cancer Institute, Inc. | Deacetylase inhibitors and uses thereof |
JP5680534B2 (en) * | 2008-07-23 | 2015-03-04 | イーライ リリー アンド カンパニー | Modified bovine G-CSF polypeptides and their use |
US9182406B2 (en) | 2008-08-04 | 2015-11-10 | Biodesy, Inc. | Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability |
KR20110039348A (en) | 2008-08-06 | 2011-04-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Conjugated proteins with prolonged in vivo efficacy |
WO2010019702A2 (en) | 2008-08-12 | 2010-02-18 | Oncomed Pharmaceuticals, Inc. | Ddr1-binding agents and methods of use thereof |
CA2733642A1 (en) | 2008-08-14 | 2010-02-18 | Cephalon Australia Pty Ltd | Anti-il-12/il-23 antibodies |
EP3199630B1 (en) | 2008-09-05 | 2019-05-08 | President and Fellows of Harvard College | Continuous directed evolution of proteins and nucleic acids |
TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
WO2010033237A2 (en) * | 2008-09-22 | 2010-03-25 | Calmune Corporation | Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules |
AU2009293640A1 (en) * | 2008-09-22 | 2010-03-25 | Calmune Corporation | Methods and vectors for display of 2G12 -derived domain exchanged antibodies |
US20100075329A1 (en) | 2008-09-23 | 2010-03-25 | O'toole Margot | Methods for predicting production of activating signals by cross-linked binding proteins |
EP2352841A2 (en) | 2008-09-23 | 2011-08-10 | President and Fellows of Harvard College | Sirt4 and uses thereof |
SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
EP3133086B1 (en) | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
CN102232085A (en) | 2008-09-26 | 2011-11-02 | Ambrx公司 | Modified animal erythropoietin polypeptides and their uses |
PE20110480A1 (en) | 2008-09-26 | 2011-07-01 | Ambrx Inc | MICROORGANISMS AND VACCINES DEPENDENT ON REPLICATION OF NON-NATURAL AMINO ACIDS |
CA2736904A1 (en) | 2008-09-26 | 2010-04-01 | Wyeth Llc | Compatible display vector systems |
LT2340038T (en) | 2008-10-10 | 2018-04-10 | Children`S Medical Center Corporation | Biochemically stabilized hiv-1 env trimer vaccine |
AU2009303453B2 (en) | 2008-10-14 | 2015-02-26 | Dyax Corp. | Use of IGF-II/IGF-IIE binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis |
JP5390621B2 (en) | 2008-10-20 | 2014-01-15 | グワンジュ・インスティテュート・オブ・サイエンス・アンド・テクノロジー | Bidentate peptide binder |
KR20110091678A (en) | 2008-10-20 | 2011-08-12 | 아보트 러보러터리즈 | Isolation and purification of antibodies using protein a affinity chromatography |
EP3351628B1 (en) | 2008-10-24 | 2023-07-26 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Human ebola virus species and compositions and methods thereof |
ES2631507T3 (en) | 2008-10-29 | 2017-08-31 | China Synthetic Rubber Corporation | Procedures and agents for the diagnosis and treatment of hepatocellular carcinoma |
MX2011004558A (en) | 2008-10-29 | 2011-06-01 | Wyeth Llc | Methods for purification of single domain antigen binding molecules. |
US9393304B2 (en) | 2008-10-29 | 2016-07-19 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
MX2011004550A (en) | 2008-10-31 | 2011-07-20 | Centocor Ortho Biotech Inc | Fibronectin type iii domain based scaffold compositions, methods and uses. |
US9221902B2 (en) | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
CA2742802C (en) | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
LT2356462T (en) | 2008-11-11 | 2017-03-10 | The Regents Of The University Of Michigan | Anti-cxcr1 compositions and methods |
EP2358392B1 (en) | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Antibody formulation |
ATE523603T1 (en) | 2008-11-21 | 2011-09-15 | Chimera Biotec Gmbh | CONJUGATE COMPLEXES FOR ANALYTE DETECTION |
EP3178478A1 (en) | 2008-11-22 | 2017-06-14 | F. Hoffmann-La Roche AG | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
CN102292101A (en) | 2008-11-26 | 2011-12-21 | 五佳医疗股份有限公司 | Compositions and methods for regulating collagen and smooth muscle actin expression by SERPINE2 |
BRPI0921321A2 (en) | 2008-11-28 | 2018-10-16 | Emory University | methods for the treatment of tumors and tumors |
NZ593314A (en) * | 2008-12-04 | 2013-03-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
TW202206454A (en) | 2008-12-09 | 2022-02-16 | 美商建南德克公司 | Anti-pd-l1 antibodies and their use to enhance t-cell function |
SG10201407908VA (en) | 2008-12-19 | 2015-01-29 | Macrogenics Inc | Covalent diabodies and uses thereof |
KR20140020368A (en) | 2008-12-23 | 2014-02-18 | 제넨테크, 인크. | Methods and compositions for diagnostic use in cancer patients |
CN102341411A (en) | 2008-12-31 | 2012-02-01 | 比奥根艾迪克Ma公司 | Anti-lymphotoxin antibodies |
US9181315B2 (en) | 2009-01-08 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
GB0900425D0 (en) | 2009-01-12 | 2009-02-11 | Ucb Pharma Sa | Biological products |
WO2010082134A1 (en) | 2009-01-14 | 2010-07-22 | Iq Therapeutics Bv | Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins |
BRPI1007345A2 (en) | 2009-01-20 | 2019-04-16 | H. ZADEH Homayoun | mediated antibody bone regeneration |
US20120058131A1 (en) | 2009-01-21 | 2012-03-08 | Oxford Biotherapeutics Ltd | Pta089 protein |
KR20110122100A (en) | 2009-01-22 | 2011-11-09 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Stable growth hormone compounds |
CA2750922A1 (en) * | 2009-01-28 | 2010-08-05 | Antigen Express, Inc. | Li-key hybrid peptides that modulate the immune response to influenza |
US8383778B2 (en) | 2009-01-29 | 2013-02-26 | Abbvie Inc. | IL-1 binding proteins |
US20110165063A1 (en) * | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
US8852608B2 (en) | 2009-02-02 | 2014-10-07 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
RU2562700C2 (en) | 2009-02-12 | 2015-09-10 | Янссен Байотек, Инк. | Compositions, methods of producing and using fibronectin type iii domain based scaffold |
EP2396035A4 (en) | 2009-02-12 | 2012-09-12 | Human Genome Sciences Inc | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
US8614295B2 (en) | 2009-02-17 | 2013-12-24 | Ucb Pharma S.A. | Antibody molecules having specificity for human OX40 |
WO2010096388A2 (en) | 2009-02-18 | 2010-08-26 | Carnegie Mellon University | Quenched dendrimeric dyes for bright detection |
US8030026B2 (en) | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof |
US20100227335A1 (en) | 2009-03-05 | 2010-09-09 | Becton, Dickinson And Company | Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer |
SG173705A1 (en) | 2009-03-05 | 2011-09-29 | Abbott Lab | Il-17 binding proteins |
EP2405920A1 (en) | 2009-03-06 | 2012-01-18 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Novel therapy for anxiety |
AU2010221188A1 (en) | 2009-03-06 | 2011-10-20 | Tripath Imaging, Inc. | Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer |
CN102333791B (en) | 2009-03-10 | 2014-06-25 | 株式会社遗传科技 | Generation, expression and characterization of the humanized k33n monoclonal antibody |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
SG174904A1 (en) | 2009-03-25 | 2011-11-28 | Genentech Inc | Anti-fgfr3 antibodies and methods using same |
KR101523127B1 (en) | 2009-03-25 | 2015-05-26 | 제넨테크, 인크. | Novel anti-alpha5beta1 antibodies and uses thereof |
CA2757382A1 (en) | 2009-04-01 | 2010-10-21 | Kristi Elkins | Anti-fcrh5 antibodies and immunoconjugates |
NZ595918A (en) | 2009-04-03 | 2013-07-26 | Decode Genetics Ehf | Genetic markers for risk management of atrial fibrillation and stroke |
EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
MA33276B1 (en) | 2009-04-20 | 2012-05-02 | Oxford Biotherapeutics Ltd | Cadherine-17 antibodies |
US9067986B2 (en) * | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
AU2010241706B2 (en) | 2009-04-29 | 2015-07-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | ERG monoclonal antibodies |
KR101721906B1 (en) | 2009-04-29 | 2017-03-31 | 애브비 바이오테크놀로지 리미티드 | Automatic injection device |
KR101224468B1 (en) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | Bispecific antibody having a novel form and use thereof |
AU2010249470B2 (en) * | 2009-05-20 | 2015-06-25 | Novimmune S.A. | Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants |
WO2010141630A1 (en) | 2009-06-03 | 2010-12-09 | University Of Southern California | Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway |
WO2010144711A2 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
EP2261242A1 (en) | 2009-06-10 | 2010-12-15 | Universite Catholique De Louvain | Aspartate-N-acetyltransferase enzyme, diagnostic method and therapeutic method |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
US20120213705A1 (en) | 2009-06-22 | 2012-08-23 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
EP2272979A1 (en) | 2009-06-30 | 2011-01-12 | Centre National de la Recherche Scientifique (CNRS) | Method for testing a subject thought to be predisposed to having cancer |
SG177583A1 (en) | 2009-07-09 | 2012-02-28 | Hoffmann La Roche | In vivo tumor vasculature imaging |
CA2767360A1 (en) | 2009-07-10 | 2011-01-13 | Decode Genetics Ehf. | Genetic markers associated with risk of diabetes mellitus |
TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
CN102498129B (en) | 2009-07-31 | 2016-03-02 | 霍夫曼-拉罗奇有限公司 | Use BV8 antagonist or the transfer of G-CSF antagonist Tumor suppression |
CN102596220A (en) | 2009-07-31 | 2012-07-18 | 韦恩州立大学 | Monophosphorylated lipid A derivatives |
US9259476B2 (en) | 2009-07-31 | 2016-02-16 | Wayne State University | Monophosphorylated lipid A derivatives |
CN105963710A (en) | 2009-08-06 | 2016-09-28 | 诺沃—诺迪斯克保健股份有限公司 | Growth hormones with prolonged in-vivo efficacy |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
KR20180105258A (en) | 2009-08-11 | 2018-09-27 | 제넨테크, 인크. | Production of proteins in glutamine-free cell culture media |
SG178335A1 (en) * | 2009-08-13 | 2012-03-29 | Crucell Holland Bv | Antibodies against human respiratory syncytial virus (rsv) and methods of use |
AR077848A1 (en) | 2009-08-15 | 2011-09-28 | Genentech Inc | ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF BREAST CANCER PREVIOUSLY TREATED |
EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
BR112012004464B8 (en) | 2009-08-28 | 2021-05-25 | Labrys Biologics Inc | use of an anti-cgrp antagonist antibody to prepare a pharmaceutical composition for treating and/or preventing visceral pain and/or one or more symptoms of visceral pain, wherein the visceral pain is associated with interstitial (ic) cystitis, and said pharmaceutical composition |
EP3029070A1 (en) | 2009-08-29 | 2016-06-08 | AbbVie Inc. | Therapeutic dll4 binding proteins |
PE20121530A1 (en) | 2009-09-01 | 2012-12-22 | Abbvie Inc | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN |
US20110059111A1 (en) | 2009-09-01 | 2011-03-10 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Mammalian receptors as targets for antibody and active vaccination therapy against mold infections |
JP5887270B2 (en) | 2009-09-02 | 2016-03-16 | ジェネンテック, インコーポレイテッド | Mutant SMOOTHENED AND METHOD OF USING THE SAME |
ES2667258T3 (en) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Multivalent antibodies |
KR20120112384A (en) | 2009-09-14 | 2012-10-11 | 애보트 게엠베하 운트 콤파니 카게 | Methods for treating psoriasis |
CA2773564A1 (en) * | 2009-09-14 | 2011-03-17 | Dyax Corp. | Libraries of genetic packages comprising novel hc cdr3 designs |
WO2011033006A1 (en) | 2009-09-17 | 2011-03-24 | F. Hoffmann-La Roche Ag | Methods and compositions for diagnostics use in cancer patients |
US20110189183A1 (en) | 2009-09-18 | 2011-08-04 | Robert Anthony Williamson | Antibodies against candida, collections thereof and methods of use |
EP2480573A1 (en) | 2009-09-22 | 2012-08-01 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
US9598692B2 (en) | 2009-09-25 | 2017-03-21 | University Of Oslo | Multivalent phage display systems and methods |
US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
JP5885664B2 (en) | 2009-09-25 | 2016-03-15 | ゾーマ テクノロジー リミテッド | Screening method |
CN103403026B (en) | 2009-09-25 | 2016-05-11 | 美国政府(由卫生和人类服务部的部长所代表) | HIV-1 neutralizing antibody and uses thereof |
EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
AR078470A1 (en) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER |
WO2011047083A1 (en) | 2009-10-13 | 2011-04-21 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
EP2488658A4 (en) | 2009-10-15 | 2013-06-19 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
PT2488204E (en) | 2009-10-16 | 2016-06-09 | Oncomed Pharm Inc | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
BR112012009289B8 (en) | 2009-10-20 | 2021-05-25 | Abbott Laboratoires | method for purifying an anti-il-13 antibody from a sample mixture comprising an anti-il-13 antibody and at least one host cell protein (hcp) |
BR112012009409A2 (en) | 2009-10-22 | 2017-02-21 | Genentech Inc | method of identifying an inhibitory substance, antagonist molecule, isolated nucleic acid, vector, host cell, method of making the molecule, composition, article of manufacture, method of inhibiting a biological activity, method of treating a pathological condition, method for detect msp in a sample and method to detect hepsin in a sample |
NZ599337A (en) | 2009-10-22 | 2013-05-31 | Genentech Inc | Anti-hepsin antibodies and methods using same |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011051350A1 (en) | 2009-10-27 | 2011-05-05 | Ucb Pharma S.A. | Function modifying nav 1.7 antibodies |
US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
US20110098862A1 (en) | 2009-10-27 | 2011-04-28 | ExxonMobil Research Engineering Company Law Department | Multi-stage processes and control thereof |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
WO2011053707A1 (en) | 2009-10-31 | 2011-05-05 | Abbott Laboratories | Antibodies to receptor for advanced glycation end products (rage) and uses thereof |
WO2011054007A1 (en) | 2009-11-02 | 2011-05-05 | Oxford Biotherapeutics Ltd. | Ror1 as therapeutic and diagnostic target |
WO2011056073A2 (en) | 2009-11-04 | 2011-05-12 | Erasmus University Medical Center Rotterdam | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
CN105274170A (en) | 2009-11-05 | 2016-01-27 | 弗·哈夫曼-拉罗切有限公司 | Methods and composition for secretion of heterologous polypeptides |
US9244063B2 (en) | 2009-11-11 | 2016-01-26 | Gentian As | Immunoassay for assessing related analytes of different origin |
EP2499159B1 (en) | 2009-11-13 | 2017-01-04 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB0920324D0 (en) | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
JP5856065B2 (en) | 2009-11-30 | 2016-02-09 | ジェネンテック, インコーポレイテッド | Compositions and methods for tumor diagnosis and treatment |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
KR20120118002A (en) | 2009-12-08 | 2012-10-25 | 애보트 게엠베하 운트 콤파니 카게 | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
US8822652B2 (en) | 2009-12-09 | 2014-09-02 | Institut National De La Sante Et De La Recherche Medicale | Monoclonal antibodies that bind B7H6 and uses thereof |
EP2509626B1 (en) | 2009-12-11 | 2016-02-10 | F.Hoffmann-La Roche Ag | Anti-vegf-c antibodies and methods using same |
WO2011084496A1 (en) * | 2009-12-16 | 2011-07-14 | Abbott Biotherapeutics Corp. | Anti-her2 antibodies and their uses |
CN102770158B (en) | 2009-12-21 | 2016-10-19 | 霍夫曼-拉罗奇有限公司 | Antibody formulations |
CA2784800A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
CA2784793A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
TW201125583A (en) * | 2009-12-23 | 2011-08-01 | Bioalliance Cv | Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same |
AU2010336485B2 (en) | 2009-12-23 | 2015-03-26 | Genentech, Inc. | Anti-Bv8 antibodies and uses thereof |
ES2905545T3 (en) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins |
IN2012DN06309A (en) | 2010-01-11 | 2015-09-25 | Alexion Pharma Inc | |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
US9745589B2 (en) | 2010-01-14 | 2017-08-29 | Cornell University | Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination |
WO2011089250A2 (en) | 2010-01-22 | 2011-07-28 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
RU2605627C2 (en) | 2010-01-22 | 2016-12-27 | Ново Нордиск Хелс Кеа Аг | Growth hormones with prolonged efficacy in vivo |
US10429384B2 (en) | 2010-01-22 | 2019-10-01 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders |
CN102959088A (en) | 2010-02-02 | 2013-03-06 | 艾博特生物技术有限公司 | Methods and compositions for predicting responsiveness to treatment with TNF-a inhibitor |
TWI518325B (en) | 2010-02-04 | 2016-01-21 | 自治醫科大學 | Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors |
RU2573994C2 (en) | 2010-02-10 | 2016-01-27 | Иммьюноджен, Инк | Anti-cd20 antibodies and thereof application |
US10393754B2 (en) | 2010-02-17 | 2019-08-27 | Cedars-Sinai Medical Center | Methods of diagnosing and treating heart failure |
US20110200595A1 (en) | 2010-02-18 | 2011-08-18 | Roche Glycart | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR |
SG183333A1 (en) | 2010-02-18 | 2012-09-27 | Genentech Inc | Neuregulin antagonists and use thereof in treating cancer |
BR112012020700A8 (en) | 2010-02-23 | 2018-01-02 | Hoffmann La Roche | method of treating ovarian cancer patients, ovarian cancer treatment kit, method of instruction to a human ovarian cancer patient, promotional and commercial method |
JP5988436B2 (en) | 2010-02-23 | 2016-09-07 | ジェネンテック, インコーポレイテッド | Compositions and methods for tumor diagnosis and treatment |
SA114360064B1 (en) | 2010-02-24 | 2016-01-05 | رينات نيوروساينس كوربوريشن | Antagonist anti-il-7 receptor antibodies and methods |
BR112012021296B1 (en) | 2010-02-24 | 2021-06-15 | Immunogen, Inc | HUMANIZED ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT SPECIFICALLY BINDS TO A HUMAN FOLATE RECEIVER 1, ITS METHOD OF PREPARATION, AS WELL AS IMMUNOCONJUGATE, DIAGNOSTIC REAGENT, AND USES |
MX348312B (en) | 2010-03-02 | 2017-06-06 | Abbvie Inc | Therapeutic dll4 binding proteins. |
EP2542578A1 (en) | 2010-03-05 | 2013-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Smoc1, tenascin-c and brain cancers |
EP2545079A2 (en) | 2010-03-11 | 2013-01-16 | Rinat Neuroscience Corporation | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
SG183542A1 (en) | 2010-03-12 | 2012-10-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
EP2547359B1 (en) | 2010-03-15 | 2016-03-09 | The Board of Trustees of the University of Illionis | Inhibitors of beta integrin-g protein alpha subunit binding interactions |
WO2011116276A2 (en) * | 2010-03-18 | 2011-09-22 | Matthew Delisa | Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates |
WO2013040142A2 (en) | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
WO2011119484A1 (en) | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
CA2791991A1 (en) | 2010-03-24 | 2011-09-29 | Genentech, Inc. | Anti-lrp6 antibodies |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
EP3187585A1 (en) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
US10472426B2 (en) | 2010-03-25 | 2019-11-12 | Ucb Biopharma Sprl | Disulfide stabilized DVD-Ig molecules |
JP2013530929A (en) | 2010-04-01 | 2013-08-01 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Frizzled binders and uses thereof |
US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
CN104744591B (en) | 2010-04-15 | 2022-09-27 | Abbvie德国有限责任两合公司 | Amyloid beta binding proteins |
WO2011131611A1 (en) | 2010-04-19 | 2011-10-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulating xrn1 |
EP2380909A1 (en) | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
CN105963694B (en) | 2010-04-30 | 2019-11-05 | 阿雷克森制药公司 | Anti- C5A antibody and the method for using the antibody |
EP2566891B1 (en) | 2010-05-03 | 2016-11-02 | University Of Rochester | Anti-glucosaminidase passive immunization for staphylococcus aureus infections |
MA34291B1 (en) | 2010-05-03 | 2013-06-01 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR |
AU2011252883B2 (en) | 2010-05-14 | 2015-09-10 | Abbvie Inc. | IL-1 binding proteins |
EP2569335B1 (en) | 2010-05-14 | 2018-08-22 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
EP2577309B1 (en) | 2010-05-25 | 2016-11-23 | Carnegie Mellon University | Targeted probes of cellular physiology |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
NZ602840A (en) | 2010-06-03 | 2014-11-28 | Genentech Inc | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
DK2575884T3 (en) | 2010-06-03 | 2018-09-03 | Abbvie Biotechnology Ltd | APPLICATIONS AND COMPOSITIONS TO TREAT HIDRADENITIS SUPPURATIVA (HS) |
US20130089538A1 (en) | 2010-06-10 | 2013-04-11 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
US9499813B2 (en) | 2010-06-10 | 2016-11-22 | President And Fellows Of Harvard College | Systems and methods for amplification and phage display |
RU2013101779A (en) | 2010-06-16 | 2014-07-27 | Эббви Инк. | COMPARISON OF PROTEIN SAMPLES |
TW201204388A (en) | 2010-06-18 | 2012-02-01 | Genentech Inc | Anti-Axl antibodies and methods of use |
US20120009196A1 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
SG186983A1 (en) | 2010-07-09 | 2013-02-28 | Genentech Inc | Anti-neuropilin antibodies and methods of use |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
PL2591006T3 (en) | 2010-07-09 | 2019-10-31 | Bioverativ Therapeutics Inc | Processable single chain molecules and polypeptides made using same |
SG10201800717UA (en) | 2010-07-09 | 2018-02-27 | Janssen Vaccines & Prevention Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
WO2012009568A2 (en) | 2010-07-16 | 2012-01-19 | Adimab, Llc | Antibody libraries |
CA2805572A1 (en) | 2010-07-16 | 2012-01-19 | Martin Hegen | Modified single domain antigen binding molecules and uses thereof |
NZ605640A (en) | 2010-07-19 | 2016-01-29 | Otago Innovation Ltd | Signal biomarkers |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
US20130143815A1 (en) | 2010-07-22 | 2013-06-06 | Novo Nordisk Health Care Ag | Growth hormone conjugates |
AU2011280969A1 (en) | 2010-07-23 | 2013-02-07 | Trustees Of Boston University | Anti-Despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
WO2012015758A2 (en) | 2010-07-30 | 2012-02-02 | Saint Louis University | Methods of treating pain |
CA2807127C (en) | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
CN103392182B (en) | 2010-08-02 | 2017-07-04 | 众有生物有限公司 | System and method for finding pathogenic mutation in genetic disease |
EP2601218A4 (en) | 2010-08-03 | 2015-02-18 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
JP2013541501A (en) | 2010-08-03 | 2013-11-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Biomarkers for chronic lymphocytic leukemia (CLL) |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
RU2013106217A (en) | 2010-08-05 | 2014-09-10 | Ф. Хоффманн-Ля Рош Аг | HYBRID PROTEIN FROM ANTIBODIES AGAINST MHC AND ANTIVIRAL CYTOKINE |
EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
MX2013001336A (en) | 2010-08-13 | 2013-03-08 | Roche Glycart Ag | Anti-tenascin-c a2 antibodies and methods of use. |
RS56702B1 (en) | 2010-08-13 | 2018-03-30 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
PT3572091T (en) | 2010-08-17 | 2024-03-01 | Ambrx Inc | Modified relaxin polypeptides and their uses |
AU2011291462A1 (en) | 2010-08-19 | 2013-03-14 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
WO2012022774A1 (en) | 2010-08-19 | 2012-02-23 | Roche Diagnostics Gmbh | An assay for measurement of antibodies binding to a therapeutic monoclonal antibody |
GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
WO2012027570A2 (en) | 2010-08-26 | 2012-03-01 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
EP2608807A1 (en) | 2010-08-27 | 2013-07-03 | Stem Centrx, Inc. | Notum protein modulators and methods of use |
AU2011295919A1 (en) | 2010-08-31 | 2013-03-07 | Genentech, Inc. | Biomarkers and methods of treatment |
NZ608814A (en) | 2010-09-03 | 2015-06-26 | Stem Centrx Inc | Novel modulators and methods of use |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
WO2012032143A1 (en) | 2010-09-10 | 2012-03-15 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and metastasis |
CN105753933A (en) | 2010-09-20 | 2016-07-13 | Abbvie 公司 | Purification Of Antibodies By Using Simulated Moving Bed Chromatography |
AR083006A1 (en) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME |
EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
US9005907B2 (en) | 2010-10-01 | 2015-04-14 | St. Jude Children's Research Hospital | Methods and compositions for typing molecular subgroups of medulloblastoma |
CA2813738A1 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
WO2012052391A1 (en) | 2010-10-19 | 2012-04-26 | Glaxo Group Limited | Polypeptide with jmjd3 catalytic activity |
CN105399831A (en) | 2010-10-29 | 2016-03-16 | 伊缪诺金公司 | Non-antagonistic egfr-binding molecules and immunoconjugates thereof |
CA2815277A1 (en) | 2010-10-29 | 2012-05-03 | Immunogen, Inc. | Novel egfr-binding molecules and immunoconjugates thereof |
PE20140238A1 (en) | 2010-11-10 | 2014-03-07 | Genentech Inc | METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY FOR NEURAL DISEASE |
US20140093506A1 (en) | 2010-11-15 | 2014-04-03 | Marc Buehler | Anti-fungal-agents |
WO2012099566A1 (en) | 2010-11-17 | 2012-07-26 | Sea Lane Biotechnologies, Llc | Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody |
US9072766B2 (en) | 2010-11-18 | 2015-07-07 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT) |
WO2012071436A1 (en) | 2010-11-24 | 2012-05-31 | Genentech, Inc. | Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
CN103619879A (en) | 2010-12-01 | 2014-03-05 | 奥尔德生物控股有限责任公司 | Anti-ngf compositions and use thereof |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
AU2011360938B2 (en) | 2010-12-08 | 2016-07-28 | Abbvie Stemcentrx Llc | Novel modulators and methods of use |
TWI732259B (en) | 2010-12-16 | 2021-07-01 | 美商建南德克公司 | Diagnosis and treatments relating to th2 inhibition |
US9029502B2 (en) | 2010-12-20 | 2015-05-12 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
UA115641C2 (en) | 2010-12-20 | 2017-11-27 | Дженентек, Інк. | DETERMINED ANTIBODY Binds Mesothelin and Immunoconjugate Containing It |
US20120275996A1 (en) | 2010-12-21 | 2012-11-01 | Abbott Laboratories | IL-1 Binding Proteins |
TW201249865A (en) | 2010-12-21 | 2012-12-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
JP6147670B2 (en) | 2010-12-22 | 2017-06-14 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Modified antibodies with improved half-life |
US9394537B2 (en) | 2010-12-22 | 2016-07-19 | President And Fellows Of Harvard College | Continuous directed evolution |
CN103261230A (en) | 2010-12-22 | 2013-08-21 | 霍夫曼-拉罗奇有限公司 | Anti-PCSK9 antibodies and methods of use |
JP2014504503A (en) | 2010-12-28 | 2014-02-24 | ゾーマ テクノロジー リミテッド | Cell surface display using PDZ domains |
EP2658869B1 (en) | 2010-12-30 | 2019-06-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigen binding formats for use in therapeutic treatments or diagnostic assays |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
BR112013014644A2 (en) | 2011-01-03 | 2017-03-07 | F Hoffmann - La Roche Ag | pharmaceutical composition and complex |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
CA2823812C (en) | 2011-01-14 | 2017-02-14 | Ucb Pharma S.A. | Antibody molecules which bind il-17a and il-17f |
JP6478214B2 (en) | 2011-01-24 | 2019-03-06 | アッヴィ バイオテクノロジー リミテッド | Automatic syringe with overmold gripping surface |
US20120189633A1 (en) | 2011-01-26 | 2012-07-26 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
CA2826453A1 (en) | 2011-02-03 | 2012-08-09 | Alexion Pharmaceuticals, Inc. | Use of an anti-cd200 antibody for prolonging the survival of allografts |
US9956236B2 (en) | 2011-02-07 | 2018-05-01 | Cornell University | Methods for increasing immune responses using agents that directly bind to and activate IRE-1 |
SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
EP2680925B1 (en) | 2011-03-02 | 2019-11-20 | Berg LLC | Interrogatory cell-based assays and uses thereof |
WO2012122219A2 (en) | 2011-03-07 | 2012-09-13 | University Of Louisville Research Foundation | Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker |
US20120238730A1 (en) | 2011-03-15 | 2012-09-20 | Abbott Laboratories | Integrated approach to the isolation and purification of antibodies |
CA2831136A1 (en) | 2011-03-21 | 2012-09-27 | Biodesy, Llc | Classification of kinase inhibitors using nonlinear optical techniques |
TW201239355A (en) | 2011-03-23 | 2012-10-01 | Abbott Lab | Methods and systems for the analysis of protein samples |
BR112013024574B1 (en) | 2011-03-29 | 2022-08-09 | Roche Glycart Ag | ANTIBODY AND ANTIBODY USE |
MX361242B (en) | 2011-03-30 | 2018-11-30 | Ablynx Nv | Methods of treating immune disorders with single domain antibodies against tnf-alpha. |
WO2012134813A1 (en) | 2011-03-31 | 2012-10-04 | St. Jude Children's Research Hospital | Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia |
EP2694551A1 (en) | 2011-04-07 | 2014-02-12 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
EP2694975A1 (en) | 2011-04-08 | 2014-02-12 | Biogen Idec MA Inc. | Biomarkers predictive of therapeutic responsiveness to ifnbeta and uses thereof |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
WO2012142526A1 (en) | 2011-04-14 | 2012-10-18 | Modiano Jaime | Use of tumor fas expression to determine response to anti-cancer therapy |
EP2699264B1 (en) | 2011-04-20 | 2018-03-14 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
CA2833404A1 (en) | 2011-04-21 | 2012-10-26 | Garvan Institute Of Medical Research | Modified variable domain molecules and methods for producing and using them b |
WO2012155019A1 (en) | 2011-05-12 | 2012-11-15 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
EP2707389B1 (en) | 2011-05-12 | 2019-10-30 | The Johns Hopkins University | Assay reagents for a neurogranin diagnostic kit |
JP5836481B2 (en) | 2011-05-16 | 2015-12-24 | ジェネンテック, インコーポレイテッド | FGFR1 agonist and method of use |
EP2714079B2 (en) | 2011-05-21 | 2019-08-28 | MacroGenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
EP2714084B1 (en) | 2011-06-02 | 2019-05-22 | Dyax Corp. | Fc RECEPTOR BINDING PROTEINS |
ES2894398T3 (en) | 2011-06-03 | 2022-02-14 | Xoma Technology Ltd | Specific antibodies to TGF-beta |
US9181553B2 (en) | 2011-06-06 | 2015-11-10 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Method of treatment of breast cancers over-expressing the SHP2 signature genes |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
WO2012170765A2 (en) | 2011-06-10 | 2012-12-13 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
AU2012267732A1 (en) | 2011-06-10 | 2014-01-09 | Medimmune Limited | Anti-Pseudomonas Psl binding molecules and uses thereof |
AU2012269075B2 (en) | 2011-06-15 | 2015-05-21 | F. Hoffmann-La Roche Ag | Anti-human EPO receptor antibodies and methods of use |
EP2726094B1 (en) | 2011-06-28 | 2016-12-14 | Oxford BioTherapeutics Ltd | Therapeutic and diagnostic target |
KR102058185B1 (en) | 2011-06-28 | 2019-12-20 | 옥스포드 바이오테라퓨틱스 리미티드 | Antibodies to adp-ribosyl cyclase 2 |
BR112013030472A2 (en) | 2011-06-30 | 2019-09-24 | Genentech Inc | pharmaceutical formulation, article of manufacture and method |
EP3574919A1 (en) | 2011-07-13 | 2019-12-04 | AbbVie Inc. | Methods and compositions for treating asthma using anti-il-13 antibodies |
BR112014000392A2 (en) | 2011-07-14 | 2017-02-21 | Pfizer | anti-pcsk9 antibody treatment |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
BR112014000765A2 (en) | 2011-07-15 | 2017-06-13 | Oncomed Pharm Inc | rspo binding agents and their uses |
US20130022551A1 (en) | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
CN103842030B (en) | 2011-08-01 | 2018-07-31 | 霍夫曼-拉罗奇有限公司 | Use the method for PD-1 axis binding antagonists and mek inhibitor treating cancer |
AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
US20140363438A1 (en) | 2011-08-17 | 2014-12-11 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
EP2748192B2 (en) | 2011-08-23 | 2022-04-20 | Foundation Medicine, Inc. | Kif5b-ret fusion molecules and uses thereof |
KR101681818B1 (en) | 2011-08-23 | 2016-12-01 | 로슈 글리카트 아게 | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
JP2014534806A (en) | 2011-08-23 | 2014-12-25 | ロシュ グリクアート アーゲー | Anti-MCSP antibody |
EP2748200B1 (en) | 2011-08-23 | 2018-04-11 | Roche Glycart AG | Fc-free antibodies comprising two fab fragments and methods of use |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
US20140234903A1 (en) | 2011-09-05 | 2014-08-21 | Eth Zurich | Biosynthetic gene cluster for the production of peptide/protein analogues |
WO2013034660A1 (en) | 2011-09-09 | 2013-03-14 | Medimmune Limited | Anti-siglec-15 antibodies and uses thereof |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
WO2013039996A1 (en) | 2011-09-13 | 2013-03-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using fndc5 |
JP2014533927A (en) | 2011-09-15 | 2014-12-18 | ジェネンテック, インコーポレイテッド | How to promote differentiation |
MX2014002990A (en) | 2011-09-19 | 2014-05-21 | Genentech Inc | Combination treatments comprising c-met antagonists and b-raf antagonists. |
DK2758073T3 (en) | 2011-09-23 | 2019-01-14 | Oncomed Pharm Inc | VEGF / DLL4 BINDING AGENTS AND APPLICATIONS THEREOF |
CA2849011A1 (en) | 2011-10-05 | 2013-04-11 | Genentech, Inc. | Methods of treating liver conditions using notch2 antagonists |
JP2014531605A (en) | 2011-10-06 | 2014-11-27 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | Myosin binding protein-C for use in methods associated with diastolic heart failure |
WO2013054200A2 (en) | 2011-10-10 | 2013-04-18 | The Hospital For Sick Children | Methods and compositions for screening and treating developmental disorders |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
KR102102862B1 (en) | 2011-10-14 | 2020-04-22 | 제넨테크, 인크. | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE |
MX2014004027A (en) | 2011-10-14 | 2014-04-30 | Genentech Inc | Zymogen activators. |
CN106977587A (en) | 2011-10-14 | 2017-07-25 | 霍夫曼-拉罗奇有限公司 | BACE1 inhibitor peptides |
US9358250B2 (en) | 2011-10-15 | 2016-06-07 | Genentech, Inc. | Methods of using SCD1 antagonists |
WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
RS20140203A1 (en) | 2011-10-24 | 2014-10-31 | Abbvie Inc. | Immunodinbers directed against tnf |
TW201323440A (en) | 2011-10-24 | 2013-06-16 | Abbvie Inc | Immunobinders directed against sclerostin |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
PE20142312A1 (en) | 2011-10-28 | 2015-01-25 | Genentech Inc | THERAPEUTIC COMBINATIONS AND METHODS TO TREAT MELANOMA |
WO2013067054A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Antibodies and methods of treating cancer |
WO2013067057A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
AU2012332593B2 (en) | 2011-11-01 | 2016-11-17 | Bionomics, Inc. | Anti-GPR49 antibodies |
AU2012332588B2 (en) | 2011-11-01 | 2017-09-07 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
AU2012332777C1 (en) | 2011-11-02 | 2015-12-24 | University Of Rochester | Anti-glucosaminidase passive immunization for Staphylococcus aureus infections |
JP6301258B2 (en) | 2011-11-03 | 2018-03-28 | トライパス イメージング インコーポレイテッド | Methods and compositions for preparing immunostained samples |
EP2773779B1 (en) | 2011-11-04 | 2020-10-14 | Population Bio, Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
KR102184343B1 (en) | 2011-11-07 | 2020-11-30 | 메디뮨 엘엘씨 | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
EP2776838A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
WO2013068431A1 (en) | 2011-11-08 | 2013-05-16 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
CN104271599A (en) | 2011-11-08 | 2015-01-07 | 辉瑞公司 | Methods of treating inflammatory disorders using anti-M-CSF antibodies |
WO2013071233A1 (en) | 2011-11-10 | 2013-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for detecting infectious agents and a novel virus detected thereby |
US9803004B2 (en) | 2011-11-11 | 2017-10-31 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
AU2012335205A1 (en) | 2011-11-11 | 2014-05-29 | Rinat Neuroscience Corp. | Antibodies specific for Trop-2 and their uses |
BR112014012005A2 (en) | 2011-11-21 | 2017-12-19 | Genentech Inc | compositions, methods, pharmaceutical formulation and article |
WO2013078271A1 (en) | 2011-11-21 | 2013-05-30 | Immunogen, Inc. | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
WO2013078191A1 (en) | 2011-11-23 | 2013-05-30 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
KR20140125351A (en) | 2011-11-23 | 2014-10-28 | 이제니카 바이오테라퓨틱스, 인크. | Anti-cd98 antibodies and methods of use thereof |
EP2786156A2 (en) | 2011-11-30 | 2014-10-08 | AbbVie Deutschland GmbH & Co KG | Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor |
WO2013083497A1 (en) | 2011-12-06 | 2013-06-13 | F. Hoffmann-La Roche Ag | Antibody formulation |
MX356933B (en) | 2011-12-14 | 2018-06-20 | Abbvie Deutschland | Composition and method for the diagnosis and treatment of iron-related disorders. |
CA2855840C (en) | 2011-12-14 | 2023-08-29 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
EP2794657B1 (en) | 2011-12-19 | 2017-10-11 | Xoma (Us) Llc | Methods for treating acne |
KR102229491B1 (en) | 2011-12-22 | 2021-03-18 | 에프. 호프만-라 로슈 아게 | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
SG10201805622QA (en) | 2011-12-22 | 2018-08-30 | Hoffmann La Roche | Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides |
SG11201403445YA (en) | 2011-12-22 | 2014-07-30 | Hoffmann La Roche | Full length antibody display system for eukaryotic cells and its use |
CA3111357A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
WO2013096791A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Process for making high concentration protein formulations |
WO2013102042A2 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
EP2800583A1 (en) | 2012-01-02 | 2014-11-12 | Novartis AG | Cdcp1 and breast cancer |
CA2862979A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
CA2863224A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
EP2802606B1 (en) | 2012-01-10 | 2018-04-25 | Biogen MA Inc. | Enhancement of transport of therapeutic molecules across the blood brain barrier |
EP2804630B1 (en) | 2012-01-18 | 2017-10-18 | F. Hoffmann-La Roche AG | Methods of using fgf19 modulators |
EP2804629A1 (en) | 2012-01-18 | 2014-11-26 | Genentech, Inc. | Anti-lrp5 antibodies and methods of use |
GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
AU2013211939C1 (en) | 2012-01-27 | 2018-06-07 | AbbVie Deutschland GmbH & Co. KG | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
EP2812452B1 (en) | 2012-02-09 | 2020-05-27 | Population Bio, Inc. | Methods and compositions for screening and treating developmental disorders |
ES2725569T3 (en) | 2012-02-10 | 2019-09-24 | Seattle Genetics Inc | Diagnosis and treatment of cancers that express CD30 |
US20130209473A1 (en) | 2012-02-11 | 2013-08-15 | Genentech, Inc. | R-spondin translocations and methods using the same |
EP2814842B1 (en) | 2012-02-15 | 2018-08-22 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
RU2624128C2 (en) | 2012-02-15 | 2017-06-30 | Ф. Хоффманн-Ля Рош Аг | AFFINITY CHROMATOGRAPHY WITH APPLICATION OF Fc-RECEPTORS |
NO2814844T3 (en) | 2012-02-15 | 2017-12-30 | ||
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
SI2817338T1 (en) | 2012-02-24 | 2017-11-30 | Abbvie Stemcentrx Llc | Dll3 modulators and methods of use |
PL2825558T3 (en) | 2012-03-13 | 2019-11-29 | Hoffmann La Roche | Combination therapy for the treatment of ovarian cancer |
EP2825549B1 (en) | 2012-03-16 | 2018-10-10 | F. Hoffmann-La Roche SA | Engineered conformationally-stabilized proteins |
CA2860994A1 (en) | 2012-03-16 | 2013-09-19 | Klaus P. Hoeflich | Methods of treating melanoma with pak1 inhibitors |
US9139863B2 (en) | 2012-03-16 | 2015-09-22 | Genentech, Inc. | Engineered conformationally-stabilized proteins |
ES2661516T3 (en) | 2012-03-20 | 2018-04-02 | Otago Innovation Limited | Biomarkers |
WO2013139956A1 (en) | 2012-03-22 | 2013-09-26 | Thrombogenics Nv | Antibodies abrogating cell binding to lactadherin |
CA2866185C (en) | 2012-03-23 | 2021-04-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pathogenic phlebovirus isolates and compositions and methods of use |
AU2013240261A1 (en) | 2012-03-27 | 2014-09-18 | Genentech, Inc. | Diagnosis and treatments relating to HER3 inhibitors |
CA2868161A1 (en) | 2012-03-28 | 2013-10-03 | Genentech,Inc. | Anti-hcmv idiotypic antibodies and uses thereof |
US20150266961A1 (en) | 2012-03-29 | 2015-09-24 | Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute | Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer |
AR090549A1 (en) | 2012-03-30 | 2014-11-19 | Genentech Inc | ANTI-LGR5 AND IMMUNOCATE PLAYERS |
CN108048521B (en) | 2012-04-02 | 2022-05-27 | 博格有限责任公司 | Interrogative cell-based assays and uses thereof |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
WO2013158275A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
EP2838917B1 (en) | 2012-04-20 | 2019-06-05 | Merus N.V. | Methods and means for the production of heterodimeric ig-like molecules |
KR20150005631A (en) | 2012-04-24 | 2015-01-14 | 쓰롬보제닉스 엔.브이. | Anti-pdgf-c antibodies |
CN104583776B (en) | 2012-04-25 | 2016-09-07 | 比奥德赛公司 | For the method detecting the allosteric modulators of protein |
AR090903A1 (en) | 2012-05-01 | 2014-12-17 | Genentech Inc | ANTI-PMEL ANTIBODIES AND IMMUNOCADES17 |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
AU2013262934B2 (en) | 2012-05-14 | 2018-02-01 | Biogen Ma Inc. | LINGO-2 antagonists for treatment of conditions involving motor neurons |
EP2849786B1 (en) | 2012-05-15 | 2019-11-06 | Eisai Inc. | Methods for treatment of gastric cancer |
US20140010820A1 (en) | 2012-05-21 | 2014-01-09 | Abbvie, Inc. | Novel purification of non-human antibodies using protein a affinity chromatography |
CA2870876C (en) | 2012-05-23 | 2019-10-01 | Genentech, Inc. | Selection method for therapeutic agents |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
ES2742379T3 (en) | 2012-05-31 | 2020-02-14 | Hoffmann La Roche | Cancer treatment procedures using PD-1 axis binding antagonists and VEGF antagonists |
EP2858673A4 (en) | 2012-06-06 | 2016-06-22 | Oncomed Pharm Inc | Binding agents that modulate the hippo pathway and uses thereof |
US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
BR112014031310A2 (en) | 2012-06-15 | 2017-07-25 | Genentech Inc | anti-pcsk9 antibodies, formulations, dosage and methods of use |
ES2631608T3 (en) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Env-glycoprotein variant of HIV-1 |
US10048253B2 (en) | 2012-06-28 | 2018-08-14 | Ucb Biopharma Sprl | Method for identifying compounds of therapeutic interest |
US20150218238A1 (en) | 2012-06-29 | 2015-08-06 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | Treating diseases by modulating a specific isoform of mkl1 |
WO2014006124A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
JP6324376B2 (en) | 2012-07-04 | 2018-05-16 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Anti-theophylline antibodies and methods of use |
WO2014006123A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-biotin antibodies and methods of use |
BR112015000125A2 (en) | 2012-07-05 | 2018-09-04 | Genentech Inc | molecules, vector, cells, process, protein, method for expressing an mbip polypeptide, polypeptides, antibody or antibody fragment and nucleotide sequence |
EP2870242A1 (en) | 2012-07-05 | 2015-05-13 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
US20150224190A1 (en) | 2012-07-06 | 2015-08-13 | Mohamed Bentires-Alj | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction |
CN104540524A (en) | 2012-07-09 | 2015-04-22 | 基因泰克公司 | Immunoconjugates comprising anti-CD22 antibodies |
MX2015000314A (en) | 2012-07-09 | 2015-04-10 | Genentech Inc | Immunoconjugates comprising anti - cd79b antibodies. |
EA201590171A1 (en) | 2012-07-09 | 2015-09-30 | Дженентек, Инк. | IMMUNOCONGATES CONTAINING ANTIBODIES TO CD79b |
US20140030281A1 (en) | 2012-07-09 | 2014-01-30 | Genentech, Inc. | Anti-cd22 antibodies and immunoconjugates |
UY34905A (en) | 2012-07-12 | 2014-01-31 | Abbvie Inc | IL-1 UNION PROTEINS |
CA2874554C (en) | 2012-07-13 | 2019-12-03 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
GB201213652D0 (en) | 2012-08-01 | 2012-09-12 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
US9297806B2 (en) | 2012-08-01 | 2016-03-29 | The Johns Hopkins University | 5-hydroxymethylcytosine in human cancer |
EP2879710B1 (en) | 2012-08-03 | 2019-11-13 | Dana-Farber Cancer Institute, Inc. | Medical uses of agents that modulate immune cell activation and corresponding screening methods |
KR20190088571A (en) | 2012-08-07 | 2019-07-26 | 제넨테크, 인크. | Combination therapy for the treatment of glioblastoma |
JP6302909B2 (en) | 2012-08-18 | 2018-03-28 | アカデミア シニカAcademia Sinica | Cell-permeable probes for sialidase identification and imaging |
LT2890717T (en) | 2012-08-31 | 2020-06-10 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
WO2014039860A2 (en) | 2012-09-07 | 2014-03-13 | University Of Louisville Research Foundation, Inc. | Compositions and methods for modulating dnmt1 inhibitor activity |
EP2895621B1 (en) | 2012-09-14 | 2020-10-21 | Population Bio, Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
CA2922005A1 (en) | 2012-09-27 | 2014-04-03 | Population Diagnostics, Inc. | Methods and compositions for screening and treating developmental disorders |
US9365641B2 (en) | 2012-10-01 | 2016-06-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
EP2904016B1 (en) | 2012-10-08 | 2018-11-14 | Roche Glycart AG | Fc-free antibodies comprising two fab-fragments and methods of use |
AU2013329311A1 (en) | 2012-10-09 | 2015-04-30 | Igenica Biotherapeutics, Inc. | Anti-C16orf54 antibodies and methods of use thereof |
AU2013329421A1 (en) | 2012-10-09 | 2015-04-30 | Biogen Ma Inc. | Combination therapies and uses for treatment of demyelinating disorders |
CA2887528C (en) | 2012-10-12 | 2023-08-29 | The Brigham And Women's Hospital, Inc. | Enhancement of the immune response |
AU2013334790A1 (en) | 2012-10-23 | 2015-04-30 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using Wnt pathway-binding agents |
US9599620B2 (en) | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
TW201811825A (en) | 2012-11-01 | 2018-04-01 | 美商艾伯維有限公司 | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
MA38144A1 (en) | 2012-11-05 | 2018-08-31 | Genzyme Corp | Compositions and methods for the treatment of proteinopathies |
BR112015010360A8 (en) | 2012-11-08 | 2018-01-16 | Eleven Biotherapeutics Inc | il-6 antagonists and their use. |
WO2014074942A1 (en) | 2012-11-08 | 2014-05-15 | Illumina, Inc. | Risk variants of alzheimer's disease |
CA2884431A1 (en) | 2012-11-08 | 2014-05-15 | F. Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
KR20150083124A (en) | 2012-11-13 | 2015-07-16 | 제넨테크, 인크. | Anti-hemagglutinin antibodies and methods of use |
US10407503B2 (en) | 2012-11-30 | 2019-09-10 | The Regents Of The University Of California | Fully human antibodies and fragments recognizing human c-Met |
BR122020023058B1 (en) | 2012-12-10 | 2023-12-05 | Biogen Ma Inc | ISOLATED NUCLEIC ACID OR NUCLEIC ACIDS |
ES2714951T3 (en) | 2012-12-21 | 2019-05-30 | Bioalliance Cv | Hydrophilic and conjugated autoimmolating linkers thereof |
GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
JP6359031B2 (en) | 2012-12-21 | 2018-07-18 | メディミューン,エルエルシー | Anti-H7CR antibody |
US9550986B2 (en) | 2012-12-21 | 2017-01-24 | Abbvie Inc. | High-throughput antibody humanization |
AU2013202668B2 (en) | 2012-12-24 | 2014-12-18 | Adelaide Research & Innovation Pty Ltd | Inhibition of cancer growth and metastasis |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
EP2945652B1 (en) | 2013-01-18 | 2021-07-07 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
AU2014215639B2 (en) | 2013-01-25 | 2017-03-23 | Thymon, Llc | Compositions for selective reduction of circulating bioactive soluble TNF and methods for treating TNF-mediated disease |
AU2014212081A1 (en) | 2013-02-04 | 2015-08-13 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
WO2014129895A1 (en) | 2013-02-19 | 2014-08-28 | Stichting Vu-Vumc | Means and method for increasing the sensitivity of cancers for radiotherapy |
JP2016509045A (en) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | How to treat cancer and prevent drug resistance |
RU2019109456A (en) | 2013-02-22 | 2019-04-10 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | NEW ANTIBODY CONJUGATES AND THEIR APPLICATIONS |
WO2014130923A2 (en) | 2013-02-25 | 2014-08-28 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
RU2015140921A (en) | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | ANTIBODIES TO MCSP |
RU2015137610A (en) | 2013-03-06 | 2017-04-10 | Дженентек, Инк. | METHODS FOR TREATMENT AND PREVENTION OF DRUG RESISTANCE OF MALIGNANT TUMORS |
TW201513880A (en) * | 2013-03-11 | 2015-04-16 | Novo Nordisk As | Growth hormone compounds |
CN105229035A (en) * | 2013-03-11 | 2016-01-06 | 诺和诺德保健股份有限公司 | Growth hormone compound |
US10653779B2 (en) | 2013-03-13 | 2020-05-19 | Genentech, Inc. | Formulations with reduced oxidation |
CN105209069B (en) | 2013-03-13 | 2019-08-23 | 豪夫迈·罗氏有限公司 | Antibody formulations |
KR102237885B1 (en) | 2013-03-13 | 2021-04-07 | 제넨테크, 인크. | Formulations with reduced oxidation |
RU2707550C2 (en) | 2013-03-13 | 2019-11-27 | Дженентек, Инк. | Compositions with reduced oxidation |
US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
US20140271634A1 (en) | 2013-03-14 | 2014-09-18 | The Regents Of The University Of California | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
CN105378099B (en) | 2013-03-14 | 2021-05-11 | 雅培制药有限公司 | HCV core lipid binding domain monoclonal antibodies |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
BR112015023239A8 (en) | 2013-03-14 | 2018-04-17 | Abbott Lab | hcv antibody-antigen combination assay and methods and compositions for use thereof |
SG11201507563SA (en) | 2013-03-14 | 2015-10-29 | Parkash Gill | Cancer treatment using antibodies that bind cell surface grp78 |
CN105209616A (en) | 2013-03-14 | 2015-12-30 | 雅培制药有限公司 | HCV NS3 recombinant antigens and mutants thereof for improved antibody detection |
MX2015011606A (en) | 2013-03-14 | 2016-05-17 | Genentech Inc | Methods of treating cancer and preventing cancer drug resistance. |
EP2970375A1 (en) | 2013-03-14 | 2016-01-20 | AbbVie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
BR112015022019A2 (en) | 2013-03-14 | 2017-08-29 | Genentech Inc | ISOLATED ANTIBODIES, NUCLEIC ACID, HOST CELL, METHOD OF PRODUCING ANTIBODIES, IMMUNOCONJUGATE, PHARMACEUTICAL FORMULATION, METHODS FOR TREATMENT OF INDIVIDUALS, INHIBITION OF CELL PROLIFERATION, DETECTION OF HUMAN B7-H4 AND CANCER DETECTION |
WO2014158231A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same |
WO2014142882A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Protein purification using displacement chromatography |
US10160797B2 (en) | 2013-03-15 | 2018-12-25 | Sanofi Pasteur Biologics, Llc | Antibodies against Clostridium difficile toxins and methods of using the same |
CA2903596C (en) | 2013-03-15 | 2023-10-03 | Genentech, Inc. | Cell culture compositions with antioxidants and methods for polypeptide production |
EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
EP2970475A1 (en) | 2013-03-15 | 2016-01-20 | Biogen MA Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
SG10201913874TA (en) | 2013-03-15 | 2020-03-30 | Biogen Ma Inc | Factor ix polypeptide formulations |
BR112015023797A2 (en) | 2013-03-15 | 2017-10-24 | Abbvie Inc | dual specificity binding proteins directed against il-1b and / or il-17 |
WO2014150877A2 (en) | 2013-03-15 | 2014-09-25 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
KR20150131177A (en) | 2013-03-15 | 2015-11-24 | 제넨테크, 인크. | Anti-crth2 antibodies and their use |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
CN105339001A (en) | 2013-03-15 | 2016-02-17 | 基因泰克公司 | Methods of treating cancer and preventing cancer drug resistance |
SG11201507432XA (en) | 2013-03-15 | 2015-10-29 | Abbvie Inc | Antibody drug conjugate (adc) purification |
CN110079599A (en) | 2013-03-15 | 2019-08-02 | 豪夫迈·罗氏有限公司 | The biomarker and method for treating PD-1 and PD-L1 related disorders |
CN105246510A (en) | 2013-03-15 | 2016-01-13 | 豪夫迈·罗氏有限公司 | Cell culture media and methods of antibody production |
PE20211272A1 (en) | 2013-03-15 | 2021-07-19 | Genentech Inc | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE |
EP2970476A1 (en) | 2013-03-15 | 2016-01-20 | F. Hoffmann-La Roche AG | Compositions and methods for diagnosis and treatment of hepatic cancers |
SG11201507430RA (en) | 2013-03-15 | 2015-10-29 | Abbvie Deutschland | Anti-egfr antibody drug conjugate formulations |
EP2981282B1 (en) | 2013-04-05 | 2020-11-04 | Novo Nordisk Health Care AG | Growth hormone compound formulation |
US9499621B2 (en) | 2013-04-08 | 2016-11-22 | Cytodyn, Inc. | Felinized antibodies and methods of treating retroviral infections in felines |
SG11201508910WA (en) | 2013-04-29 | 2015-11-27 | Hoffmann La Roche | Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases |
RU2019108429A (en) | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | MODIFIED ASYMMETRIC ANTIBODIES CONNECTING FC-RECEPTOR AND METHODS OF THEIR APPLICATION |
EA201501063A1 (en) | 2013-04-29 | 2016-05-31 | Ф. Хоффманн-Ля Рош Аг | CONNECTING HUMAN FcRn MODIFIED ANTIBODIES AND METHODS OF THEIR APPLICATION |
CA2910553A1 (en) | 2013-04-30 | 2014-11-06 | Universite De Montreal | Novel biomarkers for acute myeloid leukemia |
IL301607A (en) | 2013-05-06 | 2023-05-01 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
CA2908743A1 (en) | 2013-05-20 | 2014-11-27 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
CN106414489A (en) | 2013-05-24 | 2017-02-15 | 米迪缪尼有限公司 | Anti-b7-h5 antibodies and their uses |
SG10201708143QA (en) | 2013-06-06 | 2017-11-29 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
CA2913490A1 (en) | 2013-06-06 | 2014-12-11 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of cancer using pd-l1 isoforms |
WO2014197885A2 (en) | 2013-06-07 | 2014-12-11 | Duke University | Inhibitors of complement factor h |
US20160151486A1 (en) | 2013-06-13 | 2016-06-02 | Fast Foward Pharmaceuticals B.V. | CD40 Signalling Inhibitor and a Further Compound, Wherein the Further Compound is a Bile Acid, a Bile Acid Derivative, an TGR5-Receptor Agonist, an FXR Agonist or a Combination Thereof, for the Treatment of Chronic Inflammation, and the Prevention of Gastrointestinal Cancer or Fibrosis |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
WO2014210564A1 (en) | 2013-06-27 | 2014-12-31 | Academia Sinica | Glycan conjugates and use thereof |
TWI685349B (en) | 2013-07-16 | 2020-02-21 | 建南德克公司 | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
JP6687520B2 (en) | 2013-07-18 | 2020-04-22 | トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー | Humanized antibody with extremely long complementarity determining regions |
WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
CA2919477A1 (en) | 2013-07-31 | 2015-02-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules |
RU2675516C2 (en) | 2013-08-02 | 2018-12-19 | Пфайзер Инк. | Anti-cxcr4 antibodies and antibody-drug conjugates |
US20160178610A1 (en) | 2013-08-07 | 2016-06-23 | Friedrich Miescher Institute For Biomedical Research | New screening method for the treatment Friedreich's ataxia |
PL3036320T3 (en) | 2013-08-19 | 2021-11-02 | Biogen Ma Inc. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
PL3041507T3 (en) | 2013-08-26 | 2021-11-15 | Biontech Research And Development, Inc. | Nucleic acids encoding human antibodies to sialyl-lewis a |
PE20160674A1 (en) | 2013-08-28 | 2016-07-21 | Stemcentrx Inc | METHODS OF CONJUGATION OF SITE-SPECIFIC ANTIBODIES AND COMPOSITIONS |
MX2016002574A (en) | 2013-08-28 | 2016-06-14 | Stemcentrx Inc | Novel sez6 modulators and methods of use. |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
KR20230145514A (en) | 2013-08-30 | 2023-10-17 | 이뮤노젠 아이엔씨 | Antibodies and assays for detection of folate receptor 1 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
WO2015035337A1 (en) | 2013-09-06 | 2015-03-12 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS |
JP2016537399A (en) | 2013-09-17 | 2016-12-01 | ジェネンテック, インコーポレイテッド | Method using anti-LGR5 antibody |
WO2015048330A2 (en) | 2013-09-25 | 2015-04-02 | Biogen Idec Ma Inc. | On-column viral inactivation methods |
DK3049521T3 (en) | 2013-09-25 | 2019-04-23 | Univ Cornell | Compounds for inducing antitumor immunity and methods thereof |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
US10414818B2 (en) | 2013-09-27 | 2019-09-17 | Roche Diagnostics Operations, Inc. | Thermus thermophilus SlyD FKBP domain specific antibodies |
PT3049441T (en) | 2013-09-27 | 2020-01-21 | Hoffmann La Roche | Anti-pdl1 antibody formulations |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
AU2014331964C1 (en) | 2013-10-08 | 2019-10-31 | Immunogen, Inc. | Anti-FOLR1 immunoconjugate dosing regimens |
WO2015054670A1 (en) | 2013-10-11 | 2015-04-16 | Genentech, Inc. | Nsp4 inhibitors and methods of use |
WO2015057939A1 (en) | 2013-10-18 | 2015-04-23 | Biogen Idec Ma Inc. | Anti-s1p4 antibodies and uses thereof |
JP6677638B2 (en) | 2013-10-18 | 2020-04-08 | ジェネンテック, インコーポレイテッド | Anti-RSPO2 and / or RSPO3 antibodies and uses thereof |
AR098155A1 (en) | 2013-10-23 | 2016-05-04 | Genentech Inc | METHODS TO DIAGNOSTIC AND TREAT EOSYNOPHYL DISORDERS |
AU2014342528A1 (en) | 2013-10-28 | 2016-04-28 | Dots Technology Corp. | Allergen detection |
EP3777980B1 (en) | 2013-10-29 | 2023-12-06 | President and Fellows of Harvard College | Nuclear factor erythroid 2-like 2 (nrf2) for use in treatment of age-related macular degeneration |
US20160272674A1 (en) | 2013-11-07 | 2016-09-22 | Abbvie Inc. | Isolation and purification of antibodies |
EP3511422B1 (en) | 2013-11-12 | 2022-12-28 | Population Bio, Inc. | Methods and compositions for diagnosing, prognosing, and treating endometriosis |
KR102283408B1 (en) | 2013-11-15 | 2021-07-29 | 앵스티띠 파스퇴르 | A molecular marker of plasmodium falciparum artemisinin resistance |
MY176237A (en) | 2013-11-21 | 2020-07-24 | Hoffmann La Roche | Anti-alpha-synuclein antibodies and methods of use |
MX2016006726A (en) | 2013-11-25 | 2016-12-16 | Ccam Biotherapeutics Ltd | Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy. |
WO2015085311A1 (en) | 2013-12-07 | 2015-06-11 | Case Western Reserve University | Compositions and methods of treating thrombosis |
BR112016013514B1 (en) | 2013-12-13 | 2022-04-19 | Stora Enso Oyj (Fi) | MULTI-LAYER CARDBOARD |
TW201533060A (en) | 2013-12-13 | 2015-09-01 | Genentech Inc | Anti-CD33 antibodies and immunoconjugates |
US20160333063A1 (en) | 2013-12-13 | 2016-11-17 | The General Hospital Corporation | Soluble high molecular weight (hmw) tau species and applications thereof |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
MX2016007887A (en) | 2013-12-17 | 2016-10-28 | Genentech Inc | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies. |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
AU2014364606A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
AU2014364593A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
ES2811923T3 (en) | 2013-12-17 | 2021-03-15 | Genentech Inc | Anti-CD3 antibodies and methods of use |
RU2714902C2 (en) | 2013-12-19 | 2020-02-20 | Новартис Аг | Chimeric human mesotheliogen antigen receptors and use thereof |
JP2017500017A (en) | 2013-12-20 | 2017-01-05 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
EP2960252A1 (en) | 2014-06-26 | 2015-12-30 | Institut Pasteur | Phospholipase for treatment of immunosuppression |
TWI670283B (en) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | Antibodies and methods of use |
EA201691323A1 (en) | 2013-12-24 | 2016-11-30 | Янссен Фармасьютика Нв | ANTI-VISTA ANTIBODIES AND FRAGMENTS |
BR112016013849A2 (en) | 2014-01-03 | 2017-10-10 | Hoffmann La Roche | bispecific antihapten / blood-brain barrier receptor conjugates, their uses, and pharmaceutical formulation |
RU2682754C2 (en) | 2014-01-03 | 2019-03-21 | Ф. Хоффманн-Ля Рош Аг | Covalent bonded polypeptide toxin and antibody conjugates |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
BR112016012666A2 (en) | 2014-01-03 | 2017-09-26 | Hoffmann La Roche | conjugate, antibodies, pharmaceutical formulation and uses of conjugate |
JP6557664B2 (en) | 2014-01-06 | 2019-08-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Monovalent blood-brain barrier shuttle module |
JP6786392B2 (en) | 2014-01-15 | 2020-11-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Fc region mutant with modified FcRn binding properties and retained protein A binding properties |
WO2015109180A2 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
WO2016114819A1 (en) | 2015-01-16 | 2016-07-21 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
EP3097196B1 (en) | 2014-01-20 | 2019-09-11 | President and Fellows of Harvard College | Negative selection and stringency modulation in continuous evolution systems |
CN106413756A (en) | 2014-01-24 | 2017-02-15 | 豪夫迈·罗氏有限公司 | Methods of using anti-steap1 antibodies and immunoconjugates |
MX2016009555A (en) | 2014-01-24 | 2016-12-08 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof. |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
US11648335B2 (en) | 2014-01-31 | 2023-05-16 | Wake Forest University Health Sciences | Organ/tissue decellularization, framework maintenance and recellularization |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
ES2694857T3 (en) | 2014-02-04 | 2018-12-27 | Genentech, Inc. | Smoothened mutant and methods of using it |
US10189908B2 (en) | 2014-02-05 | 2019-01-29 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants |
AU2015214058B2 (en) | 2014-02-08 | 2020-07-09 | Genentech, Inc. | Methods of treating Alzheimer's Disease |
WO2015120280A1 (en) | 2014-02-08 | 2015-08-13 | Genentech, Inc. | Methods of treating alzheimer's disease |
CA3212977A1 (en) | 2014-02-11 | 2015-08-20 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
DK3105253T3 (en) | 2014-02-12 | 2018-09-03 | Hoffmann La Roche | Anti-Jagged1 antibodies and methods of use |
CR20160437A (en) | 2014-02-21 | 2017-02-20 | Abbvie Stemcentrx Llc | CONJUGATES OF ANTI-DROSOPHILA ANTIBODIES SIMILAR TO DELTA 3 (ANTI-DLL3) AND MEDICINES FOR USE IN THE TREATMENT AGAINST MELANOMA |
CN106029693A (en) | 2014-02-21 | 2016-10-12 | 豪夫迈·罗氏有限公司 | Anti-IL-13/IL-17 bispecific antibodies and uses thereof |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US9738702B2 (en) | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
RS59853B1 (en) | 2014-03-14 | 2020-02-28 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
KR102561695B1 (en) | 2014-03-14 | 2023-07-28 | 제넨테크, 인크. | Methods and compositions for secretion of heterologous polypeptides |
US20170107294A1 (en) | 2014-03-21 | 2017-04-20 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
IL247853B (en) | 2014-03-21 | 2022-08-01 | Teva Pharmaceuticals Int Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
CA2943329A1 (en) | 2014-03-24 | 2015-10-01 | Genentech, Inc. | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
WO2015148515A1 (en) | 2014-03-24 | 2015-10-01 | Biogen Ma Inc. | Methods for overcoming glutamine deprivation during mammalian cell culture |
WO2015148915A1 (en) | 2014-03-27 | 2015-10-01 | Academia Sinica | Reactive labelling compounds and uses thereof |
SI3126394T1 (en) | 2014-03-31 | 2020-01-31 | F. Hoffmann-La Roche Ag | Anti-ox40 antibodies and methods of use |
MA39817A (en) | 2014-03-31 | 2017-02-08 | Hoffmann La Roche | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
CN113092788A (en) | 2014-04-02 | 2021-07-09 | 豪夫迈·罗氏有限公司 | Method for detecting light chain mismatch of multispecific antibody |
AU2015240599B2 (en) | 2014-04-04 | 2020-11-19 | Bionomics, Inc. | Humanized antibodies that bind LGR5 |
EP3689325A1 (en) | 2014-04-08 | 2020-08-05 | Boston Pharmaceuticals Inc. | Binding molecules specific for il-21 and uses thereof |
CN106232139A (en) | 2014-04-11 | 2016-12-14 | 免疫医疗有限责任公司 | Bispecific HER2 antibody |
MX2016013635A (en) | 2014-04-18 | 2017-02-02 | Acceleron Pharma Inc | Methods for increasing red blood cell levels and treating sickle-cell disease. |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
ES2825080T3 (en) | 2014-04-27 | 2021-05-14 | Famewave Ltd | Humanized antibodies against CEACAM1 |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
US9753036B2 (en) | 2014-04-29 | 2017-09-05 | Edp Biotech Corporation | Methods and compositions for screening and detecting biomarkers |
AU2015253422B2 (en) | 2014-04-30 | 2020-09-03 | Abbvie Stemcentrx Llc | Anti-PTK7 antibody-drug conjugates |
US9795121B2 (en) | 2014-05-05 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Humanized C3 animals |
IL248511B (en) | 2014-05-13 | 2022-07-01 | Bavarian Nordic As | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3 |
US20170267780A1 (en) | 2014-05-16 | 2017-09-21 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
EP3145952A2 (en) | 2014-05-22 | 2017-03-29 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
WO2015179835A2 (en) | 2014-05-23 | 2015-11-26 | Genentech, Inc. | Mit biomarkers and methods using the same |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
KR20170003720A (en) | 2014-05-27 | 2017-01-09 | 아카데미아 시니카 | Anti-cd20 glycoantibodies and uses thereof |
TWI717319B (en) | 2014-05-27 | 2021-02-01 | 中央研究院 | Fucosidase from bacteroides and methods using the same |
KR102512592B1 (en) | 2014-05-27 | 2023-03-21 | 아카데미아 시니카 | Anti-her2 glycoantibodies and uses thereof |
MA47849A (en) | 2014-05-28 | 2020-01-29 | Agenus Inc | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE |
US11332523B2 (en) | 2014-05-28 | 2022-05-17 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
RU2636780C1 (en) | 2014-06-03 | 2017-11-28 | ИксБиотеч, Инк. | Compositions and methods for treatment and prevention of infections caused by staphylococcus aureus |
CA3121083C (en) | 2014-06-04 | 2023-08-15 | Biontech Research And Development, Inc. | Human monoclonal antibodies to ganglioside gd2 |
MX2016016233A (en) | 2014-06-11 | 2017-03-31 | Genentech Inc | Anti-lgr5 antibodies and uses thereof. |
AP2017009674A0 (en) | 2014-06-13 | 2017-01-31 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
EP3154589A1 (en) | 2014-06-13 | 2017-04-19 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
WO2015189816A1 (en) | 2014-06-13 | 2015-12-17 | Friedrich Miescher Institute For Biomedical Research | New treatment against influenza virus |
MX2016016490A (en) | 2014-06-20 | 2017-07-28 | Bioalliance Cv | Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof. |
EP3157535A1 (en) | 2014-06-23 | 2017-04-26 | Friedrich Miescher Institute for Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
TW201623329A (en) | 2014-06-30 | 2016-07-01 | 亞佛瑞司股份有限公司 | Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof |
US20170165261A1 (en) | 2014-07-01 | 2017-06-15 | Brian Arthur Hemmings | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
RU2742493C2 (en) | 2014-07-10 | 2021-02-08 | Аффирис Аг | Substances and methods for use in the prevention and/or treatment of huntington's disease |
WO2016007775A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Notch pathway inhibition |
EP3169801A1 (en) | 2014-07-14 | 2017-05-24 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for treatment of glioblastoma |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
PL3169361T3 (en) | 2014-07-15 | 2019-11-29 | Hoffmann La Roche | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
TN2017000008A1 (en) | 2014-07-17 | 2018-07-04 | Novo Nordisk As | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity. |
SG11201700416TA (en) | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
EP3511413B1 (en) | 2014-07-25 | 2022-09-07 | Theravectys | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule |
WO2016020799A1 (en) | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
JP2017523980A (en) | 2014-08-06 | 2017-08-24 | ライナット ニューロサイエンス コーポレイション | Method for lowering LDL-cholesterol |
JP6919118B2 (en) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | Treatment of cancer with GFRα-4 chimeric antigen receptor |
ES2791248T3 (en) | 2014-08-19 | 2020-11-03 | Novartis Ag | Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment |
EP3188746A4 (en) | 2014-09-05 | 2018-05-02 | The Johns Hopkins University | Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies |
WO2016036403A1 (en) | 2014-09-05 | 2016-03-10 | Population Diagnostics Inc. | Methods and compositions for inhibiting and treating neurological conditions |
CA2960712A1 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | Human inkt cell activation using glycolipids |
AR101848A1 (en) | 2014-09-12 | 2017-01-18 | Genentech Inc | ANTI-B7-H4 AND IMMUNOCATE PLAYERS |
ES2830385T3 (en) | 2014-09-12 | 2021-06-03 | Genentech Inc | Anti-HER2 antibodies and immunoconjugates |
EP3191520B1 (en) | 2014-09-12 | 2020-01-01 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
JP6681905B2 (en) | 2014-09-13 | 2020-04-15 | ノバルティス アーゲー | ALK inhibitor combination therapy |
MX2017003121A (en) | 2014-09-15 | 2017-08-02 | Genentech Inc | Antibody formulations. |
EP3194444B1 (en) | 2014-09-16 | 2019-07-10 | Symphogen A/S | Anti-met antibodies and compositions |
KR20170055521A (en) | 2014-09-17 | 2017-05-19 | 제넨테크, 인크. | Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines |
WO2016044697A1 (en) | 2014-09-19 | 2016-03-24 | The Johns Hopkins University | Biomarkers of cognitive dysfunction |
US10472424B2 (en) | 2014-09-23 | 2019-11-12 | Pfizer Inc. | Treatment with anti-PCSK9 antibodies |
PT3262071T (en) | 2014-09-23 | 2020-06-16 | H Hoffnabb La Roche Ag | Method of using anti-cd79b immunoconjugates |
EP3197557A1 (en) | 2014-09-24 | 2017-08-02 | Friedrich Miescher Institute for Biomedical Research | Lats and breast cancer |
AU2015327064B2 (en) | 2014-09-30 | 2021-03-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Binding molecules, especially antibodies, binding to L1CAM (CD171) |
EP3201235A1 (en) | 2014-10-01 | 2017-08-09 | Medimmune Limited | Antibodies to ticagrelor and methods of use |
EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
TN2017000129A1 (en) | 2014-10-14 | 2018-10-19 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-l1 and uses thereof |
US9732148B2 (en) | 2014-10-16 | 2017-08-15 | Genentech, Inc. | Anti-α-synuclein antibodies and methods of use |
WO2016061460A1 (en) | 2014-10-17 | 2016-04-21 | Carnegie Mellon University | Enhanced biomolecule detection assays based on tyramide signal amplification and gammapna probes |
MA41685A (en) | 2014-10-17 | 2017-08-22 | Biogen Ma Inc | COPPER SUPPLEMENT FOR THE REGULATION OF GLYCOSYLATION IN A MAMMAL CELL CULTURE PROCESS |
US10920208B2 (en) | 2014-10-22 | 2021-02-16 | President And Fellows Of Harvard College | Evolution of proteases |
EP3209697A4 (en) | 2014-10-23 | 2018-05-30 | La Trobe University | Fn14-binding proteins and uses thereof |
CN114805531A (en) | 2014-10-24 | 2022-07-29 | 百时美施贵宝公司 | Modified FGF-21 polypeptides and uses thereof |
MA40864A (en) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES |
EP3212233B1 (en) | 2014-10-31 | 2020-06-24 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
WO2016070001A1 (en) | 2014-10-31 | 2016-05-06 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind b7-h4 |
MX2017005750A (en) | 2014-11-03 | 2017-12-15 | Genentech Inc | Assays for detecting t cell immune subsets and methods of use thereof. |
CN107109484B (en) | 2014-11-03 | 2021-12-14 | 豪夫迈·罗氏有限公司 | Methods and biomarkers for efficacy prediction and assessment of OX40 agonist treatment |
JP6770966B2 (en) | 2014-11-05 | 2020-10-21 | ジェネンテック, インコーポレイテッド | Method of producing double-stranded protein in bacteria |
CA2966558C (en) | 2014-11-05 | 2024-03-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
JP6877350B2 (en) | 2014-11-05 | 2021-05-26 | ジェネンテック, インコーポレイテッド | Anti-FGFR2 / 3 antibody and how to use it |
SG10202008810QA (en) | 2014-11-05 | 2020-10-29 | Annexon Inc | Humanized anti-complement factor c1q antibodies and uses thereof |
MX2017005148A (en) | 2014-11-06 | 2017-08-08 | Hoffmann La Roche | Fc-region variants with modified fcrn-binding and methods of use. |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
CN107073126A (en) | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | Combination treatment comprising OX40 combinations activator and TIGIT inhibitor |
EP3842453A1 (en) | 2014-11-06 | 2021-06-30 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and protein a-binding properties |
PT3215530T (en) | 2014-11-07 | 2019-11-21 | Sesen Bio Inc | Improved il-6 antibodies |
WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
BR112017009728A2 (en) | 2014-11-10 | 2018-02-06 | Genentech, Inc. | isolated antibodies, isolated nucleic acid, vector, host cell, method for producing antibody, composition, uses of an antibody and methods of treating a disorder |
WO2016077369A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Animal model for nephropathy and agents for treating the same |
PT3218406T (en) | 2014-11-10 | 2021-06-17 | Medimmune Ltd | Binding molecules specific for cd73 and uses thereof |
GB2538120A (en) | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
HUE061672T2 (en) | 2014-11-12 | 2023-08-28 | Seagen Inc | Glycan-interacting compounds and methods of use |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
WO2016077789A1 (en) | 2014-11-14 | 2016-05-19 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
AU2015350242A1 (en) | 2014-11-17 | 2017-06-29 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
US10434177B2 (en) | 2014-11-17 | 2019-10-08 | Carnegie Mellon University | Activatable two-component photosensitizers |
CN107108745B (en) | 2014-11-19 | 2021-01-12 | 基因泰克公司 | Antibodies against BACE1 and their use for immunotherapy of neurological diseases |
US11008403B2 (en) | 2014-11-19 | 2021-05-18 | Genentech, Inc. | Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use |
CN107001473B (en) | 2014-11-19 | 2021-07-09 | 豪夫迈·罗氏有限公司 | Anti-transferrin receptor antibodies and methods of use |
CA2966566C (en) | 2014-11-20 | 2024-03-19 | F. Hoffmann-La Roche Ag | Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists |
EP3220900B1 (en) | 2014-11-21 | 2020-09-23 | University of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
MA41119A (en) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | METHODS OF TREATMENT OF MYELODYSPLASIC SYNDROMES AND SIDEROBLASTIC ANEMIA |
KR20170086549A (en) | 2014-12-05 | 2017-07-26 | 제넨테크, 인크. | ANTI-CD79b ANTIBODIES AND METHODS OF USE |
EP3227337A1 (en) | 2014-12-05 | 2017-10-11 | F. Hoffmann-La Roche AG | Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists |
CN107207591A (en) | 2014-12-10 | 2017-09-26 | 豪夫迈·罗氏有限公司 | Blood-brain barrier receptor antibody and application method |
PT3800202T (en) | 2014-12-11 | 2023-01-05 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
TW201809008A (en) | 2014-12-19 | 2018-03-16 | 日商中外製藥股份有限公司 | Anti-C5 antibodies and methods of use |
ES2862701T3 (en) | 2014-12-22 | 2021-10-07 | Univ Rockefeller | Anti-MERTK Agonist Antibodies and Uses Thereof |
WO2016106286A1 (en) | 2014-12-23 | 2016-06-30 | Biodesy, Inc. | Attachment of proteins to interfaces for use in nonlinear optical detection |
US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
AU2016205197B2 (en) | 2015-01-08 | 2021-10-21 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
SG10202111844VA (en) | 2015-01-09 | 2021-12-30 | Adalta Ltd | Cxcr4 binding molecules |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
US20180016327A1 (en) | 2015-01-22 | 2018-01-18 | Chugai Seiyaku Kabushiki Kaisha | A Combination of Two or More Anti-C5 Antibodies and Methods of Use |
EP3789766A1 (en) | 2015-01-24 | 2021-03-10 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
TWI710571B (en) | 2015-01-24 | 2020-11-21 | 中央研究院 | Cancer markers and methods of use thereof |
EP3250609A4 (en) | 2015-01-26 | 2018-07-11 | The University of Chicago | Il13ra alpha 2 binding agents and use thereof in cancer treatment |
US20180170992A1 (en) | 2015-01-26 | 2018-06-21 | The University Of Chicago | CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 |
CN107614521B (en) | 2015-01-30 | 2022-02-08 | 台湾地区“中央研究院” | Universal carbohydrate compositions and methods for enhancing antibody efficacy |
EP3253793A4 (en) | 2015-02-02 | 2018-11-14 | i2 Pharmaceuticals, Inc. | Anti-surrogate light chain antibodies |
ES2893114T3 (en) | 2015-02-04 | 2022-02-08 | Bristol Myers Squibb Co | Methods for selecting therapeutic molecules |
US11077132B2 (en) | 2015-02-04 | 2021-08-03 | F. Hoffmann-La Roche Ag | Tau antisense oligomers and uses thereof |
CN107636170A (en) | 2015-02-04 | 2018-01-26 | 健泰科生物技术公司 | Saltant type Smoothened and its application method |
WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
WO2016141111A1 (en) | 2015-03-03 | 2016-09-09 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
DK3265123T3 (en) | 2015-03-03 | 2023-01-30 | Kymab Ltd | ANTIBODIES, USES AND METHODS |
EP3268025B1 (en) | 2015-03-10 | 2020-05-06 | University of Massachusetts | Targeting gdf6 and bmp signaling for anti-melanoma therapy |
AR103935A1 (en) | 2015-03-16 | 2017-06-14 | Genentech Inc | METHODS OF DETECTION AND QUANTIFICATION OF IL-13 AND ITS USES IN THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH TH-2 |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
RS60270B1 (en) | 2015-03-20 | 2020-06-30 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to gp120 and their use |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
JP6944924B2 (en) | 2015-03-23 | 2021-10-06 | ジョンス セラピューティクス, インコーポレイテッド | Antibodies to ICOS |
WO2016154629A1 (en) | 2015-03-26 | 2016-09-29 | Woman & Infants' Hospital Of Rhode Island | Therapy for malignant disease |
JP2018518152A (en) | 2015-03-27 | 2018-07-12 | ユニバーシティ オブ サザン カリフォルニア | CAR T cell therapy directed to LHR for treating solid tumors |
US10167334B2 (en) | 2015-04-03 | 2019-01-01 | Xoma Technology Ltd. | Treatment of cancer using anti-TGF-BETA and PD-1 antibodies |
KR20170132793A (en) | 2015-04-03 | 2017-12-04 | 유레카 쎄라퓨틱스, 인코포레이티드 | Constructs targeting AFP peptide / MHC complexes and uses thereof |
MA41919A (en) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES |
EP3280728B1 (en) | 2015-04-06 | 2020-12-16 | Acceleron Pharma Inc. | Alk7:actriib heteromultimers and uses thereof |
CN108137648A (en) | 2015-04-06 | 2018-06-08 | 哈佛学院校长同事会 | For the composition and method of Nonmyeloablative pretreatment |
KR20180002653A (en) | 2015-04-07 | 2018-01-08 | 제넨테크, 인크. | Antigen binding complexes having an agonistic activity activity and methods of use |
PL3280441T3 (en) | 2015-04-07 | 2022-02-21 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
CA2925329C (en) | 2015-04-13 | 2024-01-02 | Pfizer Inc. | Anti-bcma antibodies, anti-cd3 antibodies and bi-specific antibodies binding to bcma and cd3 |
MX2017013298A (en) | 2015-04-13 | 2018-06-19 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen. |
US11299729B2 (en) | 2015-04-17 | 2022-04-12 | President And Fellows Of Harvard College | Vector-based mutagenesis system |
WO2016168771A2 (en) | 2015-04-17 | 2016-10-20 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
WO2016170022A1 (en) | 2015-04-21 | 2016-10-27 | Institut Gustave Roussy | Therapeutic methods, products and compositions inhibiting znf555 |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
ES2881694T3 (en) | 2015-04-24 | 2021-11-30 | Hoffmann La Roche | Procedures for Identifying Bacteria Comprising Binding Polypeptides |
US10814012B2 (en) | 2015-04-29 | 2020-10-27 | University Of South Australia | Compositions and methods for administering antibodies |
JP2018520642A (en) | 2015-05-01 | 2018-08-02 | ジェネンテック, インコーポレイテッド | Mask anti-CD3 antibody and method of use thereof |
WO2016179194A1 (en) | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
EA201792442A1 (en) | 2015-05-06 | 2018-06-29 | Янссен Байотек, Инк. | BISPECIFIC AGENTS, CONNECTING THE PROSTATIC SPECIFIC MEMBRANE ANTIGEN (PSMA), AND THEIR APPLICATION |
EA201792451A1 (en) | 2015-05-07 | 2018-05-31 | Агенус Инк. | ANTIBODIES TO OX40 AND METHODS OF THEIR APPLICATION |
WO2016183183A1 (en) | 2015-05-11 | 2016-11-17 | The Johns Hopkins University | Autoimmune antibodies for use in inhibiting cancer cell growth |
JP6963508B2 (en) | 2015-05-11 | 2021-11-10 | ジェネンテック, インコーポレイテッド | Compositions and Methods for Treating Lupus Nephritis |
IL255312B (en) | 2015-05-12 | 2022-08-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer comprising a pd-l1 binding antagonist |
EP3297674B1 (en) | 2015-05-22 | 2023-01-04 | Translational Drug Development Llc | Benzamide and active compound compositions and methods of use |
CA2987146A1 (en) | 2015-05-27 | 2016-12-01 | Ucb Biopharma Sprl | Method for the treatment of neurological disease |
ES2789500T5 (en) | 2015-05-29 | 2023-09-20 | Hoffmann La Roche | Therapeutic and diagnostic procedures for cancer |
JP2018520658A (en) | 2015-05-29 | 2018-08-02 | ジェネンテック, インコーポレイテッド | Humanized anti-Ebola virus glycoprotein antibodies and uses thereof |
AU2016271591A1 (en) | 2015-05-29 | 2017-12-21 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
EP3303619B1 (en) | 2015-05-29 | 2020-06-10 | H. Hoffnabb-La Roche Ag | Pd-l1 promoter methylation in cancer |
EP3303395B1 (en) | 2015-05-29 | 2019-12-11 | AbbVie Inc. | Anti-cd40 antibodies and uses thereof |
CN107810012A (en) | 2015-06-02 | 2018-03-16 | 豪夫迈·罗氏有限公司 | Use the composition and method of the anti-Antybody therapy sacred diseases of IL 34 |
EP3303380B1 (en) | 2015-06-02 | 2020-01-15 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2016197064A1 (en) | 2015-06-04 | 2016-12-08 | Epstein Alan L | Lym-1 and lym-2 targeted car cell immunotherapy |
CN114057872A (en) | 2015-06-05 | 2022-02-18 | 基因泰克公司 | anti-TAU antibodies and methods of use |
CA2985483A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies |
EP3303397A1 (en) | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
AU2016276981B2 (en) | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
AR104987A1 (en) | 2015-06-15 | 2017-08-30 | Genentech Inc | ANTIBODY-DRUG IMMUNOCUJADOS UNITED BY NON-PEPTIDIC LINKERS |
RS64662B1 (en) | 2015-06-16 | 2023-11-30 | Hoffmann La Roche | Humanized and affinity matured antibodies to fcrh5 and methods of use |
JP2018526972A (en) | 2015-06-16 | 2018-09-20 | ジェネンテック, インコーポレイテッド | Anti-CD3 antibody and method of use |
TW201718647A (en) | 2015-06-16 | 2017-06-01 | 建南德克公司 | Anti-CLL-1 antibodies and methods of use |
CN116327953A (en) | 2015-06-17 | 2023-06-27 | 豪夫迈·罗氏有限公司 | Methods of treating locally advanced or metastatic breast cancer using PD-1 axis binding antagonists and taxanes |
WO2016205531A2 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Anti-her2 antibodies and methods of use |
GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
US20180188257A1 (en) | 2015-06-19 | 2018-07-05 | University Of Rochester | Septin proteins as novel biomarkers for detection and treatment of müllerian cancers |
CN114805576A (en) | 2015-06-24 | 2022-07-29 | 詹森药业有限公司 | anti-VISTA antibodies and fragments |
AU2016285552B2 (en) | 2015-06-29 | 2022-10-13 | Immunogen, Inc. | Anti-CD123 antibodies and conjugates and derivatives thereof |
KR20180021864A (en) | 2015-06-29 | 2018-03-05 | 제넨테크, 인크. | Type II anti-CD20 antibodies for use in organ transplantation |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
WO2017015334A1 (en) | 2015-07-21 | 2017-01-26 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
WO2017015545A1 (en) | 2015-07-22 | 2017-01-26 | President And Fellows Of Harvard College | Evolution of site-specific recombinases |
US11524983B2 (en) | 2015-07-23 | 2022-12-13 | President And Fellows Of Harvard College | Evolution of Bt toxins |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
US10612011B2 (en) | 2015-07-30 | 2020-04-07 | President And Fellows Of Harvard College | Evolution of TALENs |
CN116327952A (en) | 2015-08-04 | 2023-06-27 | 阿塞勒隆制药公司 | Methods for treating myeloproliferative disorders |
TW202330904A (en) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | Taurine supplemented cell culture medium and methods of use |
AU2016304588A1 (en) | 2015-08-06 | 2018-02-15 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
EP3932953A1 (en) | 2015-08-28 | 2022-01-05 | F. Hoffmann-La Roche AG | Anti-hypusine antibodies and uses thereof |
EA201890630A1 (en) | 2015-09-01 | 2018-10-31 | Эйдженус Инк. | ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION |
AR105910A1 (en) | 2015-09-04 | 2017-11-22 | Obi Pharma Inc | GLICAN MATRICES AND METHOD OF USE |
LT3350220T (en) | 2015-09-15 | 2021-09-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
AU2016323968B2 (en) | 2015-09-17 | 2023-07-06 | Immunogen, Inc. | Therapeutic combinations comprising anti-FOLR1 immunoconjugates |
AR105634A1 (en) | 2015-09-18 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | ANTIBODIES THAT JOIN IL 8 AND ITS USES |
AU2016326609B2 (en) | 2015-09-23 | 2023-03-09 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
CN109310744A (en) | 2015-09-23 | 2019-02-05 | 赛通免疫有限责任公司 | FLT3 for immunization therapy orients CAR cell |
BR112018005737A2 (en) | 2015-09-23 | 2018-10-09 | Genentech Inc | antibodies, polynucleotide, vector, host cell, method for producing antibody, for reducing or inhibiting angiogenesis, for treating a disorder associated with angiogenesis, for inhibiting vascular permeability, composition, antibody conjugate, fusion protein, for identifying a change residues, antibody use, conjugate use and protein use |
BR112018005931A2 (en) | 2015-09-24 | 2018-10-09 | Abvitro Llc | hiv antibody compositions and methods of use |
JP6843868B2 (en) | 2015-09-29 | 2021-03-17 | セルジーン コーポレイション | PD-1 binding protein and its usage |
US20180282415A1 (en) | 2015-09-30 | 2018-10-04 | Merck Patent Gmbh | Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer |
MA43348A (en) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | PROTEIN CONJUGATES |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
HUE056033T2 (en) | 2015-10-02 | 2022-01-28 | Hoffmann La Roche | Anti-pd1 antibodies and methods of use |
EP3362093A4 (en) | 2015-10-13 | 2019-05-08 | Technion Research & Development Foundation Limited | Heparanase-neutralizing monoclonal antibodies |
EP3362074B1 (en) | 2015-10-16 | 2023-08-09 | President and Fellows of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
MA43354A (en) | 2015-10-16 | 2018-08-22 | Genentech Inc | CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE |
MA45326A (en) | 2015-10-20 | 2018-08-29 | Genentech Inc | CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
CN108350505A (en) | 2015-10-22 | 2018-07-31 | 震动疗法股份有限公司 | Genetic marker for measuring ICOS expression |
SG10201913247XA (en) | 2015-10-23 | 2020-02-27 | Eureka Therapeutics Inc | Antibody/t-cell receptor chimeric constructs and uses thereof |
KR20180067676A (en) | 2015-10-27 | 2018-06-20 | 유씨비 바이오파마 에스피알엘 | Treatment with anti-IL-17A / F antibody |
EP3368566A1 (en) | 2015-10-28 | 2018-09-05 | Friedrich Miescher Institute for Biomedical Research | Tenascin-w and biliary tract cancers |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
AU2016343978A1 (en) | 2015-10-29 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids |
WO2017075212A1 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-htra1 antibodies and methods of use thereof |
WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
GB201519303D0 (en) * | 2015-11-02 | 2015-12-16 | Imp Innovations Ltd | Phagemid vector |
WO2017079442A1 (en) | 2015-11-04 | 2017-05-11 | Icahn School Of Medicine At Mount Sinai | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment |
EP3371217A1 (en) | 2015-11-08 | 2018-09-12 | H. Hoffnabb-La Roche Ag | Methods of screening for multispecific antibodies |
JP7041628B2 (en) | 2015-11-10 | 2022-03-24 | ビステラ, インコーポレイテッド | Antibody molecules that specifically bind to lipopolysaccharide-drug conjugates and their use |
MY192146A (en) | 2015-11-10 | 2022-08-01 | Medimmune Llc | Binding molecules specific for asct2 and uses thereof |
CN116217729A (en) | 2015-11-12 | 2023-06-06 | 思进公司 | Glycan interaction compounds and methods of use |
CN108697793B (en) | 2015-11-23 | 2023-08-01 | 阿塞勒隆制药公司 | Methods of treating eye diseases |
LT3380522T (en) | 2015-11-25 | 2024-02-26 | Visterra, Inc. | Antibody molecules to april and uses thereof |
KR20180100122A (en) | 2015-12-02 | 2018-09-07 | 주식회사 에스티사이언스 | Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor) |
CN114470194A (en) | 2015-12-02 | 2022-05-13 | 斯特库伯株式会社 | Antibodies and molecules that immunospecifically bind to BTN1A1 and therapeutic uses thereof |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
CA2997406A1 (en) | 2015-12-09 | 2017-06-15 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
US10829562B2 (en) | 2015-12-10 | 2020-11-10 | Katholieke Universiteit Leuven | Haemorrhagic disorder due to ventricular assist device |
CN108697794A (en) | 2015-12-17 | 2018-10-23 | 诺华股份有限公司 | The combination and application thereof of C-MET inhibitor and anti-PD-1 antibody molecules |
AU2016369537B2 (en) | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
CN108401431B (en) | 2015-12-18 | 2022-01-25 | 中外制药株式会社 | anti-C5 antibodies and methods of use |
CA3048202A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by inhibition of nonsense mediated decay |
SG11201804961UA (en) | 2015-12-30 | 2018-07-30 | Genentech Inc | Formulations with reduced degradation of polysorbate |
MX2018008063A (en) | 2015-12-30 | 2018-11-29 | Genentech Inc | Use of tryptophan derivatives for protein formulations. |
WO2017118307A1 (en) | 2016-01-05 | 2017-07-13 | 江苏恒瑞医药股份有限公司 | Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof |
AR107303A1 (en) | 2016-01-08 | 2018-04-18 | Hoffmann La Roche | METHODS OF TREATMENT OF POSITIVE CANCER FOR ACE USING ANTAGONISTS OF AXISION TO AXIS PD-1 AND ANTI-ACE / ANTI-CD3, USE, COMPOSITION, KIT |
EP3400240A2 (en) | 2016-01-08 | 2018-11-14 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
EP3400239B1 (en) | 2016-01-08 | 2021-06-02 | AltruBio Inc. | Tetravalent anti-psgl-1 antibodies and uses thereof |
CN114019170A (en) | 2016-01-20 | 2022-02-08 | 基因泰克公司 | High dose treatment for alzheimer's disease |
JP6823659B2 (en) | 2016-01-21 | 2021-02-03 | ファイザー・インク | Chimeric antigen receptor targeting epidermal growth factor receptor mutant III |
DK3405490T3 (en) | 2016-01-21 | 2022-01-10 | Pfizer | MONO- AND BISPECIFIC ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND CD3 AND USES THEREOF |
WO2017136558A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
GB201602413D0 (en) | 2016-02-10 | 2016-03-23 | Nascient Ltd | Method |
CN116920085A (en) | 2016-02-12 | 2023-10-24 | 詹森药业有限公司 | anti-VISTA (B7H 5) antibodies |
WO2017151517A1 (en) | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods of treating cancer |
AU2017225854B2 (en) | 2016-02-29 | 2020-11-19 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
JP2019515876A (en) | 2016-03-08 | 2019-06-13 | アカデミア シニカAcademia Sinica | Methods for module synthesis of N-glycans and their arrays |
KR20240017421A (en) | 2016-03-10 | 2024-02-07 | 비엘라 바이오, 인크. | Ilt7 binding molecules and methods of using the same |
WO2017156488A2 (en) | 2016-03-10 | 2017-09-14 | Acceleron Pharma, Inc. | Activin type 2 receptor binding proteins and uses thereof |
MX2018010948A (en) | 2016-03-11 | 2019-06-20 | Scholar Rock Inc | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF. |
WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
BR112018067923A2 (en) | 2016-03-15 | 2019-02-05 | Chugai Pharmaceutical Co Ltd | Cancer treatment methods using pd-1 axis binding antagonists and anti-gpc3 antibodies |
US11186641B2 (en) | 2016-03-17 | 2021-11-30 | Oslo Universitetssykehus Hf | Fusion proteins targeting tumour associated macrophages for treating cancer |
CA3016563A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
CA3018081A1 (en) | 2016-03-22 | 2017-09-28 | Bionomics Limited | Administration of an anti-lgr5 monoclonal antibody |
CA3018216A1 (en) | 2016-03-25 | 2017-09-28 | Visterra, Inc. | Formulations of antibody molecules to dengue virus |
EP3433621A1 (en) | 2016-03-25 | 2019-01-30 | H. Hoffnabb-La Roche Ag | Multiplexed total antibody and antibody-conjugated drug quantification assay |
AU2017239637A1 (en) | 2016-03-29 | 2018-11-15 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
AU2017241776A1 (en) | 2016-03-29 | 2018-10-11 | Janssen Biotech, Inc. | Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
KR102611444B1 (en) | 2016-04-08 | 2023-12-06 | 지엘바이오, 인크. | Plectin-1 binding antibodies and uses thereof |
WO2017180864A1 (en) | 2016-04-14 | 2017-10-19 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
WO2017181098A2 (en) | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
AU2017250296A1 (en) | 2016-04-15 | 2018-11-01 | Genentech, Inc. | Methods for monitoring and treating cancer |
WO2017181079A2 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
SG11201809024UA (en) | 2016-04-22 | 2018-11-29 | Obi Pharma Inc | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
US11246868B2 (en) | 2016-04-26 | 2022-02-15 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
JP6675017B2 (en) | 2016-05-02 | 2020-04-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Contrast body-single chain target binding substance |
EP3455252B1 (en) | 2016-05-11 | 2022-02-23 | F. Hoffmann-La Roche AG | Modified anti-tenascin antibodies and methods of use |
US11098132B2 (en) | 2016-05-16 | 2021-08-24 | Takeda Pharmaceutical Company Limited | Anti-factor IX Padua antibodies |
EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
CN109415441B (en) | 2016-05-24 | 2023-04-07 | 英斯梅德股份有限公司 | Antibodies and methods of making same |
MA45123A (en) | 2016-05-27 | 2019-04-10 | Agenus Inc | ANTI-TIM-3 ANTIBODIES AND THEIR METHODS OF USE |
JP7022080B2 (en) | 2016-05-27 | 2022-02-17 | ジェネンテック, インコーポレイテッド | Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
ES2877548T3 (en) | 2016-06-02 | 2021-11-17 | Abbvie Inc | Glucocorticoid receptor agonist and immunoconjugates thereof |
AU2018276419A1 (en) | 2016-06-02 | 2019-10-17 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer |
JP7043425B2 (en) | 2016-06-06 | 2022-03-29 | ジェネンテック, インコーポレイテッド | Silvestrol Antibodies-Drug Conjugates and Usage |
KR102187751B1 (en) | 2016-06-06 | 2020-12-08 | 에프. 호프만-라 로슈 아게 | Ophthalmic fusion protein with increased ocular retention |
CN109563160B (en) | 2016-06-24 | 2023-02-28 | 豪夫迈·罗氏有限公司 | Anti-polyubiquitin multispecific antibodies |
MA45491A (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES |
MA45455A (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | PROCESS FOR IDENTIFYING PEPTIDIC EPITOPES, MOLECULES THAT BIND TO SUCH EPITOPES AND ASSOCIATED USES |
CN109415435B (en) | 2016-07-04 | 2024-01-16 | 豪夫迈·罗氏有限公司 | Novel antibody forms |
WO2018009417A1 (en) | 2016-07-05 | 2018-01-11 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
CA3030099A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
KR20190039134A (en) | 2016-07-13 | 2019-04-10 | 바이오젠 엠에이 인코포레이티드 | Use of LINGO-1 antagonists for the treatment regimens and for the treatment of dehydration diseases |
US20190336504A1 (en) | 2016-07-15 | 2019-11-07 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
MX2019000641A (en) | 2016-07-15 | 2019-06-10 | Poseida Therapeutics Inc | Chimeric antigen receptors (cars) specific for muc1 and methods for their use. |
US10722558B2 (en) | 2016-07-15 | 2020-07-28 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
JP2019524721A (en) | 2016-07-15 | 2019-09-05 | ポセイダ セラピューティクス, インコーポレイテッド | Chimeric antigen receptor and method of use |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
EP3487880A1 (en) | 2016-07-25 | 2019-05-29 | Biogen MA Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
BR112019001615A2 (en) | 2016-07-27 | 2019-04-30 | Acceleron Pharma Inc. | methods and compositions for treating myelofibrosis |
US11642400B2 (en) | 2016-07-27 | 2023-05-09 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
JP7121724B2 (en) | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ,インコーポレイテッド | Human antibodies, pharmaceutical compositions and methods |
WO2018021450A1 (en) | 2016-07-29 | 2018-02-01 | 中外製薬株式会社 | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
CN109803680A (en) | 2016-08-01 | 2019-05-24 | 佐马美国有限公司 | (PTH1R) antibody of parathyroid hormone receptor 1 and its purposes |
WO2018052556A1 (en) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
CA3032146A1 (en) | 2016-08-03 | 2018-02-08 | Bio-Techne Corporation | Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy |
KR102538749B1 (en) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Composition for prophylaxis or treatment of il-8 related diseases |
EA201990222A1 (en) | 2016-08-05 | 2019-07-31 | МЕДИММЬЮН, ЭлЭлСи | ANTIBODIES TO O2 AND WAYS OF THEIR APPLICATION |
EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
AU2017316663B2 (en) | 2016-08-22 | 2024-02-22 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
EP3515932B1 (en) | 2016-09-19 | 2023-11-22 | F. Hoffmann-La Roche AG | Complement factor based affinity chromatography |
US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
CA3036701A1 (en) | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating immune disorders using pd-1 binding proteins |
WO2018057955A1 (en) | 2016-09-23 | 2018-03-29 | Elstar Therapeutics, Inc. | Multispecific antibody molecules comprising lambda and kappa light chains |
WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
CA3037661A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating cluster headache |
CA3031589A1 (en) | 2016-09-23 | 2018-03-29 | Genentech, Inc. | Uses of il-13 antagonists for treating atopic dermatitis |
PE20191153A1 (en) | 2016-09-28 | 2019-09-05 | Blade Therapeutics Inc | CALPAINE MODULATORS AND THERAPEUTIC USES OF THE SAME |
EP3518969A2 (en) | 2016-09-28 | 2019-08-07 | Xoma (Us) Llc | Antibodies that bind interleukin-2 and uses thereof |
GB201616596D0 (en) | 2016-09-29 | 2016-11-16 | Nascient Limited | Epitope and antibodies |
JP2020500152A (en) | 2016-09-30 | 2020-01-09 | ヤンセン バイオテツク,インコーポレーテツド | Safe and effective method of treating psoriasis with anti-IL23 specific antibody |
US20180106818A1 (en) | 2016-10-03 | 2018-04-19 | Abbott Laboratories | Methods of assessing gfap status in patient samples |
JP7050770B2 (en) | 2016-10-05 | 2022-04-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Method for preparing antibody drug conjugate |
EP3522934A4 (en) | 2016-10-05 | 2020-04-15 | Acceleron Pharma Inc. | Compositions and method for treating kidney disease |
CA3038712A1 (en) | 2016-10-06 | 2018-04-12 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
CN110225927B (en) | 2016-10-07 | 2024-01-12 | 诺华股份有限公司 | Chimeric antigen receptor for the treatment of cancer |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
WO2018071576A1 (en) | 2016-10-14 | 2018-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Treatment of tumors by inhibition of cd300f |
WO2018075408A1 (en) | 2016-10-17 | 2018-04-26 | Alexion Pharmaceuticals, Inc. | Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin |
US11117956B2 (en) | 2016-10-19 | 2021-09-14 | Medimmune, Llc | Anti-O1 antibodies and uses thereof |
US11249082B2 (en) | 2016-10-29 | 2022-02-15 | University Of Miami | Zika virus assay systems |
CN110267678A (en) | 2016-10-29 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | Anti- MIC antibody and application method |
US20200261470A1 (en) | 2016-11-02 | 2020-08-20 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and parp inhibitors |
CA3039992A1 (en) | 2016-11-02 | 2018-05-11 | Jounce Therapeutics, Inc. | Antibodies to pd-1 and uses thereof |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
WO2018083538A1 (en) | 2016-11-07 | 2018-05-11 | Neuracle Scienc3 Co., Ltd. | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
JP2020502261A (en) | 2016-11-16 | 2020-01-23 | ヤンセン バイオテツク,インコーポレーテツド | Methods of treating psoriasis with anti-IL23 specific antibodies |
EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | Glycan-interacting compounds and methods of use |
TW201829463A (en) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | Anti-hla-g antibodies and use thereof |
CA3044274A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
EP3544601B1 (en) | 2016-11-23 | 2024-03-20 | Translational Drug Development, LLC | A composition comprising a benzamide and a tnfrsf agonist binding to 4-1bb or gitr, and the use thereof in the treatment of cancer. |
WO2018098363A2 (en) | 2016-11-23 | 2018-05-31 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
WO2018102594A1 (en) | 2016-12-01 | 2018-06-07 | Alexion Pharmaceuticals, Inc. | Methods of treating solid tumors with anti-cd200 antibodies |
KR102587130B1 (en) | 2016-12-07 | 2023-10-11 | 제넨테크, 인크. | Anti-tau antibodies and methods of using the same |
JP7106538B2 (en) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | Antibodies and methods of their use |
EP3551655A2 (en) | 2016-12-07 | 2019-10-16 | Genentech, Inc. | Anti-tau antibodies and methods of their use |
FI3551660T3 (en) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
EP3559249A1 (en) | 2016-12-21 | 2019-10-30 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of antibodies |
KR102317884B1 (en) | 2016-12-21 | 2021-10-26 | 에프. 호프만-라 로슈 아게 | In vitro glycoengineering of antibodies |
EP3559250A1 (en) | 2016-12-21 | 2019-10-30 | H. Hoffnabb-La Roche Ag | Re-use of enzymes in in vitro glycoengineering of antibodies |
AU2017382367A1 (en) | 2016-12-23 | 2019-06-13 | Visterra, Inc. | Binding polypeptides and methods of making the same |
WO2018129395A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
RS64159B1 (en) | 2017-01-06 | 2023-05-31 | Scholar Rock Inc | Treating metabolic diseases by inhibiting myostatin activation |
BR112019013908A2 (en) | 2017-01-06 | 2020-02-04 | Scholar Rock Inc | isoform-specific, context-permissive tgfss1 inhibitors, and their uses |
US11274157B2 (en) | 2017-01-12 | 2022-03-15 | Eureka Therapeutics, Inc. | Constructs targeting histone H3 peptide/MHC complexes and uses thereof |
US11135164B2 (en) | 2017-01-13 | 2021-10-05 | Academia Sinica | Reloadable hydrogel system comprising an anti-PEG antibody for treating myocardial infarction |
CN110290811A (en) | 2017-01-13 | 2019-09-27 | 中央研究院 | To treat the glue system of the repeatable loading of brain diseases |
CN110431150A (en) | 2017-01-18 | 2019-11-08 | 威特拉公司 | Antibody molecule-drug conjugates and application thereof |
CN110167967B (en) | 2017-01-18 | 2022-08-05 | 豪夫迈·罗氏有限公司 | Idiotypic antibodies directed against anti-PD-L1 antibodies and uses thereof |
CA3052095A1 (en) | 2017-01-30 | 2018-08-02 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis |
US10240205B2 (en) | 2017-02-03 | 2019-03-26 | Population Bio, Inc. | Methods for assessing risk of developing a viral disease using a genetic test |
WO2018141029A1 (en) | 2017-02-06 | 2018-08-09 | Meat & Livestock Australia Limited | Immunostimulating compositions and uses therefore |
CA3052578A1 (en) | 2017-02-07 | 2018-08-16 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
WO2018148419A1 (en) | 2017-02-08 | 2018-08-16 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
MY197534A (en) | 2017-02-10 | 2023-06-21 | Genentech Inc | Anti-tryptase antibodies, compositions thereof, and uses thereof |
WO2018148660A1 (en) | 2017-02-10 | 2018-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
JP7169979B2 (en) | 2017-02-27 | 2022-11-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Method for evaluating therapeutic efficacy of candidate therapeutic agents for complement-related nephropathy and liver fibrosis |
EP3589754B1 (en) | 2017-03-01 | 2023-06-28 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
JP7195262B2 (en) | 2017-03-02 | 2022-12-23 | ベス イスラエル デアコネス メディカル センター インコーポレイティッド | Method for Selecting Headache Patients Responsive to Antibodies Directed to Calcitonin Gene-Related Peptides |
JP7116736B2 (en) | 2017-03-02 | 2022-08-10 | ノバルティス アーゲー | engineered heterodimeric proteins |
US11253609B2 (en) | 2017-03-03 | 2022-02-22 | Seagen Inc. | Glycan-interacting compounds and methods of use |
SG11201908418RA (en) | 2017-03-13 | 2019-10-30 | Poseida Therapeutics Inc | Compositions and methods for selective elimination and replacement of hematopoietic stem cells |
EP3600441A1 (en) | 2017-03-22 | 2020-02-05 | Genentech, Inc. | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
JP7227151B2 (en) | 2017-03-22 | 2023-02-21 | ジェネンテック, インコーポレイテッド | Antibody Compositions Optimized for Treatment of Eye Disorders |
CA3052513A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
WO2018176019A1 (en) | 2017-03-24 | 2018-09-27 | The Regents Of The University Of California | Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom |
TW201900673A (en) | 2017-03-27 | 2019-01-01 | 瑞士商赫孚孟拉羅股份公司 | Modified antigen binding receptor |
TW201900672A (en) | 2017-03-27 | 2019-01-01 | 瑞士商赫孚孟拉羅股份公司 | Improved antigen binding receptor type |
DK3606946T3 (en) | 2017-04-03 | 2022-10-24 | Hoffmann La Roche | Immunoconjugates of an anti-PD-1 antibody with a mutated IL-2 or with IL-15 |
US11571459B2 (en) | 2017-04-03 | 2023-02-07 | Oncxerna Therapeutics, Inc. | Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents |
CR20190430A (en) | 2017-04-03 | 2019-11-01 | Hoffmann La Roche | Antibodies binding to steap-1 |
CN110382525B (en) | 2017-04-03 | 2023-10-20 | 豪夫迈·罗氏有限公司 | Immunoconjugates |
WO2018185046A1 (en) | 2017-04-05 | 2018-10-11 | F. Hoffmann-La Roche Ag | Anti-lag3 antibodies |
CN110505885A (en) | 2017-04-05 | 2019-11-26 | 诺和诺德股份有限公司 | Insulin-Fc the conjugate that oligomer extends |
KR102408873B1 (en) | 2017-04-05 | 2022-06-15 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies specifically binding to pd1 and lag3 |
CA3059542A1 (en) | 2017-04-12 | 2018-10-18 | Pfizer Inc. | Antibodies having conditional affinity and methods of use thereof |
TW201841942A (en) | 2017-04-13 | 2018-12-01 | 美商艾吉納斯公司 | Anti-CD137 antibodies and methods of use thereof |
CN110944665A (en) | 2017-04-14 | 2020-03-31 | 加马玛布斯制药公司 | AMHRII-binding compounds for preventing or treating lung cancer |
BR112019021472A8 (en) | 2017-04-14 | 2023-05-02 | Inst Curie | AMHRII-BINDING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF CANCER |
CA3053409A1 (en) | 2017-04-15 | 2018-10-18 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
JP2020517256A (en) | 2017-04-19 | 2020-06-18 | エルスター セラピューティクス, インコーポレイテッド | Multispecific molecules and uses thereof |
KR20190141659A (en) | 2017-04-21 | 2019-12-24 | 스태튼 바이오테크놀로지 비.브이. | Anti-APOC3 Antibodies and Methods of Use thereof |
CA3059615A1 (en) | 2017-04-21 | 2018-10-25 | Genentech, Inc. | Use of klk5 antagonists for treatment of a disease |
GB201706451D0 (en) | 2017-04-24 | 2017-06-07 | Imp Innovations Ltd | Cancer treatment |
WO2018200742A1 (en) | 2017-04-25 | 2018-11-01 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
SG11201909728XA (en) | 2017-04-26 | 2019-11-28 | Eureka Therapeutics Inc | Constructs specifically recognizing glypican 3 and uses thereof |
EP3615046A4 (en) | 2017-04-26 | 2021-03-03 | Eureka Therapeutics, Inc. | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
WO2018201096A1 (en) | 2017-04-27 | 2018-11-01 | Tesaro, Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
EP3615566B1 (en) | 2017-04-28 | 2023-12-20 | Marengo Therapeutics, Inc. | Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof |
AU2018256845B2 (en) | 2017-04-28 | 2024-03-14 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject |
TW202402800A (en) | 2017-05-01 | 2024-01-16 | 美商艾吉納斯公司 | Anti-tigit antibodies and methods of use thereof |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
JOP20190256A1 (en) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
WO2018213097A1 (en) | 2017-05-15 | 2018-11-22 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
WO2018215535A1 (en) | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
BR112019024701A2 (en) | 2017-05-25 | 2020-06-09 | Abbott Lab | methods to assist in determining whether an imaging test should be performed on a human individual who has suffered or may have suffered a head injury with the use of early biomarkers |
US10849548B2 (en) | 2017-05-30 | 2020-12-01 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers |
CA3065301A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
EP3630834A1 (en) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
TWI757499B (en) | 2017-06-02 | 2022-03-11 | 美商輝瑞大藥廠 | Antibodies specific for flt3 and their uses |
CA3062328A1 (en) | 2017-06-02 | 2018-12-06 | Pfizer Inc. | Chimeric antigen receptors targeting flt3 |
JP2020522562A (en) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー., インコーポレイテッド | Methods of treating cancer with antibodies and molecules that bind to BTN1A1 or BTN1A1 ligand |
AU2018281830B2 (en) | 2017-06-09 | 2023-11-02 | Agonox, Inc. | Utilization of CD39 and CD103 for identification of human tumor reactive cells for treatment of cancer |
GB201709379D0 (en) | 2017-06-13 | 2017-07-26 | Univ Leuven Kath | Humanised ADAMTS13 binding antibodies |
US20190062428A1 (en) | 2017-06-19 | 2019-02-28 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2018237326A1 (en) | 2017-06-22 | 2018-12-27 | 1AlMOONSHOT PHARMA LLC | Methods for treating cancer with compositions comprising amlexanox and immune modulators |
WO2019005817A2 (en) | 2017-06-26 | 2019-01-03 | Bio-Techne Corporation | Hybridoma clones, monoclonal antibodies to vsig-4, and methods of making and using |
WO2019006007A1 (en) | 2017-06-27 | 2019-01-03 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
US11169159B2 (en) | 2017-07-03 | 2021-11-09 | Abbott Laboratories | Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood |
WO2019010164A1 (en) | 2017-07-06 | 2019-01-10 | President And Fellows Of Harvard College | Evolution of trna synthetases |
CA3069438A1 (en) | 2017-07-11 | 2019-01-17 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
BR112020000698A2 (en) | 2017-07-14 | 2020-07-14 | Pfizer Inc. | antibodies against madcam |
US11827669B2 (en) | 2017-07-19 | 2023-11-28 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection |
EP3431496A1 (en) | 2017-07-19 | 2019-01-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti- isoasp7 amyloid beta antibodies and uses thereof |
CN111163798A (en) | 2017-07-20 | 2020-05-15 | 诺华股份有限公司 | Dosing regimens for anti-LAG-3 antibodies and uses thereof |
WO2019018647A1 (en) | 2017-07-20 | 2019-01-24 | Pfizer Inc. | Anti-gd3 antibodies and antibody-drug conjugates |
EP3655034A1 (en) | 2017-07-21 | 2020-05-27 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
CA3071427A1 (en) | 2017-07-28 | 2019-01-31 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof |
BR112019023789A2 (en) | 2017-08-03 | 2020-07-28 | Alector Llc | anti-cd33 antibodies and methods of using them |
UY37829A (en) | 2017-08-03 | 2019-01-31 | Amgen Inc | INTERLEUCINE MUTEINS 21 AND TREATMENT METHODS |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
EP3684811A2 (en) | 2017-08-17 | 2020-07-29 | Massachusetts Institute of Technology | Multiple specificity binders of cxc chemokines and uses thereof |
US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
JP2020532987A (en) | 2017-09-08 | 2020-11-19 | ポセイダ セラピューティクス,インコーポレイティド | Compositions and Methods for Chimeric Ligand Receptor (CLR) -mediated Conditional Gene Expression |
ES2928576T3 (en) | 2017-09-08 | 2022-11-21 | Amgen Inc | KRAS G12C inhibitors and methods of use thereof |
US11624130B2 (en) | 2017-09-18 | 2023-04-11 | President And Fellows Of Harvard College | Continuous evolution for stabilized proteins |
TW201922780A (en) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | Safe and effective method of treating Lupus with anti-IL12/IL23 antibody |
US11761963B2 (en) | 2017-09-27 | 2023-09-19 | Alexion Pharmaceuticals, Inc. | Biomarker signature for predicting tumor response to anti-CD200 therapy |
EA202090641A1 (en) | 2017-09-29 | 2020-08-07 | Чугаи Сейяку Кабусики Кайся | MULTISPECIFIC ANTIGEN-BINDING MOLECULE WITH A SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COGULATING FACTOR VIII, AND PHARMACEUTICAL COMPOSITION, COMPOSITION |
WO2019070726A1 (en) | 2017-10-02 | 2019-04-11 | Visterra, Inc. | Antibody molecules to cd138 and uses thereof |
EP3461841B1 (en) | 2017-10-02 | 2019-09-11 | Certest Biotec, S.L. | Anti-dps antibodies and test devices for the detection of bacteria of the genus campylobacter |
CN112020648A (en) | 2017-10-04 | 2020-12-01 | 赫斯佩瑞克斯股份公司 | Articles and methods for cancer-directed personalized therapy |
US11707522B2 (en) | 2017-10-13 | 2023-07-25 | Boehringer Ingelheim International Gmbh | Human antibodies to Tn antigen |
WO2019077132A1 (en) | 2017-10-19 | 2019-04-25 | Debiopharm International S.A. | Combination product for the treatment of cancer |
WO2019077165A1 (en) | 2017-10-20 | 2019-04-25 | Institut Curie | Dap10/12 based cars adapted for rush |
US20190160089A1 (en) | 2017-10-31 | 2019-05-30 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and cytarabine |
EP3703710A1 (en) | 2017-10-31 | 2020-09-09 | Allogene Therapeutics, Inc. | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells |
WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
CN111315772A (en) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | anti-APOC 3 antibodies and methods of use thereof |
CN111295392A (en) | 2017-11-01 | 2020-06-16 | 豪夫迈·罗氏有限公司 | Compbody-multivalent target binders |
WO2019086395A1 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Trifab-contorsbody |
CN111213059B (en) | 2017-11-06 | 2024-01-09 | 豪夫迈·罗氏有限公司 | Diagnostic and therapeutic methods for cancer |
CN111587123A (en) | 2017-11-09 | 2020-08-25 | 品通治疗有限公司 | Methods and compositions for generating and using humanized conformation-specific phosphorylated tau antibodies |
TW201922291A (en) | 2017-11-16 | 2019-06-16 | 瑞士商諾華公司 | Combination therapies |
EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
WO2019102435A1 (en) | 2017-11-27 | 2019-05-31 | Euro-Celtique S.A. | Humanized antibodies targeting human tissue factor |
WO2019108755A1 (en) | 2017-11-30 | 2019-06-06 | Genentech, Inc. | Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1 |
US20200377571A1 (en) | 2017-12-08 | 2020-12-03 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
CA3067055A1 (en) | 2017-12-09 | 2019-06-13 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1 |
US11022617B2 (en) | 2017-12-09 | 2021-06-01 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) |
WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
EP3729080B1 (en) | 2017-12-21 | 2023-04-19 | F. Hoffmann-La Roche AG | Universal reporter cell assay for specificity test of novel antigen binding moieties |
WO2019122052A2 (en) | 2017-12-21 | 2019-06-27 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a2/wt1 |
EP3729081A1 (en) | 2017-12-21 | 2020-10-28 | F. Hoffmann-La Roche AG | Car-t cell assay for specificity test of novel antigen binding moieties |
EP4219559A3 (en) | 2017-12-22 | 2023-10-18 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
US20190211098A1 (en) | 2017-12-22 | 2019-07-11 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
EP3732203A4 (en) | 2017-12-28 | 2021-12-15 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against pd-l1 |
WO2019129221A1 (en) | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against tigit |
US11440957B2 (en) | 2017-12-29 | 2022-09-13 | Alector Llc | Anti-TMEM106B antibodies and methods of use thereof |
CA3084370A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
CR20200330A (en) | 2018-01-12 | 2020-12-23 | Amgen Inc | Anti-pd-1 antibodies and methods of treatment |
JP7366908B2 (en) | 2018-01-15 | 2023-10-23 | ナンジン レジェンド バイオテック カンパニー,リミテッド | Single domain antibodies against PD-1 and variants thereof |
CA3088649A1 (en) | 2018-01-16 | 2019-07-25 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
JP7268038B2 (en) | 2018-01-31 | 2023-05-02 | アレクトル エルエルシー | ANTI-MS4A4A ANTIBODY AND METHOD OF USE THEREOF |
JP7404247B2 (en) | 2018-02-01 | 2023-12-25 | ファイザー・インク | Chimeric antigen receptor targeting CD70 |
TW201934580A (en) | 2018-02-01 | 2019-09-01 | 美商輝瑞大藥廠 | Antibodies specific for CD70 and their uses |
US11787857B2 (en) | 2018-02-02 | 2023-10-17 | Bio-Techne Corporation | Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using |
WO2019150309A1 (en) | 2018-02-02 | 2019-08-08 | Hammack Scott | Modulators of gpr68 and uses thereof for treating and preventing diseases |
AU2019218786A1 (en) | 2018-02-07 | 2020-07-30 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
BR112020016169A2 (en) | 2018-02-08 | 2020-12-15 | Genentech, Inc. | MOLECULES FOR BINDING THE BIESPECIFIC ANTIGEN, INSULATED NUCLEIC ACID, VECTOR, HOSTING CELL, METHODS FOR PRODUCING THE BINDING MOLECULE, SET OF NUCLEIC ACIDS, ISOLATED, VEGETABLE CONTAINER, VEGETABLE CONTAINERS, TO TREAT OR DELAY CANCER PROGRESSION, METHODS TO IMPROVE THE IMMUNE FUNCTION AND KIT |
CN111787947A (en) | 2018-02-09 | 2020-10-16 | 豪夫迈·罗氏有限公司 | Therapeutic and diagnostic methods for mast cell mediated inflammatory diseases |
TWI829667B (en) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | Antibodies binding to gprc5d |
WO2019160976A1 (en) | 2018-02-14 | 2019-08-22 | Viela Bio, Inc. | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
JP7391027B2 (en) | 2018-02-26 | 2023-12-04 | ジェネンテック, インコーポレイテッド | Medication for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies |
CN111742219A (en) | 2018-03-01 | 2020-10-02 | 豪夫迈·罗氏有限公司 | Specific assays for novel target antigen binding modules |
CA3091801A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
EP3762015A4 (en) | 2018-03-05 | 2022-04-27 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
RU2020129265A (en) | 2018-03-12 | 2022-04-12 | ЗОИТИС СЕРВИСЕЗ ЭлЭлСи | ANTIBODIES AGAINST NGF AND THEIR RELATED METHODS |
AU2019235842B2 (en) | 2018-03-14 | 2022-02-03 | Surface Oncology, Inc. | Antibodies that bind CD39 and uses thereof |
US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
US20210009711A1 (en) | 2018-03-14 | 2021-01-14 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
CN116327926A (en) | 2018-03-15 | 2023-06-27 | 中外制药株式会社 | Anti-dengue virus antibodies with cross-reactivity to Zika virus and methods of use |
JP7328983B2 (en) | 2018-03-22 | 2023-08-17 | サーフィス オンコロジー インコーポレイテッド | Anti-IL-27 antibody and use thereof |
WO2019180272A1 (en) | 2018-03-23 | 2019-09-26 | Fundación Instituto De Investigación Sanitaria De Santiago De Compostela | Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases |
JP2021519443A (en) | 2018-03-26 | 2021-08-10 | グリカノスティックス エス・アール・オーGlycanostics S.R.O. | Means and methods of protein sugar chain profiling |
WO2019190877A1 (en) | 2018-03-26 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | High throughput method for measuring the protease activity of complement c3 convertase |
US11840568B2 (en) | 2018-04-02 | 2023-12-12 | Mab-Venture Biopharm Co., Ltd. | Lymphocyte activation gene-3 (LAG-3) binding antibody and use thereof |
AR117566A1 (en) | 2018-04-02 | 2021-08-18 | Bristol Myers Squibb Co | ANTI-TREM-1 ANTIBODIES AND THEIR USES |
TW202011029A (en) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | Methods for detecting and quantifying FGF21 |
WO2019192972A1 (en) | 2018-04-04 | 2019-10-10 | F. Hoffmann-La Roche Ag | Diagnostic assays to detect tumor antigens in cancer patients |
EP3775902B1 (en) | 2018-04-04 | 2023-02-22 | F. Hoffmann-La Roche AG | Diagnostic assays to detect tumor antigens in cancer patients |
WO2019200357A1 (en) | 2018-04-12 | 2019-10-17 | Surface Oncology, Inc. | Biomarker for cd47 targeting therapeutics and uses therefor |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
AR115052A1 (en) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM |
AR114789A1 (en) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | ANTI-HLA-G ANTIBODIES AND THE USE OF THEM |
US20210230255A1 (en) | 2018-04-27 | 2021-07-29 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
CA3096703A1 (en) | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
EP4074732A1 (en) | 2018-05-11 | 2022-10-19 | Wuxi Biologics (Shanghai) Co. Ltd. | Fully human antibodies against ox40, method for preparing the same, and use thereof |
JP2021523138A (en) | 2018-05-11 | 2021-09-02 | ヤンセン バイオテツク,インコーポレーテツド | How to treat depression with IL-23 antibody |
TW202003048A (en) | 2018-05-15 | 2020-01-16 | 美商伊繆諾金公司 | Combination treatment with antibody-drug conjugates and FLT3 inhibitors |
TW202003580A (en) | 2018-05-21 | 2020-01-16 | 美商坎伯斯治療有限責任公司 | Compositions and methods for enhancing the killing of target cells by NK cells |
WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
BR112020022595A2 (en) | 2018-05-23 | 2021-02-09 | Pfizer Inc. | specific antibodies to gucy2c and uses thereof |
TWI793325B (en) | 2018-05-23 | 2023-02-21 | 美商輝瑞大藥廠 | Antibodies specific for cd3 and uses thereof |
AR115418A1 (en) | 2018-05-25 | 2021-01-13 | Alector Llc | ANTI-SIRPA ANTIBODIES (SIGNAL REGULATING PROTEIN a) AND METHODS OF USE OF THE SAME |
AR126019A1 (en) | 2018-05-30 | 2023-09-06 | Novartis Ag | ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES |
US11913044B2 (en) | 2018-06-14 | 2024-02-27 | President And Fellows Of Harvard College | Evolution of cytidine deaminases |
US11830582B2 (en) | 2018-06-14 | 2023-11-28 | University Of Miami | Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents |
KR20210028191A (en) | 2018-06-18 | 2021-03-11 | 유씨비 바이오파마 에스알엘 | GREMLIN-1 antagonists for preventing and treating cancer |
MX2020013798A (en) | 2018-06-19 | 2021-08-11 | Atarga Llc | Antibody molecules to complement component 5 and uses thereof. |
WO2019245817A1 (en) | 2018-06-19 | 2019-12-26 | Armo Biosciences, Inc. | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
WO2019244107A1 (en) | 2018-06-21 | 2019-12-26 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
SG11202012446UA (en) | 2018-06-23 | 2021-01-28 | Genentech Inc | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
TW202035444A (en) | 2018-06-27 | 2020-10-01 | 台灣浩鼎生技股份有限公司 | Glycosynthase variants for glycoprotein engineering and methods of use |
AU2019293589A1 (en) | 2018-06-29 | 2021-01-21 | Alector Llc | Anti-SIRP-beta1 antibodies and methods of use thereof |
AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
WO2020008083A1 (en) | 2018-07-05 | 2020-01-09 | Consejo Superior De Investigaciones Científicas | Therapeutic target in chemokine receptors for the screening of compounds useful for the treatment of pathological processes involving chemokine signaling |
BR112021000353A2 (en) | 2018-07-11 | 2021-08-03 | Scholar Rock, Inc. | isoform-selective, high-affinity tgfb1 inhibitors and their uses |
US11130803B2 (en) | 2018-07-11 | 2021-09-28 | Scholar Rock, Inc. | Isoform-selective TGFβ1 inhibitors and use thereof |
WO2020014473A1 (en) | 2018-07-11 | 2020-01-16 | Scholar Rock, Inc. | TGFβ1 INHIBITORS AND USE THEREOF |
LT3618928T (en) | 2018-07-13 | 2023-04-11 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
JP2021530697A (en) | 2018-07-18 | 2021-11-11 | ヤンセン バイオテツク,インコーポレーテツド | Sustained response predictor after treatment with anti-IL23 specific antibody |
KR20210034622A (en) | 2018-07-18 | 2021-03-30 | 제넨테크, 인크. | Lung cancer treatment method using PD-1 axis binding antagonist, anti-metabolite, and platinum agent |
CN112740043A (en) | 2018-07-20 | 2021-04-30 | 皮埃尔法布雷医药公司 | VISTA receptor |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
KR20210042936A (en) | 2018-08-08 | 2021-04-20 | 제넨테크, 인크. | Use of tryptophan derivatives and L-methionine for protein preparation |
WO2020033700A1 (en) | 2018-08-08 | 2020-02-13 | Pml Screening, Llc | Mathods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing |
WO2020033925A2 (en) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Antibodies that bind cd277 and uses thereof |
WO2020033926A2 (en) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Antibodies that bind cd277 and uses thereof |
US20210388089A1 (en) | 2018-08-09 | 2021-12-16 | Compass Therapeutics Llc | Antigen binding agents that bind cd277 and uses thereof |
SG11202003531WA (en) | 2018-08-10 | 2020-05-28 | Chugai Pharmaceutical Co Ltd | Anti-cd137 antigen-binding molecule and utilization thereof |
BR112021002487A2 (en) | 2018-08-10 | 2021-07-27 | Eutilex Co., Ltd. | hla-dr and car-t cell binding chimeric antigen receptor |
WO2020041360A1 (en) | 2018-08-21 | 2020-02-27 | Quidel Corporation | Dbpa antibodies and uses thereof |
CR20210155A (en) | 2018-08-31 | 2021-05-10 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
KR20210063330A (en) | 2018-09-19 | 2021-06-01 | 제넨테크, 인크. | Methods of treatment and diagnosis for bladder cancer |
KR20210062634A (en) | 2018-09-21 | 2021-05-31 | 제넨테크, 인크. | Diagnosis method for triple-negative breast cancer |
DK3883606T5 (en) | 2018-09-24 | 2024-01-02 | Janssen Biotech Inc | SAFE AND EFFECTIVE METHOD FOR TREATMENT OF ULCERATIVE COLITIS WITH ANTI-IL12/IL23 ANTIBODY |
EP3856350A1 (en) | 2018-09-27 | 2021-08-04 | Marengo Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
JP2022503865A (en) | 2018-09-28 | 2022-01-12 | 協和キリン株式会社 | IL-36 antibody and its uses |
WO2020070678A2 (en) | 2018-10-03 | 2020-04-09 | Staten Biotechnology B.V. | Antibodies specific for human and cynomolgus apoc3 and methods of use thereof |
WO2020070303A1 (en) | 2018-10-05 | 2020-04-09 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
JP7289913B2 (en) | 2018-10-11 | 2023-06-12 | ファイザー・インク | Dosing Regimens for TFPI Antagonists |
UY38407A (en) | 2018-10-15 | 2020-05-29 | Novartis Ag | TREM2 STABILIZING ANTIBODIES |
CA3116324A1 (en) | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
WO2020086736A1 (en) | 2018-10-23 | 2020-04-30 | Scholar Rock, Inc. | Rgmc-selective inhibitors and use thereof |
GB201817309D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
GB201817311D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
CA3115110A1 (en) | 2018-10-24 | 2020-04-30 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
KR20210090645A (en) | 2018-11-05 | 2021-07-20 | 제넨테크, 인크. | Methods for producing two-chain proteins in prokaryotic host cells |
BR112021009373A2 (en) | 2018-11-16 | 2021-08-17 | Memorial Sloan Kettering Cancer Center | antibodies to mucin-16 and methods of using them |
US20220332800A1 (en) | 2018-11-20 | 2022-10-20 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
SG11202104918PA (en) | 2018-11-20 | 2021-06-29 | Bavarian Nordic As | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
JP2022513094A (en) | 2018-11-20 | 2022-02-07 | ヤンセン バイオテツク,インコーポレーテツド | A safe and effective way to treat psoriasis with anti-IL-23 specific antibodies |
WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
BR112021010908A2 (en) | 2018-12-06 | 2021-08-31 | Genentech, Inc. | METHOD FOR TREATMENT OF DIFFUSED LARGE B-CELL LYMPHOMA, KIT AND IMMUNOCONJUGATE |
EP3894427A1 (en) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
US20200197517A1 (en) | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody |
EP3898993A1 (en) | 2018-12-20 | 2021-10-27 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
EP3883609A2 (en) | 2018-12-20 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
CN113227131A (en) | 2018-12-20 | 2021-08-06 | 豪夫迈·罗氏有限公司 | Modified antibody Fc and methods of use thereof |
KR20210106484A (en) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | Combination of HDM2-P53 interaction inhibitor with BCL2 inhibitor and use thereof for the treatment of cancer |
AU2019402163A1 (en) | 2018-12-20 | 2021-07-08 | Kyowa Kirin Co., Ltd. | Fn14 antibodies and uses thereof |
MX2021007421A (en) | 2018-12-21 | 2021-08-05 | Hoffmann La Roche | Antibody that binds to vegf and il-1beta and methods of use. |
KR20210107025A (en) | 2018-12-21 | 2021-08-31 | 제넨테크, 인크. | Methods for producing polypeptides using cell lines resistant to apoptosis |
EP3902824A4 (en) | 2018-12-28 | 2023-01-04 | Sparx Therapeutics Inc. | Binding molecules specific for claudin 18.2, compositons and methods thereof, for treatment of cancer and other diseases |
US20220073630A1 (en) | 2018-12-28 | 2022-03-10 | Hoffmann-La Roche, Inc. | A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response |
AU2020208828A1 (en) | 2019-01-15 | 2021-08-05 | Janssen Biotech, Inc. | Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
EP3911679A1 (en) | 2019-01-16 | 2021-11-24 | Compass Therapeutics LLC | Formulations of antibodies that bind human cd137 and uses thereof |
GB201900732D0 (en) | 2019-01-18 | 2019-03-06 | Ucb Biopharma Sprl | Antibodies |
KR20210118115A (en) | 2019-01-23 | 2021-09-29 | 제넨테크, 인크. | Methods for Producing Multimeric Proteins in Eukaryotic Host Cells |
MA54814A (en) | 2019-01-23 | 2021-12-01 | Janssen Biotech Inc | ANTI-TNF ANTIBODY COMPOSITIONS FOR USE IN METHODS OF TREATING PSORIATIC ARTHRITIS |
US20220089770A1 (en) | 2019-01-24 | 2022-03-24 | Chugai Seiyaku Kabushiki Kaisha | Novel cancer antigens and antibodies of said antigens |
US20220073600A1 (en) | 2019-01-28 | 2022-03-10 | Maple Biotech Llc | Methods for treating disease using psmp antagonists |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
KR20210121174A (en) | 2019-01-30 | 2021-10-07 | 스칼러 락, 인크. | LTBP complex-specific inhibitors of TGFβ and uses thereof |
US11738050B2 (en) | 2019-02-01 | 2023-08-29 | Regents Of The University Of Minnesota | Compounds binding to fibroblast activation protein alpha |
EP3693063A1 (en) | 2019-02-06 | 2020-08-12 | Diaccurate | Methods and compositions for treating cancer |
EP3696191A1 (en) | 2019-02-14 | 2020-08-19 | Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) | Car t-cells for the treatment of cd1a-positive cancer |
US10871640B2 (en) | 2019-02-15 | 2020-12-22 | Perkinelmer Cellular Technologies Germany Gmbh | Methods and systems for automated imaging of three-dimensional objects |
CA3131016A1 (en) | 2019-02-21 | 2020-08-27 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
SG11202109122SA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Anti-tcr antibody molecules and uses thereof |
CA3130754A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
CA3130628A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
MX2021010003A (en) | 2019-02-26 | 2021-12-10 | Inspirna Inc | High-affinity anti-mertk antibodies and uses thereof. |
CN113710706A (en) | 2019-02-27 | 2021-11-26 | 豪夫迈·罗氏有限公司 | Administration for anti-TIGIT antibody and anti-CD 20 antibody or anti-CD 38 antibody treatment |
JP7402247B2 (en) | 2019-03-08 | 2023-12-20 | ジェネンテック, インコーポレイテッド | Methods for detecting and quantifying membrane-bound proteins of extracellular vesicles |
MA55283A (en) | 2019-03-14 | 2022-01-19 | Janssen Biotech Inc | METHODS FOR PRODUCING ANTI-TNF ANTIBODY COMPOSITIONS |
CA3133388A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
US20200291107A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions |
CA3133381A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
JP2022526493A (en) | 2019-03-18 | 2022-05-25 | ヤンセン バイオテツク,インコーポレーテツド | Treatment of Psoriasis in Pediatric Subjects Using Anti-IL12 / IL23 Antibodies |
US20220169706A1 (en) | 2019-03-28 | 2022-06-02 | Danisco Us Inc | Engineered antibodies |
AU2020253833A1 (en) | 2019-03-29 | 2021-10-28 | Atarga, Llc | Anti FGF23 antibody |
WO2020205626A1 (en) | 2019-03-29 | 2020-10-08 | Genentech, Inc. | Modulators of cell surface protein interactions and methods and compositions related to same |
CN114007643A (en) | 2019-04-19 | 2022-02-01 | 中外制药株式会社 | Chimeric receptors recognizing altered sites of antibodies |
KR20220002967A (en) | 2019-04-19 | 2022-01-07 | 제넨테크, 인크. | Anti-MERTK antibodies and methods of use thereof |
EP3962523A2 (en) | 2019-05-03 | 2022-03-09 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
WO2020232169A1 (en) | 2019-05-14 | 2020-11-19 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma |
US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
CA3138241A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
CA3141531A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
MA56026A (en) | 2019-06-03 | 2022-04-06 | Janssen Biotech Inc | ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLARTHRITIS |
CA3142665A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis |
EP3983441A1 (en) | 2019-06-11 | 2022-04-20 | Alector LLC | Anti-sortilin antibodies for use in therapy |
TW202112822A (en) | 2019-06-17 | 2021-04-01 | 美商威特拉公司 | Humanized antibody molecules to cd138 and uses thereof |
JP2022538139A (en) | 2019-07-02 | 2022-08-31 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Immune complex comprising mutant interleukin-2 and anti-CD8 antibody |
JPWO2021010326A1 (en) | 2019-07-12 | 2021-01-21 | ||
AR119393A1 (en) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | ANTIBODIES THAT BIND NKG2D |
CN114144436A (en) | 2019-07-24 | 2022-03-04 | H.隆德贝克有限公司 | anti-mGluR 5 antibodies and uses thereof |
AU2020323893A1 (en) | 2019-07-26 | 2022-02-17 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
JP2022543553A (en) | 2019-07-31 | 2022-10-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Antibody that binds to GPRC5D |
EP4003519A2 (en) | 2019-07-31 | 2022-06-01 | Alector LLC | Anti-ms4a4a antibodies and methods of use thereof |
WO2021018925A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
PT4007777T (en) | 2019-08-02 | 2024-01-12 | Hospital CliNic De Barcelona | Car t-cells against bcma for the treatment of multiple myeloma |
CN114641490B (en) | 2019-08-06 | 2023-06-06 | 新旭生技股份有限公司 | Antibodies that bind to pathological TAU species and uses thereof |
EP4031658A1 (en) | 2019-08-07 | 2022-07-27 | DB Biotech, AS | Improved horseradish peroxidase polypeptides |
CN114867751A (en) | 2019-08-12 | 2022-08-05 | 阿帕特夫研究和发展有限公司 | 4-1BB and OX40 binding proteins and related compositions and methods, anti-4-1 BB antibodies, anti-OX 40 antibodies |
BR112022002406A2 (en) | 2019-08-12 | 2022-07-19 | Purinomia Biotech Inc | METHODS AND COMPOSITIONS TO PROMOTE AND ENHANCE T-CELL-MEDIATED IMMUNE RESPONSES THROUGH ADCC TARGETING OF CELLS THAT EXPRESS CD39 |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
JP2022545741A (en) | 2019-08-30 | 2022-10-28 | アジェナス インコーポレイテッド | ANTI-CD96 ANTIBODY AND METHODS OF USE THEREOF |
MX2022002672A (en) | 2019-09-04 | 2022-06-16 | Y Biologics Inc | Anti-vsig4 antibody or antigen binding fragment and uses thereof. |
US20220332799A1 (en) | 2019-09-04 | 2022-10-20 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Herv inhibitors for use in treating tauopathies |
AU2020342544A1 (en) | 2019-09-05 | 2022-03-24 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
CA3146616A1 (en) | 2019-09-12 | 2021-03-18 | Matthew Dominic CASCINO | Compositions and methods of treating lupus nephritis |
TW202124444A (en) | 2019-09-16 | 2021-07-01 | 美商表面腫瘤學公司 | Anti-cd39 antibody compositions and methods |
US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
JP2022549087A (en) | 2019-09-18 | 2022-11-24 | ジェネンテック, インコーポレイテッド | Anti-KLK7 Antibodies, Anti-KLK5 Antibodies, Multispecific Anti-KLK5/KLK7 Antibodies and Methods of Use |
TW202124446A (en) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | Combination therapies with entpd2 antibodies |
CN114423454A (en) | 2019-09-20 | 2022-04-29 | 豪夫迈·罗氏有限公司 | Administration of anti-tryptase antibodies |
CA3151078A1 (en) | 2019-09-25 | 2021-04-01 | Surface Oncology, Inc. | Anti-il-27 antibodies and uses thereof |
WO2021062323A1 (en) | 2019-09-26 | 2021-04-01 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
JP2022548978A (en) | 2019-09-27 | 2022-11-22 | ジェネンテック, インコーポレイテッド | Dosing for Treatment with Drugs Anti-TIGIT and Anti-PD-L1 Antagonist Antibodies |
CN114746119A (en) | 2019-09-27 | 2022-07-12 | 詹森生物科技公司 | anti-CEACAM antibodies and uses thereof |
EP4036116A4 (en) | 2019-09-27 | 2024-01-24 | Nanjing Genscript Biotech Co Ltd | Anti-vhh domain antibodies and use thereof |
CN114829404A (en) | 2019-10-09 | 2022-07-29 | 斯特库比公司 | Antibodies specific for glycosylated LAG3 and methods of use thereof |
MX2022004443A (en) | 2019-10-18 | 2022-05-02 | Genentech Inc | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma. |
MX2022004766A (en) | 2019-10-21 | 2022-05-16 | Novartis Ag | Combination therapies with venetoclax and tim-3 inhibitors. |
MX2022004769A (en) | 2019-10-21 | 2022-05-16 | Novartis Ag | Tim-3 inhibitors and uses thereof. |
EP3812008A1 (en) | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
US11459389B2 (en) | 2019-10-24 | 2022-10-04 | Massachusetts Institute Of Technology | Monoclonal antibodies that bind human CD161 |
CN115066613A (en) | 2019-11-06 | 2022-09-16 | 基因泰克公司 | Diagnostic and therapeutic methods for treating hematologic cancers |
MX2022005664A (en) | 2019-11-20 | 2022-09-07 | Bavarian Nordic As | Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer. |
GB201917480D0 (en) | 2019-11-29 | 2020-01-15 | Univ Oxford Innovation Ltd | Antibodies |
EP4072584A1 (en) | 2019-12-13 | 2022-10-19 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
EP4072680A1 (en) | 2019-12-13 | 2022-10-19 | Alector LLC | Anti-mertk antibodies and methods of use thereof |
EP4076666A1 (en) | 2019-12-18 | 2022-10-26 | F. Hoffmann-La Roche AG | Antibodies binding to hla-a2/mage-a4 |
EP4077376A2 (en) | 2019-12-19 | 2022-10-26 | Quidel Corporation | Monoclonal antibody fusions |
AU2020406350A1 (en) | 2019-12-20 | 2022-08-11 | Novartis Ag | Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
WO2021127505A1 (en) | 2019-12-20 | 2021-06-24 | Poseida Therapeutics, Inc. | Anti-muc1 compositions and methods of use |
US20230058982A1 (en) | 2019-12-27 | 2023-02-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-ctla-4 antibody and use thereof |
TW202138388A (en) | 2019-12-30 | 2021-10-16 | 美商西根公司 | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
AU2021205877A1 (en) | 2020-01-06 | 2022-06-09 | Vaccinex, Inc. | Anti-CCR8 antibodies and uses thereof |
CN110818795B (en) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | anti-TIGIT antibodies and methods of use |
WO2021142448A2 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock,Inc. | Tgf-beta inhibitors and use thereof |
MX2022008609A (en) | 2020-01-11 | 2022-11-10 | Scholar Rock Inc | Tgfî² inhibitors and use thereof. |
TW202140553A (en) | 2020-01-13 | 2021-11-01 | 美商威特拉公司 | Antibody molecules to c5ar1 and uses thereof |
JP2023511274A (en) | 2020-01-14 | 2023-03-17 | シンセカイン インコーポレイテッド | IL2 orthologs and usage |
TW202140037A (en) | 2020-01-17 | 2021-11-01 | 瑞士商諾華公司 | Combination therapies |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
US20230061973A1 (en) | 2020-02-05 | 2023-03-02 | Larimar Therapeutics, Inc. | Tat peptide binding proteins and uses thereof |
JP2023513400A (en) | 2020-02-10 | 2023-03-30 | 上海詩健生物科技有限公司 | CLDN18.2 antibody and uses thereof |
WO2021160155A1 (en) | 2020-02-10 | 2021-08-19 | 上海诗健生物科技有限公司 | Claudin 18.2 antibody and use thereof |
TW202144395A (en) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | Anti-CD137 antigen-binding molecule for use in cancer treatment |
US20230151108A1 (en) | 2020-02-13 | 2023-05-18 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd137 |
WO2021160269A1 (en) | 2020-02-13 | 2021-08-19 | UCB Biopharma SRL | Anti cd44-ctla4 bispecific antibodies |
WO2021160266A1 (en) | 2020-02-13 | 2021-08-19 | UCB Biopharma SRL | Bispecific antibodies binding hvem and cd9 |
US20230096030A1 (en) | 2020-02-13 | 2023-03-30 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd7 |
WO2021160268A1 (en) | 2020-02-13 | 2021-08-19 | UCB Biopharma SRL | Bispecific antibodies against cd9 |
MX2022009947A (en) | 2020-02-14 | 2022-11-07 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and uses thereof. |
BR112022016368A2 (en) | 2020-02-18 | 2023-01-10 | Alector Llc | PILRA ANTIBODIES AND THEIR METHODS OF USE |
EP4112642A1 (en) | 2020-02-28 | 2023-01-04 | Shanghai Henlius Biotech, Inc. | Anti-cd137 construct and use thereof |
JP2023516941A (en) | 2020-02-28 | 2023-04-21 | 上海復宏漢霖生物技術股▲フン▼有限公司 | Anti-CD137 constructs, multispecific antibodies and uses thereof |
JP2023516724A (en) | 2020-03-06 | 2023-04-20 | オーエヌエー セラピューティクス エセ.エレ. | Anti-CD36 antibodies and their use to treat cancer |
JP2023517889A (en) | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | Compositions and methods for immunotherapy of NPM1c-positive cancers |
EP4118107A1 (en) | 2020-03-11 | 2023-01-18 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
CN115843255A (en) | 2020-03-11 | 2023-03-24 | 约瑟夫卡雷拉斯白血病研究基金会 | CD22 targeting moieties for the treatment of B cell type acute lymphoblastic leukemia (B-ALL) |
IL296256A (en) | 2020-03-13 | 2022-11-01 | Genentech Inc | Anti-interleukin-33 antibodies and uses thereof |
KR20220156575A (en) | 2020-03-19 | 2022-11-25 | 제넨테크, 인크. | Isotype Selective Anti-TGF-beta Antibodies and Methods of Use |
MX2022011752A (en) | 2020-03-24 | 2022-10-18 | Genentech Inc | Tie2-binding agents and methods of use. |
WO2021202473A2 (en) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Engineered antibodies |
CN115397850A (en) | 2020-03-30 | 2022-11-25 | 豪夫迈·罗氏有限公司 | Antibodies that bind to VEGF and PDGF-B and methods of use thereof |
JP2023519962A (en) | 2020-03-31 | 2023-05-15 | アレクトル エルエルシー | ANTI-MERTK ANTIBODY AND METHOD OF USE THEREOF |
CA3170570A1 (en) | 2020-04-01 | 2021-10-07 | James J. KOBIE | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
EP4127724A1 (en) | 2020-04-03 | 2023-02-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
EP4126064A1 (en) | 2020-04-03 | 2023-02-08 | Visterra, Inc. | Antibody molecule-drug conjugates and uses thereof |
EP4136459A1 (en) | 2020-04-13 | 2023-02-22 | Abbott Laboratories | Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample |
WO2021211628A1 (en) | 2020-04-14 | 2021-10-21 | Poseida Therapeutics, Inc. | Compositions and methods for use in the treatment of cancer |
MX2022012541A (en) | 2020-04-15 | 2022-11-07 | Hoffmann La Roche | Immunoconjugates. |
AU2021261420A1 (en) | 2020-04-24 | 2022-12-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
CN115916822A (en) | 2020-04-24 | 2023-04-04 | 基因泰克公司 | Methods of using anti-CD 79b immunoconjugates |
KR20230002261A (en) | 2020-04-28 | 2023-01-05 | 더 락커펠러 유니버시티 | Anti-SARS-COV-2 Neutralizing Antibodies and Methods of Using The Same |
WO2021222167A1 (en) | 2020-04-28 | 2021-11-04 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
TW202204420A (en) | 2020-04-30 | 2022-02-01 | 美商建南德克公司 | Kras specific antibodies and uses thereof |
WO2021220218A1 (en) | 2020-05-01 | 2021-11-04 | Novartis Ag | Immunoglobulin variants |
US20230242647A1 (en) | 2020-05-01 | 2023-08-03 | Novartis Ag | Engineered immunoglobulins |
CA3177562A1 (en) | 2020-05-03 | 2021-11-11 | Tong Zhu | Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same |
WO2021226290A1 (en) | 2020-05-05 | 2021-11-11 | 10X Genomics, Inc. | Methods for identification of antigen-binding molecules |
AU2021275361A1 (en) | 2020-05-17 | 2023-01-19 | Astrazeneca Uk Limited | SARS-CoV-2 antibodies and methods of selecting and using the same |
WO2021239666A1 (en) | 2020-05-26 | 2021-12-02 | Diaccurate | Therapeutic methods |
CN113993900B (en) | 2020-05-27 | 2023-08-04 | 舒泰神(北京)生物制药股份有限公司 | Antibodies specifically recognizing nerve growth factor and uses thereof |
WO2021247618A1 (en) | 2020-06-02 | 2021-12-09 | 10X Genomics, Inc. | Enrichment of nucleic acid sequences |
WO2021247769A1 (en) | 2020-06-02 | 2021-12-09 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
CN116529260A (en) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | anti-CD 93 constructs and uses thereof |
EP4161653A1 (en) | 2020-06-03 | 2023-04-12 | Bionecure Therapeutics, Inc. | Trophoblast cell-surface antigen-2 (trop-2) antibodies |
US20230340081A1 (en) | 2020-06-08 | 2023-10-26 | Hoffmann-La Roche Inc. | Anti-hbv antibodies and methods of use |
GB202008651D0 (en) | 2020-06-09 | 2020-07-22 | Univ Newcastle | Method of identifying complement modulators |
EP4165415A1 (en) | 2020-06-12 | 2023-04-19 | Genentech, Inc. | Methods and compositions for cancer immunotherapy |
KR20230025691A (en) | 2020-06-16 | 2023-02-22 | 제넨테크, 인크. | Methods and compositions for treating triple negative breast cancer |
IL298946A (en) | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
WO2021262999A1 (en) | 2020-06-24 | 2021-12-30 | Visterra, Inc. | Antibody molecules to april and uses thereof |
WO2022010797A2 (en) | 2020-07-07 | 2022-01-13 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
AU2021308586A1 (en) | 2020-07-17 | 2023-03-02 | Pfizer Inc. | Therapeutic antibodies and their uses |
AU2021308653A1 (en) | 2020-07-17 | 2023-02-16 | Genentech, Inc. | Anti-Notch2 antibodies and methods of use |
KR20230038783A (en) | 2020-07-20 | 2023-03-21 | 아스트라제네카 유케이 리미티드 | SARS-COV-2 proteins, anti-SARS-COV-2 antibodies, and methods of using them |
KR20230040331A (en) | 2020-07-21 | 2023-03-22 | 알로젠 테라퓨틱스 인코포레이티드 | Chimeric Antigen Receptors with Enhanced Signal Transduction and Activity and Uses Thereof |
KR20230042032A (en) | 2020-07-21 | 2023-03-27 | 제넨테크, 인크. | Antibody Conjugation Chemical Inducers of BRM Degradation and Methods Thereof |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
AU2021315665A1 (en) | 2020-07-29 | 2023-03-16 | Dynamicure Biotechnology Llc | Anti-CD93 constructs and uses thereof |
CA3188349A1 (en) | 2020-08-04 | 2022-02-10 | A. Scott Muerhoff | Improved methods and kits for detecting sars-cov-2 protein in a sample |
AU2021328375A1 (en) | 2020-08-18 | 2023-04-13 | Cephalon Llc | Anti-PAR-2 antibodies and methods of use thereof |
AU2021333779A1 (en) | 2020-08-26 | 2023-04-13 | Marengo Therapeutics, Inc. | Methods of detecting TRBC1 or TRBC2 |
CA3190766A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
CA3190755A1 (en) | 2020-08-26 | 2022-03-03 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
AU2021339953A1 (en) | 2020-09-11 | 2023-05-18 | Medimmune Limited | Therapeutic b7-h4 binding molecules |
KR20230066095A (en) | 2020-09-12 | 2023-05-12 | 메디뮨 리미티드 | Scoring Methods for Anti-B7H4 Antibody-Drug Conjugate Therapy |
EP3981789A1 (en) | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
WO2022081718A1 (en) | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
EP4229086A1 (en) | 2020-10-15 | 2023-08-23 | UCB Biopharma SRL | Binding molecules that multimerise cd45 |
US20230382978A1 (en) | 2020-10-15 | 2023-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
JP2023545566A (en) | 2020-10-20 | 2023-10-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Combination therapy with PD-1 axis binding antagonist and LRRK2 inhibitor |
WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
WO2022090181A1 (en) | 2020-10-28 | 2022-05-05 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
IL302396A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
JP2023548878A (en) | 2020-11-04 | 2023-11-21 | ザ ロックフェラー ユニバーシティー | Neutralizing anti-SARS-COV-2 antibody |
CA3196191A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
IL302400A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
EP4251647A1 (en) | 2020-11-24 | 2023-10-04 | Bio-Techne Corporation | Anti-severe acute respiratory syndrome coronavirus antibodies |
WO2022119841A1 (en) | 2020-12-01 | 2022-06-09 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
KR20230117379A (en) | 2020-12-01 | 2023-08-08 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Heterodimeric PSMA and CD3-binding bispecific antibody |
JP2023553399A (en) | 2020-12-02 | 2023-12-21 | アレクトル エルエルシー | How to use anti-Sortilin antibodies |
WO2022118197A1 (en) | 2020-12-02 | 2022-06-09 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
WO2022120224A1 (en) | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
WO2022122652A1 (en) | 2020-12-07 | 2022-06-16 | UCB Biopharma SRL | Antibodies against interleukin-22 |
EP4255926A1 (en) | 2020-12-07 | 2023-10-11 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
AU2021399841A1 (en) | 2020-12-17 | 2023-07-06 | F. Hoffmann-La Roche Ag | Anti-hla-g antibodies and use thereof |
CN117043181A (en) | 2020-12-18 | 2023-11-10 | 基尼科萨制药有限公司 | Protein compositions and methods of making and using the same |
WO2022147147A1 (en) | 2020-12-30 | 2022-07-07 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
EP4271482A2 (en) | 2020-12-31 | 2023-11-08 | Alamar Biosciences, Inc. | Binder molecules with high affinity and/ or specificity and methods of making and use thereof |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
EP4277664A1 (en) | 2021-01-13 | 2023-11-22 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
CA3204731A1 (en) | 2021-01-13 | 2022-07-21 | John T. POIRIER | Anti-dll3 antibody-drug conjugate |
US20220227844A1 (en) | 2021-01-15 | 2022-07-21 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
US20220226442A1 (en) | 2021-01-20 | 2022-07-21 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
EP4284510A1 (en) | 2021-01-29 | 2023-12-06 | Novartis AG | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
AU2022220611A1 (en) | 2021-02-09 | 2023-08-24 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
IL304955A (en) | 2021-02-09 | 2023-10-01 | Us Health | Antibodies targeting the spike protein of coronaviruses |
WO2022182872A2 (en) | 2021-02-24 | 2022-09-01 | Alladapt Immunotherapeutics, Inc. | Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies |
JP2024509165A (en) | 2021-03-02 | 2024-02-29 | シージーアールピー ダイアグノスティクス ゲーエムベーハー | Treating and/or reducing the occurrence of migraine |
CN117440832A (en) | 2021-03-03 | 2024-01-23 | 索伦托药业有限公司 | Antibody-drug conjugates comprising anti-BCMA antibodies |
EP4301396A1 (en) | 2021-03-03 | 2024-01-10 | The United States of America, as represented by the Secretary, Department of Health and Human Services | La protien as a novel regulator of osteoclastogenesis |
EP4301786A1 (en) | 2021-03-03 | 2024-01-10 | Pierre Fabre Medicament | Anti-vsig4 antibody or antigen binding fragment and uses thereof |
JP2024509191A (en) | 2021-03-05 | 2024-02-29 | ダイナミキュア バイオテクノロジー エルエルシー | Anti-VISTA constructs and their uses |
JP2024510588A (en) | 2021-03-12 | 2024-03-08 | ヤンセン バイオテツク,インコーポレーテツド | Method of treating psoriatic arthritis patients with inadequate response to TNF therapy with anti-IL23-specific antibodies |
WO2022190033A1 (en) | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
AR125074A1 (en) | 2021-03-12 | 2023-06-07 | Genentech Inc | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, ANTI-KLK5/KLK7 MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE |
JP2024511970A (en) | 2021-03-15 | 2024-03-18 | ジェネンテック, インコーポレイテッド | Compositions and methods for the treatment of lupus nephritis |
CN117321418A (en) | 2021-03-18 | 2023-12-29 | 诺华股份有限公司 | Cancer biomarkers and methods of use thereof |
JP2024512002A (en) | 2021-03-18 | 2024-03-18 | アレクトル エルエルシー | Anti-TMEM106B antibody and method of use thereof |
EP4308607A2 (en) | 2021-03-18 | 2024-01-24 | MedImmune Limited | Therapeutic binding molecule that binds to ccr9 |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
WO2022204274A1 (en) | 2021-03-23 | 2022-09-29 | Alector Llc | Anti-tmem106b antibodies for treating and preventing coronavirus infections |
WO2022204724A1 (en) | 2021-03-25 | 2022-09-29 | Dynamicure Biotechnology Llc | Anti-igfbp7 constructs and uses thereof |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
EP4067381A1 (en) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
TW202304979A (en) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
AR125344A1 (en) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | ANTI-C1S ANTIBODY |
WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
EP4329800A1 (en) | 2021-04-30 | 2024-03-06 | F. Hoffmann-La Roche AG | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
KR20240004694A (en) | 2021-05-03 | 2024-01-11 | 유씨비 바이오파마 에스알엘 | antibody |
EP4334343A2 (en) | 2021-05-06 | 2024-03-13 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
US20220389089A1 (en) | 2021-05-07 | 2022-12-08 | Surface Oncology, Inc. | Anti-il-27 antibodies and uses thereof |
CN117396232A (en) | 2021-05-12 | 2024-01-12 | 基因泰克公司 | Methods of treating diffuse large B-cell lymphomas using anti-CD 79B immunoconjugates |
AU2022279156A1 (en) | 2021-05-18 | 2023-11-02 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
CN113278071B (en) | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | Anti-human interferon alpha receptor1 monoclonal antibody and application thereof |
CA3220629A1 (en) | 2021-05-28 | 2022-12-01 | Tobin J. CAMMETT | Methods for detecting cm-tma biomarkers |
WO2022256313A1 (en) | 2021-06-01 | 2022-12-08 | 10X Genomics, Inc. | Validation of a unique molecular identifier associated with a nucleic acid sequence of interest |
EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
CN117480184A (en) | 2021-06-04 | 2024-01-30 | 中外制药株式会社 | anti-DDR 2 antibodies and uses thereof |
CA3218590A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
CA3216220A1 (en) | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
WO2022263357A1 (en) | 2021-06-14 | 2022-12-22 | Argenx Iip Bv | Anti-il-9 antibodies and methods of use thereof |
AU2022293389A1 (en) | 2021-06-14 | 2024-01-04 | Abbott Laboratories | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
WO2022266223A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
WO2022266221A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Monovalent anti-mertk antibodies and methods of use thereof |
WO2022266660A1 (en) | 2021-06-17 | 2022-12-22 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
CA3221555A1 (en) | 2021-06-23 | 2022-12-29 | Kimberly LONG | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
AU2022297107A1 (en) | 2021-06-25 | 2024-01-18 | Chugai Seiyaku Kabushiki Kaisha | Use of anti-ctla-4 antibody |
JPWO2022270611A1 (en) | 2021-06-25 | 2022-12-29 | ||
TW202317190A (en) | 2021-06-29 | 2023-05-01 | 美商思進公司 | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
TW202317633A (en) | 2021-07-08 | 2023-05-01 | 美商舒泰神(加州)生物科技有限公司 | Antibodies specifically recognizing tnfr2 and uses thereof |
WO2023281463A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
IL309987A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Manufacturing methods for producing anti-il12/il23 antibody compositions |
IL309997A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Manufacturing methods for producing anti-tnf antibody compositions |
WO2023285878A1 (en) | 2021-07-13 | 2023-01-19 | Aviation-Ophthalmology | Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions |
IL309957A (en) | 2021-07-14 | 2024-03-01 | 2Seventy Bio Inc | Engineered t cell receptors fused to binding domains from antibodies |
WO2023284714A1 (en) | 2021-07-14 | 2023-01-19 | 舒泰神(北京)生物制药股份有限公司 | Antibody that specifically recognizes cd40 and application thereof |
CN117730102A (en) | 2021-07-22 | 2024-03-19 | 豪夫迈·罗氏有限公司 | Heterodimeric Fc domain antibodies |
WO2023004386A1 (en) | 2021-07-22 | 2023-01-26 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
AU2022320051A1 (en) | 2021-07-30 | 2024-01-25 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
CN117794953A (en) | 2021-08-03 | 2024-03-29 | 豪夫迈·罗氏有限公司 | Bispecific antibodies and methods of use |
US11807685B2 (en) | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
CA3227511A1 (en) | 2021-08-06 | 2023-02-09 | Lætitia LINARES | Methods for the treatment of cancer |
WO2023018803A1 (en) | 2021-08-10 | 2023-02-16 | Byomass Inc. | Anti-gdf15 antibodies, compositions and uses thereof |
WO2023019239A1 (en) | 2021-08-13 | 2023-02-16 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
AU2022335718A1 (en) | 2021-08-26 | 2024-03-28 | Glycanostics S.R.O | Glycoprotein biomarkers for diagnosing cancer |
TW202325727A (en) | 2021-08-30 | 2023-07-01 | 美商建南德克公司 | Anti-polyubiquitin multispecific antibodies |
WO2023034777A1 (en) | 2021-08-31 | 2023-03-09 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
WO2023032955A1 (en) | 2021-08-31 | 2023-03-09 | 大正製薬株式会社 | Anti-growth hormone antibody |
CN113603775B (en) | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | Anti-human interleukin-33 monoclonal antibody and application thereof |
CN113683694B (en) | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | Anti-human TSLP monoclonal antibody and application thereof |
AR126971A1 (en) | 2021-09-03 | 2023-12-06 | Univ Of Bern | COMPOSITIONS AND METHODS FOR TREATING LONG QT SYNDROME |
AU2022346688A1 (en) | 2021-09-14 | 2024-04-04 | Glycanostics S.R.O | Use of lectins to determine mammaglobin-a glycoforms in breast cancer |
AU2022345881A1 (en) | 2021-09-20 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
TW202321308A (en) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
WO2023056268A1 (en) | 2021-09-30 | 2023-04-06 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
WO2023060088A1 (en) | 2021-10-04 | 2023-04-13 | Poseida Therapeutics, Inc. | Transposon compositions and methods of use thereof |
WO2023057882A1 (en) | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
WO2023058705A1 (en) | 2021-10-08 | 2023-04-13 | 中外製薬株式会社 | Drug formulation of anti-hla-dq2.5 antibody |
AU2022362681A1 (en) | 2021-10-14 | 2024-04-04 | F. Hoffmann-La Roche Ag | New interleukin-7 immunoconjugates |
WO2023062048A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | Alternative pd1-il7v immunoconjugates for the treatment of cancer |
WO2023069421A1 (en) | 2021-10-18 | 2023-04-27 | Byomass Inc. | Anti-activin a antibodies, compositions and uses thereof |
WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
EP4177266A1 (en) | 2021-11-05 | 2023-05-10 | Katholieke Universiteit Leuven | Neutralizing anti-sars-cov-2 human antibodies |
WO2023086824A1 (en) | 2021-11-10 | 2023-05-19 | 10X Genomics, Inc. | Methods for identification of antigen-binding molecules |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2023084488A1 (en) | 2021-11-15 | 2023-05-19 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
TW202337494A (en) | 2021-11-16 | 2023-10-01 | 美商建南德克公司 | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
WO2023097254A1 (en) | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
US20240041981A1 (en) | 2021-12-01 | 2024-02-08 | Visterra, Inc. | Methods of using interleukin-2 agents |
WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
WO2023129942A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
WO2023141445A1 (en) | 2022-01-19 | 2023-07-27 | Genentech, Inc. | Anti-notch2 antibodies and conjugates and methods of use |
WO2023141576A1 (en) | 2022-01-21 | 2023-07-27 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
WO2023147107A1 (en) | 2022-01-31 | 2023-08-03 | Byomass Inc. | Myeloproliferative conditions |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
TW202342548A (en) | 2022-02-07 | 2023-11-01 | 美商威特拉公司 | Anti-idiotype antibody molecules and uses thereof |
WO2023154824A1 (en) | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that broadly target coronaviruses |
TW202348252A (en) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | Combination therapies for treatment of cancer with therapeutic binding molecules |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
WO2023175614A1 (en) | 2022-03-15 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof |
WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023180511A1 (en) | 2022-03-25 | 2023-09-28 | F. Hoffmann-La Roche Ag | Improved chimeric receptors |
US20230312703A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of Treating Psoriasis with IL-23 Specific Antibody |
WO2023192436A1 (en) | 2022-03-31 | 2023-10-05 | Alexion Pharmaceuticals, Inc. | Singleplex or multiplexed assay for complement markers in fresh biological samples |
WO2023192478A1 (en) | 2022-04-01 | 2023-10-05 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
WO2023196866A1 (en) | 2022-04-06 | 2023-10-12 | Mirobio Limited | Engineered cd200r antibodies and uses thereof |
GB202205200D0 (en) | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
GB202205203D0 (en) | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
US20240092921A1 (en) | 2022-04-25 | 2024-03-21 | Visterra, Inc. | Antibody molecules to april and uses thereof |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
WO2023215737A1 (en) | 2022-05-03 | 2023-11-09 | Genentech, Inc. | Anti-ly6e antibodies, immunoconjugates, and uses thereof |
WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023239803A1 (en) | 2022-06-08 | 2023-12-14 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
WO2023250402A2 (en) | 2022-06-22 | 2023-12-28 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
EP4296279A1 (en) | 2022-06-23 | 2023-12-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-transthyretin (ttr) binding proteins and uses thereof |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
WO2024020407A1 (en) | 2022-07-19 | 2024-01-25 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024026447A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
WO2024026472A2 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
WO2024050354A1 (en) | 2022-08-31 | 2024-03-07 | Washington University | Alphavirus antigen binding antibodies and uses thereof |
WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
WO2024050526A1 (en) | 2022-09-02 | 2024-03-07 | Biomarin Pharmaceutical Inc. | Compositions and methods for treating long qt syndrome |
WO2024054436A1 (en) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
WO2024054929A1 (en) | 2022-09-07 | 2024-03-14 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
WO2024062038A1 (en) | 2022-09-21 | 2024-03-28 | Elthera Ag | Novel binding molecules binding to l1cam |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3853832A (en) * | 1971-04-27 | 1974-12-10 | Harmone Res Foundation | Synthetic human pituitary growth hormone and method of producing it |
US3853833A (en) * | 1971-04-27 | 1974-12-10 | Hormone Res Foundation | Synthetic human growth-promoting and lactogenic hormones and method of producing same |
US4880910A (en) * | 1981-09-18 | 1989-11-14 | Genentech, Inc. | Terminal methionyl bovine growth hormone and its use |
US4593002A (en) * | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
US4446235A (en) * | 1982-03-22 | 1984-05-01 | Genentech, Inc. | Method for cloning human growth hormone varient genes |
US4670393A (en) * | 1982-03-22 | 1987-06-02 | Genentech, Inc. | DNA vectors encoding a novel human growth hormone-variant protein |
US4673641A (en) * | 1982-12-16 | 1987-06-16 | Molecular Genetics Research And Development Limited Partnership | Co-aggregate purification of proteins |
US4699897A (en) * | 1983-06-04 | 1987-10-13 | Amgen | Biologically active peptides structurally related to regions within growth hormones |
US4888286A (en) * | 1984-02-06 | 1989-12-19 | Creative Biomolecules, Inc. | Production of gene and protein analogs through synthetic gene design using double stranded synthetic oligonucleotides |
US4655160A (en) * | 1985-09-10 | 1987-04-07 | David R. Ligh | Deck box |
US5013653A (en) * | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
IT1223577B (en) * | 1987-12-22 | 1990-09-19 | Eniricerche Spa | IMPROVED PROCEDURE FOR THE PREPARATION OF THE NATURAL HUMAN GROWTH HORMONE IN PURE FORM |
EP1997891A1 (en) * | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
US5688666A (en) * | 1988-10-28 | 1997-11-18 | Genentech, Inc. | Growth hormone variants with altered binding properties |
US5750373A (en) * | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5534617A (en) * | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
WO1990004788A1 (en) * | 1988-10-28 | 1990-05-03 | Genentech, Inc. | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5747334A (en) * | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5770434A (en) * | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
US5780279A (en) * | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
DK1471142T3 (en) * | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
US5955341A (en) * | 1991-04-10 | 1999-09-21 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2143104C (en) * | 1992-09-04 | 2008-04-08 | James Paul Ii Light | Phagemids coexpressing a surface receptor and a surface heterologous protein |
DE614989T1 (en) * | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Method for in vivo selection of ligand binding proteins. |
SE9304060D0 (en) * | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Methods to select specific bacteriophages |
US5811093A (en) * | 1994-04-05 | 1998-09-22 | Exponential Biotherapies, Inc. | Bacteriophage genotypically modified to delay inactivations by the host defense system |
US5516637A (en) * | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
WO1995034683A1 (en) * | 1994-06-10 | 1995-12-21 | Symbiotech, Inc. | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage |
US5627024A (en) * | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
GB9500851D0 (en) * | 1995-01-17 | 1995-03-08 | Bionvent International Ab | Method of selecting specific bacteriophages |
US5702892A (en) * | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
ATE239799T1 (en) * | 1995-09-07 | 2003-05-15 | Novozymes As | DETECTION OF DETERGENT ENZYME ACTIVITY BY PHAGES. |
US5622699A (en) * | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
US6084062A (en) * | 1996-03-20 | 2000-07-04 | Dyax Corp. | Polypeptides that bind to tissue plasminogen activator (tPA) |
US6190856B1 (en) * | 1996-05-22 | 2001-02-20 | The Johns Hopkins University | Methods of detection utilizing modified bacteriophage |
KR20000016414A (en) * | 1996-06-06 | 2000-03-25 | 와이즈먼 앤드루 | a PL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR a PL ANTIBODY-MEDIATED PATHOLOGIES |
CA2257873A1 (en) * | 1996-06-10 | 1997-12-18 | The Scripps Research Institute | Use of substrate subtraction libraries to distinguish enzyme specificities |
AU3737297A (en) * | 1996-08-05 | 1998-02-25 | Brigham And Women's Hospital | Bacteriophage-mediated gene therapy |
CA2267139A1 (en) * | 1996-10-08 | 1998-04-16 | Ton Logtenberg | Methods and means for selecting peptides and proteins having specific affinity for a target |
-
1991
- 1991-12-03 US US08/050,058 patent/US5750373A/en not_active Expired - Lifetime
- 1991-12-03 DE DE69129154T patent/DE69129154T2/en not_active Expired - Lifetime
- 1991-12-03 ES ES92902109T patent/ES2113940T3/en not_active Expired - Lifetime
- 1991-12-03 EP EP92902109A patent/EP0564531B1/en not_active Expired - Lifetime
- 1991-12-03 CA CA002405246A patent/CA2405246A1/en not_active Abandoned
- 1991-12-03 CA CA002095633A patent/CA2095633C/en not_active Expired - Lifetime
- 1991-12-03 WO PCT/US1991/009133 patent/WO1992009690A2/en active IP Right Grant
- 1991-12-03 AT AT92902109T patent/ATE164395T1/en not_active IP Right Cessation
- 1991-12-03 DK DK92902109T patent/DK0564531T3/en active
-
1995
- 1995-06-05 US US08/463,587 patent/US5821047A/en not_active Expired - Lifetime
- 1995-06-05 US US08/463,667 patent/US5834598A/en not_active Expired - Lifetime
-
1997
- 1997-09-03 US US08/923,854 patent/US6040136A/en not_active Expired - Fee Related
-
1998
- 1998-03-27 GR GR980400652T patent/GR3026468T3/en unknown
-
2005
- 2005-08-08 US US11/199,062 patent/US20060115874A1/en not_active Abandoned
-
2007
- 2007-06-11 US US11/761,180 patent/US20080038717A1/en not_active Abandoned
-
2009
- 2009-07-24 US US12/508,859 patent/US20100035236A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US5821047A (en) | 1998-10-13 |
US6040136A (en) | 2000-03-21 |
US20100035236A1 (en) | 2010-02-11 |
EP0564531A1 (en) | 1993-10-13 |
WO1992009690A3 (en) | 1992-12-10 |
EP0564531B1 (en) | 1998-03-25 |
GR3026468T3 (en) | 1998-06-30 |
ES2113940T3 (en) | 1998-05-16 |
ATE164395T1 (en) | 1998-04-15 |
DK0564531T3 (en) | 1998-09-28 |
US20060115874A1 (en) | 2006-06-01 |
WO1992009690A2 (en) | 1992-06-11 |
DE69129154D1 (en) | 1998-04-30 |
US5834598A (en) | 1998-11-10 |
CA2095633C (en) | 2003-02-04 |
US20080038717A1 (en) | 2008-02-14 |
US5750373A (en) | 1998-05-12 |
CA2095633A1 (en) | 1992-06-04 |
DE69129154T2 (en) | 1998-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2405246A1 (en) | Enrichment method for variant proteins with alterred binding properties | |
US5688666A (en) | Growth hormone variants with altered binding properties | |
US5846765A (en) | Identification of novel substrates | |
US6214613B1 (en) | Expression screening vector | |
EP1127142B1 (en) | Modulation of polypeptide display on modified filamentous phage | |
AU696293B2 (en) | Process for generating specific antibodies | |
US6057098A (en) | Polyvalent display libraries | |
CA2001774C (en) | Method for identifying active domains and amino acid residues in polypeptides and hormone variants | |
US5534617A (en) | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 | |
Gram et al. | Phage display as a rapid gene expression system: production of bioactive cytokine-phage and generation of neutralizing monoclonal antibodies | |
WO1998047343A2 (en) | Antibodies or binding protein libraries displayed on phage, cells, or other replicatable genetic packages | |
EP0760012A1 (en) | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage | |
JP2006104205A (en) | Human growth hormone variant | |
JPH08505524A (en) | Soluble peptide having a secondary conformation constrained in solution, and process for producing the same | |
WO2001057065A2 (en) | Combinatorial protein domains | |
JPH07506727A (en) | Reagents for agglutination assay | |
KR100458083B1 (en) | Method for the construction of phage display library using helper phage variants | |
JP3386210B2 (en) | Methods for producing recombinant and synthetic peptides and their uses | |
JP3765959B2 (en) | Hormone variant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |